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Abstract
Non-alcoholic fatty liver disease (NAFLD) has become the most common form 
of liver disease throughout much of the World. It affects between one in five and 
one in three adults in the general population. It is now believed to be the leading 
cause of liver cirrhosis and hepatocellular carcinoma. However, the majority of 
people with NAFLD do not go on to develop terminal liver disease but instead 
have an uncertain prognosis that can often include type 2 diabetes, 
cardiovascular disease, and/or non-hepatic cancers. Indeed, NAFLD is 
frequently accompanied impaired glucose control, and almost always 
suboptimal insulin sensitivity.
This thesis explores the only currently recommended therapy – weight reduction 
by lifestyle modification. It reviews the published evidence supporting this 
recommendation by applying a systematic approach to review the literature, but 
examines the findings in the broader context of common NAFLD comorbidities 
and sequelae. It also examines interaction of age and physical activity with liver 
fat, specifically in women, using both primary and secondary research methods. 
Finally, it explores exercise, particularly high-intensity intermittent training as a 
means to reduce liver fat, improve body composition, and attenuate insulin 
resistance independent of weight change and dietary advice. 
The principle finding is that, although the literature supports the 
recommendation of weight reduction, exercise can be an effective therapy to 
reduce liver fat and improve glucose control/insulin independent of weight 
change in adults with NAFLD. High-intensity intermittent training is particularly 
ii
effective for liver fat reduction, improves glucose control/insulin resistance, and 
results in positive changes to body composition.
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Chapter 1. Introduction and Literature Review
1.1 Introduction
Non-alcoholic fatty liver disease (NAFLD) refers to a spectrum of conditions 
ranging from simple hepatic steatosis through to non-alcoholic steatohepatitis 
(NASH), fibrosis, and cirrhosis 1. The condition is closely associated with, and 
arguably a component of, metabolic syndrome 2, especially insulin resistance 
and type 2 diabetes 3,4. NAFLD is estimated to affect 20-30 percent of adults 5 
and approximately 3% of children 6. The prevalence of NAFLD is increases in 
obese populations with estimates as high as 85% in morbidly obese adults 5, 
and 77% in obese children 6. In addition to obesity, predictors of NAFLD include 
physical inactivity 7, and low cardiorespiratory fitness 7,8. As the prevalence of 
both obesity and sedentariness continue to grow, albeit not as fast as in 
previous decades 9,10, NAFLD is likely to become even more common in the 
foreseeable future. Indeed, as some of the existing prevalence data are over 10 
years old 5, the problem is already likely to be more extensive than published 
estimates suggest. 
The costs associated with NAFLD specifically are difficult to quantify given its 
close association with metabolic syndrome and type 2 diabetes, which 
themselves are causally linked to cardiovascular disease, neuropathy, and 
nephropathy 11. However, type 2 diabetes alone costs the UK National Health 
Service approximately £8.8 billion in direct costs and a further £13 billion in 
indirect costs; this is estimated to increase to £15 billion and £20 billion, 
respectively, by the year 2035 12. Much of this cost may be avoidable if NAFLD 
is prevented or appropriately managed in its early stages and therefore 
removed as a contributing factor to the development of type 2 diabetes.
There are presently no approved pharmaceutical protocols specifically for the 
treatment of NAFLD, therefore lifestyle modification with the goal of weight 
reduction is the only recommended therapy for patients with NAFLD 13,14. 
Research has shown that weight reduction, changes in diet, and exercise can 
all help to reduce intrahepatic triacylglycerol (IHTAG) concentration  and 
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increase insulin sensitivity, but the approach with the greatest effectiveness 
remains to be determined 15. 
This chapter provides a broader context for the primary and secondary research 
presented in subsequent chapters. As this thesis focuses on the effects of 
exercise on NAFLD in adults, data from paediatric populations will not be 
reviewed.
This thesis addresses the following questions through secondary research:
1. What is the efficacy of lifestyle interventions in adults with NAFLD in terms of 
(see Chapter 2):
• Reducing IHTAG and/or liver aminotransferases;
• Improving histological parameters; and
• Improving glucose control/insulin sensitivity.
2. Is high intensity intermittent training a feasible option for patients with 
NAFLD?
and seeks to address the following questions via primary research:
3. What is the relationship between ageing and physical activity, and fitness, 
body composition, glucose control, and liver fat?
4. What is the effect of high intensity intermittent training in patients with NAFLD 
on:
• intrahepatic triacylglycerol;
• glucose control and insulin sensitivity;
• substrate utilisation at rest and during moderate intensity activity;
• body composition;
• blood pressure; and
• biomarkers of cardiovascular and liver disease risk
Chapter 1 - Introduction & Literature Review
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1.2 Normal Macronutrient Metabolism
Metabolic syndrome, type 2 diabetes, and NAFLD result predominantly from 
lifestyle factors; those relating to diet and physical activity being the most 
broadly studied (see Section 1.7 for further discussion). All three conditions are 
marked by abnormalities in nutrient metabolism in both the fasted and fed, i.e. 
postprandial, states 16,17. The latter being the state in which most people not 
deliberately fasting spend the majority of the time; partly due to the ready 
availability of food and opportunities to consume it 18. An insight into normal and 
altered postprandial metabolism thus provides essential context for 
understanding NAFLD and commonly related metabolic diseases. 
The postprandial state is characterised by an array of changes in host 
physiology to facilitate the digestion, absorption, and systemic distribution of the 
nutrients consumed. Anticipation of food leads to increased production of saliva 
19, excretion of gastric juices 18, and changes in blood hormone concentrations 
20. There are marked differences in physiological responses to a meal between 
those with metabolic diseases such as NAFLD and type 2 diabetes, and those 
with ʻnormalʼ metabolism 21-24, and between those recently sedentary or active 
25-28. The bulk of what is known about postprandial metabolism in metabolic 
conditions relates to carbohydrates and lipids.
1.2.1. Carbohydrates
Dietary carbohydrates come in two distinct forms, those joined by α 1-4 and α 
1-6 glycosidic linkages and therefore able to be digested by human enzymes 
and absorbed in the form of the monosaccharides glucose, fructose, or 
galactose, and those resistant to human enzymes and hence absorption, often 
referred to as dietary fibre 29. 
Digestion of dietary carbohydrates begins in the mouth with the release of 
salivary α-amylase, but actual enzymatic digestion takes place in the stomach 
and small intestine where pancreatic α-amylase and a host of glycosidases are 
also present 18. Absorptions takes place predominantly in the small intestine 
once polysaccharides have been broken down into their respective monomers. 
Glucose is absorbed via the sodium-glucose transporter (SGLT) 1, 2, and 4, 
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and the glucose transporter (GLUT) 2 30-32. Galactose is absorbed by SGLT1, 
and fructose by GLUT5 30.
Absorbed monosaccharides enter the hepatic portal circulation and thus can 
undergo first pass metabolism. In the case of fructose and galactose hepatic 
absorption is virtually complete 18. Hepatic glucose absorption is less complete 
with the ʻdirect pathwayʼ of glucose conversion to glycogen making only a 
modest contribution to liver glycogen 33,34, which is predominantly synthesised 
from 3-carbon outputs of gluconeogenesis, e.g. lactate, glycerol, and 
gluconeogenic amino acids, via the ʻindirect pathwayʼ 34. Glycogenesis and 
gluconeogenesis are processes undergoing a continuous cycling in both the 
postprandial and fasted state; net glycogenesis however, appears to be very 
sensitive to glucose availability and is down-regulated in the presence of a large 
glucose supply 34.
Fructose and galactose absorbed by the liver are converted to fructose-1-
phosphate and galactose-1-phosphate, respectively 18. Thereafter, they are 
further converted via several pathways to be metabolised immediately to: 
generate energy via the glycolytic pathway; be stored as glycogen via 
glycogenesis; or converted to fat via de novo lipogenesis as depicted in Figure 
1.1. Glucose can enter the same pathways, but unlike fructose and galactose 
that require liver specific enzymes for their initial conversion, glucose is able to 
undergo this metabolism in a large variety of cell types. Core metabolic 
processes involving carbohydrates are summarised in Table 1.1.
Table 1.1: Metabolic Pathways of Carbohydrate Metabolism
Pathway Description Primary Tissues
Glycogenesis Conversion of glucose to 
glycogen for storage
Liver, and skeletal and 
cardiac muscle, although 
most tissues store some 
glycogen
Glycogenolysis Breakdown of glycogen into 
glucose for energy production or 
release into the blood stream 
(liver only for the latter)
Liver, and skeletal and 
cardiac muscle
Glycolysis Oxidation of glucose Most tissue types
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Pathway Description Primary Tissues
Gluconeogenesis Conversion of noncarbohydrate 
compounds to glucose
Liver
Hexose monophosphate 
shunt
Production of 5-carbon 
monosaccharides and NADPH
Most tissue types
Tricarboxylic acid cycle Oxidation of pyruvate and acetyl 
CoA
Most tissue types
De novo lipogenesis Conversion of glucose 
metabolites to fatty acids
Liver and adipose tissue
Derived from Gropper et al (2008) 18.
Galactose FructoseGlucose
Tricarboxylic 
Acid Cycle
Pyruvate
Fructose-1-phosphate
Galactose-1-phosphate
Glucose-6-phosphate
Fructose-6-phosphate
Fructose-1,6-bis-phosphate
Dihydroxyacetone 
phosphate
Glucose-1-phosphate
Lactate
Glycogen
2 Glyceraldehyde-3-phosphate
Acetyle-CoA
Citrate
Isocitrate
α-KetoglutarateSuccinyl-CoA
Succinate
Fumarate
Malate Oxaloacetate
Fatty acidsPhosphoenolpyruvate
Nucleic acid synthesis
Malonyl CoA
Triacylglycerols
Storage Export
Figure 1.1: Hepatic carbohydrate metabolism showing the potential fate of fructose, galactose 
and glucose via the pathways of: glycogenesis in orange; glycolysis in blue into the 
tricarboxylic acid cycles in red; de novo lipogenesis in yellow; or the hexosmonophosphate 
shunt in green. Solid lines indicate direct conversion whereas interrupted lines indicate that one 
or more intermediate steps have been left out of the diagram. Sources: 16,18
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1.2.2.1 The Liver in Carbohydrate Metabolism
The liver, situated in the upper right of the abdomen and largest of the internal 
organs accounting for roughly 2-4% of body weight 35, is central to nutrient 
metabolism, including that of carbohydrates 18. The liver is the second largest, 
after skeletal muscle, storage site for glucose, in the form of glycogen via 
glycogenolysis 18. Following a mixed meal in a sedentary state, liver glycogen 
rises steadily for approximately four hours before reaching a plateau and then 
declines after six hours 36. In contrast, hepatic glucose production declines 
sharply after the meal with baseline output not being paralleled until about six 
hours post consumption. The liver also represents the major site for de novo 
lipogenesis 37, which rises from ~5% after a 12 hour overnight fast to 23% 
(range:10-38%) after mixed meal and further after a second meal 38. 
In the fasted state, hepatic net glycogenolysis and gluconeogenesis dominate to 
allow the export of glucose into the blood stream for the maintenance of blood 
glucose 18. If fasting continues to the point where stored glycogen becomes 
minimal, usually after a few days, hepatic metabolism changes to channel more 
acetyl-CoA, predominantly from β-oxidation of fatty acids, towards the 
production of 3-hydroxy-3-methylglutaryl-CoA, which is further converted via 
multiple steps to acetoacetate, β-hydroxybutyrate, and propanone in the 
process of ketogenesis 39. These ʻketoneʼ bodies are then exported to supply 
the brain and other tissues with an energy alternative to glucose and lactate 
39-42.
1.2.2.2 Adipose Tissue in Carbohydrate Metabolism
Adipose tissue accounts for 10-20% of systemic glucose use 43, and absorbs 
circulating glucose via GLUT4, GLUT10, and GLUT 12 31,44. Absorbed glucose 
can undergo glycogenesis, although the capacity for glycogen storage is lower 
in adipose tissue than it is in the liver or muscle 45. As in the liver, exogenous 
glucose or that liberated by glycogenolysis can undergo de novo lipogenesis 
and be stored as TAG. In the fasted state adipose tissue glycogen can undergo 
glycogenolysis for the liberation of glucose. 
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1.2.2.3 Muscle in Carbohydrate Metabolism
Skeletal muscle, due to its total mass, has the greatest capacity for glycogen 
storage and is therefore a key tissue in blood glucose control 18. Absorption of 
glucose into skeletal muscle is believed to occur predominantly via GLUT4 31,46. 
However, the glucose transporters GLUT5, GLUT11, GLUT12, and SGLT3 are 
also expressed in adult human muscle 30,31,47,48. Once absorbed, glucose can 
undergo glycogenesis or be used in energy production via glycolysis leading to 
aerobic energy production via the tricarboxylic acid cycle and the electron 
transport chain, or anaerobic metabolism leading to lactate production 18.
1.2.2 Lipid Metabolism
Digestion of dietary lipids is initiated by chewing and the release of lingual 
lipase by the serous glands, continues in the stomach via the action of gastric 
lipase and mechanical emulsification from peristaltic motion 49, and culminates 
in the small intestine where emulsions mix with bile and pancreatic secretions 
50. Mechanical and enzymatic digestion of triacylglycerols (TAG) results in 
monoacylglycerols, non-esterified fatty acids (NEFA), and glycerol 49. 
Phospholipid hydrolysis by phospholipases, of pancreatic origin, yields free fatty  
acids and lysophosphotidylcholine 50. Cholesterol, and phytosterol and 
phytostanol-ester hydrolysis, by cholesterol esterase, yields unesterified 
cholesterol, phytosterol, and stanol, respectively 50,51. Facilitated by bile salts 
and bile acids, these hydrolysis products of ingested and endogenous lipids 
form mixed micelles, the contents of which are absorbed by enterocytes 50.
Once inside enterocytes, these lipids can be: incorporated into the structure of 
the cell; oxidised; stored; or repackaged as TAG into chylomicrons for export 
into the circulation 50,52. Lipids with carbon chain lengths >10 and not used as a 
fuel or incorporated into cell wall cholesterol esters or phospholipids, are 
converted to TAG and exported in chylomicrons, and to a lesser extent very low 
density lipoproteins (VLDL) 49,50. Medium chain fatty acids – 6-12 carbons – 
mostly pass directly into the portal circulation unmodified 18. Lipids can be 
released into either the portal vein or the lymphatic system in response to 
factors such as the form of the lipid, e.g. free fatty acid vs. TAG, the combination 
of lipids, and fatty acid chain length 49. Among published findings, the most 
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consistent are that NEFA and shorter chain TAG are preferentially transported 
by the portal vein, whereas TAG packaged in chylomicrons are first released 
into the lymphatic system prior to entering blood circulation 49. 
Appearance of ingested TAG, mostly incorporated into chylomicrons, in the 
circulation post-meal occurs in two phases 52: the first phase, culminating in the 
ʻearly peakʼ at 10-30 minutes after the onset of the meal, involves release of 
lipids consumed in an earlier meal; and the second phase has its peak 3-4 
hours post meal with lipids coming predominately from that meal. Circulating 
TAG concentrations continue to rise throughout the day with repeated meal 
consumption as each meal not only contributes directly to the TAG pool but also 
induces the release of TAG stored after prior meals in what has become known 
as the second meal effect. 
Exchange of apolipoproteins from chylomicrons with other circulating 
lipoproteins provides sufficient apoC-II to facilitate TAG hydrolysis by 
extracellular lipoprotein lipase in small blood vessels and capillary beds, 
predominantly of skeletal muscle and adipose tissue 52,53. Hydrolysis yields free 
fatty acids and diacylglycerols for absorption by surrounding tissue 52,53. The 
decreased chylomicron size results in migration of excess phospholipids to 
high-density lipoprotein cholesterols, and a shift in cholesterol ester from the 
core to the surface of the resulting chylomicron remnants 53. Incomplete 
absorption of liberated lipid results in spillover of NEFA into the circulation 52. 
Metabolism of ingested lipids is depicted in Figure1.2.
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Figure 1.2: Following digestion of consumed lipids, the resulting glycerol, monoacylglycerols, 
and NEFA are absorbed by enterocytes. There they can undergo: oxidation for energy; 
reesterification to TAG for storage or incorporation into chylomicrons for export; or conversion 
into cholesterol esters or phospholipids. Exported chylomicrons are acted on by capillary bound 
lipoprotein lipase to release NEFA and diacylglycerol for absorption into surrounding tissue, 
predominantly adipose and muscle. TAG-depleted chylomicrons become chylomicron remnants 
that are absorbed by the liver along with circulating albumin bound NEFA from its incomplete 
absorption by other tissue. The liver exports some of the absorbed and reconstituted TAG in 
VLDL, which is also a target for lipoprotein lipase. TAG-depleted VLDL transiently becomes IDL 
before forming the cholesterol rich LDL particle after TAG is removed. This LDL-cholesterol is 
then available for absorption by tissues (not depicted). Diagram based on sources: 18,39,52. 
Abbreviations: DAG, diacylglycerol; HDL, high-density lipoprotein; IDL, intermediate-density 
lipoprotein; LDL, low-density lipoprotein; NEFA, non-esterified fatty acids; TAG, triacylglycerol; 
VLDL, very low density lipoproteins.
1.2.2.1 The Liver in Lipid Metabolism
Digestion of lipids is dependent on bile salts produced by the liver 18. The liver 
first comes in direct contact with ingested lipids in the form of circulating NEFA 
released from chylomicrons by lipoprotein lipase in other tissues, and 
chylomicron remnants, which it absorbs via endocytosis 18,52. Absorption of 
lipids is facilitated by membrane proteins including: caveolins; fatty acid 
translocase/cluster of differentiation 36 (FAT/CD36); fatty acid transport proteins 
(FATP); and plasma membrane-associated fatty acid-binding protein (FABP) 17.
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Net uptake of meal TAG by the liver is 8-12% 52. Absorbed lipid can be stored in 
TAG droplets, converted into phospholipids and cholesterol esters, metabolised 
for energy and/or intermediates mainly for gluconeogenesis or ketogenesis, or 
repackaged into very low density lipoproteins for export 54. However, in the 
postprandial state, assuming an adequate carbohydrate supply, the primary fuel 
source for the liver is glucose, thus postprandial metabolism favours storage or 
export rather than oxidation of fatty acids 52. During the fasted state the main 
exogenous lipid supply comes from circulating NEFA 17. Stored TAG is broken 
down to supply substrate for gluconeogenesis, ketogenesis, and mitochondrial 
β-oxidation as described above 18,39. 
1.2.2.2 Adipose Tissue in Lipid Metabolism
Adipose tissue absorbs lipid liberated from chylomicrons by lipoprotein lipase 
and predominantly stores these in TAG droplets 18,52. In the fasted state there is 
net export of NEFA from adipose tissue 45. The majority of this adipose-derived 
circulating NEFA appears to come from abdominal subcutaneous adipose tissue 
55 
1.2.2.3 Muscle in Lipid Metabolism
As noted above, TAG bound in chylomicrons is liberated by the hydrolytic action 
of the capillary membrane bound lipoprotein lipases and the resulting NEFA and 
DAG absorbed by nearby tissue. Absorption of lipid into the muscle proceeds by 
both passive diffusion and protein mediated transport via: FAT/CD36; FABP; 
and FATP 1 and 4 56. Once absorbed, the lipids can undergo much the same 
processes as described for adipose tissue, except they do not appear to 
released back into the circulation 18. 
1.2.3 Hormonal Control of Hepatic and Systemic Metabolism
The pancreatic hormones insulin, produced by the β-cells, and glucagon, 
produced by the α-cells, are the main acute regulators of both carbohydrate and 
lipid metabolism 16. Insulin secretion increases to parallel the elevation of blood 
glucose in the postprandial period following carbohydrate consumption 57-59. 
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Elevated insulin promotes hepatic glycogenesis, down regulates 
gluconeogenesis, and decreases de novo lipogenesis 16,60. In skeletal muscle, 
glucose uptake is increased via insulin mediated translocation of GLUT4 and 
GLUT12 to the cell wall 61; glycogenesis also increases 16. And in white adipose 
tissue, elevated insulin decreases release of NEFA into the blood stream and 
promotes both glycogenesis and de novo lipogenesis 45. Insulin thus promotes a 
shift in metabolism to favour glucose as the dominant fuel source for cellular 
metabolism.
During states in which blood glucose concentration decreases within the normal 
range or below, such as in the fasted state or while exercising, more glucagon 
and less insulin are produced thus lowering insulin:glucagon ratio 16. The 
increase in glucagon increases hepatic glycogenolysis, decreases glucose 
uptake, and results in a net export of glucose into the blood stream 62. Over 
prolonged periods of hypoglycaemia, catecholamines augment the function of 
glucagon 62. Reduced insulin concentration leads to increased 
gluconeogenesis, decreased glycogenesis and de novo lipogenesis in the liver 
63, and increased release of NEFA and glycerol from the breakdown of stored 
TAG in adipose tissue 16. The effect of decreased circulating insulin on skeletal 
muscle depends on whether the muscles are resting or engaged in forceful 
contraction, such as during exercise or physical labour. During exercise glucose 
uptake remains elevated in contracting muscle independent of circulating insulin 
64. At rest, reduced insulin concentration leads to reduced absorption of 
circulating glucose and increased intramuscular glycogenolysis 16. 
1.2.4 Common Modifiers of Postprandial Macronutrient Metabolism
In healthy humans free from metabolic disease and not taking medication that 
might affect metabolism, the key modifiers of postprandial metabolism are: 
composition of the meal in question 52,65,66, and the preceding meal 36,67,68; 
physical activity prior to or shortly after the meal, and time of day 69. Meal 
composition determines insulin and glucagon response in that meals containing 
digestible carbohydrates and/or proteins lead to increased insulin release 
18,65,70, and in the case of protein, a variable glucagon response 70. No such 
change is observed with meals exclusively made of lipids 18. 
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The rate of absorption and appearance of dietary glucose in the blood is highly 
variable and dependent on both dietary and host factors 71. Nonetheless, 
multiple approaches to quantifying the glucose response to different 
carbohydrate sources exist 65: the glycaemic index (GI) compares the area 
under the blood glucose curve for a food or meal containing a standard 
carbohydrate (50 g) dose with the response for an equal amount of glucose in 
solution; the glycemic load is the product of GI multiplied by the carbohydrate 
content of the food or meal; and glycemic equivalence is established by 
measuring the response to food or meals of non-standard carbohydrate content. 
Several factors have been shown to modify glycaemic response to similar foods 
including the extent of chewing 72, the presence of fat and/or protein 70,73,74, the 
specific type of protein 75, physical and chemical attributes of foods including 
processing such as freezing and toasting 76, and cooking method 77. Being in a 
postprandial or postabsorbtive as opposed to a fasted state has also been 
shown to reduce the glycaemic response to a meal 36. Further, a prior 
carbohydrate containing meal increases the amount of glucose directed toward 
liver glycogen synthesis 78. This second meal response, noted for lipids above 
(section 1.2.2.), occurs even if meals are separated by an overnight fast 67. 
Just as postprandial response to one meal is influenced by prior meals, so prior 
meal composition can influence metabolism in exercise following a meal. For 
example, meals with a lower glycaemic index are more likely to promote higher 
fat oxidation from both circulating NEFA and intramyocellular lipid stores, 
whereas meals with a higher glycaemic index favour carbohydrate oxidation 
and lower availability of NEFA as a fuel source 67,79-81. The corollary is that 
physical activity, including exercise, also modifies postprandial metabolism. 
Simply breaking up two hours of sedentary time with two minutes of light-to-
moderate intensity walking every 20 minutes reduced postprandial glucose and 
insulin response 25. Higher intensity activities preceding or shortly after a meal 
have also been shown to: increase lipid oxidation 27; reduce plasma lipid 
response 28,82-85; improve lipoprotein profile 86,87; reduce plasma insulin and/or 
glucose response 28,83,88,89; and suppress de novo lipogenesis 90. However, not 
all findings are consistent with some reports indicating that an acute bout of 
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prolonged resistance exercise can elevate postprandial TAG area under the 
curve 91, and that post meal lower-intensity exercise is ineffective at modifying 
postprandial metabolism whereas the same exercise prior to meals reduces 
glucose response 92.
Exercise transiently increases insulin independent skeletal muscle glucose 
absorption 64, and hepatic glycogenolysis in an exercise intensity dependent 
manner 63. As hepatic glycogen stores diminish, gluconeogenesis increases 63. 
Forceful muscle contraction also increases myocellular insulin sensitivity and 
hence insulin mediated glucose absorption mediated by increased expression 
of GLUT4 and GLUT12 61. The elevation in GLUT4 mRNA production lasts less 
than 24 hours, but there is a cumulative effect of daily exercise in terms of 
GLUT4 protein expression 93. Increased insulin sensitivity following exercise 
reduces postprandial de novo lipogenesis 26. Exercise also elevates the activity 
of lipoprotein lipase 94, and muscle contraction drives the relocation of the fatty 
acid transport protein FAT/CD36 to the plasma membrane of myocytes, thereby 
contributing to enhanced uptake of circulating lipids 95. 
1.3 Metabolism in Non-Alcoholic Fatty Liver Disease 
Obesity, insulin resistance, and the presence of hepatic steatosis all contribute 
to altered fasting and postprandial metabolism both systemically and in specific 
tissues, particularly the liver, adipose tissue, muscle, and the pancreas 96. In 
NAFLD, the most fundamental change is an imbalance between hepatic lipid 
uptake and de novo lipid production relative to overall export leading to net 
hepatic fat accumulation 17. 
In obese volunteers with hypertriglyceridaemia and NAFLD circulating NEFA, 
hepatic de novo lipogenesis, and dietary lipids accounted for 59±10%, 26±7%, 
and 15±7% of labelled IHTAG after four days of a labelled mixed diet, 
respectively 97. The same study also showed chronically elevated de novo 
lipogenesis without the diurnal and fasted vs. postprandial variation found in 
healthy volunteers 38,97. This elevation of hepatic de novo lipogenesis had been 
previously demonstrated in an insulin resistant NAFLD cohort relative to healthy 
controls 98, and also obese and insulin resistant cohorts of unknown NAFLD 
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status 99-101. Elevated de novo lipogenesis is accompanied by a reduction in 
hepatic and muscle glycogen synthesis in conditions of insulin resistance 
78,102-104. 
In addition to increased de novo lipogenesis, volunteers with an IHTAG over 6% 
also exhibited a 25% higher rate of gluconeogenesis than those with IHTAG 
under 6% 105. The degree of change in gluconeogenesis was greater when 
NAFLD was accompanied by overweight/obesity 106.These findings in NAFLD 
cohorts are consistent with earlier observations that gluconeogenesis is 
elevated in obesity and linked to increased postabsorptive protein breakdown 
107.
Adipose tissue storage of fat was reduced after meals in abdominally obese 
men relative to lean controls 108. In diet controlled type 2 diabetes, postprandial 
absorption of fatty acids into skeletal muscle and hepatic TAG pools is greater 
and more rapid following a mixed meal relative to healthy controls 109. Hepatic 
lipoprotein lipase activity is elevated in NAFLD 110, and was 4.5 times higher in 
morbidly obese type 2 diabetics prior to vs. post massive weight loss through 
bariatric surgery 111. The transmembrane lipid transporter FAT/CD36 protein 
and/or gene expression is reduced in the adipose tissue of those with NAFLD, 
while it is increased in their hepatic and muscle tissues 112,113. Thus availability 
of lipid to the liver appears to be matched by increased absorption. 
Plasma concentrations of ß-hydroxybutyrate indicate hepatic fatty acid oxidation 
similar or up to two-fold greater in NAFLD than in healthy controls 105,114-116. 
Also, VLDL-TAG secretion increases linearly with liver fat concentration, but 
plateaus at 10% 117. Further, synthesis of apoB-100, a protein component of 
VLDL, was reduced in NASH relative to obese and lean controls suggesting a 
reduced capacity for VLDL-TAG synthesis and thus export 118. Nonetheless, 
although comparable in the fasting state, plasma VLDL and TAG increased 
more in simple steatosis and NASH cohorts than in healthy controls following a 
fat tolerance test 119. These findings suggest that in NAFLD the total VLDL-TAG 
clearance rate is reduced, adipose tissue clearance is particularly impaired, but 
muscle and liver lipid absorption are increased. 
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Patients with biopsy-confirmed NASH had greater adipose and hepatic insulin 
resistance, and poorer β-cell function than patients with simple steatosis or non-
NAFLD controls matched for abdominal adiposity and symptoms of the 
metabolic syndrome 119. The difference in β-cell function remained even after 
excluding patients with impaired glucose tolerance. Further, elevated IHTAG is 
associated with reduced insulin clearance, and hepatic insulin resistance 120. 
Elevated intramuscular lipid is similarly associated with muscle insulin 
resistance 121, and liver fat concentration was found to be closely associated 
with intramuscular fat concentration when assessed at baseline, and following a 
weight reduction intervention 122.
Collectively, these observations from NAFLD and closely related cohorts 
indicate that NAFLD at various stages is associated with as yet not fully 
characterised changes in postprandial macronutrient metabolism, and to a 
lesser extent fasting metabolism. These changes result in, and derive from, a 
disproportionately high ectopic lipid storage best characterised in skeletal 
muscle and the liver, which in turn contribute to central and peripheral insulin 
resistance.
1.4 Definition and Assessment of Non-Alcoholic Fatty Liver Disease 
NAFLD refers to a spectrum of conditions ranging from simple hepatic steatosis, 
non-alcoholic steatohepatitis, to fibrosis, and cirrhosis 1. Its early stage is 
defined by excess fat in the liver in the absence of excessive alcohol intake, 
other liver pathologies such as viral and autoimmune disease hepatitis, and 
pharmacological causes 13,14, and is therefore a diagnosis by exclusion. 
However, no single objective and quantitative definition for NAFLD exists as 
multiple techniques are used to assess liver fat; some of which are semi-
quantitative in nature (see below). If analysed by biopsy, 5% of hepatocytes 
containing visible fat droplets is considered the lowest end of steatosis 123. In 
the case of assessment by proton magnetic resonance spectroscopy (1H-MRS) 
the threshold for excess liver fat has been variously established at 5.6% and 3% 
124,125. In both cases based on the 95th centile of an apparently healthy non-
insulin resistant sample. The definition of what constitutes excessive alcohol 
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intake and the methods used to assess intake also vary considerably across 
studies of NALFD 15. 
The primary characteristic of the early stages of NAFLD, hepatic steatosis can 
be identified by ultrasound, computed tomography (CT), magnetic resonance 
imaging (MRI), 1H-MRS, and histological examination of biopsy samples 126. CT, 
MRI, and 1H-MRS are quantitative methods of analysis, whereas ultrasound 
and histological analysis are semiquantitative 126. 
1.4.1 Biopsy 
Histological examination, by light microscopy, of biopsy samples can assess the 
presence of necroinflammation and fibrosis, and can differentiate between 
macro- and micro-vesicular steatosis as shown in Figure 1.3; it remains the 
reference standard for the grading and staging of NAFLD 13,14, but caries some 
risk due to its invasive nature 127,128. To date, no imaging or other noninvasive 
techniques exist that can fully replace histological examination in terms of 
grading and staging NAFLD 129,130. However, biopsy is subject to sampling error 
131-133, and inter-rater differences in scoring/grading are recognised limitations 
123,133,134. The potential for sampling error exists due to tissue heterogeneity 
between lobes 131, and even closely adjacent areas 135,136. Biopsy length and 
fragmentation also influence diagnosis 137,138. Further, the scoring/grading 
systems have evolved over time and not all are suitable for scoring the full 
spectrum of NAFLD 123.
Histological examination of liver biopsies has been used to validate imaging 
techniques 139-142. The key caveat to this approach is that it involves comparing 
a semi-quantitative subjectively scored technique with more quantitative and 
objective techniques. More objective, e.g. computer-assisted, quantitative 
methods of histological and histochemical biopsy assessment have been 
investigated and advocated, but not routinely adopted in clinical care or 
research 134,139,143,144.
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Figure 1.3: Liver histology under light microscopy: A.normal liver; B. microvesicular steatosis 
shown by arrows; C. notable macrovesicular steatosis; D. inflammation with steatosis; E. fatty 
liver ballooning shown by arrow; F. steatosis with fibrosis (stained blue).
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1.4.2 Magnetic Resonance Spectroscopy and Imaging
Magnetic resonance scanners provide images or chemical spectra by using a 
very large permanent magnetic field in conjunction with other temporary applied 
electromagnetic radiation 145. The magnetic field causes the angular momentum 
of the atomic nuclei, known as spins, to be quantized to two energy states by 
aligning the spins to face either the same direction as the main field – up – or 
directly against it – down. A radio frequency pulse with a frequency specific to 
the nucleus of interest – the resonant frequency – is applied to alter the 
distribution of spins in the up and down states. Cessation of the pulse allows 
these nuclei to return to their original state resulting in the release of a 
measurable radio frequency pulse at the resonant frequency of the nuclei 
concerned. The timing and frequency of this emitted pulse is modified by the 
chemical environment of the nuclei, and this information is used, either with 
spatial encoding to construct an image, or to generate spectra. 
Liver fat can be measured by focusing on the spectra created by the single 
proton nuclei of hydrogen atoms that are abundant in both water and fat 146. As 
illustrated in Figure 1.4, the nuclei of hydrogen in water resonate at a slightly 
different frequency, 435 Hz difference at 3 T, to those in fat. The frequency thus 
identifies the chemical responsible for each peak, i.e. water or fat, and the area 
of the peak gives the quantity of nuclei detected. The volume of tissue to which 
the spectra corresponds is the volume element or VOXEL, whose size can be 
varied but is usually several cubic centimetres 147.
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Figure 1.4: Water and lipid spectrum from liver 1H-MRS in a control volunteer and one with 
NAFLD
An alternative to spectroscopy is 3-Point Dixon MRI 148. For this, three gradient 
echo scans of several liver sections going from superior to inferior are acquired. 
The three adjacent scans comprise of one that is out-of-phase (the water and 
fat signal cancel), one that is in-phase (the water and fat signals are additive), 
and an out-of-phase echo 149. The resulting data are processed to yield 
separate fat and water images, and software used to determine fat percentage 
derived from the contrast of images. Fat content is reflected in how dark or light 
the slice is with more fat resulting in lighter slices (see Figure 1.5). 
1H-MRS provides a non-invasive fully quantitative measure of liver fat, unlike 
biopsy, and it has superior accuracy and sensitivity to CT and ultrasound 140. 
The technique has also been validated against biopsies 141,150. The key 
limitation of 1H-MRS relative to biopsy is its present inability to reliably detect 
other components of NAFLD such as inflammation and fibrosis 151. The other 
notable limitation of 1H-MRS is that it examines only a portion of the liver, the 
designated VOXEL. However, at several cubic centimetres this area is several-
fold larger than that obtainable by biopsy. 
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MRI makes it feasible to examine a larger portion of the liver, and makes it 
easier to assess the homogeneity of liver fat distribution 148. However, imaging 
methods have been less extensively validated than spectroscopy 147.!! BA
Figure 1.5. shows two ʻfat onlyʼ magnetic resonance images of livers. Image A is from a 
volunteer with hepatic steatosis – approximately 32% liver fat – as indicated by the relative 
brightness of the liver. Image B is from a control volunteer without hepatic steatosis – 
approximately 3% liver fat – as indicated by the relative darkness of the liver.
1.4.3 Computed Tomography
CT provides a semi-quantitative method for the evaluation of IHTAG based on 
the change in image intensity, measured in Hounsfield units, between the liver 
and either the spleen, which stores no fat, or an external lipid standard 126. An 
increase in liver:spleen ratio or liver density is indicative of reduced IHTAG.
1.4.4 Ultrasound
Ultrasound is the most readily available and inexpensive imaging technique for 
assessing degree of steatosis. It provides a semi-quantitative assessment of 
liver fat based on diffuse increases in image echogenicity with reported 
sensitivities and specificities varying between 60-94% and 66-95%, respectively 
126. Sensitivity is improved when liver fat exceeds 30% 152. However, sensitivity 
is reduced in the morbidly obese in whom the prevalence of NAFLD is 
particularly high 153. Inter- and intra-observer variability for the assessment of 
the presence of steatosis has been reported as 72% and 76%, respectively, 
with an observer agreement of severity of 55-68% 154.
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1.4.5 Liver Enzymes
Liver enzymes, specifically alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and/or γ-glutamyl transferase (GGT), are sometimes 
used in the diagnosis and/or tracking of NAFLD where other common causes 
for hepatic steatosis have been ruled out 15. However, liver enzymes are 
markers of liver injury 155, and are non-specific for the presence, degree, or 
progression of NAFLD. 
In a cohort of 708 individuals with elevated intrahepatic lipid (>5.6% assessed 
by 1H-MRS) 79% had normal ALT 156. Larger ultrasound assessed cohorts show 
similar discrepancies between the presence of steatosis and transaminase 
concentrations 157,158. Normal ALT and AST concentrations have also been 
reported in the presence of histological evidence of steatosis, fibrosis, and 
cirrhosis 159-162. Even when the conservative serum ALT cutoff of19 IU was 
employed, sensitivity and specificity for NAFLD remained poor at 74% and 42%, 
respectively 163. Further, some clinical cohorts predominantly display raised 
GGT, not ALT, concentrations in the presence of NAFLD 164,165. 
As well as being a poor static measure, 3-monthly ALT, AST, and GGT 
measurements in 73 untreated NAFLD patients with repeat biopsy data, at 
baseline and two years, showed a mean downward trend in all three enzymes 
despite no change in body weight 166. There was no significant correlation 
between liver enzyme and histological profile change.
Despite the recognised limitations of individual biomarkers, multiple biomarkers 
in combination with other data such as diabetes status have been successfully 
used to develop composite scores that predict risk of more advanced liver 
disease, for example the NAFLD fibrosis score 167. The use of ALT:AST ratio is 
also predictive of fibrosis 168. Further, recent work suggests that a specific form 
of GGT, big GGT, may be more predictive of and specific to NAFLD 169. 
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1.4.6 Stability of Liver Lipid Concentration and Time Course of Changes
No work describing either circadian or serial day-to-day variation in liver lipid 
concentration under free living or specific intervention conditions has been 
published. The temporal variation in two key contributors to liver lipid, circulating 
NEFA and de novo lipogenesis, suggest IHTAG could vary accordingly. Day-to-
day serum NEFA concentrations have an intra-individual coefficient of variation 
(CV) of 45%; although there appears to be a trend over time as indicated by 
measures greater than two weeks apart showing a CV of 24% 55. Further, de 
novo lipogenesis is elevated during the follicular phase of menstruation 99; 
potentially leading to differences in IHTAG by menstrual phase.
Nonetheless, 1H-MRS quantified IHTAG after an overnight fast appeared stable 
over four weeks with CVs of 4.1% and 9.5% in volunteers with NAFLD (n = 8) 
and a mixed group of NALFD and non-NAFLD volunteers (n = 24), respectively 
170. The within 4-hour CV was 4.5% in a mixed NAFLD and non-NAFLD group 
with both scans performed in the fasted state (n = 12). Further, no significant 
difference in IHTAG, assessed by 1H-MRS, was found when comparing 
measurement after a 10-hour overnight fast and 4-hours post high-fat – 50 g of 
fat – breakfast on the same day 124. The study was tightly controlled with an 
inpatient protocol, but there were only eight participants of whom only one had 
an IHTAG above 5%. The meal was almost exclusively fat, whereas there is 
reason to believe carbohydrates may have a much stronger acute effect on 
IHTAG. 
Comparison of two hypocaloric diets, both1000 kcal below estimated 
requirement, in NAFLD cohorts, showed a much greater reduction in IHTAG 
after 48 hours when carbohydrate was restricted to 20% of energy than when 
fat was restricted to 10% of energy: IHTAG decreased from 12.4% to 8.7% and. 
11.2 % to 10.2%, respectively 171. One week on a 600 kcal/day diet in an 
overweight cohort with type 2 diabetes, resulted in a similar clear and rapid 
reduction in IHTAG from 12.8% to 9.0%, 172. Two weeks of an 8% carbohydrate 
diet led to greater reductions than a 50% carbohydrate diet – IHTAG 22% to 
10% vs. 19% to 14%, respectively 173. Tracer work indicating that de novo 
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lipogenesis accounts for a greater proportion of IHTAG than dietary lipid would 
seem to offer an explanation for these findings (see Section 1.3) 97.
In healthy non-NAFLD volunteers caloric restriction in the form of fasting has 
shown variable effects. Twelve hours of fasting resulted in no change in liver fat 
174; Twenty four hours of fasting reduced liver fat by 34% (only relative decrease 
reported)175, Conversely, 36 and 48 hours of fasting lead to increased IHTAG in 
men 174,176. Whereas 48 hours of fasting left liver fat concentration unchanged in 
women; who instead showed increased intramuscular lipid accumulation 176. 
Although none of these studies set out to systematically evaluate the time 
course of IHTAG changes under the conditions studied, they show that IHTAG 
concentration can respond rapidly to changing energy and macronutrient intake, 
and that responses to energy restriction may differ substantially between those 
with NAFLD and those with low IHTAG.
1.5 Symptoms
The most commonly reported symptoms of NAFLD and NASH are pain near the 
liver, general fatigue, and/or a noticeably enlarged liver, but the majority of 
patients report no symptoms 177,178. Studies have also observed a link with 
fatigue and daytime sleepiness, and identified overall reduced quality of life 
179,180, autonomic dysfunction 180, and reduced exercise capacity 181. 
In a cohort of 156 with histologically-confirmed NAFLD assessed by a validated 
fatigue specific questionnaire, fatigue was considerably higher than in a control 
cohort – 51±38 vs. 8±12 179. The same cohort also took fewer daily steps than 
controls, indicating less physical activity, and reported worse overall quality of 
life. However, NAFLD severity was not correlated with fatigue severity. Self-
reported fatigue was found to correlate with autonomic dysfunction in a cohort 
of 34 non-diabetic, non-cirrhotic patients with histologically confirmed NAFLD 
180. Specifically, questionnaire assessed fatigue correlated positively with 
orthostatic symptoms, and inversely with 24-hour ambulatory blood pressure. 
The absence of self-reported symptoms in the clinical setting but presence on 
specific investigation suggests that patients may simply not be fully aware that 
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their physical state is suboptimal, or that they attribute this to non-medical 
factors. It does however suggest that improvements in autonomic function and 
reduced fatigue would be perceived as tangible benefits to therapy to motivate 
adherence.
1.6 International Prevalence of Fatty Liver
Good data on national prevalences of non-alcoholic or indeed alcoholic fatty 
liver disease are scarce due to a lack of population representative sampling and 
frequent reliance on less sensitive and/or specific methods for measuring 
steatosis 5. Even when hepatic steatosis is clearly established, ruling out the 
contribution of alcohol intake is complicated by the difficulty in accurately 
measuring alcohol intake as well as inconsistent definitions of moderate intake 
15,182. 
A recent systematic review of published adult cohorts indicated an international 
prevalence of NAFLD of 9-33% 5. Estimates in children and adolescents of 
approximately 3%, are based on a much smaller dataset than prevalence in 
adults 6. Figure 1.6 shows regional and demographic distributions of fatty liver 
prevalence using either ultrasound or 1H-MRS. The summarised data illustrates 
regional differences, as well as an influence of ethnicity. Texas-based hispanics 
had higher prevalence than caucasians from the same region, and African-
Americans had the lowest prevalence 156,183. NAFLD prevalence also increases 
with increasing obesity and the presence of type 2 diabetes 5
Data on the prevalence of NASH are even more limited due to the need for 
histological assessment to confirm the diagnosis. One study of a volunteer 
cohort (n = 328) recruited from a military primary care facility in Texas evaluated 
steatosis by ultrasound and followed up those with the appearance of NAFLD 
with biopsy assessment 183. The prevalence of NASH in this cohort was 12%. 
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Figure 1.6. International Adult Percentage Prevalence of Non-Alcoholic Fatty Liver Disease
Source references: 156,157,183-198
1.7 Risk Factors
The prevalence data above already defines some key risk factors for NAFLD, 
notably: overweight/obesity, type 2 diabetes, age, and hispanic ethnicity. These 
are all easy to assess. As noted in Section 1.4, NAFLD is a diagnosis by 
exclusion, the most commonly excluded contributors to hepatic steatosis being: 
excessive alcohol consumption; viral and autoimmune hepatitis, human 
immunodeficiency virus; some medications; haemachromatosis; certain 
gastrointestinal surgical procedures being most commonly excluded by 
objective measures 13,14. Other contributors to hepatic steatosis are not routinely 
excluded and whether these fall under the umbrella of NAFLD is open to debate 
199. Table 1.2 outlines both common and rare factors associated with hepatic 
steatosis.
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Table 1.2: Factors Associated with the Development of Hepatic Steatosis
Category Substance/Condition
Toxic causes Alcohol
Toxins: thinners, solvents, rapeseed cooking oil, 
dimethylflormamide, petrochemicals, pesticides
Cocaine
Pharmaceuticals: nifedipine, diltiazem, 
diethylaminoethoxyhexestol, tamoxifen, oestrogens, 
corticosteroids, methotrexate, perhexiline, amiodarone, highly 
active antiretroviral therapy
Nutrition Total parenteral nutrition
Starvation related: cachexia, rapid weight loss, anorexia nervosa, 
marasmus, kwashiorkor
Surgical procedures Bypass surgery: bariatric surgery, Scopinaro procedure
Whipple procedure (removal of part of the pancreas)
Blind loop with bacterial overgrowth
Infectious agents Hepatitis C, B, and D viruses
Inborn errors of 
metabolism
Amino acid disorders: heptorenal tyrosinaemia type I, 
homocystinuria, type II citrullinemia, neonatal intrahepatic 
cholestasis
Bile acid synthesis defects
Carbohydrate disorders: Galactosaemia, hereditary fructose 
intolerance, glycogen storage diseases (type I, III, IV, VI, Fanconi-
Bickel)
Channelopathy: Cystic fibrosis
Disorders of glycosylation
Lipid & fatty acid disorders: hypobetalipoproteinaemias, α- & β-
oxidation defects, Dorfman-Chanarin syndrome
Wilson disease
Mitochondrial disorders: Alpers syndrome, mitochondrial DNA 
depletion syndrome
Organic acidoses: propionic acidaemia, methylmalonic acidaemia, 
methylcrotonyl acidaemia, methylglutaconic acidaemia
Peroxisomal disorders: adrenoleucodystrophy, Zellweger 
syndrome
Protein folding disorders: α1-antitrypsin deficiency 
RNA processing disorders: Shwachman-Diamond syndrome
Other disorders Polycystic ovary syndrome
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Category Substance/Condition
Alstrom syndrome
Bardet-Biedl syndrome
Prader-Willi syndrome
Lipodystrophy syndromes
Insulin receptor & post-binding defects
Thyroid disorders
Hypothalamo-pituitary disorders
21-α-hydroxylase deficiency 
Celiac disease
Inflammatory bowel disease
Hepatic Weber-Christian disease
Adapted from reference Cassiman and Jaeken 199
Many of the factors outlined in Table 1.2 that are not already specifically 
excluded from the spectrum of NAFLD, are rare, or at least rare in economically 
more developed countries, and it is therefore reasonable to assume that the 
majority of the NAFLD disease burden can be attributed to more prevalent risk 
factors explored below. Nonetheless, the heterogeneity within the aetiology of 
NAFLD may in part explain any heterogeneity in treatment response.
1.7.1 Overweight and Obesity
The prevalence of NAFLD increases with increasing obesity as defined by body 
mass index (BMI) and increased adiposity, particularly abdominal visceral 
adiposity 5. Understandably, prevalence also increases with waist circumference 
as it is closely associated with visceral adiposity 200. 
1.7.2 Gender
Surveys of disease prevalence conflict with respect to whether gender is a risk 
factor and if so whether males or females are at greater risk 5.
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1.7.3 Age
The prevalence and severity of NAFLD increase with age 5,183,187,201. The 
association between age and prevalence of NAFLD has been shown in several 
populations: Northeast England 201; Hong Kong 187; Texas 183; India 193; China 
157; and Korea 191. Several cohorts also suggest that age increases the risk of 
NASH and fibrosis 202-205.  The absence of good quality data on physical activity 
and measures of cardiorespiratory fitness in these cohorts is noteworthy, as 
these are potential modifiers of the association between liver health and age 
(see Section 1.7.5 below).
Interestingly, in an octogenarian cohort no association between the high 
prevalence of fatty liver and metabolic disease was found 206; suggesting the 
disease phenotype is different for the longer-lived.
1.7.4 Diet
The close association between adiposity and NAFLD, and between excess 
energy intake and adiposity, suggests a clear link between energy intake and 
NAFLD. The rapid response of liver fat to energy restriction described in Section 
1.3.7 and Chapter 2 illustrate the close link between liver fat and energy 
balance. Patients with NAFLD and NASH have been reported as having higher 
energy intakes than healthy controls in some 207, but not all reports 208. Liver fat 
has also been associated with soft drink consumption 209,210, overall fructose 
consumption 211, and overall carbohydrate consumption 212, and inversely 
associated with very long chain n-3 polyunsaturated fatty acid intake 213, and 
low liver and circulating n-3 and n-6 polyunsaturated fatty acids 208. 
Experimental data also suggest a deleterious effect of high saturated fat 
consumption 214. 
Although human studies conflict with respect to the role of fructose in NAFLD, 
the totality of the evidence suggests above average fructose consumption is a 
risk factor for NAFLD in the context of eucaloric and hypercaloric diets 215, and 
reduction of fructose, albeit accompanied by similar reduction in glucose, can 
reduce liver fat with minimal weight reduction 216. The association of saturated 
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fat intake and IHTAG is supported by an intervention reporting higher IHTAG in 
a cohort fed a high saturated fat vs. a high n-6 polyunsaturated fat diet 217. 
Interventions providing an increased intake of n-3 polyunsaturated have also 
reported liver fat reductions 218-220. However, interventions to reduce liver fat 
demonstrate that a broad range of dietary compositions, including very high fat 
low-carbohydrate diets, are effective in the reduction of liver fat provided the 
diet is hypocaloric (see Chapter 2 for detailed discussion of these interventions). 
A comparison of eucaloric, hypercaloric, and hypocaloric diets of different 
carbohydrate and fat contents each consumed for five days, showed dose-
dependent elevation in hepatic de novo lipogenesis following carbohydrate 
surplus and an absence of de novo lipogenesis with carbohydrate restriction 221. 
Caloric surplus from fat had no effect on hepatic de novo lipogenesis. Elevation 
of hepatic de novo lipogenesis after carbohydrate excess was also shown after 
one 222, and four days 222,223. A very low fat high carbohydrate eucaloric diet has 
also been shown to promote whole-body fat synthesis relative to high fat 
moderate carbohydrate diet 224. However, these studies were done in healthy 
and mostly young volunteers given diets only likely to be consumed in a 
research setting, and with no measures of liver fat reported.
Recently, overfeeding with sugar of patients, 56% of whom had NAFLD, was 
shown to result in mean liver increasing from 9.2% to 11.7% (27% relative 
increase) alongside a 2% body weight increase 225. However, a 90% relative 
increase in liver fat has also been achieved with four days of a high fat 
hypercaloric diet 226, but in healthy young males without NAFLD and exact 
mean IHTAG unspecified . This increase was attenuated by doubling the protein 
content of the diet despite a resulting further ~15% increase in energy intake. 
Such a liver fat modifying effect is supported by reports of reduced liver fat 
following whey protein or amino acid supplementation in NASH patients 227, in 
obese women with elevated liver fat 228, and elderly patients 229. It is also 
supported by a fructose overfeeding trial in young healthy males wherein 
supplementation with ~20 g of essential amino acids attenuated the increase in 
IHTAG induced by fructose overfeeding 230. 
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The majority of studies assessing the relationship of NAFLD and NASH, both 
prospectively and retrospectively, have had small sample sizes. Retrospective 
assessment has relied on dietary intake at a single time point. Further, the 
accuracy of even reference standard dietary assessment is recognised as being 
poor 231. Nonetheless, the more tightly controlled studies reviewed above and in 
Chapter 2 demonstrate that macronutrient composition plays a role in liver fat 
accumulation, but one that is not yet clearly defined and is likely to be 
secondary to actual energy balance.
1.7.5 Physical Inactivity and Low Fitness
Physical activity and exercise are inversely and independently correlated with 
direct 232-234, and biomarker indicators of intrahepatic lipid concentrations 234-236. 
In a prospective cohort, total leisure time physical activity and anaerobic/
resistance training physical activity were lower in those going on to develop 
NAFLD 237. There is also an inverse association between liver fat and 
cardiorespiratory fitness 238, i.e. peak oxygen consumption (VO2peak). Indeed, 
NAFLD was found to be ~10-times more prevalent in the lowest relative to the 
highest tertile of cardiorespiratory fitness independent of BMI, though not 
independent of waist circumference 239. In a cohort of over 72000 Korean adults 
exercising regularly, defined as more than three times per week for at least 30 
minutes over the preceding three months, was associated with reduced odds or 
having NAFLD independent of BMI 234. Among the subset of adults with NFALD, 
those exercising regularly had reduced odds of elevated ALT and AST. 
Retrospective analysis of a cohort with NAFLD also showed those meeting US 
guidelines for vigorous exercise to be less likely to have NASH 240. However, no 
such association was shown for moderate-intensity or total exercise. Self-
reported physical activity was lower in patients with NASH than simple steatosis 
208. Further, cardiorespiratory fitness was identified as an independent predictor 
of liver fat reduction in lifestyle therapy 8. 
The corollary to the inverse association of physical activity and fitness with liver 
fat is that the capacity to perform vigorous activity is impaired in NAFLD, 
consistent with disease severity 181. Physical activity interventions indicate a 
causal link between inactivity and NAFLD, and show that those with the 
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condition are able to increase their physical activity 241,242. Exercise only 
interventions can reduce liver fat and improve markers of metabolic risk 
independent of weight reduction 243-245, and also improve markers of autonomic 
function 246 (see Chapter 2 for further discussion).
1.7.6 Ethnicity
As shown in Figure 1.6. above, the ethnic distribution of NAFLD prevalence is 
not uniform. In Texas, hepatic steatosis was more prevalent in hispanics and 
least prevalent in those of African ancestry 156. A higher prevalence among 
hispanics, and lower prevalence among African Americans has also been 
reported in other studies in Texas 183, and California 247. In a US cohort with 
biopsy proven NASH, being hispanic was associated with more inflammation 
but less advanced fibrosis; the latter possibly due to younger age 248. A higher 
prevalence of NAFLD has also been reported in Indian men living in 
Connecticut relative to Caucasians of similar BMI and physical activity 
history125. This effect of ethnicity was confirmed by a multinational study with 
over 4500 male and female patients showing an influence of ethnicity on the 
association of body fat distribution and liver fat 249. This is also consistent with a 
relatively higher cardiometabolic risk at lower BMI in Southeast Asian and 
Indian populations related to a tendency for greater body fat and less favourable 
body fat distribution in these groups at a given BMI 250. There is evidence of 
lifestyle differences contributing to this observed variation in risk and aetiology, 
e.g. hispanics with NASH were younger and reported higher carbohydrate 
intakes and less physical activity than other groups 248. However, to what extent 
differences in lifestyle influence these apparent relationships is not yet firmly 
established. These findings suggest ethnicity is related to the prevalence of 
NAFLD, and may also influence its aetiology.
1.7.7 Genetic Factors
The heritability of hepatic steatosis was estimated to be 0.27 251, and there is 
evidence to indicate the ethnic differences may have a genetic component 252. 
The most consistently identified genetic contributor to NAFLD being the 
PNPLA3 gene 253, which encodes the adipose tissue associated protein 
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adiponutrin 254. The precise function of this protein remains unclear 253, however 
homozygous carriers of the I148M allele of PNPLA3 show markedly higher liver 
fat than non-carriers 252,255. Consistent with the ethnic differences in NAFLD 
prevalence, the I148MM allele was most prevalent in hispanics, whereas a 
protective gene variant – PNPL3-S453I – was most prevalent in African 
Americans 255.
Genetic factors appear not only to contribute to the risk of hepatic steatosis but 
also to its phenotype, progression and comorbidities. Despite achieving similar 
weight reduction following short-term dietary restriction, liver fat reduction was 
approximately halved in patients homozygous for I148M relative to those 
carrying the 148MM allele 256. Further, in patients with the 148II genotype, the 
increase in liver fat following sugar overfeeding was closely associated with 
changes in the fatty acid composition of serum triacylglycerols, whereas no 
such association was observed in patients with the 148MM genotype 225. 
Similarly, the relationship between NAFLD and broader metabolic disfunction, 
notably insulin resistance, was weaker in SNP rs738409 257. The I148M allele is 
associated with an increased risk of NASH development and fibrosis 258-260; this 
may be independent of other metabolic abnormalities 259.
Collectively these findings suggest not only a diverse risk profile based on 
genetic factors, but also the likelihood of relatively low and high responders to 
different interventions intended to reduce liver fat. However, to date study 
cohorts have mostly been small and further work is needed to confirm these 
findings.
1.7.8 Endocrine Abnormalities
In addition to factors listed in Table 1.2, the prevalence of NAFLD is increased 
in people with several metabolic and endocrine dysfunctions, most notably type 
2 diabetes 5; metabolic syndrome 2,121; polycystic ovary syndrome 261; women 
with a history of gestational diabetes 262; clinical and subclinical hypothyroidism 
263,264; and low testosterone in men 265.
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1.8 Progression, Comorbidities and Sequelae of Non-Alcoholic Fatty Liver 
Disease
Simple steatosis can progress to NASH characterised by excess liver fat in the 
presence of inflammation, and subsequently liver fibrosis, cirrhosis, and/or 
hepatocellular carcinoma 1. Reports of progression from simple steatosis to 
NASH have been as high as 37% over 13.7 years 266, but studies to date have 
been very small with samples sizes of 6-170 and follow-up periods of 3-20 
years; 5,267. Given the heterogeneity of patient characteristics involved, much 
larger cohorts are required to obtain a clear picture of quantitative disease 
progression. Progression from simple steatosis to end stage liver disease is 
estimated to be less than 3% 5. 
The largest longitudinal study to date, with a 15 year follow-up, reported 7% of 
deaths attributed directly to liver disease in a NAFLD cohort 268. This study was 
conducted in a general population but did not employ direct measures of 
steatosis or disease stage, instead relying on composite waist circumference, 
plasma GGT and TAG concentrations, and is therefore at high risk of 
misdiagnosis (see Section 1.4.5). Other studies employing more rigorous 
methods of NAFLD assessment, specifically biopsy or imaging, have reported 
broadly similar findings, but have had smaller cohorts, shorter follow-up periods, 
and mostly been in patients drawn from secondary care, and therefore are not 
likely to be fully representative of the broader community 5,269.
Despite relatively low rates of progression to advanced liver disease, non-
hepatic comorbidities are common in cohorts with NAFLD as are deaths 
attributed to cardiovascular disease and non-hepatic cancers 268,270. Thus given 
the high prevalence of NAFLD (see Section 1.5), even the seemingly low rate of 
liver disease progression represents a large clinical burden. However, the 
concern from an individual patient perspective is more likely to be that related to 
the comorbidities and sequelae described below.
1.8.1 Metabolic Syndrome
NAFLD has been described as the hepatic expression of metabolic syndrome 
because it is frequently associated with the same cluster of central obesity, 
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dyslipidaemia, insulin resistance, and hypertension 271. Several groups have 
developed their own set of criteria for diagnosing the metabolic syndrome as 
shown in Table 1.3 272,273. None of these definitions include hepatic steatosis, 
however cross-sectional data indicating that NAFLD is a better predictor of 
insulin resistance, oxidative stress, and endothelial dysfunction than the ATP III 
criteria for metabolic syndrome (Table 1.3), has led some to suggest NAFLD be 
added 2. In practice, this close association of conditions means that most 
patients with NAFLD will need treatment for multiple comorbidities, which in the 
case of components of the metabolic syndrome, are all receptive to lifestyle 
intervention 274-280(discussed in greater detail in Chapter 2 and Chapter 3).
Table 1.3: Criteria for Metabolic Syndrome
WHO (1999)* NCEP ATP III (2001)! Joint (2009)‡
Impaired glucose tolerance or type 
2 diabetes and/or insulin resistance 
combined with two or more of the 
following:
Three or more of the following: Three or more of the following:
Waist–hip ratio (and/or BMI > 30 
kg/m2):
men > 0.9
women > 0.85
Waist circumference:
men > 102 cm
women > 88 cm
Elevated waist circumference 
(population and country 
specific)
Triacylglycerols ≥1.7 mmol/L 
or treatment thereof 
Triacylglycerols ≥1.7 mmol/L Triacylglycerols ≥1.7 mmol/L
or treatment thereof
HDL-cholesterol:
men < 0.9 mmol/L 
women < 1.0 mmol/L 
HDL-cholesterol:
men < 1.03 mmol/L
women < 1.29 mmol/L
HDL-cholesterol:
men ≤ 1.0 mmol/L 
women ≤ 1.3 mmol/L 
or treatment thereof
Blood pressure  ≥ 140/ 90 mm Hg Blood pressure  ≥ 130/ ≥ 85 
mm Hg
Blood pressure  ≥ 130/ ≥ 85 
mm Hg) or anti-hypertensive 
therapy
Fasting glucose ≥ 5.6 mmol/L Fasting glucose ≥ 5.6 mmol/L
or treatment thereof
Elevated fasting glucose 5.6 
mmol/L or treatment thereof
*World Health Organization - definition for elevated fasting glucose was modified in 2001 from 
6.1 to that shown 273
! National Cholesterol Education Program – Third Adult Treatment Panel 281
‡ Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology 
and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World 
Heart Federation; International Atherosclerosis Society; and International Association for the 
Study of Obesity 272
Abbreviations: BMI, body mass index; HDL, high density lipoprotein.
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1.8.2 Type 2 Diabetes
The association between NAFLD and type 2 diabetes appears bidirectional in 
that elevated liver fat is a risk factor for type 2 diabetes and vice versa 282. 
Repeated detection of NAFLD by ultrasound even non-obese and non-diabetic 
men was associated with substantially elevated 5-year odds for the 
development of type 2 diabetes 283. The presence of type 2 diabetes with 
NAFLD increases the risk of NASH 284, as well as hepatic fibrosis, cirrhosis, 
portal hypertension, and hepatocellular carcinoma 285. Whereas, the presence 
of NAFLD alongside impaired glucose tolerance independently (of age, sex, 
BMI, blood lipid profile, and smoking status) predicted development of type 2 
diabetes 282,286. There is a clear inherited component whereby family history of 
type 1 or 2 diabetes predicts NASH and fibrosis even in those without diabetes 
287. Despite findings to date, the mechanisms of the association between 
NAFLD and type 2 diabetes remain to be firmly established and not all 
phenotypic expressions of NAFLD appear causally linked with type 2 diabetes 3.
1.8.3 Cardiovascular Disease
Longitudinal studies indicate cardiovascular complications may account for up 
to 45% of deaths in cohorts with NAFLD 268,269. Given the close association of 
NAFLD with major cardiovascular risk factors such as metabolic syndrome and 
type 2 diabetes, discussed above, this comes as no surprise. However, there is 
evidence to suggest NAFLD may be an independent risk factor for 
cardiovascular disease 4,288. Intima-media thickness was higher in patients with 
ultrasound confirmed NAFLD than controls without signs of hepatic steatosis 
289-292. This was also true for coronary artery calcification 293. Intima-media 
thickness was found to increase with severity of NAFLD 294. Further, left 
ventricular diastolic dysfunction in a cohort with type 2 diabetes was also 
associated with NAFLD 295. These associations between NAFLD and heart 
diseases or markers of heart disease, were independent of traditional risk 
factors including age, sex, BMI, plasma lipid profile, insulin resistance, smoking 
status and blood pressure 291-294. However, disease severity, NASH vs. simple 
steatosis, was not associated with an increased risk of cardiovascular disease 
in another cohort once results were controlled for age, sex, BMI, and the 
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presence of type 2 diabetes 296. These studies suggest that the presence of 
NAFLD increases the risk of cardiovascular disease beyond that explained by 
traditional risk factors. However, the magnitude of this increased risk and the 
exact mediators remain unclear. 
1.8.4 Cancer
Cancer contends with cardiovascular disease as the leading cause of mortality 
in cohorts with NALFD with 28-36% of deaths related to non-liver cancers
204,268,297. Ultrasound detected NAFLD has been identified as an independent (of 
age, sex, BMI, and glucose tolerance) risk factor for colorectal neoplasia 298. 
NAFLD was associated with risk of colorectal adenomas independent of age, 
sex, BMI, blood lipid profile, fasting glucose, and smoking status 299. Patients 
with NAFLD also had more adenomas than controls showing no hepatic 
steatosis on ultrasound 300. However, the presence of NAFLD did not change 
prognosis in patients with colorectal cancers 301. Thus although data on 
mortality clearly show an association between NAFLD and cancer, more work is 
required to define the nature of this relationship.
1.8.5 Kidney Disease
NAFLD was an independent – of age, sex, diabetes duration, BMI, components 
of metabolic syndrome – predictor of chronic kidney disease in patients with 
type 1 302,303, and type 2 diabetes 304, as well as non-diabetic Korean men 305. 
The annual incidence of chronic kidney disease in one cohort of patients with 
NAFLD was 1.2% 306. The research in type 1 and 2 diabetes is restricted to 
cross-sectional analysis of relatively small geographically collocated samples 
302-304. The only prospective study indicated fatty liver only increases risk of 
chronic kidney disease in the presence of elevated serum GGT 305. However, 
this study was restricted to non-diabetic normotensive Korean males. Elevated 
serum GGT was also identified as a predictor of chronic kidney disease 
development in Japanese patients with fatty livers 306. Collectively, these results 
justify further investigation in other ethnically, and geographically diverse 
prospectively assessed cohorts, to confirm the suggested associations. 
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1.8.6 Altered Drug Metabolism
In addition to predicting and potentially being part of the pathology of the 
aforementioned conditions, and altering nutrient metabolism (see Section 1.2), 
non-alcoholic fatty liver has also been shown to affect expression and activity of 
many enzymes central to drug and other xenobiotic metabolism 307-309. Human 
data are limited due to the difficulties in accurately identifying and staging 
NAFLD and obtaining liver samples (see Section 1.4). Nonetheless, there is 
evidence from biopsy samples showing changes in messenger RNA 
expression, protein concentration, and/or in enzymes involved in the 
metabolism of the vast majority of therapeutic drugs including those of the 
cytochrome P450 family, glutathione, and sulfotransferases 307. 
The direction of change is not universal with some enzymes showing increased 
and others decreased activity 310, which would be expected to increase and 
decrease drug clearance rate, respectively. The degree of change tends to 
increase with disease progression 310. Although not confirmed, several 
mechanisms have been suggested for these changes; notably NAFLD 
associated changes in inflammatory mediators, nonesterified fatty acids, and 
oxidative stress 307. The clinical implications of these changes remain unclear 
but are noteworthy as direct assessment of hepatic steatosis is not a routine 
practice in drug trials.
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1.9 Summary
NAFLD encompasses a diverse spectrum of liver conditions ranging from 
simple steatosis, through steatohepatitis, fibrosis, cirrhosis, and hepatocellular 
carcinoma. A diagnosis of NAFLD requires alcohol, hepatotoxic drugs, hepatic 
viral infection, and other common hepatic morbidities have been ruled out. 
Nonetheless, NAFLD remains a broad term encompassing a range of 
phenotypes and genotypes, which require further characterisation. 
Defined on the basis of hepatic steatosis, NAFLD affects 20-40% of the general 
population. The prevalence is higher among certain ethnic groups, the obese, 
and those with type 2 diabetes. There is a close association between NAFLD 
and the components of the metabolic syndrome, type 2 diabetes, and 
cardiovascular disease. Emerging evidence also suggests an independent 
association of NAFLD with kidney disease as well as some non-hepatic 
cancers, most notably of colon.
Altered nutrient and drug metabolism are hallmarks of NAFLD. Most notably 
hepatic lipid and glucose production are markedly increased. Correction of 
these metabolic derangements are recognised targets for treatment. Modifiable 
risk factors for NAFLD include insulin resistance, adiposity, sedentariness, and 
hypercaloric diets. Modification of these risk factors using diet and physical 
activity interventions is the currently recommended treatment approach as well 
as the focus of this thesis.
The rest of this thesis comprises of five more chapters and a set of electronic 
appendices provided on an accompanying CD.
Chapter 2 is a systematic review of interventions in NAFLD cohorts that have 
employed nutrition, physical activity, exercise, or a combination thereof. 
Chapter 3 is an assessment of the safety, tolerability, and efficacy of high 
intensity intermittent training in healthy and clinical populations sharing 
characteristics with NAFLD patients.
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Chapter 4 provides the methods and results of a cross-sectional analysis 
examining the associations of age and physical activity with cardiorespiratory 
fitness, glucose control, insulin sensitivity, body composition, and intrahepatic 
lipid concentration.
Chapter 5 provides the methods and results of parallel design randomised 
controlled trial assessing the effect of high intensity intermittent training on 
glucose control, intrahepatic lipid concentration, and body composition in an 
adult population with clinically defined NAFLD.
Chapter 6 provides a discussion of the broader findings of this thesis, and 
implications of those findings.
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Chapter 2. Systematic Review of Lifestyle Interventions for the 
Treatment of Non-alcoholic Fatty Liver Disease in Adults
2.1 Introduction
Given the common risk factors and comorbidities, and in the absence of 
approved pharmacotherapy, lifestyle modifications with the aim of weight 
reduction and increased physical activity are the recommended treatment for 
NAFLD 14,311. However, until recently, the evidence base for this 
recommendation had not been systematically reviewed. The following section is 
a systematic review of lifestyle interventions for the treatment of NAFLD. The 
review was published in the Journal of Hepatology 15, and updated in February 
2012 for this thesis. The following sections define, in adults, the:
1. Efficacy of different lifestyle interventions in reducing IHTAG and/or 
liver aminotransferases;
2. Effect of lifestyle interventions on histological parameters; and
3. The efficacy of different lifestyle interventions on glucose control/
insulin sensitivity.
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2.2 Methods
2.2.1 Eligibility Criteria
The review is restricted to published prospective interventions reporting the 
effects of lifestyle modification on IHTAG, liver enzymes, and/or insulin 
sensitivity in adults (≥19 years) with NAFLD, including non-alcoholic 
steatohepatitis (NASH) but not late stage liver diseases i.e. cirrhosis or 
hepatocellular carcinoma. Eligible publications included: randomised controlled 
trials or specific arms thereof, and non-randomised interventions. Only full 
reports were considered to provide sufficient information to allow critical 
evaluation. 
No specific criteria defining NAFLD were set as the methods of diagnosis and 
cut-offs vary between studies. It was considered sufficient for reports to provide 
their own diagnostic criteria based on one or more of the following in order of 
preference: 1) histological examination of biopsies; 2) proton-magnetic 
resonance spectroscopy (1H-MRS); 3) computed tomography (CT); 4) 
ultrasound; and/or 5) blood concentrations of alanine aminotransferase (ALT) 
and/or aspartate aminotransferase (AST). 
Lifestyle modification could include general recommendations or specific diet, 
physical activity, and/or exercise prescription. Studies or study arms designed to 
test pharmaceuticals, dietary supplements, or herbal preparations were 
excluded. Study arms in which pharmaceutical agents were used as part of 
standard treatment and where participants were receiving these prior to the 
study, without a reported increase in dose during the study, were eligible for 
inclusion.
The primary outcomes of interest were changes in IHTAG assessed by liver 
biopsy, 1H-MRS, CT, or ultrasound, and histological indicators of inflammation 
and fibrosis. Blood ALT and/or AST concentrations were also considered. The 
secondary outcome was glucose tolerance and/or insulin sensitivity as 
assessed directly by insulin clamp techniques, oral glucose tolerance tests, or 
inferred by validated formulae.
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Only studies that clearly described or appropriately referenced their 
intervention, and that provided some direct indicators of protocol adherence or 
those conducted under very close supervision, e.g. inpatient protocol delivery, 
were eligible for inclusion. 
2.2.2 Search Strategy and Study Selection
The following databases were searched: Medline (Pubmed), Scopus, and the 
Cochrane Controlled Trials Register. The last search of all three databases was 
done on June 26, 2010. However, automatic updates of the Scopus search 
were reviewed up to October 18, 2010. A medical librarian assisted with the 
selection of the search strategies. Further searches were conducted in February 
2012 to update this chapter. 
The selected search terms and related MESH headings were: (NAFLD or "non-
alcoholic fatty liver" or "nonalcoholic fatty liver" or "non-alcoholic steatohepatitis" 
or "nonalcoholic steatohepatitis" or "non-alcoholic steatosis" or "nonalcoholic 
steatosis" or "non-alcoholic liver steatosis" or "nonalcoholic liver steatosis" or 
"non-alcoholic hepatic steatosis" or “nonalcoholic hepatic steatosis”) AND 
(lifestyle or exercise or "diet*" or diet or training or behaviour or behavior or 
nutrition or sport or "physical activity" or "weight reduction" or "weight loss" or 
"energy restriction"). These were restricted to title, abstract, and keyword 
(Scopus only). The database permitting, the following were excluded: reviews; 
letters; editorials; commentaries; animal studies; and studies in those aged 
under 19 years. Review of articles was restricted to those published in English.
Titles and abstracts of studies identified were evaluated against eligibility 
criteria. Studies appearing eligible based on their abstract were read in full. 
2.2.3 Data Items
The items of interest from each report included: study type/design; diagnostic 
criteria for NAFLD; inclusion and exclusion criteria; blinding; similarity of groups 
at baseline; sex; age; definition of participant adherence; treatment protocol, 
including professions involved and contact time; reported adherence; criteria for 
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dealing with medication; methods used to assess diet and physical activity; loss 
to follow-up; analysis, i.e. intention-to-treat vs. per-protocol; IHTAG; measures 
of glucose control/insulin sensitivity; ALT and/or AST concentration.
2.2.4 Data Extraction
Relevant data from included reports were recorded in itemised tables. Results 
were converted to SI units or otherwise standardised, and changes from 
baseline converted to percentages to facilitate comparison across studies. 
Where liver fat is given as a percentage, a change from 10% fat to 5% fat is 
referred to as an absolute reduction of 5% (10%-5%) and a relative reduction of 
50%. 
Multiple publications from the same study were identified by comparing author 
names, sample sizes, and intervention protocols. Where papers noted that 
other reports of the study existed, these were also obtained to allow consistency 
between different reports to be assessed and/or missing data to be obtained.
2.2.5 Risk of Intra- and Inter-Study Reporting and Publication Bias
Included studies were compared to their published protocols when available to 
identify omissions of outcome data. Alternatively, the methods section of each 
report was compared to the results section to assess reporting bias. The 
International Clinical Trials Registry, EU Clinical Trial Register, and 
metaRegister of Controlled Trials were searched using the key words fatty liver 
and steatohepatitis to identify trials described as completed. Studies registered 
prior to 2009 with records not updated in the past 12 months were assumed to 
be completed. A literature search using the relevant principal investigator was 
conducted to identify publications resulting from relevant registered trials.
2.2.6 Description and Critique of Primary Outcome
A description and critique of methods used in the analysis of hepatic steatosis is 
provided in Section 1.4 of this thesis.
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2.3 Results
A flow diagram of study selection consistent with Preferred Reporting Items for 
Systematic Reviews  is provided in Figure 2.1 312.
Figure 2.1: Diagram of Study Selection. NB: one dataset was analysed in 
multiple ways published in two papers but is counted as one study.
2.3.1 General Limitations of Studies Reviewed
Specific details about individual studies reviewed can be found in Tables 
2.1-2.4. There was considerable heterogeneity of assessment methods used, 
diagnostic criteria for NAFLD applied, and the detail with which exclusion 
criteria were reported. With one exception, studies employing 1H-MRS either did 
not report a minimum IHTAG or report including participants <5%. Those 
employing histological examination of biopsies applied cutoffs, but used 
Database search: 
n = 514
Once duplicates removed: 
n = 455
Records screened: 
n = 455
Full text assessed: 
n = 72
Studies included: 
n = 31
Additional records: 
n = 5
Records excluded
n = 383
Excluded: 
2 case reports
1 retrospective study
6 not fatty liver cohorts
31 insufficient detail of 
intervention and/or adherence
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different scoring systems. Eligibility based on history of alcohol consumption 
varied between no alcohol intake and 560 g/week, and assessment methods 
were seldom cited. Although most studies noted excluding participants with 
other liver conditions, including potential drug induced steatosis, few provided 
comprehensive criteria, e.g. of drugs deemed steatogenic, or details of the 
relevant analytical methods employed. 
Monitoring of adherence to diet or exercise was often limited. No studies 
reported using objective measures of physical activity such as accelerometers, 
instead questionnaires were used. Dietary assessment methods were not 
reported in sufficient detail to assess likely accuracy and, except for β-
hydroxybutyrate in ketogenic diets, no biomarkers of adherence were reported. 
The greater the complexity of interventions, the less precisely the actions of 
participants tended to be reported. Interventions involving diet, exercise, and 
behaviour change methods were reported with a focus on outcomes, and 
limited information on diet and physical activity adherence or how behaviour 
change methods were applied. None of the reviewed papers reported an 
assessment of which particular behaviour change techniques accounted for the 
changes reported.
Studies did not report allocation concealment during data analysis except for 
blinding during the analysis of liver biopsy samples. Some studies doing per 
protocol analysis did not provide baseline data for the specific group in the final 
analysis. Most studies did not have a control group; those that did, provided this 
group with some form of limited intervention. 
2.3.2 Study Findings 
The studies identified fell into four broad categories: those involving only dietary 
intervention; exercise only interventions; and combined interventions with either 
broad physical activity recommendations; or specific exercise prescriptions. A 
further subcategory would have been those employing one or more formal 
models of behaviour change. However, to-date, no study has published 
sufficient data to critically evaluate the application of different theories, or 
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determine which aspects of each theory are most closely associated with 
particular disease outcome measures or biomarkers.
2.3.2.1 Diet Only Interventions
Fourteen studies, summarised in Table 2.1, lasting 2-26 weeks and including 
428 participants (approximately ⅔ women) that described diet only interventions 
were identified: 10 using low-to-moderate fat (≥30% of energy) with moderate-
to-high carbohydrate (≤50% of energy) energy restricted diets 171,173,313-319, one 
of which also specifically restricted iron intake 314; four interventions assessed 
low carbohydrate ketogenic diets 171,173,320,321; and four high protein (≥25% of 
energy) diets 173,318,322,323. Two studies employed biopsies 314,320, but only one at 
follow-up 320, the other study used ALT and AST at follow-up 314; seven used 1H-
MRS 171,173,315,317-319,322, two used CT 313,321, three studies relied on ALT and 
AST 316,323,324. Only two studies had a no-intervention/standard care control 
group 313,314; however in one the control group were those with low adherence 
to the intervention protocol 313.  
Three studies compared hypocaloric diets focusing on fat vs. carbohydrate 
reduction 171,173,319. Carbohydrate restriction to 10% of energy in a diet with a 
1000 kcal/day deficit led to a much greater mean reduction in IHTAG than an 
isocaloric 65% carbohydrate diet within 48 hours (approximately 30% vs. 10%) 
171. Greater mean reductions in IHTAG (55% vs. 26%) were also reported after 
two weeks of low carbohydrate (8% of energy) vs. moderate carbohydrate and 
fat diet (50% and 34% of energy, respectively) 173. However, after several weeks 
and with similar weight reductions in low carbohydrate and low-to-moderate fat, 
IHTAG reductions were similar 171,319.
Interventions lasted 2 weeks to 6 months and achieved mean bodyweight 
reductions of 4-14%. All studies using biopsy or imaging techniques to estimate 
IHTAG reported reductions. The seven studies using 1H-MRS reported absolute 
reductions of 4 -12%, and relative reductions of 26 - 81%. The only study to do 
a post intervention biopsy (n = 5) reported reduced inflammation and a trend 
toward reduced fibrosis (p =0 .07), as well as the reduction in steatosis, 
following a ketogenic diet and a mean weight reduction of 14% 320. Five out of 
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seven studies reporting liver enzymes showed reductions, and one showed no 
change. The study that found an increase in ALT and AST, but only in women, 
suggested this might have been due to the analysis being done before weight 
had stabilised 323. Five of six studies reporting glucose control/insulin sensitivity 
noted improvements.
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Table 2.1: Diet Only Interventions
Reference  
& Design
n (M/F) Clinical 
Group
Age 
(years)
BMI (kg/
m2)
Intervention Length 
(weeks)
Outcome Measures & 
Adherence
Results
(171) RT
11(n/r) NAFLD 45±4 37±1
High CHO: (65% CHO 20% fat, 
15% PRO): 1000 kcal/d below 
estimated (RMR x 1.3) until 7% 
BW reduction achieved at wk 
6.2±1.0, then E adjusted to 
maintain BW until week 11
11
IHTAG (1H-MRS), E-HC: 
HISI, GRa, HOMA 
Food provided by metabolic 
kitchen. Plasma 3-
hydroxybutyrate indicated 
good adherence to low CHO 
diet 
Relative to baseline: 
At 48 h (BW ↓1.6%): IHTAG ↓~10%, HOMA 
↓24±6%, HISI ↑~35%, GRa ↓~7%. 
At 11 wk  (BW -7.3%): IHTAG ↓~42%, HOMA 
↓27.1±5.1%, HISI ↑~28%, GRa ↓~7%.
11(n/r) NAFLD 42±3 36±1
Low CHO: (10% CHO, 75% fat, 
15% PRO): 1000 kcal/d below 
estimated (RMR x 1.3) until 7% 
BW reduction achieved at wk 
5.9±1.0, then E adjusted to 
maintain BW until wk 11
11
Relative to baseline: 
At 48 h (BW ↓2.2%): IHTAG ↓~30%, HOMA 
↓40%, HISI ↑~140%, GRa ↓23%. IHTAG, HISI, 
HOMA, GRa were all significantly different 
between groups. 
At 11 wk (BW -7.6%): IHTAG ↓~38%, HOMA 
↓44%, HISI↑~115%, GRa ↓~20%.
IMGU was reported for both groups combined: no 
change after 48 hrs, ↑~30% after 11 weeks. 
(320) Pilot 5(2/3) NAFLD 35.6 102±12 kg
Ketogenic diet: <20 g CHO/d, 
unlimited meat/fish/poultry, 
unlimited eggs, 2 cups/d ʻsaladʼ 
vegetables, 133 g cheese, 1 
cup/d low-CHO vegetables.
24
Histopathology, ALT, AST
Diet records & urinary 
ketones indicated good 
compliance in 4 participants. 
No change in non-compliant 
participant. Actual intake n/r.
BW ↓14% 
Adherent (n=4): steatosis, necroinflammation & 
centrilobular fibrosis ↓1-2 categories (e.g. 
moderate to mild or none), ALT ↓44%, AST n.s.
Non-adherent (n=1): steatosis ↑ from mild to 
moderate, ALT ↓20%, AST ↓21%.  
(322) UCT 34(10/24) NAFLD (~50%) n/r 31±1
6 wk of 550 kcal/d diet from 
ready made product (50% CHO, 
7% fat, 43% PRO), then 1 wk 
eucaloric diet before final 
assessments.
7
IHTAG (1H-MRS), EGP 
(euglycaemic clamp with 
radiolabelled glucose), 
HbA1c
BW ↓11%
IHTAG ↓60%, IS ↑32%, EGP ↓34%, HbA1c 
↓3.6%.
Reference  
& Design
n (M/F) Clinical 
Group
Age 
(years)
BMI (kg/
m2)
Intervention Length 
(weeks)
Outcome Measures & 
Adherence
Results
(315) UCT 8(5/3) T2D 47±3 30±1
Liquid formula low fat diet (50% 
CHO, 3% fat, 43% PRO) + 12 g 
dietary fibre + raw fruit & 
vegetables to ~ 1200 kcal/d. Diet 
continued until normoglycaemia,  
then 4 wk maintenance: 35 kcal/
kg/d (60% CHO, 20% fat, 20% 
PRO)
7-12
IHTAG (1H-MRS), E-HC: 
HISI, GRa, IMGU, IMSGP, 
HOMA 
Weekly checkup visits 
including weigh ins & 
provision of food during 
study. 
BW ↓8%
IHTAG ↓81±4% (to 2.2±0.8%), GRa ↓~18%, 
IMGU n.s., IMSGP ↑221% (to 93±5%)
(321) UCT 14(5/9)
Pre- 
bariatric 
surgery
24-45 46(40-57)
CHO restriction to 30 g/d but no 
other restriction under weekly 
supervision of a dietician + 
resources on the CHO content 
of vegetables & dairy foods
4
CT: liver:spleen ratio & liver 
volume; ALT, AST & fasting 
glucose.
Daily food dairy indicated: 
1520±285 kcal/d (1109-1922 
kcal/d) (14% CHO, 56% fat, 
29%). 
BW ↓3.7%.
Liver:spleen ↑16% (p=0.06); liver volume ↓8.2% 
(223 mL); ALT, AST, & glucose n.s.
(313) UCT
17(6/9) NAFLD 47±3 33±1
Adherent: dietary deficit of 
500-1000 kcal/d (55% CHO, 
30% fat, 15% PRO) (weight 
↓≥5%) 
26
Liver density (CT); ALT, AST, 
HOMA.
Food dairy reported ↓641 
cal/day  (47% CHO, 33% 
fat, 20% PRO)
Change relative to baseline: BW ↓9.4
Adherent: ALT ↓28%, AST n.s., liver density 
↑15%, HOMA ↓42%.
14(7/7) NAFLD 47±3 35±2 Non-adherent as above but BW↓<5%)
Liver density (CT); ALT, AST, 
HOMA. 
Food dairy reported ↓479 
kcal/d (48% CHO, 31% fat, 
21% PRO)  
Change relative to baseline: BW ↓1.8% 
ALT, AST, liver density & HOMA n.s
Reference  
& Design
n (M/F) Clinical 
Group
Age 
(years)
BMI (kg/
m2)
Intervention Length 
(weeks)
Outcome Measures & 
Adherence
Results
(314) RCT
12(n/r) 9 NASH 3 NAFLD!
58±3 26±1
Diet: 30 kcal/kg BW/d (20% fat, 
1.1-1.2 g PRO/kg BW/d, iron <6 
g/kg BW/d) 
26
ALT & AST.
3-d diet records:
At 3 months: 30 kcal/kg BW/
d (20% fat, 6.1 g iron/kg 
BW/d, 1.3 g PRO/kg BW/d), 
serum ferritin ↓42%.
At 6 months: 25 kcal/kg BW/
d (20% fat, 5.3 iron/kg BW/
d,1.2 g PRO/kg BW/d), 
serum ferritin ↓54%.
Relative to baseline:
3 months: BW ↓3.2%, ALT ↓45% & AST ↓34%.
 6 months: BW ↓4.8, ALT ↓60%, AST ↓52%.
6(n/r) 2 NASH4 NAFLD! Control: no intervention 26 n/r at 6 months: BW n/r) ALT & AST n.s.
(323) UCT 147 (33/104)
Obese + 
elevated 
ALT
44 
20-69 38±0
Diet: 800 kcal/d soy-based meal 
replacement (38% CHO, 17% 
fat, 45% PRO)
8 ALT & AST
BW ↓11%
Men: ALT ↓21%, AST ↓13%
Women: ALT ↑52%, AST ↑32%
(324) UCT 30(8/22)
Obese + 
elevated 
ALT
44±3 37±1 Diet: 1520 kcal/d (52% CHO, 25% fat, 23% PRO) 12
ALT, AST, HOMA
Diet (3-d diet records): 
1509±373 kcal/d (40% CHO, 
39% fat, 21% PRO) 
BW ↓4.6% 
ALT ↓28%, AST ↓48%, HOMA ↓39
(316) UCT 14(7/7) NAFLD by US 45±1 28±0
Diet: 25 kcal/kg of ideal BW (1.3 
g PRO/kg; 20.8% energy, 0.7 g 
of fat/kg; 25% E, 3.4 g of CHO/
kg; 54.2% E, PUFA:SAFA ratio 
1.0–1.5; n-6:n-3 PUFA ratio 3.0–
3.5) rich in fish & vegetables & 
low in meat.
24
ALT & AST
(3-d diet records): 28.6 kcal/
kg ideal BW/d (56% CHO, 
28% fat, 17% PRO), 
PUFA:SAFA 0.8:1, n-6:n-3 
2.4:1.
BMI ↓3.6%, ALT ↓52%, AST ↓42%
Reference  
& Design
n (M/F) Clinical 
Group
Age 
(years)
BMI (kg/
m2)
Intervention Length 
(weeks)
Outcome Measures & 
Adherence
Results
(173) RCT‡
9(3/6) NAFLD 47±12 34±9
Low E:1200 kcal/d for women, 
1500 kcal/d for men; prepared 
by metabolic kitchen based on 
individual food records
2
IHTAG (1H-MRS), ALT, AST, 
fasting glucose
Diet (7-d diet record): 1325 
kcla/d (50% CHO, 34% fat, 
16% PRO).
BW ↓4.2%
IHTAG ↓26% (less than low CHO group), AST 
↓73%, ALT n.s., fasting glucose n.s.
9(2/7) NAFLD 42±11 36±4
Low CHO: target >20 g CHO/
day; 7 d self-administered + 7 d 
prepared by metabolic kitchen 2
IHTAG (1H-MRS), ALT, AST, 
fasting glucose
Diet (7-d diet record): 1553 
kcal/d (8% CHO, fat 59%, 
33% PRO).
BW ↓5.2%
IHTAG ↓55% (greater than in low E group), AST 
↓66% (n.s. relative to low E group), ALT n.s., 
fasting glucose n.s.
(317) UCT 25(15/10) 21 NAFLD 57±8 33±4
Diet: 597 kcal/d below 
maintenance & defined as low 
fat but no % was specified.
16+6*
IHTAG (1H-MRS), HOMA
Diet (2 x 24 hr record): 1405 
kcal/d (50% CHO,  26% fat, 
21% PRO).
BW ↓6% 
IHTAG ↓29%
HOMA ↓16%
(318) UCT 15(0/15)
Pre- 
bariatric 
surgery
34±8 43±3
Diet: 800-1100 kcal/d from 
Modifast® (45% CHO, 15% fat, 
40% PRO). 4
IHTAG (1H-MRS)
Diet: food provided as liquid 
supplement - Modifast® 
BW ↓6% 
IHTAG ↓42%
(319) RCT
20(15/5) NAFLD 45±8 36±5
Low CHO: baseline E intake 
-30% (minimum 1200 kcal/d): 
≤90 g CHO/d; 0.8 g PRO/kg/d; 
≥30% fat
26
IHTAG (1H-MRS)
Bimonthly 7-day food 
record: E & CHO ↓n.r. 
(graphic data) relative to 
baseline & Low Fat
BW ↓8% 
IHTAG ↓50%
27(8/19) NAFLD 46±9 34±4
Low Fat: baseline E intake 
-30% (minimum 1200 kcal/d): 
≤20% fat, 0.8 g PRO
26
IHTAG (1H-MRS)
Bimonthly 7-day food 
record: E & Fat ↓n.r. (graph 
data)
BW ↓7% 
IHTAG ↓44%
Data are mean ± standard errors usually rounded to the nearest full number; changes reported were statistically significant p <0.05 unless noted otherwise. Sample 
size based reflects those in the final analysis. Abbreviations: ALT - alanine aminotransferase; AST - aspartate aminotransferase; BMI - body max index (kg/m2); BW - 
bodyweight; d - day(s); CHO - carbohydrate; CT – computed tomography; d - day(s); E - energy; EGP- endogenous glucose production; E-HC - euglycaemic-
hyperinsulinaemic clamp; GRa - glucose rate of appearance; h - hour(s); HbA1c – glycated haemoglobin; HISI - hepatic insulin sensitivity index; HOMA - homeostasis 
model assessment; IHTAG - intrahepatic triacyglycerol concentration; IMSGP - insulin mediated suppression of glucose production; IMGU - insulin mediated glucose 
uptake; IS - whole body insulin sensitivity; ITT – intention to treat analysis; LBM - lean body mass; MUFA - monounsaturated fatty acid; n - sample size of cohort in 
final statistical analysis; NAFLD - non-alcoholic fatty liver disease; NASH - non-alcoholic steatohepatitis; n/r, data not reported; n.s. – result not statistically 
significant; PP – per protocol analysis; PRO - protein; PUFA - polyunsaturated fatty acid; RCT – randomised controlled trial; RT – randomised trial with no control; 
RMR - resting metabolic rate; SAFA - saturated fatty acid; UCT – uncontrolled trial; US – ultrasound; w – week(s).
! Diagnoses by histopathology at baseline only, no repeat biopsies on completion of the intervention.
‡ Semi-randomised to achieve baseline characteristic equivalence between groups, specific measures matched were not reported.
* Weight reduction followed by maintenance.
2.3.2.2 Exercise Only Interventions
Five studies, summarised in Table 2.2, lasting 4-16 weeks and including 107 
participants (approximately 50% women) assessed exercise only interventions. 
Three studies tested moderate intensity continuous aerobic exercise such as 
walking, running, stationary cycling, and rhythmic movement for 30-60 minutes 
per session three 244, five 245, and four to six times per week 325. One study used 
a circuit resistance training programme covering all major muscle groups and 
performed three days per week for eight weeks 243. One study employed 
electrical stimulation to create resistance during knee flexion and extension 
twice a week 326.
Moderate intensity aerobic activity resulted in mean relative 1H-MRS-measured 
IHTAG reductions of 10-21% 244,245, and 47% and 48% reductions in ALT and 
AST, respectively 325. Circuit resistance training, also assessed by 1H-MRS, 
gave a mean relative reduction of 13% 243. The effect of electrical stimulation 
exercise was assessed by biopsy, and a reduction in steatosis reported 326. 
These results were achieved despite no significant reduction in body weight in 
exercising groups.
The shorter, 4 week, aerobic intervention reported no change in homeostatic 
model of insulin resistance (HOMA-IR) 244. However, electrical stimulation 
exercise reduced HOMA-IR by 54% after 12 weeks. Circuit resistance training 
reduced area under the glucose curve of a two-hour frequently sampled oral 
glucose tolerance test and HOMA-IR by 12% and 22%, respectively 243. The 
other two studies did not report measures of glucose control/insulin resistance.
It is noteworthy that the electrical stimulation exercise group was drawn from a 
population that had previously been given lifestyle intervention counselling, but 
with minimal change to disease biomarkers 326. It is feasible therefore that the 
exercise intervention may have motivated participants to change their lifestyle 
more in line with previous advice thereby exaggerating the apparent effect of 
the intervention.
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 Table 2.2: Exercise Only Interventions
Reference  
& Design
Sample 
(M/F)
Clinical 
Group
Age 
(years)
BMI 
(kg/m2)
Intervention Length 
(weeks)
Outcome Measures 
& Adherence
Results
(244) RCT
12(n/r) NAFLD 47±4 31±1
Aerobic: 3 supervised cycle 
ergometer sessions per wk x 4 wk. 
Weekly progression of VO2peak: 50%, 
60%, 70% (wk 3 & 4) for 2-3 bouts of  
15 min with 5 min rest between. 
4
IHTAG (1H-MRS), 
ALT, HOMA.
Participants attended 
all 12 sessions.
HTAG ↓21% in intervention group (8.55% to 
6.79%); no change in ALT.
No change in HOMA-IR, fasting glucose, or 
insulin within or between groups.
7(n/r) NAFLD 49±2 32±2 CON: 3 home-based whole body stretching sessions/wk. 4
IHTAG (1H-MRS), 
ALT, HOMA. IHTAG, ALT, and HOMA n.s.
(325) UCT 16(n/r) Elevated ALT ~37! 23±0
Aerobic exercise: 45 min/6 d/wk 
with 60-70% estimated HRmax 
maintained for 20 min/session. 
Exercise options included walking, 
jogging, and rhythmic aerobic 
exercises.
12
ALT & AST
From baseline: ALT ↓47%, AST ↓48%.
(243) RCT
11(9/2) NAFLD 52±13 32±5
Resistance training: 3 session per 
wk: 8 exercises covering all major 
muscle groups done in a circuit for 
2-3 sets with repetitions increasing 
from 8-12 over the course of each 
week.
8
IHTAG (1H-MRS)
fsOGTT AUC
IHTAG ↓13% (greater change than CON)
fsOGTT AUC ↓12% (greater change than 
CON)
8(6/3) NAFLD 62±7 32±5
CON: no intervention, participants 
advised to keep their current diet and 
physical activity.
8 IHTAG (
1H-MRS)
fsOGTT AUC
IHTAG n.s.
fsOGTT AUC ↑12% relative to baseline & 
↑24% relative to exercise group
Reference  
& Design
Sample 
(M/F)
Clinical 
Group
Age 
(years)
BMI 
(kg/m2)
Intervention Length 
(weeks)
Outcome Measures 
& Adherence
Results
(326) 
RCT‡
12(5/7) NAFLD 55±4 28±1
Hybrid training: 2 sessions per 
week in which antagonist muscle 
contraction was increased by 
electrical stimulation during knee 
flexion & extension.
12
Steatosis grade (US)
ALT, AST, HOMA
Full attendance of 
sessions
Steatosis grade ↓ relative to baseline & CON.
ALT ↓22% (greater change than in CON), 
AST n.s.
HOMA ↓54% (greater change than in CON)
23(14/9) NAFLD 52±4 27±1
CON: no intervention, however all 
participants had been previously 
given lifestyle advice but without 
positive change in biomarkers.
12
Steatosis grade (US)
ALT, AST 
HOMA
Steatosis grade, ALT, AST, and HOMA n.s.
(245) RCT
12(4/8) NAFLD 49±2 37±1
Aerobic exercise: 30-60 min 
moderate intensity continuous 
aerobic exercise 5/w
16
IHTAG (1H-MRS)
ALT
Completers did 94% 
of prescribed exercise
IHTAG ↓10% (relative to CON)
ALT ↓13% (relative to CON)
6(1/5) NAFLD 48±3 40±2 CON: continuation with prior physical activity and dietary habits. 16
IHTAG (1H-MRS)
ALT
IHTAG n.s.
ALT n.s
Data are mean ± standard errors; changes were statistically significant p <0.05 unless noted otherwise; Abbreviations: 1H-MRS – proton energy magnetic resonance 
spectroscopy; ALT - alanine aminotransferase; AST - aspartate aminotransferase; BMI - body max index (kg/m2); BW - bodyweight; d - day(s); CON - control group; 
F, females; fsOGTT AUC - area under the glucose curve from a frequently sampled oral glucose tolerance test; HOMA - homeostasis model assessment insulin resistance; 
IHTAG - intrahepatic triacylglycerol concentration; M, males; min - minute; n/r – not reported; non-RCT - non-randomised but with a control group; n.s. - not 
statistically significant change; PP – per protocol analysis; UCT – uncontrolled trial; US - ultrasound; VO2peak – peak oxygen consumption ml/min/kg; wk - week(s).
! Age was only reported for the combined study groups - see Table 4 for other study group.
‡ Treatment allocation by geographic location.
2.3.2.3 Diet Combined with Physical Activity and/or Exercise Advice
Seven studies involving 434 participants (approximately 50% women; 98 
controls) employed a selection of behaviour change methods to decrease 
energy intake and increase physical activity/exercise over 3-12 months 
8,241,242,327-331. These studies provided general physical activity guidelines, but 
did not prescribe specific exercise protocols. Key study details are summarised 
in Table 2.3. The focus was predominantly on body weight reduction and 
maintenance with mean reductions of 2.2-8.8%. Only two studies reported an 
objective measure of physical activity adherence, specifically changes in 
cardiorespiratory fitness 8,241,242. One reported energy intake 241, another stated 
target energy intakes were achieved but did not report any details 8, and one 
reported energy intake reductions but not macronutrient composition 331. Six of 
seven reported reductions in IHTAG and/or circulating liver enzyme in the 
intervention groups, with absolute mean reductions in IHTAG, measured by 1H-
MRS, of 2-4.6% 8,328. Relative mean reductions assessed by biopsy 327, CT 
329,330, or 1H-MRS were 13-51% 8,328. Six of the seven studies reported 
improvements in glucose control//insulin sensitivity 8,241,242,328-330.
Promrat et al. assessed histopathology and reported significant (p ≤ 0.05) 
reductions in overall NAFLD histological activity score (NAS) and steatosis. But 
reductions in parenchymal inflammation and ballooning injury were not 
significant, and there was no mean change in fibrosis in the intervention relative 
to the control group or baseline 327. Huang et al. also assessed histopathology, 
but reported only a trend in reductions in hepatitis score (p = 0.06) 331.
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Table 2.3: Interventions Combining Diet and Broad Physical Activity/Exercise Advice
Reference 
& Design
Sample 
(M/F)
Clinical 
Group
Age 
(years)
BMI (kg/
m2)
Intervention Length 
(weeks)
Outcome Measures & 
Adherence
Results
(327) RCT
21(14/7) NASH 49±2 34±1
LI: weekly sessions for 6 months then 
biweekly covering: diet (1000-1200 kcal 
for <91 kg BW & 1200-1500 kcal for >91 
kg with 25% E from fat), PA & exercise 
(progress to 200 min/w mod intensity) & 
behaviour modification (stimulus control, 
problem solving & relapse prevention). 
Goals: 7-10% weight reduction in 6 
months then maintenance.  
48
Histopathology (NAS), 
ALT, AST, HOMA, 
HbA1c
(Actual diet & PA 
achieved was not 
reported)
LI relative to CON: 
BW ↓8.8%
NASH score ↓26%, steatosis ↓42%; n.s. 
change in inflammation, ballooning, fibrosis.
ALT -39%; n.s. change in   AST, HOMA & 
HbA1c.
LI relative to baseline:
NASH score ↓55%, steatosis score ↓58%; n.s. 
change in inflammation, ballooning, fibrosis.
ALT ↓50%; n.s. change in AST, HOMA & 
HbA1c. 
10(8/2) NASH 48±4 34±2
CON: education session on NASH, 
healthy eating, PA & weight 
management every 12 wk, but without 
behaviour change skills training.
48
Histopathology (NAS), 
ALT, AST, HOMA, 
HbA1c
(Actual diet & PA 
achieved was not 
reported)
(331) Pilot 16(8/8) NASH 50±3 34±1
Weekly (8 wks), biweekly (month 3-6), 
then monthly visits with dietitian: E 
restriction n/r (40-45% CHO, 35-40% 
fat, 15-20% PRO). Weight loss target of 
400-800 g/w. Advice to increase PA; 
frequency & duration n/r.
48
Histopathology 
(Modified Brunt), ALT, 
AST, HOMA.
E intake ↓195 kcal/d 
from baseline (food 
dairy); specific 
composition n/r. PA ↑ 
in those with improved 
NASH Score.
BW ↓3.3%
NASH score ↓32% (p=0.06) & ↓47% HOMA 
p=0.06); steatosis, fibrosis, total NASH score, 
ALT & AST n.s. 
Reference 
& Design
Sample 
(M/F)
Clinical 
Group
Age 
(years)
BMI (kg/
m2)
Intervention Length 
(weeks)
Outcome Measures & 
Adherence
Results
(328) RCT
46(n/r)
T2D 
(33% 
NAFLD)
61±1
35±1
LI: Weekly sessions (group to individual 
ratio 3:1) for 6 months, then 3 sessions/
month at 2:1 ratio for 6 months. Portion 
control & energy intake targets. Meal 
replacements in first several weeks. Fat 
intake <30%. Goal to ↓ BW ≥7% & ↑ 
moderate intensity PA  ≥175 min/wk. 
48
IHTAG (1H-MRS), ALT, 
AST, HbA1c
Actual diet & PA of 
these subgroups not 
reported.
Relative to baseline:
BW ↓8.3% 
IHTAG ↓51%, ALT & AST n.s., HbA1c ↓8.5%. 
Changes significantly greater than in CON
50(n/r)
T2D 
(54% 
NAFLD)
35±1 CON: standard care + 3 educational group sessions/year. 48 IHTAG ↓23%, ALT & AST n.s., HbA1c n.s.
(8) UCT 50 (28/22) NAFLD 47±2 32±1
≤10 sessions with a dietitian to: ↓ E 
intake, particularly from fat & ↑fibre 
intake. Advice to do 3h/w of moderate 
aerobic activity.
39
IHTAG (1H-MRS), ALT, 
AST.
VO2peak ↑9.4%, 3-day 
diet records indicated 
E and SAFA intake 
decreased, but 
quantitative data n/r
BMI ↓3.5%
IHTAG ↓35%, ALT ↓18%, AST ↓8.7%, 2 hour 
glucose ↓11% (75 g OGTT)
(329) RCTS
26(26/0) T2D n/r 32±1
LI: Weekly sessions (group to individual 
ratio 3:1) for 6 months, then 3 sessions/
month at 2:1 ratio for 6 months. Portion 
control & energy intake targets. Meal 
replacements in first several weeks. Fat 
intake <30%. Goal to ↓ BW ≥7% & ↑ 
moderate intensity PA  ≥175 min/wk. 
48
Liver:spleen ratio (CT), 
E-HC
Actual diet & PA of 
these subgroups not 
reported.
Men: BW ↓12%
Liver:spleen ratio ↑16%, GRd ↑56% (E-HC), 
fasting glucose ↓18%.
32(0/32) T2D n/r 35±1 48
Women: BW ↓8% 
Liver:spleen ratio ↑14%, GRd ↑36% (E-HC), 
fasting glucose ↓6.4%.  
Reference 
& Design
Sample 
(M/F)
Clinical 
Group
Age 
(years)
BMI (kg/
m2)
Intervention Length 
(weeks)
Outcome Measures & 
Adherence
Results
(241) RCT
38(20/18) High AST 49±2 32±1
Personalised exercise & diet advice: PA  
- 150 or 200 min/wk of mod intensity 
exercise for health or weight reduction, 
respectively: diet - reduced E by 
406-574kcal/day, low in SAFA, high in 
n-3 fats & fibre. Using: Social Cognitive 
Theory, Transtheoretical Model, Theory 
of Self-Determination, and Motivational 
Interviewing.
MI: 6 fortnightly sessions.
LI: 3 counselling sessions in first month. 
CON: 1 baseline session.
12
ALT, AST, HOMA
PA ↑124 min/wk, BMI 
↓3.2%, E intake 
↓266±3 1kcal/day. 
Relative to CON: ALT ↓28%, AST & HOMA n.s.
76(50/26) High AST 48±2 32±1 12
ALT, AST, HOMA
PA ↑115 min/wk, BMI 
↓2.2%, E intake n.s.
Relative to CON: ALT ↓22%, AST & HOMA n.s.
38(25/13) High AST 47±2 32±1 12
ALT, AST, HOMA
CON: PA & E intake 
n.s.
(242) RCT
Same group as ref 39 divided as 
described in next column.
Baseline data for the post hoc groups 
were not reported. 
These analyses do not include the 
participants with hepatitis C.
Reanalysis of data set from ref 39 on 
the basis of changes in physical activity 
relative to controls rather than group 
allocation:
Increased - increased PA by ≥ 60 min/
week;
Maintained - maintained baseline PA of 
>150 min/wk;
Low - maintained or ↓ PA from baseline 
at 60-150 min/wk;
Sedentary - maintained or ↓ PA <60 
min/wk.
12
ALT, AST, HOMA
As per Intervention 
column.
Results relative to sedentary group:
Increased (n=85): ALT ↓15 U/L, AST ↓7.6 U/L, 
2 h glucose n.s. & HOMA ↓1.
Maintained (n=29): ALT ↓20 U/L, AST n.s., 2 h 
glucose n.s., HOMA ↓0.3.
Low (n=19): ALT ↓15 U/L, AST ↓10 U/L, 2 h 
glucose & HOMA n.s.
(330) UCT 31(15/16) NAFLD 55±2 27±1
Home-based lifestyle modification 
targeting 5% BW reduction: daily 
weighing, monthly 30 min visit for 
lifestyle advice, additional nutrition 
counselling every 3 months, target 
25-30 kcal/kg BW/d, 23 MET/wk of PA + 
4 MET/wk exercise
12
Liver:spleen ratio (CT), 
ALT, AST, HOMA
Diet records were 
collected but findings 
n/ r; PA n/r.
BW ↓8.5%, ALT ↓21%, AST ↓7%, liver spleen 
ratio ↑13%, HOMA ↓48%.
24
(from baseline n=22): BW ↓7.6%, ALT ↓41%, 
AST ↓23%, liver spleen ratio ↑11%, HOMA 
↓33%.
Data are mean ± standard errors usually rounded to the nearest full number. Arrows indicate the direction of change; changes reported were statistically significant p 
<0.05 unless noted otherwise. Sample size based reflects those in the final analysis. Abbreviations: ALT - alanine aminotransferase; AST - aspartate 
aminotransferase; BMI - body max index (kg/m2); BW - bodyweight; d - day(s); CHO - carbohydrate; CT – computed tomography; d - day(s); E - energy; E-HC - 
euglycaemic-hyperinsulinaemic clamp; GRa - glucose rate of appearance; GRd - glucose rate of disappearance; h - hour(s); HbA1c – glycated haemoglobin; HOMA 
- homeostasis model assessment; IHTAG - intrahepatic triacyglycerol concentration; IS - whole body insulin sensitivity; ITT – intention to treat analysis; LI, light 
intervention; MI, moderate intervention; MUFA - monounsaturated fatty acid; n - sample size of cohort in final statistical analysis; NAFLD - non-alcoholic fatty liver 
disease; NASH - non-alcoholic steatohepatitis; n/r, data not reported; n.s. – result not statistically significant; PP – per protocol analysis; PRO - protein; PUFA - 
polyunsaturated fatty acid; RCT – randomised controlled trial; RCTS, single arm of an RCT; RT – randomised trial with no control; RMR - resting metabolic rate; 
SAFA - saturated fatty acid; T2D, type 2 diabetes; UCT – uncontrolled trial; w – week(s).
2.3.2.4 Diet Combined with specific Physical Activity and/or Exercise 
Prescriptions
Five studies involving 306 participants (approximately 50% women, 10 controls) 
prescribed specific diets and aerobic exercise programs for 3-6 months 
325,332-335. Key study details are summarised in Table 2.4 The focus was 
predominantly on body weight reduction and maintenance with mean reductions 
of 4.2-10.6%. All studies reported reductions in direct measures of liver fat and/
or liver enzymes; none used 1H-MRS. Vilar-Gomez et. al. had the single largest 
cohort of biopsy assessed participants of the studies reviewed (n = 30) and 
reported significant (p < 0.5) reductions in inflammation, ballooning injury, and 
fibrosis, relative to baseline, following a six month intervention with a mean 
10.6% weight reduction 332. Ueno et al. reported significant reductions in 
steatosis, but reductions in other parameters were not statistically significant 333. 
Relative mean reductions in IHTAG based on biopsy scores were 40-43% 
332,333. The four studies reporting glucose control/insulin sensitivity showed 
improvements 331-334.
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Table 2.4: Interventions Combining Diet and Specific Physical Activity/Exercise Advice
Reference 
(Design)
Sample 
(M/F)
Clinical 
Group
Age 
(years)
BMI (kg/
m2)
Intervention Length 
(weeks)
Outcome Measures & 
Adherence
Results
(332) RCTS 30(16/14) NASH 49±2 32±2
Diet: 500 kcal/d reduction (64% CHO, 
22% fat, 14% PRO).
Physical Activity: walking or jogging 
40 min ≥5 d/wk.
26
Histopathology (NAS), ALT, AST, 
HOMA
Daily E deficit of 370 kcal, 
macronutrient composition as 
prescribed (recall method n/r), PA 
related adherence was a score 
(questionnaire)
BW ↓10.6%
NAS ↓51% , steatosis ↓40%, 
ballooning -58%,  necroinflammation 
↓65%, fibrosis ↓55%.
ALT ↓41%, AST ↓48%, HOMA 
↓35%
(333) NRCT
15 (8/7) NAFLD 39±3.5 31±1
LI: 25 kcal/kg ideal BW/day (height
(cm)-100x0.9) (50% CHO, 30% fat, 
20% PRO) + exercise: 3000 steps/d 
increased by 500 every 3 days until 
10000, then jogging for 20 min 2/d.
12 Histopathology 
ALT, AST, fasting glucose
LI were inpatients for 4 wks then 
food provided.
Relative to baseline: BMI ↓9.7%. 
Steatosis ↓43%; n.s. change in 
portal or lobular infiltration, or 
fibrosis. ALT ↓67%, AST ↓59%, 
fasting glucose ↓14%.
10 (5/5) NAFLD 54±3 31±1
CON: (not randomised - inability to 
undertake inpatient protocol): no 
intervention.
12 N.s. changes in outcome measures. BMI ↑3.4%
(334) RCTS 22(8/14) T2D 52±2 36±1
2002 American Diabetes Association 
position stand diet. Weekly dietitian 
visits. Fat ≤30% of E & negative E 
balance of ~ 500 kcal/d. Advice to 
increase moderate activity by 40-60 
min/d.
26
CT (liver to spleen ratio). Glucose 
clamp & indirect calorimetry: GRd, 
EGP, HbA1c
Diet (24 hr recall): -568 kcal/d, no 
change in macronutrients from 
baseline. PA n/r.
BW ↓9.8%
Liver:spleen ratio ↑24%, GRd 
↑35%, EGP ↓47%, HbA1c ↓12%.
(325) UCT 28(n/r) High ALT 37(n/r) 29±1
Diet of 25 kcal/kg ideal BW ((height in 
cm - 100) x 0.9)) NCEP step 1 (60% 
CHO, 20% fat,  20% PRO & 200 mg 
cholesterol). PA: 45 min 6 d/wk at 
60-70% estimated HRmax
12
ALT & AST
Some sessions supervised. Only 
results for those completing ≥4 
sessions/week included. Diet: n/r.
BMI ↓9.7%
ALT ↓35%, AST ↓38%.
Reference 
(Design)
Sample 
(M/F)
Clinical 
Group
Age 
(years)
BMI (kg/
m2)
Intervention Length 
(weeks)
Outcome Measures & 
Adherence
Results
(335) RCT
64(31/33) T2D 56±1 32±0.5
American Diabetes Association: 23 
kcal/kg/d (50-55% mixed GI CHO, 30% 
FAT, 15-20% PRO). PA: 30 min aerobic 
activity ≥3 d/wk
48
ALT
Diet (FFQ): 2089 kcal (46% CHO, 
37% fat, 19% PRO) & energy 
-39% vs. baseline (1348 kCal). PA: 
n/r
BW n/r
ALT - 22%
73(40/33) T2D 57±1 31±0.5
Low GI Diet: 23 kcal/kg/d (50-55% low 
GI CHO, 30% FAT, 15-20% PRO). PA: 
30 min aerobic activity ≥3 d/wk
48
ALT 
Diet (FFQ): 1987 kCal (45%CHO, 
36% fat, 20% PRO) -37% vs. 
baseline (1189 kCal). PA: n/r
BW n/r
ALT -18
64(32/32) T2D 55±1 31±0.5
Modified Mediterranean Diet: 23 kcal/
kg/d (35% low GI CHO, 45% high 
MUFA FAT, 20% PRO). PA: 30 min 
aerobic activity ≥3 d/wk
48
ALT
Diet (FFQ): 2226 kCal (42% CHO, 
41% fat, 19% PRO) & energy 
-37% vs. baseline (1189 kCal). PA: 
n/r
BW n/r 
ALT -40
Data are mean ± standard errors usually rounded to the nearest whole number. Changes reported as percentages where possible. Changes reported were 
statistically significant p <0.05 unless noted otherwise; Abbreviations: 2 h glucose - blood glucose concentration at 2 hours post oral glucose tolerance challenge; 
ALT - alanine aminotransferase; AST - aspartate aminotransferase; BMI - body max index (kg/m2); BW - bodyweight; d - day(s); CHO - carbohydrate; CT - computed 
tomography; d - day; E - energy; EGP - endogenous glucose production; E-HC - euglycaemic-hyperinsulinemic clamp; FFQ – food frequency questionnaire; GI - 
glycaemic index; GRa - glucose rate of appearance; GRd - glucose rate of disappearance; HISI - hepatic insulin sensitivity index; HOMA - homeostasis model 
assessment; IHTAG - intrahepatic triacylglycerol concentration; ITT - intention to treat analysis; MET - metabolically equivalent tasks; min - minute; mod - moderate; 
MUFA - monounsaturated fatty acid; NAFLD - non-alcoholic fatty liver disease; n/r - data not reported; n.s. - no statistically significant change; NAS - Non-Alcoholic 
Fatty Liver Disease Activity Score; NASH - non-alcoholic steatohepatitis; LBM - lean body mass; NRCT – non-randomised control group; OGTT - oral glucose 
tolerance test; PA - physical activity;  PP - per protocol; PRO - protein; PUFA - polyunsaturated fatty acid;  RCTS, single arm of an RCT; SAFA - saturated fatty acid; 
T2D, type 2 diabetes; wk - week.
2.3.2.5 Mediators of Liver Fat Reduction and Glucose Control/Insulin Sensitivity
Additional post hoc analyses to identify key determinants of liver fat reduction 
were done in three studies 8,242,327,331. The percentage change in body weight 
was positively correlated with reductions in liver enzymes (r = 0.5), hepatic 
steatosis (r = 0.6), and overall NASH disease activity (r = 0.5) 327. 
Cardiorespiratory fitness at baseline was found to be a better predictor of 
change in liver fat than baseline IHTAG, and visceral or total adipose tissue 
mass following a combined diet and physical activity intervention 8. 
Improvements in overall NASH Score, steatosis, inflammation, ballooning injury, 
and fibrosis were significantly (p < 0.05) greater in those achieving weight 
reductions ≥7% of baseline body weight compared to those with smaller 
reductions 327. When dividing their group (n = 15) into responders and non-
responders based on total NASH Score, Huang et al. reported statistically 
significantly greater weight reduction (-6.6 vs. +1.8 kg) and questionnaire 
reported physical activity among responders compared with non-responders 331. 
Further, increasing duration and frequency of physical activity was associated 
with increasing reductions in liver enzymes 242. A similar relationship was 
observed between changes in cardiorespiratory fitness and liver enzymes, but 
only when results were compared relative to baseline rather than controls 242. 
The only study included in this review to asses multiple time points over several 
weeks, showed a rapid – within 48 hours – positive effect of energy, particularly 
carbohydrate, restriction on IHTAG, hepatic insulin sensitivity, and hepatic 
glucose production 171. An average of seven weeks later at a mean body weight 
reduction of approximately 7%, peripheral aspects of insulin action, specifically 
insulin mediated glucose uptake and insulin signalling, also improved.
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2.4 Discussion
Lifestyle modification, with an emphasis on weight reduction, is the cornerstone 
of NAFLD management 13. The findings of this systematic review support this 
recommendation. Lifestyle interventions focussing on weight reduction 
produced a consistent improvement in liver health, whether assessed by liver 
enzymes, imaging or biopsy. Weight reductions of 4-14% resulted in a relative 
reduction in IHTAG of 26 - 81%, with liver fat reductions tending to parallel body 
weight reduction. A limited number of exercise only interventions also identified 
the potential for more modest 10-20% reductions in IHTAG in the absence of 
weight change, and one study suggesting liver fat reduction can be rapid .
However, this review identified numerous study design and methodological 
issues with the current evidence base (Section 2.3.1). Others have noted that 
the few available randomised controlled trials of weight reduction in NAFLD 
carry a high risk of bias, and that poor reporting of adverse events leaves 
questions about the safety of these interventions incompletely addressed 336. 
Such observations highlight the limitations of the current evidence base, but 
also the limitations of adhering strictly to best practice in the performance of 
systematic reviews, which requires that only studies in populations with the 
condition in question be considered. 
Given the close association of NAFLD with the metabolic syndrome 2, and its 
high prevalence in the morbidly obese and those with type 2 diabetes 5,337, it 
seems prudent to consider the findings from interventions in these groups. 
Expanding the discussion beyond NAFLD research is particularly relevant in a 
review focusing on lifestyle modification, which is an acknowledged component 
of evidence-based treatment for the comorbidities and sequelae of NAFLD 2. 
The evidence for the feasibility of weight and cardiometabolic risk reduction with 
lifestyle intervention in populations with a high probability of elevated IHTAG is 
substantial when considering findings from major diabetes prevention studies 
(DPS) and diabetes treatment trials including: the Diabetes Prevention Program 
338; the Finish DPS 339,340; the China Da Qing DPS 341; the European DPS 342,343; 
meta-analyses of these and several smaller trials 344; and the Look AHEAD trial 
328,345-347. 
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The DPS and Look AHEAD trials employed multifactorial interventions 
encompassing dietary and physical activity advice often combined with various 
behaviour change techniques 339,342,343,348,349. Interventions were often delivered 
in a multi-disciplinary setting with dieticians/nutritionists 339,342,349, exercise 
physiologists 349, physiotherapists 342, behavioural psychologists 349, and/or 
nurses providing dietary, physical activity, and behaviour change advice 349. 
Seven of the interventions included in the present systematic review employed 
a comparable approaches 241,257,328-331; one was a subset of the Look AHEAD 
cohort 329.
Initial mean weight reductions at one year in the DPS and the Look AHEAD 
cohorts have been 2%-10% 344,350. Long-term followup of the DPS show 
significant reductions in the incidence of type 2 diabetes and improvements in 
cardiometabolic risk factors with intensive lifestyle intervention 351-353, but the 
effect on actual incidence of disease remains unclear 352,353. The reviewed trials 
in NAFLD patients reported 4-14% weight reduction and similar reductions in 
cardiometabolic risk factors as the DPS; in addition they demonstrate 
reductions in IHTAG. However, studies in NAFLD cohorts lack long-term follow-
up.
In NAFLD cohorts predictors of IHTAG reduction were: percentage weight 
reduction 327; cardiorespiratory fitness at baseline 8; and physical activity 241,331. 
The key determinants of improvement in glucose control in DPS were: weight 
reduction 342,344; increased cardiorespiratory fitness 343; and increased physical 
activity 341,342,354,355. Whereas the strongest predictors of weight reduction were 
self-reported physical activity and treatment attendance 356. Weight 
maintenance following reduction in NAFLD cohorts has not been assessed. 
However, lifestyle interventions in closely related patient groups indicate better 
weight maintenance was related to: larger initial reductions in weight 357-359; 
sustained weight reduction during the active intervention period 359; more 
physical activity 358, and greater attendance of lifestyle counselling sessions 358.
Translation of the DPS programmes has proven feasible and modestly 
successful, but so far only on a small scale 360,361. In the absence of specific 
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lifestyle programmes for NAFLD, more generic weight reduction and physical 
activity promotion schemes may be appropriate. In the UK, exercise on referral 
schemes allow primary and secondary care to refer patients to regional 
initiatives promoting exercise and weight reduction 362-364, and the 
Counterweight programme offers evidence-based weight reduction counselling 
designed for delivery in the primary care setting 365,366. 
Dietary advice in multi-factorial lifestyle interventions has tended to focus on 
overall dietary energy reduction by fat restriction 241,257,328-331,339,342,343,348,349. 
Conversely, diet only interventions in the reviewed NAFLD cohorts ranged from 
modest daily energy reduction to very-low calorie approaches, and from high-
carbohydrate/low-fat to high-fat/low-carbohydrate diets.
Low- and very low-calorie diets led to the significant weight, IHTAG, and liver 
enzyme reductions 171,313-315,318,319,322-324,367. A recent study of very-low calorie 
consumption in type 2 diabetes similarly reported a large and rapid, significant 
within one week, reduction in IHTAG associated with the normalisation of 
several metabolic parameters over eight weeks 172. Unfortunately, long-term 
followup was absent from all these studies. However, meta-analysis of 
randomised controlled trials, not specifically in NAFLD patients, reported 
comparable long-term (1-5 years) 5-6% bodyweight reduction from low and 
very-low calorie diets 368. Further, a review of several weight reduction trials 
showed that the magnitude of initial weight reduction, irrespective of the 
approach used, is a good predictor of long-term maintenance 357. Thus low-
calorie diets followed by a programme to support weight maintenance should be 
considered an option in clinical care.
The composition of the diets affected how rapidly they reduced IHTAG. 
Compared to low-fat/high-carbohydrate diets severely restricting carbohydrates 
to <90 g/day showed greater reductions in IHTAG over 48 hours 171, and 14 
days 173. Indeed a 1000 kcal/day energy deficit with 10% of energy coming from 
carbohydrates and 75% from fat, resulted in a ~30% reduction in IHTAG and 
marked improvements in glucose control and insulin sensitivity within 48 hours, 
and with no significant further improvements after a 7% weight reduction 171. 
However, over periods of 11 weeks or longer there was no difference with 
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respect to IHTAG reduction between diets either low or high in carbohydrates 
171,319. The utility of low-carbohydrate, sometimes ketogenic diets, was also 
shown in single arm studies 320,321. 
Interestingly, a study forming part of the present systematic review most 
elegantly demonstrates that low-carbohydrate intake has a different 
physiological effect than weight reduction per se. Hepatic insulin sensitivity was 
improved by ~150% after 48 hours of energy and carbohydrate restriction with 
no further change after a 7% weight and 30% IHTAG reduction 171. Whereas 
energy reduction with fat restriction resulted in a much more modest 50% 
improvement in hepatic insulin sensitivity within 48 hours with no further 
improvement following a 7% weight reduction despite further reductions in 
IHTAG. Multiple mechanisms would explain this rapid reduction in IHTAG with 
low carbohydrate intake: 1) the likely shift from TAG synthesis to ketone 
production and export 369; reduction of de novo lipogenesis 101,370,371, a major 
contributor to IHTAG in NAFLD 97; and greater reliance of the liver on 
endogenous and exogenous lipid as a fuel source (Section 1.3 & Section 1.7.4.)
Concern about the safety of low-carbohydrate and therefore higher fat and/or 
protein diets is often voiced. Assessment of the available literature comes with 
the key caveats: 1 many trials reporting their use did not achieve sufficient 
adherence to the intended diet to answer questions of safety or effectiveness 
372-380; and 2) the studies reporting elevated cardiometabolic risk did not include 
any groups that were truly low-carbohydrate 381-383. 
When considering only controlled studies in which published intake data 
indicates close adherence to low-carbohydrate intake of ≤100 g/day, and for the 
period in which this intake was maintained, such diets were comparable or 
superior to low-fat high-carbohydrate diets in terms of: weight reduction 
372,377,384-390; blood lipid profile 372,377,384,386-393; fasting glucose 372,377,384,385,392,394; 
fasting insulin 372,377,389,392,394; HOMA-IR 388,392,394; 24-hour glucose response 385; 
24-hour insulin response 385; HbA1c 388,389,395; and postprandial lipaemic 
response 392. 
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Anthropological evidence of modern and paleo/neolithic hunter gatherer 
societies support a long history of diets relatively low (approximately 35%) in 
energy from plant material and therefore carbohydrates, and high 
(approximately 65%) in energy from animals and therefore protein and fat 
396-398. Within these hunter gatherer populations such relatively animal protein 
and fat rich diets were not associated with indicators of elevated 
cardiometabolic risk 397. The few interventions seeking to mimic such diets 
supports their positive effects on: insulin sensitivity 399; glucose control 400, blood 
lipids399,400; blood pressure 399,400; body weight 400; and satiety 401. The studies to 
date have been small with no long-term followup published. They are 
compelling because one study intentionally maintained weight 399, one used the 
Consensus Mediterranean diet in their comparison group 401,402, and one was 
designed as a cross-over with the comparison diet consistent with standard 
recommendations for management of type 2 diabetes 400.
There is considerable evidence to support a broad range of macronutrient 
distributions, which if consumed in an amount that induces weight reduction, are 
consistent with improved cardiometabolic risk profiles and IHTAG reduction. 
Specific restriction of carbohydrates is particularly appropriate in NAFLD and 
those with impaired insulin sensitivity. However, ultimately the decision of what 
dietary approach to recommend should be pragmatic and consistent with what 
each patient feels willing and able to do. Any diet should also be consistent with 
established recommended protein 403, essential fat 404, and micronutrient 
intakes 405. Appropriate support to achieve prolonged adherence to the chosen 
dietary approach is likely to be more important than its macronutrient 
composition. This support should ideally come in the form of theory-based 
behaviour change programmes. The most appropriate programme for NAFLD 
remains to be determined. In the interim, use of locally available schemes is 
appropriate.
It is evident from multifactorial lifestyle interventions that physical activity is 
associated with treatment success in terms of weight maintenance and long-
term disease prevention 351-353. The exercise only arm of the Da Qing DPS had 
the greatest reduction in six year incidence of type 2 diabetes 341. As noted in 
Section 1.7.5, cross-sectional and retrospective data indicate that total physical 
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activity, vigorous physical activity, cardiorespiratory fitness, and resistance 
training are all inversely associated with the risk of NAFLD and its severity. 
Notably, these findings were largely independent of BMI, but unfortunately body 
composition was not assessed more directly.
Prospective investigations support a protective role of physical activity with 
respect to NALFD. In a diet and exercise intervention, baseline 
cardiorespiratory fitness predicted IHTAG reduction in both NAFLD and non-
NAFLD cohorts, and remission in the NAFLD cohort, independent of change in 
total physical activity 8. However, increased total physical activity was also 
associated with IHTAG reduction. The five exercise only interventions included 
in this review consistently reported modest reductions in IHTAG independent of 
weight reduction. This was despite the range of frequency and exercise types 
employed. Increased cardiorespiratory fitness was positively related to 
reductions in IHTAG 313, and liver enzymes 328. The effect of exercise on 
glucose control/insulin sensitivity was not so conclusive. This was in part due to 
only three studies reporting relevant markers, and one study finding no change 
in HOMA-IR following a four week intervention. However, meta-analyses 
indicate that continuous aerobic exercise has the potential to produce clinically 
meaningful improvements in: glucose control 274, blood pressure, and serum 
triacylglycerol in type 2 diabetes 275; visceral fat 406, markers of inflammation 407; 
HDL-cholesterol 277,278; and blood pressure in those with hypertension 276. 
Similar analysis of interventions employing resistance exercise have shown 
benefits including: improved glucose control in type 2 diabetes 274,408; reductions 
in hypercholesterolaemia and hypertriacylglycerolaemia 409,410; and reductions 
in body fat 410.
Collectively observational and intervention data support the utility of a broad 
range of physical activity options in the prevention and treatment of NAFLD; as 
both an adjunct too and independent of weight reduction. Exercise of higher 
intensity and exercise of an anaerobic nature, e.g. resistance training, may be 
particularly effective. However, simply increasing time spent active is likely to be 
beneficial and should be strongly encouraged, especially in those reluctant to 
do structured vigorous exercise, but also as an adjunct in those who are willing 
to exercise. As with dietary and broader lifestyle interventions, long-term 
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adherence is likely to be improved by employing formal behavioural modification 
techniques such as those employed in multifactorial lifestyle interventions.
2.4.1 Critique of NAFLD Studies and Recommendations
Overall, the studies on lifestyle intervention in patients in NAFLD have several 
limitations. Most notably: considerable heterogeneity in the populations studied; 
limited characterisation of risk factors prevalent in volunteers, adherence to 
specific aspects of the interventions or recording/reporting of lifestyle changes 
beyond those advocated by the interventions; and too little published detail on 
interventions to allow accurate replication in research or clinical practice. Future 
studies should focus on:
Improved reporting by:
• transparent and comprehensive descriptions of diagnostic markers of 
NAFLD including inclusion and exclusion criteria;
• thorough assessment of potential contributors to NAFLD, such as 
nutrient excess or deficiency where these are likely to be prevalent in 
the study population and influenced by the intervention; and
• publication of supplementary material describing complex lifestyle 
interventions in sufficient detail for these to be replicated or adapted to 
clinical practice.
Selection of study methods:
• quantitative assessments of hepatic steatosis;
• quantitative assessment of NASH activity via biopsy or closely 
correlated activity scores such as the NAS Activity Score;
• objective physical activity monitoring methods;
• validated dietary assessment methods;
• comprehensive exclusion of specific causes of steatosis, e.g. nutrient 
excess or deficiency; and
• validated methods to quantitatively assess alcohol consumption
Research focus:
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• characterisation of behavioural change techniques most effective in 
NAFLD cohorts;
• definition of the dose response relationship for physical activity/exercise 
intervention and IHTAG reduction;
• the effect of dietary macronutrient composition on IHTAG, especially 
carbohydrate restriction and higher protein intakes;
• a graduated progression from Phase II to Phase III trials; and
• a focus on how both diet and physical activity/exercise can be used to 
produce sustained benefit in NAFLD.
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2.5 Conclusions
This systematic review of lifestyle interventions identified consistent evidence 
that lifestyle interventions designed to reduce energy intake and/or increase 
physical activity to induce weight reduction can reduce IHTAG and improve 
insulin sensitivity in patients with NAFLD. A more limited data set indicates a 
trend for reductions in necroinflammation following weight reduction focused 
intervention. The effect on fibrosis is least consistent across studies. Degree of 
weight reduction is positively correlated with improvements, as is 
cardiorespiratory fitness. 
However, contrary to the current emphasis on weight reduction, studies of 
carbohydrate restriction indicate this to be effective at reducing IHTAG and 
improving glucose metabolism even with very modest weight reduction. Notably, 
exercise only interventions, although underrepresented in the literature, appear 
to be a therapeutic option that is effective in the absence of dietary advice and 
independent of weight change.
When broadening the evidence base beyond clinically defined NAFLD or NASH 
to include groups with a probable high prevalence of NAFLD, the evidence base 
becomes stronger. Energy restriction resulting in weight reduction, irrespective 
of macronutrient composition, is likely to reduce IHTAG. However, sufficient 
protein and micronutrient consumption should be ensured. 
Exercise, with or without concomitant weight reduction is likely to result in 
modest reductions in IHTAG and a substantial reductions in cardiometabolic 
risk. However, the NAFLD specific evidence base in terms of appropriate mode 
and dose of exercise remains in considerable need of expansion.
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3.0 Review of High-Intensity Intermittent Training 
3.1 Introduction
Exercise is a recommended component of lifestyle therapy for non-alcoholic 
fatty liver disease (NAFLD) 14,311. Exercise is also recommended for the 
treatment and prevention of several common NAFLD comorbidities and 
sequelae, including obesity 411,412, impaired glucose tolerance and type 2 
diabetes 413,414, and cardiovascular diseases 415. The benefits of exercise for 
these conditions are recognised in related UK treatment and prevention 
guidelines 416. Meta-analyses support these guidelines by indicating that 
continuous moderate intensity exercise (CMIE) has the potential to produce 
clinically meaningful improvements in glucose control 274, blood pressure, and 
serum triacylglycerol in type 2 diabetes 275, and blood pressure in those with 
hypertension 276, as well as reductions in visceral fat 406, markers of 
inflammation 407 and HDL-cholesterol in mixed populations 277,278. Similar 
analyses of interventions employing resistance exercise have shown improved 
glucose control in type 2 diabetes 274,408, reductions in hypercholesterolaemia 
and hypertriacylglycerolaemia 409,410, and body fat 410 in mixed populations. As 
well as physical benefits, exercise has been shown to improve depression 
secondary to chronic illness 417. Exercise is also a valuable adjunct to energy 
restriction when weight, particularly body fat reduction, is the goal, and is a key 
of component in weight maintenance 412,418,419. 
However, only five published studies have looked at exercise only interventions 
in patients with clinically defined NAFLD 243-245,325,326: one assessed steatosis by 
liver histology following resistance exercise 326, one relied on aminotransferase 
changes to measure change following CMIE 325, and the remaining three 
employed proton-magnetic resonance spectroscopy to quantify liver fat 
following CMIE 244,245 and resistance exercise 243, respectively. All studies 
reported modest relative reductions in liver fat of 10-21% independent of weight 
reduction (see Chapter 2).
High-intensity intermittent training (HIIT), often referred to as interval training, is 
a particularly time efficient mode of exercise, which has shown promise in 
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populations with metabolic syndrome and those with type 2 diabetes 420-425, but 
has not been formally assessed in populations with confirmed NAFLD. 
Incorporation of HIIT into lifestyle therapies for NAFLD patients would seem 
consistent with recent findings indicating regular vigorous physical activity is 
associated with a reduced risk of developing NASH 240, and a recent meta-
analysis encompassing data from over 1.3 million volunteers enrolled in cohort 
studies reporting risk reduction of all cause mortality was greatest in response 
to vigorous activity on a per unit time basis 426. Further, intensity of continuous 
aerobic exercise is associated with improvements in insulin sensitivity 427-429, 
reductions in visceral fat 430-432, and blood pressure reductions 433. However, 
prolonged periods of exercising at high intensity are unsuitable for many 
patients with NAFLD, many of whom are generally sedentary 232,233,236,434, have 
reduced exercise tolerance 181, and lack confidence in performing exercise 435. 
HIIT represents an approach to exercise that allows accumulation of time 
exercising at high intensity without demanding this to be maintained for 
prolonged periods.
This chapter will summarise the rationale for testing this mode of exercise in a 
group with NAFLD by reviewing research conducted in non-athletic populations 
with emphasis on findings in those with common comorbidities of NAFLD, and 
research looking specifically at relevant physiological changes induced by HIIT. 
The following sections assess the likely suitability of HIIT for the treatment of 
NAFLD by:
• Defining the nature of HIIT;
• Establishing the safety and tolerability profile of HIIT; and
• Reviewing the known physiological changes likely to be of relevance in 
the context of NAFLD, specifically with respect to:
• Cardiorespiratory and cardiovascular fitness and health;
• Body weight and composition; and
• Fasting and postprandial metabolism
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3.2 Methods
3.2.1 Selection Criteria and Search Strategy
The review is restricted to published prospective studies reporting the effects of 
HIIT, as defined in Section 3.2.3 below, in healthy and clinical populations, but 
not those engaged in a formal training programme for competitive sport. Clinical 
populations considered most relevant were those with one or more components 
of the metabolic syndrome present (Section 1.8.1). Research in those with 
chronic obstructive pulmonary disease, cystic fibrosis, spinal injury, intermittent 
claudication, or other rarer conditions potentially requiring very specific 
adjustment of exercise prescription were excluded 436. Emphasis is placed on 
studies examining the safety and tolerability of HIIT in clinical populations, and 
those reporting its effects on cardiorespiratory fitness, body composition, and 
recognised cardiometabolic risk factors. 
The online version of Medline (Pubmed) was searched via Papers 2.0 
(Mekentosj, Aalsmeer, The Netherlands) using the search terms: high intensity 
intermittent training, sprint interval training, and interval training in the title or 
abstract of papers. The reference lists of papers identified, including reviews, 
were also searched for potentially relevant papers. This was not a formal 
systematic review and only English language papers available through the 
libraries of Newcastle University were included. 
3.2.2 Data Extraction
Data on study volunteer demographics, intervention protocols, and outcomes 
were extracted into tables. Outcome data were converted to give percentage 
change for all parameters of interest. 
3.2.3 Types and Definitions of High Intensity Intermittent Training
No single universally adopted definition of HIIT exists. Published protocols 
generally 
involve multiple intervals of high-intensity activity, commonly walking/running or 
cycling, lasting 1-4 minutes and interspersed with active or passive recovery 
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periods of similar length (see Tables 3.1-3.5 for examples). Intensity is 
commonly defined in terms of the percentage of peak volume of oxygen 
consumed (VO2peak or VO2max), peak heart rate (HRpeak or HRmax), or self-
reported rating of perceived exertion. High intensity has generally been defined 
as 80-95% of VO2peak/VO2max, HRpeak/HRmax, or a perceived rate of exertion ≥16 
on a scale of 6-20 (see Appendix 1). Passive recovery involves rest, whereas 
active recovery involves light to moderate intensity activity corresponding to 
≤60% VO2peak/VO2max or HRpeak/HRmax (see Tables 3.1-3.5 for examples). Peak 
or maximum intensity are obtained using graded maximal exercise tests. 
However, actual VO2 was not generally assessed during exercise outside of 
graded exercise testing, instead the resistance or speed of each interval are 
matched to correspond with the point during a graded maximal exercise test at 
which the desired intensity was reached. Sprint interval training (SIT) is a 
subset of HIIT in which intervals are less than a minute long and often exceed 
maximum aerobic capacity by requiring volunteers give an ʻall outʼ effort for the 
prescribed time. Both HIIT and SIT use multiple intervals to accumulate total 
time at intensities the trainee could not maintain for prolonged periods. 
Chapter 3 - Review of High-Intensity Intermittent Training
91
3.3 Results
3.3.1 Safety and Tolerability of High-Intensity Intermittent and Sprint 
Interval Training
The high intensity nature and therefore cardiac demand of HIIT and SIT 
exercise raises the question of their safety in clinical populations at increased 
risk of or with coronary heart disease. Studies assessing the safety, tolerability, 
and/or acute cardiovascular response to HIIT & SIT are summarised in Table 
3.1. The largest assessment of safety for HIIT was a clinical audit involving 
4846 coronary heart disease patients enrolled in Norwegian cardiac 
rehabilitation programs 437. This survey identified only two non-fatal cardiac 
arrests in 46,364 exercise hours for the HIIT protocol, whereas there was one 
fatal cardiac arrest in 129,456 exercise hours of CMIE. Although this translates 
into a higher rate for HIIT, this was a function of time as the HIIT protocol only 
required 36% of the exercise time required by the CMIE protocol. Due to the low 
frequency of events, the study was underpowered in terms of being able to 
detect a difference in risk for HIIT vs. CMIE, but indicated the risk for either 
exercise approach is low. Intervention trials with much smaller cohorts in 
populations with chronic heart failure 438-446, recent stroke survivors with 
hemiparesis 447, and patients with coronary heart disease have reported no 
serious adverse events 448. 
3.3.1.1 Acute Cardiovascular Response
Studies examining the acute cardiovascular response to exercise are 
summarised in Table 3.1. In patients with coronary heart disease undergoing 
various ECG and blood pressure monitored HIIT and SIT (≤100% of peak 
aerobic capacity, not supramaximal as is common with SIT) protocols, no 
contraindications to continuing the protocols were observed and undesirable 
changes such as ST-segment depression recovered during between-interval 
recovery periods 448,449. In patients with chronic heart failure, cardiac stress as 
assessed by rate pressure product (heart rate x systolic blood pressure) stayed 
within acceptable values 450. In patients with metabolic syndrome, flow mediated 
dilation – a measure of arterial response to shear stress – increased following 
HIIT 423. In patients with pharmacologically treated hypertension, 24-hour and 
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daytime systolic blood pressure were reduced following HIIT 451. Further, the 
blood pressure of healthy individuals performing a common SIT protocol was 
not excessively elevated, and reductions in central and peripheral pulse-wave 
velocity – a measure of arterial stiffness – observed immediately following 
exercise returned to baseline within 20 minutes post-exercise 452. Supine resting 
blood pressure was reduced by HIIT in active volunteers for at least an hour 
post-exercise, but returned to baseline by 24 hours 453. Likewise, in a healthy 
cohort, R-R interval – a measure of heart rate variability and sympathetic/
parasympathetic balance – was decreased following HIIT relative to CMIE but 
recovered within 48 hours 453,454, whereas pulse wave velocity was comparable 
between HIIT and CMIE 454. Thus the acute cardiovascular response to HIIT is 
within acceptable parameters even in patients with diagnosed stable 
cardiovascular disease. 
Three studies comparing SIT and HIIT protocols of different interval lengths 
reported that longer intervals result in greater periods spent at higher intensities 
in terms of VO2, and therefore represent a greater physiological stimulus 455-457. 
A fourth study, notably in men with chronic heart failure, observed marked 
reductions in total exercise time when passive between interval recovery 
periods were replaced with active ones 444. However, total time at intensities 
greater than 100%, 95%, and 90% of VO2peak were maintained even as total 
exercise time was reduced. 
3.3.1.2 Tolerability
Studies seeking to assess the participant tolerance of HIIT and SIT protocols 
are summarised in Table 3.1. Interval power output tends to decline from 
interval-to-interval 452, whereas feelings of leg fatigue and breathlessness tend 
to increase 450. Volunteer reported post session ratings of perceived exertion 
ranged from 14-18 on scale going from 6-20 points 448,449. Despite this relatively 
high perceived exertion volunteers rate HIIT and SIT preferable to CMIE 
protocols at similar total workloads 449,458,459. A comparison of protocols in a 
cohort with chronic heart failure reported a greater perception of exertion with 
active vs. passive recovery periods; this was accompanied by markedly 
reduced time to exhaustion 444. Tolerability was maintained in cohorts on heart 
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rate limiting β-blockers 444,448,450. Thus intermittent exercise protocols with 
intervals at maximum aerobic capacity are tolerated in a broad range of clinical 
populations. However, SIT protocols with efforts exceeding maximal aerobic 
capacity remain largely untested in clinical populations with evidence of 
cardiovascular disease. 
3.3.1.3 Alternative Measures of Intensity
There are inherent difficulties with setting intensity using objective laboratory 
measures, most notably the need for equipment to measure these parameters, 
and/or to set exact work rates/resistance. There is also the need for the 
exerciser to understand what is required if exercising unsupervised or be 
supervised. Such requirements are potentially difficult to meet outside a 
supervised research setting. Recent work in trained runners has examined the 
suitability of using rating of perceived exertion and a perceived readiness scale 
in self pacing HIIT sessions 460. Use of rating of perceived exertion resulted in a 
better time to complete multiple 1000 m runs with self-pacing than pacing based 
on heart rate recovery, and a shorter rest times than when using a set 1:1 rest-
to-work ratio. Rating of perceived exertion was also successfully employed in 
active young women to produce comparable elevations in VO2peak to those 
achieved using an objective intensity prescription 461.
3.3.1.4 Risk Assessment Summary
Although not definitive, these data are reassuring as they suggest a low cardiac 
risk of HIIT protocols even in particularly vulnerable populations. Nonetheless, 
the remaining uncertainty justifies screening of at risk populations, preferably by 
ECG-monitored graded maximal exercise test to help identified previously 
undiagnosed cardiac abnormalities. Until there is more data on the safety and 
tolerability of supramaximal effort SIT protocols in higher risk populations, these 
should not be utilised outside of supervised and appropriately monitored 
situations.
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Table 3.1: Safety and Tolerability of High-Intensity Intermittent Training and Sprint Interval Training
Reference Population Protocol Tolerability Safety
437
3392 men & 1454 women,  
cardiac rehabilitation 
patients, 58±n.r. years, 
BMI n.r., VO2peak n.r.
HIIT: walking at 80-90% VO2peak for 4x4 
min with 3 min active recovery at 50-60% 
VO2peak for a total of 46364 person hours
2 non-fatal cardiac arrests
CME: walking at 60-70% VO2peak for ~ 60 
min for a total of 175820 person hours
1 fatal cardiac arrest
448
17 men & 2 women, 
coronary heart disease, 
65±8 years, BMI 28±4, 
VO2peak 27±7
SIT1: 15 s at 100% WRmax & 15 s passive 
recovery until volitional exhaustion or a 
maximum of 35 min
RPE post session 15; time to 
exhaustion 29 min; time above 90% & 
95% VO2max 7.2 min & 4.6 min, 
respectively
n.s. arrhythmias or abnormal BP response 
(parameters not defined), mild ischaemia 
(ST depression 1.1 mm, n=3)
SIT2: 15 s at 100% WRmax & 15 s active 
recovery 50% WRmax until volitional 
exhaustion or a maximum of 35 min
RPE post session 17, time to 
exhaustion 12 min, time above 90% & 
95% VO2max 7.4 min & 5.6 min, 
respectively 
n.s. arrhythmias, mild ischaemia (ST 
depression 1.1 mm, n=3), no abnormal BP 
response 
HIIT1: 1 min at 100% WRmax & 1 min 
passive recovery until volitional exhaustion 
or a maximum of 35 min
RPE post session 17, time to 
exhaustion 25 min, time above 90% & 
95% VO2max 5.5 min & 3.7 min, 
respectively
n.s. arrhythmias, mild ischaemia (ST 
depression 1.6 mm, n=3), vagal reaction 
(n=2), no abnormal BP response
HIIT2: 1 min at 100% WRmax & 1 min active 
recovery 50% WRmax  until volitional 
exhaustion or a maximum of 35 min
RPE post session 18, time to 
exhaustion 14 min, time above 90% & 
95% VO2max 7.2 min & 5.1 min, 
respectively
n.s. arrhythmias, mild ischaemia (ST 
depression 1.5 mm, n=3), no abnormal BP 
response 
Reference Population Protocol Tolerability Safety
449
19 men & 1 women, 
coronary heart disease, 
62±11 years, 27±4, 
VO2peak 28±9
SIT: 2 x 10 min bouts of 15 s cycle sprints at 
peak power output (corresponding to 
VO2peak) with 15 s passive rest & 4 min 
passive rest between bouts
RPE post session 14; preferred over 
CME
n.s. arrhythmias or abnormal BP response 
(parameters not defined); serum cTnT <0.04 
mg/L at all times (baseline, 20 min and 24 hr 
post exercise)
CME: 70% of peak power output 
(corresponding to VO2peak); duration set to 
be isocaloric with SIT session (mean 
duration of 28.7 minutes)
RPE post session 16
n.s. arrhythmias or abnormal BP response; 
serum cTnT <0.04 mg/L at all times 
(baseline, 20 min and 24 hr post exercise)
454
11 men, healthy, 23±2 
years, BMI 22±n.r., 
VO2peak n.r.
HIIT: 1 min interval at >85% HRmax with 3 
min active recovery at ~ 65% HRmax x 6
Mean Q 15.9 L/min, max Q 21.7 L/min 
both greater than CME 
R-R interval ↓28% greater than CME 
Arterial stiffness (assessed by pulse wave 
velocity) n.s.
CME: workload adjusted to maintain the 
average HR of HIIT for 30 minutes
Mean Q 13.9 L/min, max Q 14.8 L/min R-R interval ↓17%
Arterial stiffness (assessed by pulse wave 
velocity) n.s.
450
16 men, chronic heart 
failure, 54±9 years, BMI 
25±n.r., VO2max 15±1
SIT1: 30 s cycle intervals at 50% Wmax with 
60 s active recovery against 15 W resistance 
x 6
Δ between early & later intervals: leg 
fatigue ↑6%; dyspnoea ↑6%; HR, VO2 
& VCO2, adrenaline & noradrenaline 
n.s.
cardiac stress (RPP) at last interval 84 
(<than at 75% VO2peak during graded 
maximal exercise test)
SIT2: 15 s cycle intervals at 70% Wmax with 
60 s active recovery against 15 W resistance 
x 9 matched for work with Trial 1
Δ between early & later intervals: leg 
fatigue ↑9%; dyspnoea ↑14%; 
adrenaline ↑42%; noradrenaline ↑41% 
HR, VO2 & VCO2 n.s.
cardiac stress (RPP) at last interval 88 
(<than at 75% VO2peak during graded 
maximal exercise test)
SIT3: 10 s cycle intervals at 80% Wmax with 
60 s active recovery against 15 W resistance 
x 11 matched for work with Trial 1
Δ between early & later intervals: leg 
fatigue ↑10%; dyspnoea ↑8%; HR 
↑4%; SBP ↑8%; VO2 & VCO2, 
adrenaline & noradrenaline n.s.
cardiac stress (RPP) at last interval 86 
(<than at 75% VO2peak during graded 
maximal exercise test)
Reference Population Protocol Tolerability Safety
457 9 men, active, 20±1 years, 24±n.r., VO2peak 46±6
SIT single: 1 x 30 s cycle sprints against 
7.5% BW resistance; measurements done 
for 60 min post exercise
specific aspects n.r.; all volunteers 
completed the protocol
SBP ~ 155 mmHg & DPB ~ 74 mmHg 2 min 
post exercise; HR remained elevated over 60 
min; BP returned to baseline by 15 min; 
central PWV ↑ n.r. returning to baseline by 
20 min; peripheral  PWV ↓ n.r. returning to 
baseline
SIT multiple: 4 x 30 s cycle sprints against 
7.5% BW resistance with 4.5 min active 
recovery (40 W at >50 rpm) between sprints; 
measurements done for 60 min post 
exercise
relative to first bout mean power 
decreased by 15%, 25%, 28% in 
subsequent three bouts, respectively 
SBP ~ 155 mmHg & DPB ~ 74 mmHg 2 min 
post exercise; HR remained elevated over 60 
min; BP returned to baseline by 15 min; 
central PWV ↑ n.r. returning to baseline by 
20 min; peripheral  PWV ↓ n.r. returning to 
baseline
451
8 men & 18 women, 
pharmacologically treated 
hypertension, 44±9 years, 
BMI 28±5, VO2peak n.r.
HIIT: 40 min alternating 2 min 50% HRR & 1 
min 80% HRR.
24 hr SBP ↓2.2% & night time SBP ↓2.9%; 24 hr, daytime, & nighttime  DBP n.s.
16 men & 10 women,  
pharmacologically treated 
hypertension, 48±7 years, 
BMI 27±4, VO2peak n.r.
CME: 40 min cycling at 60% HRR 24 hr SBP ↓2.1%, 24 hr DBP ↓2.9%, nighttime  SBP ↓4.1%, & nighttime  DBP ↓6.2%
453
10 men, active, 25±2 
years,  BMI ±n.r., VO2peak 
n.r.
HIIT: 1 min cycling at Wmax x 9 bouts with 4 
min active recovery periods at VT
5, 10, 15, 60 min, & 24 hr post exercise relative to baseline: RRI ↓35%, SBP ↓5.1% & 
DBP n.s.; RRI ↓32%, SBP ↓3.7% & DBP n.s.; RRI ↓29%, SBP ↓4.1%& DBP ↓6.2%; 
RRI, SBP & DBP n.s., respectively
N.s. differences vs. CME
CME: cycling at VT matched with HIIT for 
total work performed
5, 10, 15, 60 min, & 24 hr post exercise relative to baseline: RRI ↓33%, SBP ↓6.3% & 
DBP n.s.; RRI 29%, SBP ↓7.5% & DBP n.s.; RRI 25%, SBP ↓9.5% & DBP n.s.; RRI 
↓9.4%, SBP ↓7.8% & DBP ↓10%; RRI, SBP & DBP n.s., respectively
Reference Population Protocol Tolerability Safety
456
14 men & 3 women, 
moderately trained, 22±4 
years, BMI n.r. (BW 74±11 
kg), VO2peak 57±
HIIT1: 10 x 1 min intervals at 100% VO2peak 
with 1 min active recovery periods at 50% 
VO2peak x single session
Mean VO2 was 75.7% VO2peak
HIIT2: 5 x 2 min intervals at 100% VO2peak 
with 1 min active recovery periods at 50% 
VO2peak x single session
Mean VO2 was 78.6% VO2peak (greater than HIIT1 & CME)
CME: 20 min cycling at 75% VO2peak x single 
session Mean VO2 was 71.6% VO2peak
423
4 men & 7 women, 
metabolic syndrome, 
55±13 years, BMI 30±2, 
VO2max 34±3
HIIT: 4 x 4 min incline treadmill walking at 
90-95% HRmax with 3 min recovery periods 
at 70% HRmax  
FMD ↑120% for 48 hrs & above baseline for 72 hr, FG ↓~15% below baseline for 72 
hr vs CON
4 men & 4 women, 
metabolic syndrome, 
52±11 years, BMI 29±2, 
VO2max 36±3
CME: 47 min at 70% HRmax (matched for 
energy expenditure with HIIT)
FMD ↑60% acutely & above baseline for 24 hr, FG ↓~15% below baseline for 24 hr 
5 men & 4 women, 
metabolic syndrome, 50±9 
years, BMI 32±1, VO2max 
32±3
CON: resting FMD & FG n.s.
Reference Population Protocol Tolerability Safety
444
22 men, chronic heart 
failure, 60±9, BMI 30±5, 
VO2peak 17±5
SIT1: 30 s intervals at peak power (100% 
VO2peak) with 30 s passive recovery until 
exhaustion or 30 min
Total exercise time 27.5 min (longer than SIT2 & HIIT2)
Time % of VO2peak: >100% 109 s ., >95% 190 s , >90% 316 s (all shorter than other 
protocols)
Association of VO2peak with total exercise time r= 0.48
RPE15
SIT2: 30 s intervals at peak power (100% 
VO2peak) with 30 s active recovery at 50% 
peak power until exhaustion or 30 min
Total exercise time 16.4  min
Time % of VO2peak: >100% 194 s, >95% 332 s,  >90% 458 (all n.s. to other protocols 
except SIT1)
Association of VO2peak with total exercise time r= 0.61
RPE18
HIIT1: 90 s intervals at peak power (100% 
VO2peak) with 90 s passive recovery until 
exhaustion or 30 min
Total exercise time 26.2 min (longer than SIT2 & HIIT2)
Time % of VO2peak: >100% 132 s, >95% 228 s, >90% 344 s  (all n.s. to other protocols 
except SIT1)
Association of VO2peak with total exercise time n.s.
RPE 16
HIIT2: 90 s intervals at peak power (100% 
VO2peak) 90 s recovery at 50% peak power 
until exhaustion or 30 min
Total exercise time 16.0 min 
Time % of VO2peak: >100% 184 s, >95% 324 s, >90% 488 (all n.s. to other protocols 
except SIT1)
Association of VO2peak with total exercise time r= 0.54
RPE 17
Study population demographics (sample size by sex, health or activity description, body mass index in kg/m2, and either VO2peak or VO2max in mL/kg/min as reported 
by study authors in are provided as means ± standard deviation, where reported, rounded to nearest whole number. Sample sizes are based on those included in 
the final analysis. Where data was reported in graph form it may not have feasible to accurately calculate percentage change so ~ is used to indicate this. The 
protocol column contains the core exercise but does not describe warm up and cool down protocols, which consisted predominantly of 5-10 minutes periods of light-
to-moderated intensity activity. Abbreviations: BP, blood pressure; bpm, beats per minute; CME, continuous moderate-intensity exercise; cTnT, cardiac troponin; 
DBP, diastolic blood pressure; HIIT, high intensity intermittent training; HR, heart rate; n.r., data not reported or not reported in numerical form (e.g. only shown as a 
graph); n.s., no statistically significant change/difference; Q, cardiac output; rpm, revolutions per minute; RPE, rate of perceived exertion;  RPP, rate pressure 
product (HR x SBP); SBP, systolic blood pressure; SIT, sprint interval training; ST, the ST segment of an electrocardiogram; VO2, volume of oxygen consumption; VT, 
ventilatory threshold; WR, work rate.
3.3.2 Cardiorespiratory Effects of High Intensity Intermittent and Sprint 
Interval Training
Summaries of studies examining the cardiorespiratory and cardiovascular 
adaptations to HIIT and SIT are provided in Table 3.2. Numerous studies have 
shown marked improvements in cardiorespiratory fitness (fitness) and work 
capacity following HIIT and SIT (n=703) 421,422,424,438,445-447,451,457,461-501. Changes 
ranged from 0-35% improvements in VO2peak (unadjusted median 15%); 
6.5-33% improvements in peak work rate, and 23-56% improvements in time to 
exhaustion.
Improvements in fitness were achieved in as few as six sessions of HIIT or SIT. 
Although not entirely consistent across studies, durations above six weeks and 
18 sessions resulted in greater improvements in fitness and work capacity than 
shorter intervention durations. The three studies that measured changes in 
fitness at intermediate time points indicated improvements were rapid and 
increased over at least eight weeks 482,497,501. Thirty seven (79%) of studies 
used a training frequency of three sessions per week, two used two or fewer, 
and seven used four or more sessions per week. No study compared multiple 
training frequencies. Given the heterogeneity of intervention designs, study 
lengths, and cohorts no clear dose response can be established. However, no 
clear advantage of frequencies exceeding thrice weekly is evident, and as few 
as 6 sessions over four weeks had a notable effect. Approximately two thirds of 
study volunteers were men, but participant sex was not always specified. 
However, studies comparing response by sex reported no significant difference 
between men and women 471,481,483,497. One study compared different protocols 
of SIT and reported similar improvements with 10 or 30 second sprints 486. 
However, the protocol was particularly intense and conducted in healthy active 
men and women, so is unlikely to be suitable in patient populations.
SIT or HIIT resulted in similar or greater improvements in cardiorespiratory 
fitness and/or work capacity than CMIE matched for total work 
422,445,451,466-469,474-478,482,484,485,487,489,491,493,498. One study reported a similar 
change despite the CMIE protocol requiring 10 times the energy output of the 
SIT protocol. Further, SIT produced increases in VO2peak faster than CMIE 482.
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Some of the improvements observed may be attributable to the fact that 
formerly sedentary or even moderately active individuals would be 
unaccustomed to near maximal efforts and thus perform below their true 
maximum capacity during baseline assessments. Following several sessions of 
repeated near maximal or supramaximal efforts these individuals may be more 
likely to achieve their true maximum during a followup test. Nonetheless, HIIT 
and SIT represent time efficient means to substantially increase 
cardiorespiratory fitness and work capacity over a short period of time.
3.3.2.1 Cardiovascular Effects 
In patients with chronic heart failure and coronary heart disease, HIIT improved 
cardiac output 446,462,463 and left ventricular ejection fraction 446,462. Increased 
cardiac output and left ventricular ejection fractions were also observed in 
sedentary middle-aged cohorts 489,491, sedentary elderly 490, and overweight 
young women 493. Changes were greater with HIIT than CMIE; the latter often 
showing no change 446,462,489,491,493. The only study to assess the effect of 
multiple bouts of HIIT on heart rate variability reported increased 24-hour heart 
rate variability across multiple frequencies, indicating an increase predominantly 
in parasympathetic activity, in elderly men after 14 weeks of HIIT 472.
3.3.2.2 Blood Pressure
Reports of blood pressure changes following multiple sessions of HIIT have 
been varied. In women with a family history of hypertension 502, and men and 
women with hypertension, HIIT reduced ambulatory blood pressure with greater 
reductions reported overnight 489. However, no change in resting blood pressure 
was observed following HIIT in patients with a recent percutaneous coronary 
intervention 464, or chronic heart failure 446. Resting diastolic and systolic blood 
pressure were reduced in patients with metabolic syndrome after 16 weeks of 
HIIT 422, but blood pressure changes after 12 weeks in a similar cohort using a 
similar exercise protocol did not reach statistical significance 424. Interestingly, 
the second study also showed more modest increases in VO2peak and flow 
mediated dilation indicating less overall change in this cohort 424. Neither study 
clearly specified when measurements were taken relative to the last bout of 
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exercise. HIIT reduced resting systolic and/or diastolic blood pressure in two 
sedentary cohorts after 12 weeks 474,490. However, no effect was observed in 
overweight men after two weeks 473, eight weeks 475, 12 weeks 476, or in elderly 
men after 14 weeks 472. It is notable that the only study to report blood pressure 
at multiple time points following the last bout of exercise observed a reduction 
relative to baseline after 24 but not 72 hours 479. Comparisons of HIIT and SIT 
with CMIE showed similar changes irrespective of exercise approach 
422,424,446,474-476,502. However, ambulatory monitoring suggests HIIT is superior to 
CMIE for blood pressure reduction 489.
3.3.2.3 Haemodynamics
Multiple haemodynamic parameters were reported across studies. Flow-
mediated dilation was routinely substantially increased following HIIT in a range 
of populations, and did so to a similar or greater extent than CMIE 
422,424,465,466,469,489,499. Conversely, SIT did not change flow-mediated dilation in 
chronic heart failure patients unless combined with resistance training 438. 
Fourteen weeks of HIIT increased spontaneous cardiac baroreflex in elderly 
men 472, and SIT improved peripheral artery distensibility in already active 
young men and women 499. Thus, HIIT and SIT appear to provide time efficient 
means to improve haemodynamic parameters in multiple clinical populations.
3.3.2.3 Summary of Cardiovascular and Cardiorespiratory effects of High-
Intensity Intermittent and Sprint Interval Training
HIIT and SIT is a time efficient and effective means of rapidly increasing fitness 
and aerobic work capacity. Very limited data from patients with heart disease 
suggest that some of these cardiac output is improved. Reports on reduction of 
blood pressure are inconsistent with population and measurement time 
following exercise being the likely explanatory factors. The more consistently 
reported improvements in flow-mediated dilation and other blood pressure 
related parameters support a therapeutic role of HIIT in hypertensive 
populations. Improvements following HIIT were predominantly shown to be 
similar or greater than those reported for CMIE.
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Table 3.2: Cardiorespiratory and Cardiovascular Effects of High Intensity Intermittent and Sprint Interval Training
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
446
9 men & 5 women, chronic heart failure, 68±6 
years, BMI 24±n.r., VO2peak 16±4 
HIIT: 5 x 3 min cycling intervals at 80% VO2peak with 3 active 
recovery periods at 40% VO2peak x 3/wk x 12 wk
VO2peak ↑23%, WRmax ↑29%, Qmax ↑31%, LVEF 
↑27% vs baseline/CME/CON; SBP & DBP n.s.
8 men & 5 women, chronic heart failure, 66±8 
years BMI 24±n.r., VO2peak 16±3 CME: 30 min cycling at 60% VO2peak x 3/wk x 12 wk VO2peak, WRmax, Qmax, LVEF, SBP & DPB, n.s. 
9 men & 4 women, chronic heart failure, 68±9 
years, 25±n.r., VO2peak 21±5
CON: usual care with advice for home-based physical 
activity
VO2peak & WRmax n.s.; Qmax ↓17% vs baseline & 
HIIT; LVEF, SBP & DBP n.s. 
438
12 men & 2 women, chronic heart failure, 
52±11 years, BMI 29±5, VO2peak 16±4
SIT: 30 s cycle intervals at 50% Wmax with 60 s passive 
recovery for 40 min x 3/wk x 12 wk VO2peak ↑9.6%, Wmax ↑14% vs baseline; FMD n.s.
12 men & 2 women, chronic heart failure, 
54±10 years, BMI 28±4, VO2peak 16±6
SIT&RET: 30 s cycle intervals at 50% Wmax with 60 s passive 
recovery for 20 min & 20 min of resistance exercises (3 sets 
of 12 repetitions for hip flexors & extensors, biceps, & 
shoulders) x 3/wk x 12 wk
VO2peak ↑17%, Wmax ↑18% vs. baseline; FMD 
↑63% vs baseline & SIT
447 13 men & 3 women, post stroke, 54±9 years, BMI 25±n.r., VO2peak 19±4
HIIT: 4 min cycling at 40% of the max workload & 1 min at 
80%, repeated 6 times x 3/wk x 12 weeks VO2peak 15%, 6-min walk test distance ↑16%
462
6 men & 2 women, coronary heart disease, 
61±4 years, BMI 26±3, VO2peak 27±5
HIIT: 4 x 4 min incline treadmill walking at 85-95% HRpeak 
with 3 min active recovery periods at 60-70% HRpeak x 8 wk 
(sessions/week: 5/5/5/5/3/3/3/3)
VO2peak ↑17%, Wmax ↑25%, Qmax ↑29% & LVEF 
↑5% (p=0.06) vs baseline & RET
10 men, coronary heart disease, 67±6 years, 
BMI 27±3, VO2peak 29±4
RET: 4 sets of 4 repetitions of horizontal leg press at 85-90% 
1RM 3/wk x 8 wk VO2peak, Wmax, Qmax & LVEF n.s.
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
463
7 men & 3 women, coronary heart disease, 
63±7 years, BMI 26±3, VO2peak 27±5
HIIT: 4 x 4 min incline treadmill walking at 85-95% HRpeak 
with 3 min active recovery periods at 60-70% HRpeak x 3/wk x 
10 wk
VO2peak ↑16%, Wmax ↑32%, Q80% VO2peak ↑23% vs 
baseline vs baseline
6 men & 2 women, coronary heart disease, 
61±7 years, BMI 27±3, VO2peak 26±4
HIIT+O2: 4 x 4 min incline treadmill walking at 85-95% 
HRpeak with 3 min active recovery periods at 60-70% HRpeak 
x 3/wk x 10 wk with 100% O2 enriched air provided during 
exercise
VO2peak ↑15%, Wmax ↑29%, Q(80% VO2peak) ↑28 vs 
baseline
445
8 men, post infarction heart failure, 62±8, BMI 
28±2, VO2peak 19±5
HIIT: 2-4 x 4 min incline treadmill walking at 75-80% HRR 
with 3 min active recovery at 45-50% HRR 3-5/wk x 12 week 
(sessions/week:2/2/2/3//3/3/4/4/4/5/5/5)
VO2peak ↑22% vs baseline
8 men, post infarction heart failure, 63±9, BMI 
27±3, VO2peak 18±4
CME: 30-45 min incline treadmill walking at 45-60% HRR 
3-5/wk x 12 week (sessions/week:2/2/2/3//3/3/4/4/4/5/5/5) 
with variables matched to the HIIT group week by week
VO2peak ↑22% vs baseline
464, 465
17 men & 3 women following percutaneous 
coronary intervention, 57±10 years, BMI 27±4, 
VO2peak 23±6
HIIT: 4 x 4 min incline treadmill walking at 80-90% HRmax 
with 3 min active recovery periods at 60-70% HRmax 3/wk x 
26 wk
VO2peak ↑17% & FMD ↑338% vs. baseline & 
CON; SBP & DBP n.s.
16 men & 4 women following percutaneous 
coronary, 61±10 years, BMI 28±3, VO2peak 
23±6
CON: usual care VO2peak ↑8%; SBP & DBP n.s.
466, 467
24 men & 4 women, following CABG, 60±7 
years, BMI 26±6, VO2peak 27±5
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax 
with 3 min recovery periods at 70% HRmax 5/wk x 4 wk 
supervised, then advised to continue at home
At 4 wk: VO2peak ↑12% & FMD ↑45% vs. baseline
At 6 months: VO2peak ↑18%; FMD declined to 
baseline
24 men & 7 women, following CABG, 62±8 
years, BMI 28±4, VO2peak 26±5
CME: 47 min at 70% HRmax 5/wk for 4 wk (matched for 
energy expenditure with HIIT), then advised to continue at 
home
At 4 wk: VO2peak ↑9% & FMD ↑34%
At 6 months: VO2peak ↑13%; FMD declined to 
baseline
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
468, 469
25 men & 5 women, post myocardial 
infarction, 57±10 years, BMI 27±3, VO2peak 
32±6
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax 
with 3 min recovery periods at 70% HRmax 3/wk x 12 wk
At 12 weeks: VO2peak ↑15% vs baseline & group 
exercise
At 6 months: decline in VO2peak
At 30 months: further decline in VO2peak but still 
above baseline
49 men & 10 women, post myocardial 
infarction, 58±9 years, BMI 27±4, VO2peak 
32±7
Group session: 10 min warmup, 35 min aerobic exercise 
(walking/jogging/lunges), 15 min cool down, stretching & 
relaxation x 3/wk x 12 wk
At 12 weeks: VO2peak ↑8% vs baseline
At 6 months: n.s. decline in VO2peak
At 30 months: further decline in VO2peak to 
baseline
470  8 (sex n.r.), type 2 diabetes, 63±8 years, BMI 32±6, VO2peak n.r.  
HIIT: 10 x 1 min intervals at  ~90% HRmax with 1 min rest 
periods 3/wk x 2 wk VO2peak n.r., Wmax, ↑10% 
471
16 men, elderly, 65±4 years, BMI 21±n.r., 
VO2peak 27±5 HIIT: 6 x 1 min cycling at VT2 with active recovery at VT1 2/
wk x 9 wk
VO2peak ↑11%, WRmax ↑15% vs baseline
19 women, elderly, 65±4 years, BMI 25±n.r., 
VO2peak 19±4 VO2peak ↑13%, WRmax ↑21% vs baseline & men
472 11 men, elderly, 74±4 years, BMI 28±4, VO2peak 
HIIT: 9 x 1 min cycling intervals at 85% HRR with 4 min 
active recovery at 65% HRR x 4/wk x 14 wk
VO2peak ↑19%; R-Rdaytime ↑12%, R-R24hr 7.7%, 
slSBR ↑40%; SBP & DBP n.s.
422, 423, 
425
4 men & 7 women, metabolic syndrome, 
55±13 years, BMI 30±2, VO2max 34±3
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax 
with 3 min recovery periods at 70% HRmax 3/wk x 16 wk
VO2peak ↑35% vs baseline/CME/CON; SBP 
↓6.3%, DBP ↓6.3% & FMD ↑180% vs. baseline 
& CON
4 men & 4 women, metabolic syndrome, 
52±11 years, BMI 29±2, VO2max 36±3
CME: 47 min at 70% HRmax 3/wk for 16 wk (matched for 
energy expenditure with HIIT)
VO2peak ↑16%; , SBP ↓7.6%, & FMD ↑80% vs 
baseline & CON
5 men & 4 women, metabolic syndrome, 50±9 
years, BMI 32±1, VO2max 32±3 CON: no intervention VO2peak, SBP & DBP n.s.
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
424
11 (sex n.r.), metabolic syndrome, 50±10 
years, BMI 31±4, VO2peak 34±10
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax 
with 3 min recovery periods at 70% HRmax 3/wk x 12 wk
VO2peak ↑11% & FMD ↑~28% vs baseline; SBP, 
DBP n.s. 
11 (sex n.r.), metabolic syndrome, 51±8 years, 
BMI 32±4, VO2peak 32±5
RET: 3 sets of 8-12 repetitions x 3-5 exercises x 3/wk x 12 
wk
VO2peak n.s.; FMD ↑~28% vs baseline; SBP, DBP 
n.s. 
10 (sex n.r.), metabolic syndrome, 53±10 
years, BMI 30±4, VO2peak 28±6
HIIT+RET: HIIT as above 2/wk, 3 resistance exercises for 
8-12 repetitions 1/wk, all for 12 wk
VO2peak ↑10%; FMD ↑~38% vs baseline; SBP, 
DBP n.s. 
11 (sex n.r.), metabolic syndrome, 47±10 
years, BMI 32±4, VO2peak 34±10 CON: no exercise VO2peak, FMD SBP & DBP n.s. 
502
11 women, familial history of hypertension, 
24±4 years, BMI 24+5, VO2max 29±4, BP 
106/65
HIIT: walking: 1 min at 80-90% VO2max 2 min walking at 
50-60% for 40 min + 15 min calisthenics 3/wk x 16 wk
VO2max ↑16% vs baseline & CME, HRR ↑75% vs 
baseline & CON; 24 hr SBP ↓1.8% & DBP ↓2.8% 
vs baseline, daytime BP n.s., nighttime SBP 
↓3.8% & DBP ↓5.8. vs baseline
11 women, familial history of hypertension, 
27±5 years, BMI 24±5, VO2max 30±4, BP 
105/65
CME: walking at 60-70% VO2max for 40 minutes + 15 min 
calisthenics 3/wk x 16 wk
VO2max ↑8% vs baseline, HRR n.s.; 24 hr SBP 
↓2.4% & DBP ↓3.0% vs baseline, daytime BP 
n.s., nighttime SBP ↓3.4% & DBP ↓5.0% vs 
baseline
9 women, familial history of hypertension, 
25±4 years, BMI 24±4, VO2max 30±4, BP 
106/62
CON: No intervention VO2max, HRR, 24 hr, daytime & nighttime BP n.s.
473 12 men, overweight/obese, 24±5  years, BMI 29±3, VO2peak 38±6
HIIT: 6 x 4 min cycling at 85% VO2peak, with 2 min rest x 6 
sessions over 14 d. VO2peak ↑8.3%; SBP & DBP n.s.
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
474
8 men, sedentary, 37±8 years, BMI n.r. (BW 
96±11 kg), VO2peak 36±5
HIIT: 5 x 2 min running >95% HRmax with 2 min rest periods 
3/wk x 12 wk VO2max ↑14% vs baseline & other groups; SBP ↓6.2% vs baseline; DBP n.s.
9 men, sedentary, 31±6 years, BMI n.r. (86±16 
kg), VO2peak 39±7
CME: 60 min running at 80% HRmax (~65% VO2peak) 3/wk x 
12 wk
VO2max ↑7%, SBP ↓6.1% & DBP ↓6.2% vs 
baseline
8 men, sedentary, 36±6 years, BMI n.r. (95±24 
kg), VO2peak 38±9
RET: 60 min 3-4 sets of:  squat, hack squat, incline leg pres, 
isolated knee extension, hamstring curls, and calf raises 3/
wk x 12 wk VO2max, SBP & DBP n.s.
11 men, sedentary, 30±6 years, BMI n.r. 
(87±11 kg ), VO2peak 39±8 CON: no exercise x 12 wk VO2max , SBP & DBP n.s. 
475
7 (sex n.r.), sedentary overweight, 41±12 
years, BMI 31±3, VO2peak ~23±n.r.%
HIIT: 10 x 1 min cycling at 90% VO2peak with 2 min recovery 
at 30%  VO2peak x 4 sessions/wk for 8 wk, & diet education (1 
hour seminar)
VO2peak ↑24% & time to exhaustion on exercise 
test ↑23% vs baseline; SBP & DBP n.s.
6 (sex n.r.), sedentary overweight, 45±17 
years, BMI 30±3, VO2peak ~24±n.r.% 
CME: 50% VO2peak matched to energy expenditure of HIIT for 
time, & diet education (1 hour seminar).
VO2peak ↑19% & time to exhaustion on exercise 
test ↑24% vs baseline; SBP & DBP n.s.
8 (sex n.r.), sedentary overweight, 40±13 
years, BMI VO2peak ~23±n.r.% Diet: diet education only (1 hour seminar). VO2peak, SBP & DBP n.s.
476
3 men & 11 women, sedentary, 47±8 years, 
BMI 37±4 , VO2peak 24±5
HIIT: 4 x 4 min treadmill walking/running at 85-95% HRmax 
with 3 min active recovery periods at 50-60% HRmax 3/wk x 
12 wk
VO2max ↑33% vs baseline/CME/RET; DBP ↓7% 
vs. baseline/RET; SBP n.s.
2 men & 11 women, 44±8 years, BMI 37±5, 
VO2peak 25±5 CME: 47 min walking/jogging at 50–60% of HRmax
VO2max ↑16% vs baseline; DBP ↓9% vs. baseline/
RET; SBP n.s.
3 men & 10 women, 46±10 years, VO2peak 
25±7
RET: 4 sets of 5 repetitions on leg press/squat & 3 sets of 30 
repetitions on unspecified abdominal & back exercises VO2max ↑10% vs baseline; SBP & DBP n.s.
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
477
5 men & 5 women, sedentary, 18-32 years, 
BW 64±11, VO2peak 39±9
HIIT&SIT:  4 sessions/wk for 15 weeks with a mix of CME at 
70% HRR, SIT (15-30 s intervals) and HIIT (60-90 s 
intervals) sessions. Recovery periods were based on HR 
returning to 120-130 bpm
VO2peak ↑26% vs. baseline
8 men & 9 women, sedentary, 18-32 years, 
BW 61±13, VO2peak 37±8
CME: 4 sessions/wk x 20 weeks: 30-45 min at 60-85% HRR 
at approximately twice the E expenditure of HIIT&SIT VO2peak ↑32% vs. baseline
478
8 (sex n.r.), sedentary overweight/obese, 
40±8 years, BMI 28±4, VO2peak n.r.
HIIT: Thrice weekly cycle ergometry at 20% above anaerobic 
threshold at a 2:1 exercise/rest ratio: wk 1-4 for 20, 30, 40, 
50 min, respectively, then 60 min sessions x 3/wk x 12 wk
Anaerobic threshold ↑92% vs. baseline
8 (sex n.r.), sedentary overweight/obese, 
40±8 years, BMI 28±2, VO2peak n.r.
CME: Thrice weekly cycle ergometry at 10% below 
anaerobic threshold: wk 1-4 for 20, 30, 40, 50 min, 
respectively, then 60 min sessions for 8 wk (total duration of 
12 wk).
Anaerobic threshold ↑42% vs. baseline & CME
479 10 men, sedentary overweight/obese, 32±9 years, BMI 31±4, VO2peak 33±1
SIT: 4-7 bouts of 30 s cycle sprints at 6.5% FFM resistance 
3/wk for 2 wk (sprints/session: 4/4/5/5/6/6) with 4.5 min 
active at 30 W resistance
VO2peak ↑9.5% & SBP ↓4.7%; DBP n.s. (change 
in SBP was only significant at 24 hr but not 72 hr 
post-exercise)
480
14 women, overweight/obese, 30±7 years, 
BMI 36±6, VO2max 22±1
SIT: Six sessions over 28 days: 4-7 (increased by 1 every 
week) 30 s sprints against resistance of 5% BW with 4 min 
recovery between sprints. 
VO2max ↑13% vs baseline & CON
14 women, overweight/obese, 31±6 years, 
BMI 35±6, VO2max 21±1 CON: Maintenance of baseline physical activity VO2max n.s.
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
481
8 women, sedentary, 23±3 years, BMI 23±2, 
VO2peak 33±2 
SIT: cycling 10 min total containing 2 all out sprints for 
10/15/20/20/20/20 s in wk 1-6 x 3/wk, respectively, remaining 
time was at 60 W
VO2peak ↑12% vs baseline & CON
8 women, sedentary, 22±1 years, BMI 23±2, 
VO2peak 33±2 CON: no exercise VO2peak n.s.
7 men, sedentary, 26±3 years, BMI 24±2, 
VO2peak 36±2
SIT: cycling 10 min total containing 2 all out sprints for 
10/15/20/20/20/20 s in wk 1-6, respectively, remaining time 
was at 60 W
VO2peak ↑15% vs baseline & CON
6 men, sedentary, 25±2 years, BMI 24±2, 
VO2peak 38±3 CON: no exercise VO2peak n.s.
457
3 men & 6 women, sedentary, 24±4 years, 
BMI 25±2, VO2peak 35±7
SIT moderate:10:20 s sprint:active recovery at 120% Wpeak 
& 20 W, respectively, done for 30, 35, & 40 minutes in wk 
1-2, 3-4, & 4-6, respectively x 3/wk
VO2peak & FMD n.s.
4 men & 7 women, sedentary, 23±3 years, 
BMI 23±3, VO2peak 41±8
SIT heavy: 30:60 s sprint:active recovery at 120% Wpeak & 
20 W, respectively, done for 30, 35, & 40 minutes in wk 1-2, 
3-4, & 4-6, respectively x 3/wk
VO2peak ↑15% vs. baseline & SIT moderate; FMD 
n.s.
482
5 men & 5 women, sedentary, 24±1 years, 
BMI 24±n.r., VO2peak 41±2 ml/kg/min  
SIT: 4-6 bouts of 30s cycle sprints braked at 7.5% body 
weight 3/wk x 6 wk (bouts/session/week: 4/4/5/5/6/6/) VO2peak ↑7% (at week 3 & 6 vs baseline)
5 men & 5 women, 23±1 years, BMI 24±n.r., 
VO2peak 41±2 ml/kg/min
CME: Continuous cycling ~65% VO2peak 40-60 min (length 
↑10 min/fortnight) 5/wk for 6 weeks. 
VO2peak ↑2% &↑10% at week 3 & 6 vs baseline, 
respectively
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
483
11 men, active, 25±6 years, BMI 25±n.r., 
VO2peak 46±4 SIT: 4-6 30 s cycle sprints against resistance of 7.5% BW 
with 5 min unloaded cycling between sprints (sprints per 
session: 4/4/5/5/6/6)
VO2max ↑5.9% & Wpeak ↓10%
9 women, active, 25±3 years, BMI 22±n.r., 
VO2peak 41±6 VO2max ↑6.8% & Wpeak ↓9.0%
5 men, active, 23±3 years, BMI 25±n.r., 
VO2peak 46±7
CON: before & after tests but no intervention
VO2max n.s.
4 women, active, 23±3 years, BMI 24±n.r., 
VO2peak 39±2 VO2max n.s.
484
5 men & 3 women, healthy active, 21±5 years, 
BMI 25±n.r., VO2peak 42±6 ml/kg/min
SIT: Six sessions over 14 days: 4-7 30 s sprints against 
resistance of 7.5% BW with 4 min recovery between sprints 
(sprints per session: 4/5/6/6/7/7). 
VO2peak ↑7%,& VO2 slow component amplitude 
↓23% vs. baseline/CME/CON
5 men & 3 women, healthy active, 20±4 years, 
BMI 24±n.r., VO2peak 43±5 ml/kg/min
CME: 80 rpm continuous cycling at 80% GET for a duration 
matched to give work equivalent to SIT group. VO2peak & VO2 slow component amplitude n.s.
5 men & 3 women, healthy active, 20±1 years, 
BMI 23±n.r., VO2peak 47±8 ml/kg/min CON: Habitual physical activity. VO2peak & VO2 slow component amplitude n.s.
485
15 women, healthy, 22±1 years, BMI 24±2, 
VO2peak 29±8
SIT: 3 sessions/wk over 15 wk: 8 s sprints/12 s active (20-30 
rpm) recovery at 0.5 kg resistance. Progressing from 5 min 
sessions to 20 min sessions with 0.5 kg resistance added 
once 20 minutes
VO2peak ↑24% vs baseline & CON
15 women, healthy, 21±1 years, BMI 22±1, 
VO2peak 31±8
CME: 3 sessions/wk over 15 weeks: 10-20 min at 60% 
VO2peak for 10-20 min progressing to 40 minutes VO2peak ↑20% vs baseline & CON
15 women, healthy, 22±1 years, BMI 24±1, 
VO2peak 31±6 CON: No change in physical activity over 15 wk VO2peak n.s.
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
486
35 men & 13 women, active, 24±3 years, BMI 
25±n.r., VO2peak n.r. (NB: data were reported 
for the entire cohort only with groups matched 
for VO2peak & sex)
SIT: 4-6 bouts of 30 s cycle sprints 10% BW resistance with 
4 min active recovery (no resistance) 3/wk for 2 wk (bouts/
session: 4/4/5/5/6/6)
VO2peak ↑9.3%; 5 km time trial time ↓5.2%; peak 
power ↑9.5% vs baseline & CON
SIT: 4-6 bouts of 10 s cycle sprints 10% BW resistance with 
4 min active recovery (no resistance) 3/wk for 2 wk (bouts/
session: 4/4/5/5/6/6)
VO2peak ↑9.2%; 5 km time trial time ↓3.5%; peak 
power ↑8.5% baseline & CON
SIT: 4-6 bouts of 10 s cycle sprints 10% BW resistance with 
2 min active recovery (no resistance) 3/wk for 2 wk (bouts/
session: 4/4/5/5/6/6)
VO2peak ↑3.8% (p=0.06); 5 km time trial time 
↓3.0%; peak power ↑4.2% baseline & CON
CON: no exercise VO2peak; 5 km time trial time; & peak power n.s. vs baseline
487
5 men & 5 women, healthy, 24±1 years, BMI 
24±n.r., VO2peak 41±2
SIT: 4-6 bouts of 30 s cycle sprints 7.5% BW resistance with 
4.5 min active recovery (30 W resistance) 3/wk x 6 wk 
(intervals/session/week: 4/4/5/5/6/6)
VO2peak ↑7%
5 men & 5 women, healthy, 23±1 years, BMI 
24±n.r., VO2peak 41±2
CME: 40-60 min cycling at 65% VO2peak 5/wk x 6 wk (time/
session/week: 40/50/60) VO2peak ↑10%
488 16 men, active, 22±2 years, BMI 24±3, VO2peak 48±9 
SIT: 4-6 30 s cycle sprints against resistance of 7.5% BW 
with 4 min unloaded cycling between sprints x 3/wk x 2 wk 
(sprints per session: 4/4/5/5/6/6)
Work output during time trial ↑6%
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
489
15 men & 10 women, hypertensive, 53±7 
years, BMI 27±4, VO2peak 36±9
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax 
with 3 min recovery periods at 60-70% HRmax 3/week x 12 
weeks
VO2max ↑14% vs baseline & CME; 24-hour SBP 
↓7.8% & nighttime SBP ↓7.5% vs. baseline & 
CME; 24 hour DBP ↓8.6%, daytime SBP ↓8.1% 
& DBP ↓8.7%, nighttime DBP ↓6.1% vs baseline; 
FMD ↑64% & LVEF ↑11% vs. baseline & CME; 
SV ↑11% & CO ↑13% vs. baseline 
13 men & 10 women, hypertensive, 54±7 
years, BMI 28±4, VO2peak 34±7
CME: walking/running on treadmill at 70% of HRmax, for 47 
min to ensure isocaloric training sessions to the HIIT group
VO2max ↑5%, 24-hour SBP 3.2% & DBP ↓3.8%, 
daytime SBP ↓3.2% & DBP ↓4.3% vs. baseline; 
nighttime BP, FMD, SV, CO, & LVEF n.s.
14 men & 11 women, hypertensive, 51±9 
years, BMI 29±4, VO2peak 35±8
CON: standard advice for essential hypertension, including 
ʻregular light-moderate intensity exerciseʼ
VO2max & BP n.s. except nighttime SBP ↓3.9%; 
FMD, SV, CO, & EF all n.s.
490 10 men & 6 women, sedentary seniors, 72±2 years, BMI 25±1, VO2max 33±6
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax 
with 3 min recovery periods at 60-70% HRmax 3/wk x 12 wk
VO2max ↑14%, SBP ↓12%, DBP ↓8.8%, SV ↑9% 
& LVEF ↑13%; CO n.s.
491
7 men, sedentary, 47±7 years, BMI 26±!; 4 
women, sedentary, 42±6 years, BMI 21±1, 
VO2peak ~29 (combined men & women)
HIIT: 1 min intervals at 90% Wmax with 3 min active recovery 
at 1st ventilatory threshold x 3/wk x 8 wk; total duration 20, 
25, 30, & 35 min in wk 1-2, 2-4, 5-6, & 7-8, respectively
VO2peak ↑15%; Qmax ↑11%, SV ↑8%, & 
arteriovenous oxygen difference ↑16% vs. 
baseline
CME: intensity = (4 x 1st ventilatory threshold + 90% Wmax)/5 
to match energy expenditure & exercise time with HIIT
VO2peak ↑9% & arteriovenous oxygen difference 
↑10% vs baseline; Qmax & SV n.s.
492
20 men, sedentary & overweight, 25±5 years, 
BMI 28±1, VO2peak 34±1
SIT: 8 s sprints with 12 s recovery periods at a cadence of 
120-130 & 40, respectively, for 20 min at 80-90% HRpeak x 3/
wk for 12 w
VO2peak ↑15% vs baseline & CON
18 men, sedentary & overweigh, 25±4 years, 
BMI 29±1, VO2peak 29±1 CON: no exercise VO2peak n.s.
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
493
17 women, BF >30%, 20±1 years, BMI 28±2, 
VO2peak 33±4
HIIT: 5 x 3 min of track running at 85% VO2max with 3 min 
active recovery at at 50% VO2max 5/wk x 12 wk
VO2max ↑8.4% vs baseline/CON/CME; LVEF 
↑4.7% vs. baseline & CON
16 women, BF >30%, 19±1 years, BMI 28±2, 
VO2peak 33±5 CME: 40 min walking/jogging at 50% VO2max 5/wk x 12 wk VO2max ↑4.8% & LVEF ↑1.5% vs CON
19 women, BF >30%, 20±1 years, BMI 29±2, 
VO2peak 33±4 CON: no exercise VO2max & LVEF n.s.
494
2 men & 8 women, obese,  37±10 years, BMI 
32±4, VO2peak 27±5
HIIT+Diet: Up to 10 x 4 minutes cycling at 90% VO2peak with 
2-3 minutes rest periods, for 6 supervised sessions over 14 
days.
(see below for diet)
VO2peak ↑16%
3 men & 6 women, obese, 41±14 years, BMI 
32±3, VO2peak 26±9 Diet: 75% of food record estimated requirement (35% CHO) VO2peak n.s.
495
7 men, active, 20-40 years, BMI 25±3, VO2peak 
37±7
HIIT: 4 x 4 min treadmill running at 90% VO2peak with  min 
recovery periods at 60% VO2peak 3/wk x 8 wk VO2peak ↑20% vs baseline & CON
8 men, active, 20-40 years, BMI 23±2, VO2peak 
40±16 CON: no intervention VO2peak n.s.
496
20 men, active, 30±5 years, BMI 23±4, 
VO2peak n.r.
HIIT: 4 x 800 m runs at ~90% age predicted HRmax (220-age) 
with a 1:1 work-to-rest ratio 3/wk x 8 wk time to run 2.4 km ↓9.2% vs baseline & CON
16 men, active, 30±5 years, BMI 23±2, 
VO2peak n.r. CON: no vigorous exercise time to run 2.4 km n.s. vs baseline
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
461
9 women, active, 23±3 years, BMI 22±1, 
VO2peak 41±5 
HIIT1: 1 min cycling bouts at MTP x 9 with 4 min active 
recovery periods at VT x 3/wk x 6 wk VO2peak ↑6.5%; WRmax ↑20% vs baseline & CON
9 women, active, 22±3 years, BMI 21±2, 
VO2peak 43±5 
HIIT2: 1 min cycling bouts x 9 with 4 min active recovery 
periods at VT x 3/wk x 6 wk with intensity based on a 10 
point RPE scale
VO2peak ↑9.9%; WRmax ↑12% vs baseline & CON
9 women, active, 23±2 years, BMI 22±2, 
VO2peak 42±5 CON: no exercise VO2peak & WRmax n.s.
497
7 women, active, 23±7 years, BMI 23±n.r., 
VO2peak 40±n.r.
HIIT: 3 x 2 min cycling intervals at ~100% VO2peak with 6 min 
recovery x 3/wk x 8 wk
After 4 wk: time to exhaustion ↑29% vs baseline
After 8 wk: VO2peak n.s., Wmax ↑11%, time to 
exhaustion ↑56% vs baseline
7 men, active, 24±4 years, BMI 23±n.r., 
VO2peak 44±n.r.
After 4 wk: time to exhaustion ↑31% vs baseline
After 8 wk: VO2peak ↑7.9% vs baseline & women, 
Wmax ↑11%, time to exhaustion ↑73% vs baseline
498
12 men, active, 25±4 years, BMI n.r. (BW 
83±7 kg), VO2peak 44±n.r. (NB: volunteer 
demographics were not provided by 
intervention group)
HIIT: 8-12 1 min cycling bouts at 120% WRmax x 8 sessions 
(intervals/session: 8/8/9/9/10/10/12/12) VO2peak ↑4.3%; WRmax ↑8.8% vs. baseline
CME: 90-120 min cycling at 65% VO2peak x 8 sessions 
(time/session: n.r.) VO2peak ↑7.0%; WRmax ↑8.4% vs. baseline
499
5 men & 5 women, healthy, 23±3 years, BMI 
24±2, VO2peak 41±2
SIT: 4-6 bouts of 30s cycle sprints braked at 7.5% body 
weight 3/wk for 6 wk (bouts/session/week: 4/4/5/5/6/6/)
VO2peak ↑7%, FMD ~↑17% & popliteal artery 
distensibility ↑~60% vs. baseline; carotid artery 
distensibility n.s.
5 men & 5 women, healthy, 24±3 years, BMI 
24±2, VO2peak 41±2
CME: Continuous cycling ~65% VO2peak 40-60 min (length 
↑10 min/fortnight) 5/wk for 6 weeks. 
VO2peak ↑10%, FMD ~↑40%; popliteal artery 
distensibility ↑~57% vs baseline; carotid artery 
distensibility n.s.
500 5 men & 3 women, active, 24±1 years, BMI 23±n.r., VO2peak 45±n.r.
HIIT: 4 min cycle intervals at ~90% VO2peak x 10 intervals 
with 2 min rest 3/wk x 6 wk VO2peak ↑9%
Reference Baseline Population Protocol Cardiorespiratory and Cardiovascular Changes
470 7 men, active, 21±1 years, BMI n.r. (BW 83±4 kg), VO2peak n.r.
HIIT: 8-12 x 1 min cycling at VO2peak with 75 s active 
recovery against 30 W resistance x 2 weeks (intervals per 
session: 8/8/10/10/12/12)
750 kJ exercise test: time to complete ↓9%, 
mean power ↑10%
501 10 women, active, 22±1 years, BMI n.r. (BW 65±2 kg), VO2peak ~43±n.r.
HIIT: 10 x 4 min cycling at 90% VO2peak with 2 min active rest 
periods 3/wk x 6 wk
Average power output by wk (1 vs. 2, 1 vs. 3… 
1vs. 6): ↑9.1%, ↑19%, ↑23%, ↑28%, ↑33%.
Study population demographics (sample size by sex, health or training status, body mass index in kg/m2, and either VO2peak or VO2max in mL/kg/min, as reported by 
study authors, are provided as means ± standard deviation, where reported, rounded to nearest whole number. Sample sizes are based on those included in the 
final analysis. Results have been converted to percentage change from baseline if the change was statistically significant followed by indication if this was significant 
relative to comparison group(s). Results are provided to two significant figures. Where data was reported in graph form it may not have feasible to accurately 
calculate percentage change so ~ is used to indicate this. The protocol column contains the core exercise but does not describe warm up and cool down protocols, 
which consisted predominantly of 5-10 minutes periods of light-to-moderated intensity activity. Abbreviations: ABP, ambulatory blood pressure; AUGC, area under 
the glucose curve; AUIC, area under the insulin curve; AUNC, area under the non-esterified fatty acid curve; BF, body fat; BMI, body mass index (kg/m2); BP, blood 
pressure systolic/diastolic mm Hg; BW, body weight; CABG, coronary artery bypass graft; CGM, continuous glucose monitoring; CO, cardiac output; CON, control 
group; DBP, diastolic blood pressure; FMD, flow mediated dilations; GET, gas exchange threshold; hr, hour; HRR, heart rate reserve; hsCRP , high sensitivity c-
reactive protein; HDL, high-density lipoprotein; HIIT, high intensity intermittent training group;  IS, insulin sensitivity; ISI; insulin sensitivity index; LVEF, left ventricular 
ejection fraction; min, minutes; MTP, maximum tolerated power (the maximum power output that could be sustained for 1 minute); NEFA, non-esterified fatty acids; 
n.r., not reported; n.s., no statistically significant change/difference; OGTT, oral glucose tolerance test; OGIS, insulin sensitivity calculated from 2 hour oral glucose 
tolerance test; s, seconds; Q, cardiac output; RER, respiratory exchange ratio at rest; RET, resistance exercise training group; RM, repetition maximum; RPE, rate of 
perceived exertion; RQ, respiratory quotient; SBP, systolic blood pressure; SIT, sprint interval training group; slSBR; spontaneous cardiac baroreflex; SV, stroke 
volume; TAG, triacylglycerol; TC, total cholesterol;  TPR, total peripheral resistance; VLDL, very low-density lipoprotein; VT, ventilatory threshold; Wmax, maximum 
workload; WR, work rate.
3.3.3 Weight and Body Composition Changes with High-Intensity 
Intermittent and Sprint Interval Training
The 27 studies reporting body weight and/or composition changes following 
HIIT and SIT are summarised in Table 3.3. Of these 27 (n=423), 11 (n=151) 
reported weight or BMI reductions of 1.1-8.4% 
422,425,464,465,476,478,479,485,490,492-494,498,503, and the rest (n=272) no change 
424,446,466-471,473-475,477,481,486,496,500,502,504. However, the 8.4% reduction was an 
extreme outlier as all other studies reported reductions of 0-2.5%. Further, one 
study included caloric restriction but only reported a 1.1% weight reduction over 
two weeks 494. Fourteen studies reported some measure of fat mass, and of 
these eight reported a reduction 424,476-478,485,492-494, and six no change 
471,473,474,486,496,504. Collectively, 13 studies (n=172) showed a weight reduction 
and/or fat reduction. The only two studies to compare genders both reported no 
change in either body weight or fat mass 471,481. One study, with a female only 
cohort, showed that fat reduction was greater in those with a higher fat mass at 
baseline 485.
Thirteen studies compared HIIT/SIT with CMIE for weight change 
422,423,425,446,451,466-469,474-478,485,493,494,498. Seven reported no weight change in 
either group 424,446,451,466-469,475,477, five reported largely comparable modest 
changes of 1-3.9% 422,425,474,478,485,498,503, and one reported greater weight 
reductions of 8.4% and 5.9% in the HIIT and CMIE group, respectively 493. This 
larger reduction followed 12 weeks of track running five times per week. This is 
in contrast to the majority of studies, which assessed thrice weekly training on 
cycle ergometers or treadmills.
Seven studies compared HIIT/SIT with CMIE for change in body composition 
474-478,485,493. Six reported reductions in the HIIT/SIT and/or CMIE groups relative 
to baseline with either no significant difference between groups or slightly 
greater reductions with HIIT/SIT 474,476-478,485,493. 
Given the heterogeneity of study designs and cohorts, it was not feasible to do 
statistical analysis to ascertain the reason for the discrepancy. However, data 
on weight, body composition, fitness of volunteers, sample size, and duration of 
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each intervention were tabulated in a spreadsheet to facilitate informal analysis. 
Studies reporting weight and/or fat mass reduction tended to be longer or 
contain volunteers with a higher mean VO2peak. However, this conclusion 
requires confirmation via more rigorous analysis preferably of pooled original 
data. It is noteworthy that any weight and body composition changes following 
HIIT/SIT were not only comparable in magnitude to CMIE, but were achieved 
with <50% of the time investment.
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Table 3.3: Weight and Body Composition after High-Intensity Intermittent and Sprint Interval Training
Reference Baseline Population Protocol Weight & Body Composition 
421  8 adults (sex n.r.), type 2 diabetes, 63±8 years, BMI 32±6, VO2peak n.r.  
HIIT: 10 x 1 min intervals at  ~90% HRmax with 1 min rest periods 
3/wk x 2 wk BW n.s.
422, 423, 
425
4 men & 7 women, metabolic syndrome, 55±13 years,  
BMI 30±2, VO2max 34±3
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax with 3 
min recovery periods at 70% HRmax 3/wk x 16 wk BW ↓2.5% 
4 men & 4 women, metabolic syndrome, 52±11 years, 
BMI 29±2, VO2max 36±3
CME: 47 min at 70% HRmax 3/wk for 16 wk (matched for energy 
expenditure with HIIT) BW ↓3.9% 
5 men & 4 women, metabolic syndrome, 50±9 years, 
BMI 32±1, VO2max 32±3 CON: no intervention
BW n.s.
424
11, metabolic syndrome, 50±10 years, BMI 31±4, 
VO2peak 34±10
HIIT: treadmill walking/running at 90-95% HRpeak for 4 min x 4 
bouts with active recovery periods of 3 min at 70% HRpeak x 3/wk 
x 12 wk
BW n.s.; FM ↓7% vs. baseline; FFM 
n.s. 
11, metabolic syndrome, 51±8 years, BMI 32±4, 
VO2peak 32±5 RET: 3 sets of 8-12 repetitions x 3-5 exercises x 3/wk x 12 wk
BW n.s.; FM ↓6% vs. baseline; FFM 
n.s. 
10, metabolic syndrome, 53±10 years, BMI 30±4, 
VO2peak 28±6
HIIT+RET: HIIT as above 2/wk, 3 resistance exercises for 8-12 
repetitions 1/wk, all for 12 wk
BW & FM  n.s.; FFM ↑ n.r. vs. 
baseline
11, metabolic syndrome, 47±10 years, BMI 32±4, 
VO2peak 34±10 CON: no exercise
BW & FM n.s.; FFM ↑ n.r. vs. 
baseline
446
9 men & 5 women, chronic heart failure, 68±6 years, 
BMI 24±n.r., VO2peak 16±4 
HIIT: 5 x 3 min cycling intervals at 80% VO2peak with 3 active 
recovery periods at 40% VO2peak  x 3/wk x 12 wk BW n.s
8 men & 5 women, chronic heart failure, 66±8 years 
BMI 24±n.r., VO2peak 16±3 CME: 30 min cycling at 60% VO2peak x 3/wk x 12 wk BW n.s.
9 men & 4 women, chronic heart failure, 68±9 years, 
25±n.r., VO2peak 21±5 CON: usual care with advice for home-based physical activity BW n.s
Reference Baseline Population Protocol Weight & Body Composition 
464, 465
25 men & 5 women, post myocardial infraction, 57±10 
years, BMI 27±3, VO2peak 32±6
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax with 3 
min recovery periods at 70% HRmax 3/wk x 12 wk
BW n.s
At 6 months: BW n.s.
At 30 months: BW n.s.
49 men & 10 women, post myocardial infraction, 58±9 
years, BMI 27±4, VO2peak 32±7
Group session: 10 min warmup, 35 min aerobic exercise 
(walking/jogging/lunges), 15 min cooldown, stretching & 
relaxation 3/wk x 12 wk
BW n.s.
At 6 months: BW n.s.
At 30 months: BW n.s.
466, 467
24 men & 4 women, following CABG, 60±7 years, 
BMI 26±6, VO2peak 27±5
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax with 3 
min recovery periods at 70% HRmax 5/wk x 4 wk supervised, then 
advised to continue at home
At 4 wk: BW n.s.
At 6 months: BW n.s.
24 men & 7 women, following CABG, 62±8 years, 
BMI 28±4, VO2peak 26±5
CME: 47 min at 70% HRmax 5/wk for 4 wk (matched for energy 
expenditure with HIIT), then advised to continue at home
At 4 wk: BW n.s.
At 6 months: BW n.s.
479
10 men, sedentary overweight/obese 
normoglycaemic/tensive, 32±9 years, BMI 31±4, 
VO2peak 33±1
SIT: 4-7 bouts of 30 s cycle sprints at 6.5% FFM resistance 3/wk 
for 2 wk (sprints/session: 4/4/5/5/6/6) with 4.5 min active at 30 W 
resistance
BW ↓1.1% (p=0.055)
475
7 (sex distribution matched but n.r.), sedentary 
overweight, 41±12 years, BMI 31±3, VO2peak ~23±n.r.
HIIT: 10 x 1 min cycling at 90% VO2peak with 2 min recovery at 
30% VO2peak x 4 sessions/wk for 8 wk, & diet education (1 hour 
seminar)
BW & FM n.s.
6 (sex distribution matched but n.r., sedentary 
overweight, 45±17 years, BMI 30±3, VO2peak ~24±n.r. 
CME: 50% VO2peak matched to energy expenditure of HIIT for 
time x 4 sessions/wk for 8 wk, & diet education (1 hour seminar). BW & FM n.s.
8 (sex distribution matched but n.r.), sedentary 
overweight, 40±13 years, BMI VO2peak ~23±n.r. Diet: diet education only (1 hour seminar). BW & FM n.s.
494
2 men & 8 women, 37±10 years, BMI 32±4, VO2peak 
27±5
HIIT+Diet: Up to 10 x 4 minutes cycling at 90% VO2peak with 2-3 
minutes rest periods, for 6 supervised sessions over 14 days.
(see below for diet)
BW ↓1.1% & FM ↓2.6% vs baseline; 
FFM ↑2.1% vs baseline & Diet
3 men & 6 women, 41±14 years, BMI 32±3, VO2peak 
26±9 Diet: 75% of food record estimated requirement (35% CHO)
BW ↓2.2%, FM ↓2.4% & FFM ↓2.1% 
vs baseline 
Reference Baseline Population Protocol Weight & Body Composition 
473 12 men, overweight/obese, 24±5 years, BMI 29±3, VO2peak 38±6
HIIT: 6 x 4 min cycling at 85% VO2peak, with 2 min rest x 6 
sessions over 14 d. BW n.s.; WC ↓1.4% 
496
20 men, active, 30±5 years, BMI 23±4, VO2peak n.r. HIIT: 4 x 800 m runs at ~90% age predicted HRmax (220-age) with a 1:1 work-to-rest ratio 3/wk x 8 wk BW & BF% n.s. 
16 men, active, 30±5 years, BMI 23±2, VO2peak n.r. CON: no vigorous exercise BW & BF% n.s.
492
20 men, sedentary & overweight, 25±5 years, BMI 
28±1, VO2peak 34±1
SIT: 8 s sprints with 12 s recovery periods at a cadence of 
120-130 & 40, respectively, for 20 min at 80-90% HRpeak x 3/wk 
for 12 w
BW ↓1.7%, FM ↓6.7%, visceral fat 
area ↓10% vs baseline & CON
18 men, sedentary & overweight, 25±4 years, BMI 
29±1, VO2peak 29±1 CON: no exercise BMI, FM & visceral fat area n.s., 
474
8 men, sedentary, 37±8 years, BMI n.r. (BW 96±11 
kg), VO2peak 36±5
HIIT: 5 x 2 min running >95% HRmax with 2 min rest periods 3/wk 
x 12 wk BW & BF% n.s.
9 men, sedentary, 31±6 years, BMI n.r. (86±16 kg), 
VO2peak 39±7
CME: 60 min running at 80% HRmax (~65% VO2peak) 3/wk x 12 
wk BW ↓1.2%, BF% ↓7.0% vs baseline
8 men, sedentary, 36±6 years, BMI n.r. (95±24 kg), 
VO2peak 38±9
RET: 60 min 3-4 sets of:  squat, hack squat, incline leg pres, 
isolated knee extension, hamstring curls, and calf raises 3/wk x 
12 wk
BW ↑1.8% vs. baseline; BF% n.s.
11 men, sedentary, 30±6 years, BMI n.r. (87±11 kg ), 
VO2peak 39±8 CON: no exercise x 12 wk BW & BF% n.s.
Reference Baseline Population Protocol Weight & Body Composition 
481
8 women, sedentary, 23±3 years, BMI 23±2, VO2peak 
33±2 
SIT: cycling 10 min total containing 2 all out sprints for 
10/15/20/20/20/20 s in wk 1-6, respectively, remaining time was 
at 60 W
BW n.s.
8 women, sedentary, 22±1 years, BMI 23±2, VO2peak 
33±2 CON: no exercise BW n.s.
7 men, sedentary, 26±3 years, BMI 24±2, VO2peak 
36±2
SIT: cycling 10 min total containing 2 all out sprints for 
10/15/20/20/20/20 s in wk 1-6, respectively, remaining time was 
at 60 W
BW n.s.
6 men, sedentary, 25±2 years, BMI 24±2, VO2peak 
38±3 CON: no exercise BW n.s.
485
15 healthy women, 22±1 years, BMI 24±2, VO2peak 
29±8
SIT: 3 sessions/wk over 15 weeks: 8 s sprints/12 s active (20-30 
rpm) recovery at 0.5 kg resistance. Progressing from 5 min 
sessions to 20 min sessions with 0.5 kg resistance added once 
20 minutes was achieved 
BW ↓2.4% vs. baseline & ↓4.4% vs 
CON, FM ↓11% vs baseline,  ↓13% 
vs CME & ↓12.5% vs CON; FFM n.s.
15 healthy women, 21±1 years, BMI 22±1, VO2peak 
31±8
CME: 3 sessions/wk over 15 weeks: 10-20 min at 60% VO2peak 
for 10-20 min progressing to 40 minutes BW & FM n.s.
15 healthy women, 22±1 years, BMI 24±1, VO2peak 
31±6 CON: No change in physical activity BW n.s. & FM n.s.
476
3 men & 11 women, sedentary, 47±8 years, BMI 
37±4 , VO2peak 24±5
HIIT: 4 x 4 min treadmill walking/running at 85-95% HRmax with 3 
min recovery periods at 50-60% HRmax 3/wk x 12 wk BW ↓2.0% & FM ↓2.2% vs. baseline
2 men & 11 women, 44±8 years, BMI 37±5, VO2peak 
25±5 CME: 47 min walking/jogging at 50–60% of HRmax BW ↓3.0% & FM ↓2.5% vs. baseline
3 men & 10 women, 46±10 years, BMI 35±1, VO2peak 
25±7
RET: 4 sets of 5 repetitions on leg press/squat & 3 sets of 30 
repetitions on unspecified abdominal & back exercises  BW & FM n.s. 
Reference Baseline Population Protocol Weight & Body Composition 
451, 502
11 women, familial history of hypertension, 24±4 
years, BMI 24+5, VO2max 29±4, BP 106/65
HIIT: walking: 1 min at 80-90% VO2max 2 min walking at 50-60% 
for 40 min + 15 min calisthenics 3/wk x 16 wk BW n.s.
11 women, familial history of hypertension, 27±5 
years, BMI 24±5, VO2max 30±4, BP 105/65
CME: walking at 60-70% VO2max for 40 minutes + 15 min 
calisthenics 3/wk x 16 wk BW n.s.
9 women, familial history of hypertension, 25±4 years, 
BMI 24±4, VO2max 30±4, BP 106/62 CON: No intervention BW n.s.
477
5 men & 5 women, sedentary, 18-32 years, BMI n.r. 
(BW 64±11 kg), VO2peak 39±9
HIIT&SIT:  4 sessions/wk for 15 weeks with a mix of CME at 
70% HRR, SIT (15-30 s intervals at  60-80% WR sustainable for 
10 s) and HIIT (60-90 s intervals at 70-90% WR sustainable for 
90 s) sessions. Recovery periods were based on HR returning to 
120-130 bpm
BW n.s.; sum of six skinfolds ↓14.8% 
vs baseline & ↓9.1% vs CME
8 men & 9 women, sedentary, 18-32 years, BW 
61±13, VO2peak 37±8
CME: 4 sessions/wk x 20 weeks: 30-45 min at 60-85% HRR at 
approximately twice the E expenditure of HIIT&SIT BW n.s.; sum of six skinfolds n.s.
464, 465
17 men & 3 women following percutaneous coronary 
intervention, 57±10 years, BMI 27±4, VO2peak 23±6
HIIT: 4 x 4 min incline treadmill walking at 80-90% HRmax with 3 
min active recovery periods at 60-70% HRmax 3/wk x 26 wk BMI ↓2.2% vs. baseline & CON
16 men & 4 women following percutaneous coronary, 
61±10 years, BMI 28±3, VO2peak 23±6 CON: usual care BMI ↑1.8% 
478
8 (sex n.r.), overweight/obese, 40±8 years, BMI 28±4, 
VO2peak n.r.
HIIT: cycling at 20% above AT at a 2:1 exercise/rest ratio 3/wk x 
12 wk: wk 1-4 for 20, 30, 40, 50 min, respectively, then 60 min 
sessions for 8 wk
BMI ↓1.4 & BF%↓2% vs. baseline
8 (sex n.r.), overweight/obese, 40±8 years, BMI 28±2, 
VO2peak n.r.
CME: cycling at 10% below anaerobic threshold 3/wk x 12 wk: 
wk 1-4 for 20, 30, 40, 50 min, respectively, then 60 min sessions 
for 8 wk 
BMI ↓1.5 & BF% ↓3% vs. baseline
490 10 men & 6 women, sedentary seniors, 72±2 years, BMI 25±1, VO2max 33±6
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax with 3 
min recovery periods at 60-70% HRmax 3/wk x 12 wk BMI ↓1.6% vs. baseline
Reference Baseline Population Protocol Weight & Body Composition 
500 5 men & 3 women, active, 24±1 years, BMI 23±n.r., VO2peak 45±n.r.
HIIT: 4 min cycle intervals at ~90% VO2peak x 10 intervals with 2 
min rest 3/wk x 6 wk BW n.s.
486
35 men & 13 women, active, 24±3 years, BMI 25±n.r., 
VO2peak n.r. (NB: data were reported for the entire 
cohort only with groups matched for VO2peak & sex)
SIT: 4-6 bouts of 30 s cycle sprints 10% BW resistance with 4 
min active recovery (no resistance) 3/wk for 2 wk (bouts/session: 
4/4/5/5/6/6)
BW & BF% n.s.
SIT: 4-6 bouts of 10 s cycle sprints 10% BW resistance with 4 
min active recovery (no resistance) 3/wk for 2 wk (bouts/session: 
4/4/5/5/6/6)
BW & BF% n.s.
SIT: 4-6 bouts of 10 s cycle sprints 10% BW resistance with 2 
min active recovery (no resistance) 3/wk for 2 wk (bouts/session: 
4/4/5/5/6/6)
BW & BF% n.s.
CON: no exercise BW & BF% n.s.
489
12 men, active, 25±4 years, BMI n.r., BW 83±7 kg, 
VO2peak 44±n.r. (NB: data were reported for the entire 
cohort only)
HIIT: 8-12 1 min cycling bouts at 120% WRmax x 8 sessions 
(bouts/session: 8/8/9/9/10/10/12/12) BW ↓2.5% vs baseline
CME: 90-120 min cycling at 65% VO2peak x 8 sessions (time/
session: n.r.) BW ↓3.3% vs baseline
502
7 men, active, 20-40 years, BMI 25±3, VO2peak 37±7 HIIT: 4 x 4 min treadmill running at 90% VO2peak with  min recovery periods at 60% VO2peak 3/wk x 8 wk BW & BF% n.s.
8 men, active, 20-40 years, BMI 23±2, VO2peak 40±16 CON: no intervention BW & BF% n.s.
471
16 men, elderly, 65±4 years, BMI 21±n.r., VO2peak 
27±5 HIIT: 6 x 1 min cycling at VT2 with active recovery at VT1 2/wk x 9 
wk
BW & BF% n.s.
19 women, elderly, 65±4 years, BMI 25±n.r., VO2peak 
19±4 BW & BF% n.s.
Reference Baseline Population Protocol Weight & Body Composition 
493
17 women, BF >30%, 20±1 years, BMI 28±2, VO2peak 
33±4
HIIT: 5 x 3 min of track running at 85% VO2max with 3 min active 
recovery at 50% VO2max 5/wk x 12 wk
BW ↓8.4% & FM ↓10% vs CON & 
CME
16 women, BF >30%, 19±1 years, BMI 28±2, VO2peak 
33±5 CME: 40 min walking/jogging at 50% VO2max 5/wk x 12 wk BW ↓5.9% & FM ↓5.2% vs CON
19 women, BF >30%, 20±1 years, BMI 29±2, VO2peak 
33±4 CON: no exercise BW & FM n.s.
Study population demographics (sample size by sex, health or activity description, body mass index in kg/m2, and either VO2peak or VO2max in mL/kg/min as reported 
by study authors in are provided as means ± standard deviation, where reported, rounded to nearest whole number. Sample sizes are based on those included in 
the final analysis. Results have been converted to percentage change from baseline if the change was statistically significant followed by indication if this was 
significant relative to comparison group(s). Results are rounded to two significant figures. Where data was reported in graph form it may not have feasible to 
accurately calculate percentage change so ~ is used to indicate this. The protocol column contains the core exercise but does not describe warm up and cool down 
protocols, which consisted predominantly of 5-10 minutes periods of light-to-moderated intensity activity. Abbreviations: BF%, percent body fat; BMI, body mass 
index (kg/m2); bpm, beats per minute; BW, body weight; CABG, coronary artery bypass graft; CON, control group; FFM, fat free mass; FM, fat mass; hr, hour or 
hours; HIIT, high intensity intermittent training group;  min, minutes; n.r., not reported; n.s., no statistically significant change/difference; RET, resistance exercise 
training group; RM, repetition maximum; RPE, rate of perceived exertion; SIT, sprint interval training group; VT, ventilatory threshold; WR, work rate.
3.3.4 Metabolic Effects of High Intensity Intermittent and Sprint Interval 
Training
3.3.4.1 Acute Effect on Fasting and Postprandial Metabolism
Studies examining the effects of a single session of HIIT or SIT on postprandial 
and 24-hour metabolism are summarised in Table 3.4. In patients with type 2 
diabetes HIIT improved 24-hour and postprandial glucose control 420. In patients 
with metabolic syndrome, fasting plasma glucose was reduced for 72 hours 
following HIIT, whereas a reduction of comparable magnitude following CMIE 
was observed at 24 but not 72 hours 423. Unsurprisingly, fasting glucose was 
unaffected by HIIT or SIT in individuals with normal glucose control as was 
insulin sensitivity 72 hours post-exercise 82,505,506. The postprandial insulin and 
glucose concentrations following a high fat mixed meal were similarly 
unaffected by SIT in healthy active individuals 82,507. However, both an HIIT and 
CMIE protocol resulted in a reduced postprandial insulin response following a 
high fat meal 83. This latter cohort was larger, had a higher average VO2peak, and 
exercised to expend 500 kcal/session on a longer protocol than the two cohorts 
reporting no effect of SIT. Some or all of these factors may account for the 
difference in findings between studies. But the most plausible explanations is 
that glycogen depletion is a mediator of exercise related insulin sensitisation 
508-510, and depletion may have been inadequate following SIT. Both SIT and 
HIIT protocols reduced postprandial plasma triacylglycerol response 82,83,507. 
This response was similar for CMIE when postprandial response was tested 
shortly after exercise 83, but was not maintained when tested the day following 
exercise 507, suggesting superior longevity of the effect induced by higher 
intensity exercise.
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Table 3.4: Acute Effects of High-Intensity Intermittent and Sprint Interval Training on Metabolism
Reference Baseline Population Protocol Metabolism
420
7 adults (sex n.r.), type 2 
diabetes, 63±3 years, BMI 
31±2, VO2peak n.r.
HIIT: 10 x 60 s  cycling at ~89% WRmax with 60 s 
passive rest periods 
Relative to values on a non-exercising control day: 3 hr postprandial 
GAUC ~↓35%, post meal peak glucose ↓16%, time in hyperglycaemia 
↓65% 
423
4 men & 7 women, metabolic 
syndrome, 55±13 years, BMI 
30±2, VO2max 34±3
HIIT: 4 x 4 min incline treadmill walking at 90-95% 
HRmax with 3 min recovery periods at 70% HRmax  
FG ↓~15% below baseline for 72 hr vs CON
4 men & 4 women, metabolic 
syndrome, 52±11 years, BMI 
29±2, VO2max 36±3
CME: 47 min at 70% HRmax (matched for energy 
expenditure with HIIT)
FG ↓~15% below baseline for 24 hr 
5 men & 4 women, metabolic 
syndrome, 50±9 years, BMI 
32±1, VO2max 32±3
CON: resting FG n.s.
506 8 men, healthy, 42±4 years, BMI 29±1, VO2max 53±3
HIIT: 4 x 4 min intervals of treadmill running at 85-95% 
HRmax interspersed with 3 min at  50-60% HRmax 
followed by high fat meal 16-18 hours later
N.s. effect on 30 min, 2 hr, and 4 hr postprandial glucose, TAG or HDL 
between groups.
CME: 47 min of treadmill walking at 60-70% HRmax (to 
achieve an isocaloric protocol to HIIT) followed by high 
fat meal 16-18 hours later
CON: no exercise followed by high fat meal 16-18 
hours later
505
5 men & 7 women, sedentary 
or active, 24±3 years, BMI 
26±4, VO2peak 38±12
SIT: 6 bouts of 30 s cycle sprints at 7.5% BW 
resistance x 1 session with 4 min active or passive 
recovery between sprints
72 hours post exercise: FG, insulin & ISI (hyperinsulinemic euglycemic 
clamp) n.s.
Reference Baseline Population Protocol Metabolism
82
6 men, active, 22±3 years, 
BMI 25±n.r., & 6 women, 
active 21±1 years, BMI 
22±n.r., VO2peak n.r.
SIT1: 30 s cycle sprint at 8.8% BW resistance with 4 
min active recovery (no resistance) x 4 in the evening; a 
high fat mixed meal was consumed after a 13 hour 
overnight fast
Fasting: glucose, TAG, glucose, insulin & NEFA n.s. from SIT2 & CON; 
Postprandial AUC vs CON: TAG ↓21%; glucose, insulin & NEFA n.s.
Postprandial AUC vs SIT2: TAG ↓12%; glucose, insulin & NEFA n.s.
SIT2: as above, but the energy used during exercise 
was replaced immediately post exercise
FG, TAG, insulin & NEFA n.s. from SIT1 & CON; 
Postprandial AUC vs. CON: TAG ↓10%; glucose, insulin & NEFA n.s. 
CON: no exercise followed by a high fat mixed meal 
consumed after a 13 hour overnight fast
CON used as comparison group only with no within group baseline vs. 
post meal comparisons
83 20 men, active, 22±4 years, BMI 23±3, VO2max 53±8
HIIT: treadmill running at 115% AT for 3 min intervals 
with 1.5 min passive rest periods until 500 kcal were 
expended; high-fat meal 30 min post exercise
Postprandial AUC vs CON: TAG ↓15%, insulin ↓21, VLDL ↓13%
Postprandial AUC vs CME: 
CME: treadmill running at 85% AT until 500 kcal were 
expended; high-fat meal 30 min post exercise
Postprandial AUC vs CON: TAG ↓18%, insulin ↓25%, VLDL n.s.
CON: no exercise; high-fat meal after 30 min rest CON used as comparison group only with no within group baseline vs. 
post meal comparisons
507 9 men, active, 24±3 years, BMI 25±n.r., VO2peak n.r.
SIT: 30 s cycle sprint at 7.5% BW resistance with 4 min 
active recovery (no resistance) x 5 at 1400 hr; see next 
day meal below
Insulin & glucose response n.s. between groups; TAG AUC ~↓30% v.s. 
CON
CME: 30 min brisk (~7 km/h) treadmill walking at 1400 
hr; ; see next day meal below
Insulin, glucose, and TAG AUC n.s. vs CON
CON: 30 min resting at 1400 hr; ; see next day meal 
below
CON used as comparison group only with no within group baseline vs. 
post meal comparisons
Test day: at 0900 the next day a high fat (~59 g fat, ~76 g carbohydrate, 26 g protein) was consumed. An identical meal was 
consumed at lunch
Study population demographics (sample size by sex, health or activity description, body mass index in kg/m2, and either VO2peak or VO2max in mL/kg/min as reported 
by study authors in are provided as means ± standard deviation, where reported, rounded to nearest whole number. Sample sizes are based on those included in 
the final analysis. Results have been converted to percentage change from baseline if the change was statistically significant followed by indication if this was 
significant relative to comparison group(s). Results are provided to two significant figures. Where data was reported in graph form it may not have feasible to 
accurately calculate percentage change so ~ is used to indicate this. The protocol column contains the core exercise but does not describe warm up and cool down 
protocols, which consisted predominantly of 5-10 minutes periods of light-to-moderated intensity activity. Abbreviations: AT, anaerobic threshold; AUC, are under 
the curve; BMI, body mass index in kg/m2; BW, body weight; FAS, fatty acid synthase; FG, fasting plasma glucose concentration; h, hour(s), ISI, insulin sensitivity 
index; MAP, maximal aerobic power; min, minutes; n.r., not reported or data not presented in non numerical formats; s, seconds; TAG, triacylglycerol.
3.3.4.2 Effect of Multiple Bouts
Studies reporting the metabolic effects of HIIT and SIT are summarised in Table 
3.5. 
3.3.4.2.1 Glucose Control and Insulin Sensitivity 
Fourteen studies reported fasting glucose (n=179) 
422,424,445,446,467,473,474,479,485,488,492,494,505,511, and three noted a reduction post-
intervention 422,445,474. Two further studies noted a reduction in fasting insulin 
only 485,511. Studies reporting change generally had greater baseline fasting 
glucose than those reporting no change. Further, the majority of studies showed 
a trend toward fasting glucose reduction even when this did not reach statistical 
significance. The three exceptions were in cohorts with chronic heart failure 446, 
recent coronary artery bypass grafts 467, and metabolic syndrome 424. In the 
case of the first two studies the conditions of the patients severely limited the 
absolute intensity of the exercise, which may explain the discrepancy in 
findings. Not finding an effect in metabolic syndrome is less readily explicable. 
A weight reduction of ~2.5% may have been a contributing factor in the 
observed change of two studies (see Table 3.3) 422,455, but a third study reported 
reduced fasting glucose without weight change 445 while one study omitted 
reporting post-intervention weight 511. Unfortunately, fasting measures are a 
relatively insensitive to metabolic changes 512,513.
Only seven studies assessed glucose control and/or insulin sensitivity by more 
rigorous means: five by oral glucose tolerance test (n = 59) 474,479,481,488,494, one 
by 24-hour continuous glucose monitoring 421, and one by hyperinsulaemic 
euglycemic clamp 505. Some studies reported reductions in the area under the 
insulin curve 479,488, area under the glucose curve 488, improved insulin 
sensitivity index479,481,488, or clamp assessed insulin sensitivity 505. The last 
study highlighted heterogeneity in response – insulin sensitivity improved in 10 
volunteers, remained unchanged in one, and worsened in one 505. The only 
study conducted in patients with type 2 diabetes reported reductions in 24-hour 
and postprandial glucose 421. However, studies in normal and overweight/obese 
adults without marked glucose intolerance reported no significant changes in 
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area under the insulin curve 481, or area under the glucose curve 479,481. The one 
study to conduct assessments at multiple time points post-exercise reported 
changes in area under the insulin curve and insulin sensitivity index at 24 but 
not 72 hours post-intervention 479. Given the common practice to ask volunteers 
to not undertake vigorous physical activity for 48-72 hours prior to metabolic 
assessment, this may explain discrepancies in study findings.
Six studies compared HIIT/SIT with CMIE 422,445,446,467,474,485, and two with 
resistance training 424,474. Overall, the reports suggest HIIT and SIT 
interventions are comparable or slightly superior to CMIE and conventional 
resistance exercise for improving markers of glucose control 422,445,474,485. 
3.3.4.2.2 Fasting & Postprandial Lipids
Several studies reported pre- and post-intervention fasting lipids: nine 
triacylglycerol422,424,445,446,466,468,479,492,494,504, five total cholesterol 445,474,475,494,496, 
nine high-density lipoprotein cholesterol 424,445,446,466-469,474,475,479,496, and five and 
low-density lipoprotein cholesterol 445,446,474,475,494. Only two studies reported any 
change - an increase in high-density lipoprotein cholesterol 466,468,496. One study 
reported reductions in total and low-density lipoprotein cholesterol, and 
triacylglycerol 494, however this study also employed a calorie-restricted diet, 
which achieved similar reductions without an HIIT component. Studies 
comparing HIIT/SIT with CMIE and conventional resistance training indicated 
that the effects of the latter two were no better. One notable finding was a 
reduction in circulating very low-density lipoprotein triacylglycerol following eight 
weeks of HIIT 504. The observed reduction was shown to relate to reduced 
hepatic secretion rather than changes in clearance.
3.3.4.2.3 Substrate Utilisation
Four studies reported markers of substrate utilisation following HIIT: two 
reported no change in respiratory exchange ratio 48 and 72 hours post-
exercise, respectively 504,505; one reported a reduction in respiratory quotient 492; 
and one study showed marked increases in fat oxidation and reduction in 
carbohydrate oxidation 15-60 minutes following exercise 501. Again, the most 
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plausible explanation for the differences in findings is the difference in elapsed 
time between the last bout of exercise and the assessment.
3.3.4.3 Summary of Metabolic Changes following High-Intensity Intermittent and 
Sprint Interval Training
HIIT and SIT were similarly effective to CMIE in improving glucose control and/
or insulin sensitivity in populations where these are impaired, and at a 
substantially reduced time commitment. HIIT and SIT appear to have little 
capacity to modify fasting blood lipids. It is unfortunate that none of the studies 
assessing blood lipids following multiple exercise sessions measured 
postprandial lipid response as this was shown to be improved in single bout 
studies. Interestingly, studies reporting improvements with HIIT/SIT also tended 
to report improvements with CMIE, and vice versa, further suggesting that 
assessment methods and timing at least partly account for inter-study 
discrepancies.
Future studies and clinical exercise prescriptions should take into account that 
metabolic changes following exercise can be short-lived. The common practice 
of asking study volunteers to refrain from vigorous activity for 48-72 hours prior 
to metabolic assessments may explain negative findings in several small 
studies. It would seem prudent to assess metabolic response consistent with 
the frequency of the exercise prescription; e.g. in a thrice weekly intervention 
with evenly spaced exercise sessions volunteers would, in theory, never go 
more than 48 hours without exercise. Assessing the ʻchronicʼ effects of exercise 
would best be achieved by measuring longer-term metabolic markers such as 
HbA1c. Further, postprandial rather than fasting assessments are likely to be 
both more sensitive and more meaningful. 
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Table 3.5: Metabolism after Prolonged High-Intensity Intermittent or Sprint Interval Training
Reference Baseline Population Protocol Metabolism
421  8 adults (sex n.r.), type 2 diabetes, 63±8 years, BMI 32±6, VO2peak n.r.  
HIIT: 10 x 1 min intervals at  ~90% HRmax with 1 min rest 
periods 3/wk x 2 wk
 CGM (24 hours): mean glucose ↓13%, 24 hr 
AUGC ↓14%, sum of 3 hr postprandial AUGC 
↓30%.
422, 423, 425
4 men & 7 women, metabolic syndrome, 
55±13 years, BMI 30±2, VO2max 34±3
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax with 
3 min recovery periods at 70% HRmax 3/wk x 16 wk
IS (from HOMA) ↑24% vs baseline & CME & 
CON; FG ↓4.3% vs. baseline; TAG n.s.
4 men & 4 women, metabolic syndrome, 
52±11 years, BMI 29±2, VO2max 36±3
CME: 47 min at 70% HRmax 3/wk for 16 wk (matched for 
energy expenditure with HIIT) IS (from HOMA), FG & TAG n.s.
5 men & 4 women, metabolic syndrome, 50±9 
years, BMI 32±1, VO2max 32±3 CON: no intervention
IS (from HOMA), TAG & FG n.s.
424
11, metabolic syndrome, 50±10 years, BMI 
31±4, VO2peak 34±10
HIIT: treadmill walking/running at 90-95% HRpeak for 4 min x 4 
bouts with active recovery periods of 3 min at 70% HRpeak x 3/
wk x 12 wk
TAG, HDL & FG n.s. 
11 (sex n.r.), metabolic syndrome, 51±8 years, 
BMI 32±4, VO2peak 32±5 RET: 3 sets of 8-12 repetitions x 3-5 exercises x 3/wk x 12 wk TAG, HDL & FG, n.s. 
10 (sex n.r.), metabolic syndrome, 53±10 
years, BMI 30±4, VO2peak 28±6
HIIT+RET: HIIT as above 2/wk, 3 resistance exercises for 8-12 
repetitions 1/wk, all for 12 wk TAG, HDL & FG n.s. 
11 (sex n.r.), metabolic syndrome, 47±10 
years, BMI 32±4, VO2peak 34±10 CON: no exercise TAG, HDL & FG n.s. 
446
9 men & 5 women, chronic heart failure, 68±6 
years, BMI 24±n.r., VO2peak 16±4 
HIIT: 5 x 3 min cycling intervals at 80% VO2peak with 3 active 
recovery periods at 40% VO2peak  x 3/wk x 12 wk FG, TC, HDL, LDL, & TAG n.s.
8 men & 5 women, chronic heart failure, 66±8 
years BMI 24±n.r., VO2peak 16±3 CME: 30 min cycling at 60% VO2peak x 3/wk x 12 wk FG, TC, HDL, LDL, & TAG  n.s.
9 men & 4 women, chronic heart failure, 68±9 
years, 25±n.r., VO2peak 21±5 CON: usual care with advice for home-based physical activity FG, TC, HDL, LDL, & TAG n.s
Reference Baseline Population Protocol Metabolism
445
8 men, post infarction heart failure, 62±8 
years, BMI 28±2, VO2peak 19±5
HIIT: 2-4 x 4 min incline treadmill walking at 75-80% HRR with 
3 min active recovery at 45-50% HRR 3-5/wk x 12 week 
(sessions/week:2/2/2/3//3/3/4/4/4/5/5/5)
FG ↓10% vs baseline; insulin, HOMA-IR & TAG 
n.s. vs baseline but greater reductions than 
CME; TC, HDL & LDL n.s.
8 men, post infarction heart failure, 63±9 
years, BMI 27±3, VO2peak 18±4
CME: 30-45 min incline treadmill walking at 45-60% HRR 3-5/
wk x 12 week (sessions/week:2/2/2/3//3/3/4/4/4/5/5/5) with 
variables matched to the HIIT group week by week
TC ↓6%; FG, insulin, HOMA-IR, HDL, LDL, & 
TAG n.s.
466, 467
25 men & 5 women, post myocardial 
infraction, 57±10 years, BMI 27±3, VO2peak 
32±6
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax with 3 
min recovery periods at 70% HRmax 3/wk x 12 wk
HDL ↑3% vs baseline; TAG n.s.
At 6 months: HDL declined to baseline level; 
TAG n.s.
49 men & 10 women, post myocardial 
infraction, 58±9 years, BMI 27±4, VO2peak 
32±7
Group session: 10 min warmup, 35 min aerobic exercise 
(walking/jogging/lunges), 15 min cooldown, stretching & 
relaxation.
HDL & TAG n.s.
At 6 months: HDL & TAG n.s.
468, 469
24 men & 4 women, following CABG, 60±7 
years, BMI 26±6, VO2peak 27±5
HIIT: 4 x 4 min incline treadmill walking at 90-95% HRmax with 3 
min recovery periods at 70% HRmax 5/wk x 4 wk supervised, 
then advised to continue at home
At 4 wk: HDL & glucose n.s.
At 6 months: HDL & glucose n.s.
24 men & 7 women, following CABG, 62±8 
years, BMI 28±4, VO2peak 26±5
CME: 47 min at 70% HRmax 5/wk for 4 wk (matched for 
energy expenditure with HIIT), then advised to continue at 
home
At 4 wk: HDL & glucose n.s.
At 6 months: glucose & HDL n.s.
479 10 men, sedentary overweight/obese, 32±9 years, BMI 31±4, VO2peak 33±1
SIT: 4-7 bouts of 30 s cycle sprints at 6.5% FFM resistance 3/
wk for 2 wk (sprints/session: 4/4/5/5/6/6) with 4.5 min active at 
30 W resistance
AUIC ↓15% & ISI ↑23% 24 hr post last session 
but n.s. 72 hr post; AUGC, TAG, HDL, FG, 
fasting insulin all n.s. at 24 & 72 hours post last 
session 
Reference Baseline Population Protocol Metabolism
474
7 (sex n.r.), sedentary overweight, 41±12 
years, BMI 31±3, VO2peak ~23±n.r.%
HIIT: 10 x 1 min cycling at 90% VO2peak with 2 min recovery at 
30%  VO2peak x 4 sessions/wk for 8 wk, & diet education (1 
hour seminar)
TC, LDL-C & HDL-C n.s.
6 (sex n.r.), sedentary overweight, 45±17 
years, BMI 30±3, VO2peak ~24±n.r.% 
CME: 50% VO2peak matched to energy expenditure of HIIT for 
time, & diet education (1 hour seminar). TC, LDL-C & HDL-C n.s.
8 (sex n.r.)., sedentary overweight, 40±13 
years, BMI VO2peak ~23±n.r.% Diet: diet education only (1 hour seminar). TC, LDL-C & HDL-C n.s.
494
2 men & 8 women, obese, 37±10 years, BMI 
32±4, VO2peak 27±5
HIIT+Diet: Up to 10 x 4 minutes cycling at 90% VO2peak with 
2-3 minutes rest periods, for 6 supervised sessions over 14 
days.
(see below for diet)
TC ↓7.8%, LDL ↓7.1%, TAG ↓27% vs 
baseline; FG, fasting insulin, 2 hr glucose, & 
AUGC n.s.
3 men & 6 women, obese, 41±14 years, BMI 
32±3, VO2peak 26±9 Diet: 75% of food record estimated requirement (35% CHO)
TC ↓10%, LDL ↓7.6%, TAG ↓27% vs baseline; 
FG, fasting insulin, 2 hr glucose, & AUGC n.s.
473 12 men, overweight/obese, 24±5  years, BMI 29±3, VO2peak 38±6
HIIT: 6 x 4 min cycling at 85% VO2peak, with 2 min rest x 6 
sessions over 14 d. FG, & fasting insulin n.s.
505
2 men & 7 women, sedentary or active, 29±9 
years, BMI 26±4, VO2peak 33±6
SIT: 4-7 bouts of 30 s cycle sprints at 7.5% BW resistance 3/
wk for 2 wk (sprints/session: 4/5/6/6/7/4) with 4 min active or 
passive recovery between sprints
IS (from hyperinsulinemic euglycemic clamp) 
↑~20% (72 hours post last exercise session); 
RER n.s. vs. CON; FG, insulin & NEFA n.s.
2 men & 8 women, sedentary or active, 23±3 
years, BMI 28±5, VO2peak 35±9 CON: no exercise
IS (from hyperinsulinemic euglycemic clamp); 
RER, FG, insulin & NEFA n.s.
496
20 men, active, 30±5 years, BMI 23±4, 
VO2peak n.r.
HIIT: 4 x 800 m runs at ~90% age predicted HRmax (220-age) 
with a 1:1 work-to-rest ratio 3/wk x 8 wk
HDL ↑18%, TC/HDL ↓18% vs baseline & CON; 
TC n.s. 
16 men, active, 30±5 years, BMI 23±2, 
VO2peak n.r. CON: no vigorous exercise TC, HDL & TC/HDL n.s.
Reference Baseline Population Protocol Metabolism
511 4 men & 3 women, sedentary, 45±5 years, BMI 27±5, VO2peak 30±3
HIIT: 1 min intervals at 60% Wmax with 1 min active recovery at 
30 W resistance x 10 intervals x 3/wk x 2 wk
72 hr post last exercise: insulin ↓16%; HOMA-
IR ↓35%; glucose n.s.
492
20 men, sedentary & overweight, 25±5 years, 
BMI 28±1, VO2peak 34±1
SIT: 8 s sprints with 12 s recovery periods at a cadence of 
120-130 & 40 RPM, respectively, for 20 min at 80-90% HRpeak 
x 3/wk for 12 w
RQ ↓2.4% vs. CON; glucose, HOMA-IR, TAG 
& TC n.s.
18 men, sedentary & overweigh, 25±4 years, 
BMI 29±1, VO2peak 29±1 CON: no exercise Only used as a comparator for SIT
474
8 men, sedentary, 37±8 years, BMI n.r. (BW 
96±11 kg), VO2peak 36±5
HIIT: 5 x 2 min running >95% HRmax with 2 min rest periods 3/
wk x 12 wk FG↓8.8% & 2-hr glucose ↓16% (OGTT); fasting insulin, TC, LDL, & HDL n.s.
9 men, sedentary, 31±6 years, BMI n.r. (86±16 
kg), VO2peak 39±7
CME: 60 min running at 80% HRmax (~65% VO2peak) 3/wk x 12 
wk
FG ↓8.8% & 2-hr glucose ↓13% (OGTT) vs 
baseline; TC, LDL-C, & HDL-C n.s.
8 men, sedentary, 36±6 years, BMI n.r. (95±24 
kg), VO2peak 38±9
RET: 60 min 3-4 sets of:  squat, hack squat, incline leg pres, 
isolated knee extension, hamstring curls, and calf raises 3/wk 
x 12 wk
TC↑10%; FG, 2-hr glucose (OGTT), fasting 
insulin, LDL-C, & HDL-C n.s.
11 men, sedentary, 30±6 years, BMI n.r. 
(87±11 kg ), VO2peak 39±8 CON: no exercise x 12 wk
FG, 2-hr glucose (OGTT), fasting insulin, TC, 
LDL-C, & HDL-C n.s.
481
8 women, sedentary, 23±3 years, BMI 23±2, 
VO2peak 33±2 
SIT: cycling 10 min total containing 2 all out sprints for 
10/15/20/20/20/20 s in wk 1-6 x 3/wk, respectively, remaining 
time was at 60 W
Glucose AUC ↑6% vs baseline but n.s. vs 
CON; insulin AUC (OGGT), & ISI (Cederholm) 
n.s.
8 women, sedentary, 22±1 years, BMI 23±2, 
VO2peak 33±2 CON: no exercise
Glucose AUC ↑14% vs baseline; insulin AUC 
(OGGT), & ISI (Cederholm) n.s. vs baseline or 
CON
481
Reference Baseline Population Protocol Metabolism
481
7 men, sedentary, 26±3 years, BMI 24±2, 
VO2peak 36±2
SIT: cycling 10 min total containing 2 all out sprints for 
10/15/20/20/20/20 s in wk 1-6 x 3/wk, respectively, remaining 
time was at 60 W
ISI (Cederholm) ↑28%; glucose & insulin AUC 
(OGGT) n.s. vs baseline or CON
6 men, sedentary, 25±2 years, BMI 24±2, 
VO2peak 38±3 CON: no exercise
glucose & insulin AUC (OGGT), & ISI 
(Cederholm) n.s.
501 10 women, active, 22±1 years, BMI n.r. (BW 65±2 kg), VO2peak ~43±n.r.
HIIT: 10 x 4 min cycling at 90% VO2peak with 2 min active rest 
periods 3/wk x 6 wk
Baseline vs wk 2 15-60 min post exercise: FA 
oxidation ↑64%, CHO ↓18% oxidation.
Baseline vs wk 6 15-60 min post exercise: FA 
oxidation ↑68%, CHO ↓21% oxidation.
488 16 men, active, 22±2 years, BMI 24±3, VO2peak 48±9 
SIT: 4-6 30 s cycle sprints against resistance of 7.5% BW with 
4 min unloaded cycling between sprints x 3/wk x 2 wk (sprints 
per session: 4/4/5/5/6/6)
Glucose AUC ↓12%, insulin AUC ↓37%, IS 
(Cederholm index) ↑23%, NEFA AUC ↓26%
485
15 healthy women, 22±1 years, BMI 24±2, 
VO2peak 29±8
SIT: 3 sessions/wk over 15 weeks: 8 s sprints/12 s active 
(20-30 rpm) recovery at 0.5 kg resistance. Progressing from 5 
min sessions to 20 min sessions with 0.5 kg resistance added 
once 20 minutes
HOMA-IR ↓33% vs baseline but n.s. vs. CME 
& CON; fasting insulin ↓31% vs baseline & 
CON
15 healthy women, 21±1 years, BMI 22±1, 
VO2peak 31±8
CME: 3 sessions/wk over 15 weeks: 10-20 min at 60% VO2peak 
for 10-20 min progressing to 40 minutes 
HOMA-IR ↓11% but n.s. vs CON, fasting 
insulin ↓9% vs baseline but n.s. vs CON
15 healthy women, 22±1 years, BMI 24±1, 
VO2peak 31±6 CON: no change in physical activity
HOMA-IR n.s. vs baseline, fasting insulin n.s. 
vs baseline
495
7 men, active, 20-40 years, BMI 25±3, VO2peak 
37±7
HIIT: 4 x 4 min treadmill running at 90% VO2peak with  min 
recovery periods at 60% VO2peak 3/wk x 8 wk
48 hr post last session RER, NEFA, TAG n.s.; 
VLDL-TAG ↓28% vs baseline & CON
8 men, active, 20-40 years, BMI 23±2, VO2peak 
40±16 CON: no intervention RER, NEFA, TAG & VLDL-TAG n.s.
Study population demographics (sample size by sex, health or activity description, body mass index in kg/m2, and either VO2peak or VO2max in mL/kg/min as reported 
by study authors in are provided as means ± standard deviation, where reported, rounded to nearest whole number. Sample sizes are based on those included in 
the final analysis. Results have been converted to percentage change from baseline if the change was statistically significant followed by indication if this was 
significant relative to comparison group(s). Results are rounded to two significant figures. Where data was reported in graph form it may not have feasible to 
accurately calculate percentage change so ~ is used to indicate this. The protocol column contains the core exercise but does not describe warm up and cool down 
protocols, which consisted predominantly of 5-10 minutes periods of light-to-moderated intensity activity. Abbreviations: AUC, area under the curve; BMI, body 
mass index (kg/m2); BW, body weight; CABG, coronary artery bypass graft; CGM, continuous glucose monitoring; CON, control group; FG, fasting plasma glucose 
concentration; hr, hour or hours; HRR, heart rate reserve; HDL, high-density lipoprotein; HIIT, high intensity intermittent training group;  IS, insulin sensitivity; ISI; 
insulin sensitivity index; min, minutes or minutes; NEFA, non-esterified fatty acids; n.r., not reported; n.s., no statistically significant change/difference; OGTT, oral 
glucose tolerance test; OGIS, insulin sensitivity calculated from 2-hour oral glucose tolerance test; s, seconds; RER, respiratory exchange ratio; RET, resistance 
exercise training group; RM, repetition maximum; RPE, rate of perceived exertion; RPM, revolutions per minute; RQ, respiratory quotient; SIT, sprint interval training 
group; TAG, triacylglycerol; TC, total cholesterol; VLDL, very low-density lipoprotein; Wmax, maximum workload.
3.3.5 Study Protocols and Study Quality
A broad range of exercise protocols were used (see Tables 3.1 - 3.5). The 
duration of multi-session interventions was between 2 and 26 weeks with the 
single most common duration being 12 weeks. Session frequency was ranged 
between 1.5 and 5 times per week, but was usually three times per week with 
only 5 studies exceeding this. The criteria for HIIT interventions are provided in 
Section 3.2.3 above. Most protocols accumulated between 10 and 16 minutes 
at high intensity using either cycle ergometers or treadmills; consistent with 
what is generally available in an exercise laboratory setting. SIT in healthy 
populations commonly involved some variant of the Wingate protocol: 30 
second all out efforts against a resistance of 5-10% of an individuals body 
weight with either passive or low intensity active rest. SIT was also used in 
cardiac rehabilitation settings, but in this scenario submaximal rather than 
supramaximal efforts were required, i.e. although interval length met the 
proposed definition of SIT in Section 3.2.3, the intensity of the effort was 
consistent with the definition for HIIT. 
In the studies reviewed, sample sizes tended to be low and exercise sessions 
were either always or frequently supervised. This is suited to establishing 
efficacy and may even reflect effectiveness in cardiac rehabilitation and similar 
short-term supervised approaches to clinical exercise, but it is a poor model for 
assessing the likely effectiveness of such interventions in the community where 
cost prohibits close supervision of the many people with NAFLD and related 
conditions. Thus most if not all these trials are essentially phase 1 or phase 2 in 
nature, and their protocols remain to be tested in trials designed to assess 
effectiveness in a scenario more closely reflecting the clinical situation.
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3.4 Summary and Conclusion
The studies reviewed suggest that, provided undiagnosed and unstable 
cardiovascular disease is ruled out, HIIT has a good safety profile and is well 
tolerated in a range of healthy and clinical populations relevant to NAFLD. 
Indeed the limited number of reports assessing patient preference indicate 
many would prefer an intermittent approach to their exercise sessions and, 
despite greater intensities being reached, perceive such an approach as overall 
less hard than the same amount of work performed in a continuous fashion. The 
safety of SIT using supramaximal aerobic intensities have not been tested in 
groups with or at high risk of heart disease, so it is prudent not to use this 
approach in clinical populations as present. Further, SIT may simply be too hard 
for some deconditioned patients to perform as intended, although this is not 
clearly established.
HIIT and SIT at frequencies of three or more times per week and a total time or 
20-40 minutes per session, have consistently been reported to result in 
substantial and rapid improvements in cardiorespiratory fitness and work 
capacity. These improvements have generally exceeded those observed in 
CMIE groups when matched for total work, and been similar even when the 
total work performed for HIIT or SIT was well below that performed by CMIE 
groups. Although not as consistent across studies, reports in patients with or at 
elevated risk of hypertension showed a reduction in blood pressure and 
improvements in other haemodynamic responses following single and multiple 
bouts of HIIT. Given the inverse association of physical activity and 
cardiorespiratory fitness and intrahepatic fat 232,233,238,239, the strong tendency 
toward sedentariness in those with NAFLD 237, and the inverse association 
between physical activity and disease progression 208,240, HIIT presents a 
plausible and time efficient means by which to reduce intrahepatic fat and risk of 
disease progression. 
Studies to date showed a tendency toward modest weight reduction and, more 
consistently, positive changes in body composition following 12 or more weeks 
of HIIT. Further, single bouts of HIIT improved glucose control in patients with 
type 2 diabetes and metabolic syndrome and even healthy young volunteers, 
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but in the latter case only when exercise related energy expenditure was high. 
Single bouts of both HIIT and SIT also reduced postprandial lipid response. The 
majority of studies in populations with impaired glucose tolerance/insulin 
resistance also reported improvements in glucose control and/or insulin 
sensitivity following multiple sessions of HIIT and SIT, whereas studies in 
normoglycaemic populations were equivocal. A likely confounding factor was 
the heterogeneity of time between last bout of exercise and measurements 
being made. Further, despite acute changes to postprandial lipid metabolism, 
fasting lipids commonly assessed in clinical practice appeared largely 
unaffected by HIIT or SIT. Overall, changes to metabolism were generally only 
detectable 24-48 hours following exercise suggesting a frequency of roughly 
every other day is appropriate and tolerable. Of note is that HIIT and SIT 
induced changes tended to last longer than those following CMIE.
The principle of HIIT, although most frequently tested on cycle ergometers and 
treadmills, can easily be applied to a range of equipment available to patients in 
their homes or at commercial fitness facilities. It is also feasible to apply HIIT 
approaches to outdoor walking/running/jogging or cycling. Although not formally 
assessed, the use of cycle ergometers most likely provides the safest option for 
many patients as there is minimal joint impact, low likelihood of falling, and it 
can take place in a safe controlled environment. Although most studies 
employed supervised exercise with prescriptions based on preset parameters 
such as cycle resistance or treadmill speed and incline, using self-assessed 
rating of perceived exertion was equally effective. Such self-guided intensity is 
much more applicable in the clinical context. 
Thus HIIT has a good potential to be a safe and well tolerated, and above all 
time efficient means by which to improve fitness, metabolic health, and 
potentially body composition in patients with NAFLD.
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Chapter 4. The Physiological Effect of Age and Activity on 
Metabolism Study
4.1 Introduction
The prevalence of metabolic conditions such as non-alcoholic fatty liver disease 
(NAFLD) 5, metabolic syndrome 514,515, and type 2 diabetes increases with age 
516,517. Similarly, the prevalence of metabolic diseases and the risk of all-cause 
mortality increases with increasing sedentary time and decreasing physical 
activity 518. Further, low cardiorespiratory fitness, independent of BMI, is 
associated with increased general morbidity and mortality, particularly in relation 
to metabolic diseases and cardiovascular conditions 519-523, and also cancer 524. 
There is an inverse association of cardiorespiratory and muscular fitness with 
parameters such as intrahepatic triacylglycerol (IHTAG) concentration 8,239, 
insulin resistance 519, and all cause mortality 525-529. The association of better 
physical fitness with better long-term health prospects was still evident among 
populations already with impaired fasting glucose 527, type 2 diabetes 527,530, and 
pre-existing cardiovascular disease 526,531,532. This is still evident among the 
those aged over 80 years 533.
Age and physical activity are generally closely and inversely associated 534, 
which in turn explains at least some of the association between age and 
metabolic conditions. Thus there is a need to identify to what extent the 
unmodifiable risk factor of chronological age and the readily modifiable risk 
factor of inactivity account for shifts in disease prevalence and severity. And a 
further need to identify to what extent cardiorespiratory fitness influences this 
relationship.
To address these questions, cross-sectional data were collected from three age 
groups of women 20-30 years (young), 40-50 years (middle-aged), and 65 
years and over (older). Data were subdivided into those from sedentary and 
active volunteers. Step count was averaged over seven days; volunteers with a 
daily step count under 7500 were admitted to the study as the sedentary group 
and those exceeding 12500 were admitted as the active group.
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The aims of this analysis were to: 
• Define the relationship between age and:
• IHTAG
• Glucose control
• Insulin sensitivity (HOMA-IR)
• Total body fat and fat distribution (abdominal visceral and 
subcutaneous fat)
• Define the modifying effect of physical activity category on:
• IHTAG
• Glucose control
• Insulin sensitivity (HOMA-IR)
• Total body fat and fat distribution (abdominal visceral and 
subcutaneous fat)
• Assess the modifying effect of cardiorespiratory fitness and body 
composition on the above relationships.
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4.2 Methods
This was a case-control study aiming to enrol 24 age-matched active (n=12) 
and sedentary (n=12) adult females in the following age categories: 20-30 years 
(young); 40-50 years (middle-aged); and over 60 years (older) for a total n=72. 
Objectively assessed 7-day average step-count: ≥12500 steps/day was 
classified as active; over 7500 steps/day was considered sedentary. Those with 
step counts between 7500 and 12500 were excluded (see Section 4.2.1 for 
details). Women who did regular pre-planned exercise were excluded in line 
with a desire to determine the effects of general physical activity. Additional 
exclusion criteria were: pregnancy; implanted ferrous material; conditions or 
medication precluding maximal exercise testing; mental illness; and chronic 
disease.
The study was given ethical approval by the Newcastle and Northeast Tyneside 
Local Research Ethics Committees. All volunteers were provided with a 
participant information sheet (see Appendix 2) before providing written informed 
consent (see Appendix 3).
Volunteers were recruited from the Northeast of England by advertising on 
physical and electronic notice boards, and word of mouth.
4.2.1 Physical Activity Screening and Monitoring
Step count was measured by the SenseWear BMS multisensor array 
(BodyMedia Inc., Pittsburgh, PA, USA). Armbands were worn at the midline of 
the triceps of the right arm for seven days (see Figure 4.1).
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Figure 4.1: SenseWear BMS multisensor array for as worn by study volunteers.
4.2.2 Medical History and Physical Examination 
Volunteers were asked to complete the American College of Sports Medicine 
(ACSM) Physical Activity Readiness Questionnaire (Appendix 4), and 
underwent a physical examination comprising of: anthropometry including 
height, weight, and waist and hip circumference; auscultation of the heart and 
lungs; evaluation of the abdomen for any abnormalities; inspection of the lower 
extremities for oedema and arterial pulses; assessment of reflexes; resting 12 
lead electrocardiogram (ECG) (Custo med GmbH, Ottobrunn, Germany ) and 
resting blood pressure (Suntech Tango+, Suntech Medical Ltd, Oxford). These 
determined if the volunteer was suitable for maximal progressive exercise 
testing according to the guidelines of the American College of Sports Medicine 
436.
4.2.3 Maximal Progressive Exercise Test
Exercise testing was carried out on a Corival Recumbent cycle ergometer (Lode 
BV, Groningen, the Netherlands). Cardiac rhythm was measured throughout, 
and blood pressure every three minutes and at peak capacity; with the 
equipment noted above. Respiratory parameters including peak oxygen uptake 
(VO2peak) and respiratory exchange ratio were measured by a Metalyzer 
(CORTEX Biophysik GmbH, Leipzig, Germany). The device was calibrated daily 
for gas volume and composition, and before each test for ambient air pressure.
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Volunteers were asked to sit quietly on the ergometer for 2-3 minutes to obtain 
resting measures and calibrate equipment. Thereafter the exercise test 
proceeded with a 5-minute warmup at 25 W resistance before an increase to 50 
W followed by 10 W/minute increase in resistance until the participant could no 
longer maintain a cadence ≥60 rpm, chose to stop, or a contraindication to 
continuing arose (see of Appendix 5 for contraindications to exercise).
4.2.4 Magnetic Resonance Imaging
All magnetic resonance imaging and spectroscopy was done using a 3T Philips 
Achieva scanner (Philips, Netherlands).
4.2.4.1 Liver Fat Magnetic Resonance Imaging 
IHTAG was assessed by three-point-Dixon analysis. Three gradient echo scans 
were acquired with adjacent out-of-phase (OP), in-phase (IP) and out-of phase 
echoes. (TR/TE/NSA/FA=50/3.45,4.60,5.75/1/30, matrix: 160x109, median FOV 
440 mm, range 400-480 mm to suit subject size with 70% phase FOV), 
bandwidth 2.7 kHz/pixel. Sets of 6 slices were acquired within a 16 second 
breath-hold. Three contiguous blocks of 6 slices were acquired in three 
separate breath-holds to cover the largest cross-section of liver with 10 mm 
thick slices. Correction was made from the first and third echoes for T2* 
relaxation, and from prior knowledge for T1-weighted correction. Images were 
analysed using a custom Matlab script, and registered using FSL tools 
(University of Oxford, United Kingdom) before region of interest analysis using 
the polygon function of ImageJ. The average of 5 slices was taken.
4.2.4.2 Abdominal Visceral and Subcutaneous Fat Determination
Abdominal visceral and subcutaneous fat were measured at L4/L5 using a 
three-point Dixon sequence (TR/TE/number of averages/flip angle 50 ms/ 3.45, 
4.60, 5.75 ms/1/308, matrix 160x109, median field of view (FOV) 440 mm, 
range 400-480 mm to suit subject size with 70% phase FOV). The slice was 
acquired during a breath-hold and with slice thickness of 10 mm 535,536. Fat and 
water were separated, and binary gating applied to produce a map of structures 
containing more than 50% fat. ImageJ (National Institute of Health, USA) was 
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used to calculate total, subcutaneous, and visceral fat area by creating a binary 
image and using a watershed algorithm 537.
4.2.5 Blood Collection and Analysis
Blood was collected by venipuncture (BD Vacutainer Safety-Lok™, BD 
Diagnostics, Plymouth, UK) of an antecubital vein into BD K3E and SST™ 
advance vacutainers (BD Diagnostics, Plymouth, UK) after a 10-12 hour 
overnight fast. Fasting samples were analysed for: total and high-density 
lipoprotein (HDL)cholesterol; triacylglycerols (TAG); aspartate aminotransferase 
(AST); alanine aminotransferase (ALT); γ-glutamyltransferase (GGT); and 
haemoglobin A1c (HbA1c). Except for whole blood glucose, plasma insulin, and 
serum NEFA concentrations (see Section 4.2.6), all blood sample analyses 
were carried out in Clinical Pathology Accredited (CPA) laboratory (Newcastle 
Upon Tyne Hospital NHS Foundation Trust, Department of Clinical 
Biochemistry). 
Total cholesterol 538, HDL-cholesterol 539, ALT 540, and AST 541 were measured 
using the Roche Modular P and test kits (Roche Diagnostics Ltd, Burgess Hill, 
UK). LDL-cholesterol was calculated using the the Friedewald equation 542. 
GGT was measured using a Roche Modular E170 543. HbA1c was measured 
using a TOSOH HLC-723G7 (Tosoh Corporation, Tokyo, Japan). Serum ferritin 
was measured by radioimmunoassay 544.
4.2.6 Oral Glucose Tolerance Test
Fasting and blood collection was as described above. Participants were given a 
394 mL Lucozade Original glucose drink (GlaxoSmithKline, Gloucestershire, 
UK), corresponding to 75 g of glucose, to consume within three minutes. Blood 
samples were taken at time 0 and 120 minutes. 
Whole blood glucose was collected into fluoride oxalate tubes (Teklab, 
Sacriston, UK) and measured immediately with a YSI 2300 Stat Plus-D (Yellow 
Springs Instruments, Yellow Springs, Ohio, USA). Additional whole blood was 
collected in K-EDTA tubes (Teklab, Sacriston, UK) and centrifuged at 3000 rpm 
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(2133 RCF) for 10 minutes in a Sigma 6K15 laboratory centrifuge (Sigma 
Laborzentrifugen GmbH, Osterode am Harz, Germany).
Fasting plasma insulin was measured by the hospital laboratory described 
above.
Insulin sensitivity was assessed by homeostatic model assessment of insulin 
resistance (HOMA-IR) 545: 
HOMA-IR = FI x fasting glucose concentration /22.5 
where FI is fasting insulin concentration in mU/mL and FG is fasting glucose 
concentration in mmol/L.
4.2.7 Body Composition and Anthropometry
4.2.7.1 Air Displacement Plethysmography
Patient body composition, in terms of total body weight, fat mass (FM), fat free 
mass (FFM), and percentage of body fat, was measured by air displacement 
plethysmography using a BodPod (Life Measurement Inc., Concord, CA, USA). 
Participants were asked to wear minimal and/or tight fitting clothing, and a 
swimming cap, to minimise the potential for air trapped in clothing or hair to 
affect the measurement. Scales were calibrated weekly. 
4.2.7.2 Anthropometry
Height was measured using a stadiometer (SECA 799; SECA, Birmingham, 
UK). Weight was measured using the scales of the BodPod described above. 
Waist and hip circumference were measured at the widest point between the 
lower costal margin and the superior iliac crest, and the widest point around the 
buttocks, respectively, using a non-stretch tape measure.
4.2.8 Statistics
Statistical analysis was performed using Microsoft Excel 2008 for Mac 
(Microsoft Corporation, Silicon Valley, USA) descriptive statistics and SPSS 19 
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(IBM, New York, USA) for all other analyses. Three sets of analyses were 
performed: 
1) comparison by age category only; 
2) comparison by age and physical activity categories; and
3) correlations including the full dataset 
Skewness and kurtosis for each parameter of interest were assessed by 
dividing each by its respective standard error to assess the likelihood of a given 
variable not being normally distributed. Variables for which both skewness and 
excess kurtosis were between 2 and -2 were analysed without adjustment, 
whereas those above 2 or below -2 were transformed by the natural logarithm 
to improve the normality of distributions where parametric tests were used.
Analyses of variance (ANOVA) were performed for all variables of interest and 
Tukeyʼs honest significance test was performed where the ANOVA indicated a 
statistically significant difference existed between groups. Analyses of 
covariance (ANCOVA) were also performed for comparisons done by age and 
physical activity:
1) adjusting for cardiorespiratory fitness as assessed by VO2peak calculated 
relative to fat free mass (VO2peakFFM) to try and differentiate between the 
effects of physical activity and cardiorespiratory fitness; and
2) adjusting for body composition as assessed by body fat percentage to 
assess if differences were strongly mediated by body composition.
VO2peakFFM was used in preference to VO2peak per kg body weight to reduce 
confounding from the marked differences in body composition between some 
groups.
Only those comparisons where ANOVA showed significant differences between 
groups and where the adjustment was not for a clearly related parameter to the 
one being assessed were subjected to ANCOVA. Thus for the first ANCOVA 
comparisons of BMI, body fat percentage, fasting glucose, 2-hour glucose, 
IHTAG, abdominal subcutaneous fat area, and abdominal visceral fat area were 
adjusted for VO2peakFFM. And for the second ANCOVA comparisons of fasting 
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glucose, 2-hour glucose, IHTAG, and abdominal visceral fat were adjusted for 
body fat percentage. 
Spearmanʼs rank correlations were used to further examine the relationships 
between indicators of cardiorespiratory fitness, physical activity, body 
composition, glucose control, and age. This technique is relatively robust even 
when correlating non-normally distributed variables, therefore none of the 
variables were transformed irrespective of distribution. Because HOMA-IR is a 
composite of glucose and insulin no correlations were calculated for this 
variable.
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4.3 Results
A total of 61 women were included in the analysis. The participant flow and 
reasons for exclusion are presented in Figure 4.2. Comparisons between 
groups by age are shown in Table 4.3.1, those by age and physical activity level 
in Table 4.3.2., and correlations in Table 4.3.3. Figure 4.2 shows the participant 
flow.
Assessed for eligibility (n=129)
Invited for full assessment (n=66)
40-50 years ʻmiddle-agedʼ
Completed (n= 22)
≥65 years ʻolderʼ
Completed (n= 20)
20-30 years ʻyoungʼ
Completed (n= 22)
Completed all assessments 
(n=64)
Excluded (n=63)
Not eligible (n=58)
Declined to participate (n=5)
Excluded (n=2)
Declined to complete all 
assessments (n=2)
Active 
(n=11)
Sedentary 
(n=10)
Active 
(n=11)
Sedentary 
(n=10)
Active 
(n=10)
Sedentary 
(n=9)
Excluded (n=1)
Undiagnosed diabetes
Excluded (n=1)
Regular exercise
Excluded (n=1)
Missing data
Figure 4.2: Diagram showing participant flow.
The original protocol defined volunteers with a daily step count ≤7500 as 
sedentary and those with a daily step count ≥12500 as active with those in 
between excluded from the study. It proved extremely difficult to recruit women 
aged 20-30 years with daily steps counts <7500, so six volunteers with steps 
counts >7500 (range: 7710-10778) were included in the sedentary group. For 
much the same reason four women were included in the active older group 
despite not quite meeting the ≥12500 step count criteria (range of counts for 
those four: 11323-11839). In the 40-50 year old group only two volunteers in the 
active group had step counts below the predefined criteria (counts: 10828 and 
11106). Despite these variations, when groups were pooled by age there was 
no statistically significant difference between groups in step count. When 
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groups were further subdivided by age and physical activity category – 
sedentary and active – there were no significant differences in mean step 
counts between women in the same physical activity category across the three 
age categories. Scatter plots by age (see Figure 4.2), and by age and physical 
activity category (see Figure 4.3), suggest a tendency for sedentary young 
women in this cohort to be more active than sedentary middle-aged or older 
women.
Figure 4.3: Scatter plots of average daily step count distribution by age category.
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Young Middle-Aged Older
Figure 4.4: Scatter plots of average daily step count distribution by age and physical activity 
category.
By design, the three age groups were significantly different in terms of age. 
However, within each age category sedentary and active women were not 
significantly different.
4.3.1 Body Composition and Liver Fat by Age
Results by age category are shown in Table 4.1. The three groups had similar 
BMI, body fat percentage, and abdominal subcutaneous adipose area. 
However, body fat was weakly correlated with age (r = 0.274, p ≤ 0.05). Visceral 
fat area was significantly lower in young and middle-aged relative to older 
women, and was positively correlated with age (r = 0.409, p= 0.01). 
IHTAG concentration was lower in young than older women, notably so in active 
young women relative to sedentary older women. The difference between 
middle-aged and older women suggested an increase with age but did not 
reach significance (2.04% vs 3.88%, p = 0.067). The correlation between 
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Young Middle-Aged Older
Sedentary Active SedentarySedentary Active Active
IHTAG and age also did not reach significance but again suggested a weak 
relationship (r = 0.246, p = 0.056) (Table 4.3). However, fasting insulin and 
glucose were correlated with IHTAG (r = 372, p ≤ 0.01; and r = 330 p ≤ 0.05, 
respectively. 
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Table 4.1: Volunteer Comparison by Age
Young Middle Older young vs. middle vs. 
older
p(n of 21) (n of 21) (n of 19) middle p
older
p
Age (years) 26.5 (25.3, 27.7) 44.9 (43.4, 46.4) 71.7 (69.2, 74.1) - - -
BMI (kg/m2) 24.2 (21.9, 26.5) 26.9 (25.3, 28.6) 26.0 (24.6, 27.4) 0.658 0.390 0.886
Weight (kg) 66.0 (59.6, 72.4) 71.4 (66.4, 76.3) 65.2 (61.2, 69.2) - - -
Height (m) 1.65 (1.62, 1.68) 1.63 (1.60, 1.65) 1.58 (1.56, 1.60) - - -
Body fat (%) 32.5 (28.2, 36.7) 36.3 (33.1, 39.4) 37.9 (34.2, 41.6) 0.977 0.129 0.189
Subcutaneous fat (cm2)‡ 174 (112, 235) 313 (263, 364) 187 (151, 222) 0.619 0.553 0.993
Visceral fat (cm2)‡ 54 (35, 74) 133 (107, 158) 113 (87, 138) 0.259 <0.001 0.032
Steps/day 11588 (9972, 13203) 9836 (7642, 12030) 10547 (8182, 12912) 0.891 0.769 0.967
VO2peak (ml/kg/min) 29.4 (26.6, 32.1) 27.6 (24.6, 30.7) 21.2 (19.2, 23.2) 0.65 <0.001 0.004
VO2peak (ml/kgFFM/min) 43.3 (41.0, 45.5) 43.2 (39.8, 46.5) 34.2 (31.6, 36.8) 0.351 <0.001 0.008
WRmax (W/min) 148 (140, 157) 155 (141, 169) 98 (89, 106) 0.840 <0.001 <0.001
Resting RER 0.94 (0.90, 0.97) 0.98 (0.94, 1.01) 0.92 (0.88, 0.96) 0.555 0.837 0.897
Fasting glucose (mmol/L) 5.1 (4.9, 5.3) 4.4 (4.2, 4.6) 5.2 (5.0, 5.3) 0.001 0.903 <0.001
Fasting insulin (μIU/mL) 8.2 (6.5, 9.8) 6.2 (4.4, 8.0) 5.8 (4.3, 7.3) 0.052 0.107 0.912
HOMA-IR 1.90 (1.47, 2.31) 1.21 (0.84, 1.58) 1.36 (1.00, 1.73) 0.015 0.136 0.577
2-hour glucose (mmol/L) 4.7 (4.2, 5.2) 4.7 (4.4, 5.1) 6.1 (5.5, 6.8) 1.000 0.001 <0.001
IHTAG (%)‡ 1.86 (1.44, 2.28) 2.04 (1.44, 2.63) 3.88 (2.36, 5.39) 0.862 0.02 0.067
Results shown as means (95% confidence interval). To avoid unnecessary statistical comparisons, height, weight, and age were not compared.
‡ Means and confidence intervals are provided as original data, but statistical comparisons were performed on natural log transformed data.  Abbreviations: IHTAG, 
intrahepatic triacylglycerol concentration.
Table 4.2: Volunteer Comparison by Age and Activity Category
20-30 Years 40-50 Years ≥65 Years
Sedentary
n of 10
Active
n of 11 
Sedentary
n of 10
Active
n of 11
Sedentary
n of 9
Active
n of 10
Age (years) 25.0 (23.0, 26.9)c,d,e,f 27.9 (27.1, 28,8)c,d,e,f 45.6 (43.1, 48.1)a,b,e,f 44.3 (42.6, 46.0)a,b,e,f 74.1 (70.8, 77.4)a,b,c,d 69.5 (66.4, 72.6)a,b,c,d
BMI (kg/m2) 27.4 (23.8, 31.1)b 21.3 (19.7, 23.0)a,e 26.2, (23.8, 28.6) 24.7 (22.5, 26.9) 27.8 (26.4, 29.3)b 24.4 (22.5, 26.2)
Weight (kg) 73.0 (61.7, 84.3) 59.7 (55.3, 64.1) 72.07 (66.2, 78.0) 68.8 (60.7, 76.8) 70.6 (66.0, 75.1) 60.3 (55.5, 65.1)
Height (m) 1.63 (1.58, 1.67) 1.67 (1.64, 1.71) 1.66 (1.63, 1.70) 1.67 (1.64, 1.70) 1.59 (1.57, 1.61) 1.57 (1.54, 1.61)
Body fat (%) 40.8 (35.9, 45.8)b,d 25.0 (22.5, 27.5)a,c,e, 35.8 (31.8, 39.8)b 30.6 (26.1, 35.1)a,e 42.7 (40.0, 45.3)b,d, 33.7 (28.3, 39.1)
Subcutaneous fat (cm2)‡ 263 (160, 366)b 93 (71, 114)a,c,e 238 (164, 311)b 153 (92, 214) 224 (175, 274)b 151 (107, 194)
Visceral fat (cm2)‡ 83 (51, 115)b 28, (19, 37)a,c,e,f 93 (56, 129)b 60 (25, 94)e 141 (101, 182)b,d 90 (70, 109)b
Step Count 8597 (7710, 9484)b,d,f 14306 (12474, 16139)
a,c,e
6100 (5515, 6685)b,e 15294 (13671, 16917)
a,c,e
6219 (4629, 7808)b,d,f 14442 (12084, 16801)
b,d,e
VO2peak (ml/kg/min) 23.6 (21.9, 25.4)b,d,e 34.6 (32.4, 36.7)a,c,e,f 22.2 (20.7, 23.7)b,d, 32.7 (29.0, 36.4)a,c,e,f 18.0 (16.6, 19.4)a,b,d,f 24.1 (21.8, 26.5)b,d,e
VO2peak (ml/kgFFM/min) 40.2 (37.9, 42.5)e 46.0 (43.0, 49.1)c,e,f 34.9 (32.2, 37.6)b,d, 45.6 (41.7, 49.5)c,e,f 31.4 (29.2, 33.6)a,b,d, 36.7 (32.8, 40.6)b,d
WRmax (W/min) 135 (126, 144)b,d,e,f 160 (151, 170)a,c,e,f 127 (120, 134)b,d,e 176 (160, 192)a,c,e,f 86 (80, 92)a,b,c,d 108 (96, 121)a,b,d
Resting RER 0.93 (0.89, 0.97) 0.94 (0.87, 1.00) 0.91 (0.86, 0.96) 0.90 (0.86, 0.94) 0.94 (0.87, 1.01) 0.90 (0.86, 0.95)
Fasting glucose (mmol/L) 5.1 (4.9, 5.3) 5.1 (4.8, 5.5) 4.6 (4.3, 4.9) 4.6 (4.3, 4.9)e,f 5.2 (4.9, 5.4)d 5.2 (4.9, 5.4)d
Fasting insulin (μIU/mL) 8.5 (6.2, 10.9) 7.8 (5.5, 10.1) 5.8 (3.3, 8.2) 4.9 (2.2, 7.6) 6.7 (4.3, 9.0) 5.1 (3.2, 6.9)
HOMA-IR 1.99 (1.37, 2.60) 1.80 (1.22, 2.39) 1.15 (0.66, 1.63) 0.99 (0.41, 1.57) 1.55 (0.98, 2.11) 1.19 (0.71, 1.67)
2-hour glucose (mmol/L) 5.1 (4.5, 5.8) 4.3 (3.7, 4.9)e,f 4.9 (4.4, 5.4) 4.5 (3.9, 5.0)e 6.5 (5.4, 7.5)b,d 5.9 (5.0, 6.7)b
IHTAG (%)‡ 2.1 (1.7, 2.4) 1.7 (0.9, 2.4)e 2.2 (1.5, 2.9) 2.2 (1.2, 3.1) 4.7 (2.1, 7.2)b 3.2 (1.4, 4.9)
Results shown as means (95% confidence interval). For basic anthropometry only BMI was compared across groups. Abbreviations: BMI, body mass index; FFM, 
fat free mass; HOMA-IR, homeostasis model of insulin resistance; hr, hour; min, minute; RER, respiratory exchange ratio; SBP, systolic blood pressure; VO2, volume 
of oxygen; W, watts; WR, work rate; 
‡ Means and confidence intervals are provided as original data, but statistical comparisons were performed on natural log transformed data.
a significantly different from sedentary 20-30 year olds (p<0.05).
b significantly different from active 20-30 year olds (p<0.05).
c significantly different from sedentary 40-50 year olds (p<0.05). 
d significantly different from active 40-50 year olds (p<0.05). 
e significantly different from sedentary ≥65 year olds (p<0.05).
f significantly different from active ≥65 year olds (p<0.05).
Table 4.3: Correlations of Age, Physical Activity and Fitness, Body Composition and Fat Distribution, and Glucose Control
VO2peak by FFM Body fat % Visceral fat IHTAG Fasting glucose Fasting insulin 2-hour glucose
Age -0.519** 0.274* 0.409** 0.246 0.082 -0.244 0.393**
Step count 0.513** -0.564** -0.447** -0.263* -0.023 -0.082 -0.268*
VO2peak by FFM -0.319* -0.452** -0.346** -0.033 0.098 -0.177
Body fat % 0.627** 0.321* 0.178 0.114 0.527**
Visceral fat area 0.546** 0.182 0.238 0.483**
Intrahepatic lipid 0.251 0.372** 0.248
Fasting glucose 0.330* 0.245
Fasting insulin 0.039
Spearmanʼs Rank correlations of unadjusted variables. Abbreviations: FFM, fat free mass; IHTAG, intrahepatic triacylglycerol concentration.
* p ≤0.05
** p ≤0.01
4.3.2 Body Composition and Liver Fat by Age and Physical Activity 
Category
Results by age and physical activity category are shown in Table 4.2. Young 
active women had significantly lower body fat than sedentary women of any age 
category. There was a trend toward a difference between young active women 
and older active women (p = 0.052). Active middle-aged women had lower body 
fat than sedentary young and sedentary older women, but they were not 
significantly different from their sedentary middle-aged counterparts. 
Active young women had significantly less subcutaneous abdominal fat than 
sedentary women in all age categories. However, active middle-aged and older 
women did not differ significantly from their sedentary counterparts. Young 
active women had significantly less visceral fat than all other groups except 
active middle-aged women. Active middle-aged women had significantly less 
visceral fat than sedentary older women. Visceral fat area was similar across all 
sedentary groups. Active young women also had lower IHTAG than sedentary 
older women, but this difference was no longer significant after adjustment for 
either VO2peakFFM or body fat percentage. No other differences between groups 
reached statistical significance before or after adjustment. Step count was 
inversely correlated with body fat percentage (r = -0.564, p≤0.01), visceral fat (r 
= -0.447, p ≤ 0.01), IHTAG (r = -0.263, p ≤ 0.05)(Table 4.3). Whereas, 
VO2peakFFM was inversely correlated with body fat (r =- 0.319, p ≤ 0.05) and 
visceral fat (r = -0.452, p ≤ 0.01) (Table 4.3).
4.3.3 Metabolism, Glucose Control, and Insulin Sensitivity by Age
Results by age category are shown in Table 4.1. Resting respiratory exchange 
ratio and fasting insulin were similar across age categories. Fasting glucose 
was lowest in middle-aged women and similar between young and older 
women. HOMA-IR was higher in young than in middle-aged women. Two-hour 
glucose concentration was highest in older women, but similar in young and 
middle-aged women. Age was associated with 2-hour glucose, but not fasting 
glucose or insulin (Table 4.3). 
Chapter 4 - The Physiological Effect of Age and Activity on Metabolism Study
158
4.3.4 Metabolism, Glucose Control, and Insulin Sensitivity by Age and 
Physical Activity Category
Results by age and physical activity category are shown in Table 4.2. Resting 
respiratory exchange ratio was similar across all groups. Two-hour glucose was 
lowest in active young women and highest in sedentary older women with 
significant differences between active young and active middle-aged women 
relative to sedentary older women. Fasting glucose was lower in active middle-
aged women than older women, but similar across all other groups. Fasting 
insulin and HOMA-IR were similar across all groups. Neither adjustment for 
VO2peakFFM nor body fat percentage altered these findings. Step count was 
inversely correlated with 2-hour glucose concentration (r = -0.447, p ≤ 0.01), but 
not fasting glucose or insulin. However, VO2peakFFM was not correlated with 
fasting or 2-hour glucose, or fasting insulin. 
4.3.5 Cardiorespiratory Fitness and Work Capacity by Age
Results by age category are shown in Table 4.1. Cardiorespiratory fitness as 
assessed by VO2peak relative to both total body weight and fat free mass, and 
work capacity assessed by WRmax were similar between young and middle-aged 
women but lower in older women by approximately 25%, 21%, and 35%, 
respectively. Age was inversely correlated with VO2peakFFM (r = -0.519, p ≤ 0.01). 
4.3.6 Cardiorespiratory Fitness and Work Capacity by Age and Physical 
Activity Category
Results by age and physical activity category are shown in Table 4.2. 
Cardiorespiratory fitness expressed as VO2peak was 47% higher in active young 
and middle aged women, and 34% higher in active older women relative to their 
sedentary peers. Adjusting for body composition by using VO2peakFFM 
substantially reduced this difference especially in young and older women: 
VO2peakFFM was 14%, 31%, and 18% higher in active young, middle-aged, and 
older women, respectively. WRmax was 19%, 39%, and 26% higher in active 
young, middle-aged, and older women, respectively. However, the difference 
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between active and sedentary older women did not reach significance (p = 
0.094).
Sedentary young and middle-aged women had similar VO2peak, VO2peakFFM, and 
WRmax, but these parameters were all higher than in sedentary older women, 
and WRmax was also higher than in active older women. Active young and 
middle-aged women had comparable VO2peak, VO2peakFFM, and WRmax, but both 
groups had higher values than sedentary and active older. Step count 
correlated with VO2peakFFM (r = 0.513, p ≤ 0.01)
4.3.7 Correlations Between Body Composition, Fat Distribution, and 
Glucose Control
All correlations are shown in Table 4.3. Body fat was strongly correlated with 
visceral fat (r = 0.627, p ≤ 0.01) and 2-hour glucose (r = 0.527, p ≤ 0.01), and 
more modestly with IHTAG (r = 0.321, p ≤ 0.05), but not fasting glucose or 
insulin. Visceral fat correlated with IHTAG (r = 0.546, p ≤ 0.01) and 2-hour 
glucose (r = 0.483, p ≤ 0.01), but not fasting glucose or insulin. IHTAG 
correlated with fasting insulin (r = 0.372, p ≤ 0.01), and almost significantly with 
fasting and 2-hour glucose (r = 0.25, p = 0.051 and r = 0.248, p = 0.054, 
respectively).
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4.4 Discussion
This cross-sectional study presents physical fitness and regional fat data from 
young, middle-aged and older women subdivided into sedentary and physically 
active groups. The data suggest a decline in physical fitness from the middle-
age onwards. Physical activity did not attenuate the decline in cardiorespiratory 
fitness but was associated with a higher starting point. Cardiorespiratory fitness 
was inversely associated with adiposity even when calculated relative to fat free 
mass. Liver fat showed a tendency to increase with age.
The most consistent finding across groups was a positive association between 
physical activity and fitness. However, older women had markedly lower 
cardiorespiratory fitness than their younger counterparts even when physical 
activity was comparable. Overall, age was inversely associated with 
cardiorespiratory fitness. Comparison of groups sub-divided by age and 
physical activity indicated that being active somewhat attenuated the decline in 
fitness among older women but did not eliminate it entirely. 
Other cross-sectional work suggests VO2peak declines by 8-10% per decade in 
healthy men and women 546,547. Longitudinal observation confirms this decline 
548, and shows it to be non-linear as it accelerates to a 20-25% reduction in 
VO2peak per decade in those over 70 years 549,550. As these findings were in 
apparently healthy populations, they suggest an inevitability of this decline. 
Indeed, although an active lifestyle including regular exercise is associated with 
a higher cardiorespiratory fitness across the lifespan 551, a decline with age is 
still evident in both men 552, and women 553, and may actually be greater in 
absolute terms among regular exercisers.
Nonetheless, the ability to respond to aerobic exercise is maintained in 
populations over 60 years with a meta-analysis reporting an average 
improvement in VO2peak of 16% 554. Some attenuation of response with age has 
been demonstrated in postmenopausal women 555. However, increasing 
exercise volume increased the likelihood of a clear improvement in 
cardiorespiratory fitness in that cohort 556. As no data on the menstrual status 
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was collected, and women regularly engaging in planned exercise were 
excluded, the present dataset cannot address these issues.
4.4.1 Age, Physical Activity and Body Composition
In the present cohort, physical activity was inversely associated with total as 
well as regional fat, and age was weakly positively associated with body fat 
percentage. The correlation was stronger for visceral fat and age suggesting a 
shift in fat distribution from areas less to areas more closely linked with all 
cause mortality and cardiometabolic risk 557. Prior cross-sectional and 
longitudinal observations have shown similar inverse associations between 
physical activity and body fat 558-563, and several longitudinal studies have 
shown an increase in fat mass and decrease in lean mass with age 564. Others 
have suggested that women have an annual increase in fat mass from 40-66 
years of approximately 0.41 kg/year 561, or a 7.5% increase per decade in those 
over 45 years 565. One of the mediators of this change in body composition is 
menopause, which was more closely associated with increasing fat mass than 
age 561. As in our cohort, others have reported an age related shift in fat 
distribution to one more dominated by central, and specifically visceral 
abdominal fat 566. Despite a tendency for a gradual increase in adiposity over 
several decades, there appears to be a decline after the age of 80 years 567. No 
data on menstrual status or history were collected in the present cohort, and the 
age range in the ʻolderʼ group did not include a sample set of women over 80 
years.
The decline in fat free mass has previously been shown to become more 
marked after the age of 45 years 568. Between 40-66 years this is approximately 
0.06-0.07 kg/year in healthy adults 561,569, but followed by an accelerated 
decline in the seventh decade of life 570. After the seventh decade of life there is 
clear trend toward total body weight reduction predominantly from fat free mass 
with increasing infiltration of muscle with adipose tissue, i.e. myosteatosis 571. 
This phenomenon, coined as sarcopenic obesity, is not only associated with 
HOMA-IR 572, but leads to substantial deficits in functional capacity and risk of 
mortality 573. 
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The present cohort may have been too young, on average, to detect such a 
major shift in body composition beyond the weak correlation. The moderating 
influence for physical activity in this age-related tendency to increase fat mass 
identified in Guatemalan women aged 20-87, a population in whom relatively 
high levels of physical activity are maintained throughout life 574, also suggests 
that activity was a attenuating factor in the present cohort. However, the present 
study and that done in Guatemalan women used different and not readily 
comparable measures of physical activity, and it seems probable that women in 
Guatemala were more physically active in 1997 than women in United Kingdom 
in 2010. Notably, higher physical activity did not attenuate the decline in fat free 
mass in Guatemalan women 574.
The most plausible explanation for us not observing a greater shift in body fat 
percentage or stronger correlations is the secular trend in body fatness. Given 
the population wide trajectory of obesity has been upward for some decades 
and there appears to be a generational lag 567, it seems plausible that any 
natural trend in age-related changes to body composition are interacting with 
non-age related factors 575. 
Collectively our observations and those of others highlight the importance of 
physical activity throughout the adult lifecycle in terms of attenuating the 
increase in fat mass and the associated health risks over time. However, further 
work is warranted to see what approach to physical activity is both effective and 
feasible for large portions of our ageing population. 
4.4.2 Insulin Sensitivity and Age
Fasting glucose and insulin were mostly too insensitive a measure to detect 
differences in insulin sensitivity and glucose control between groups in the 
present cohort. This was consistent with the deliberate exclusion of volunteers 
with metabolic disease. Nonetheless, the pooled aged group comparison 
showed young women to have the highest degree of fasting insulin and HOMA-
IR with similar fasting glucose to older women, but a normal blood glucose 
response to the oral glucose tolerance test. Interestingly, dividing young women 
into sedentary and active groups revealed no significant intergroup differences 
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in any of the measures of glucose control. The presence of insulin resistance in 
young women was likely compensated by increased insulin production to 
maintain glucose control, whereas in older women any capacity to compensate 
for insulin resistance was reduced. Middle-aged women had the HOMA-IR and 
comparable glucose control to young women. Older women had the highest 2-
hour glucose response, and age showed a modest significant correlation with 2-
hour glucose indicating poorer glucose control with age.
The observed trend in reduced glucose control with age in the present cohort is 
reflected by the increase in type 2 diabetes with age observed by others 576, and 
similar observations in larger cross-sectional studies also excluding volunteers 
with diabetes. In 20 European cohorts encompassing men and women aged 
18-85 years with normal glucose tolerance insulin action, as assessed by the 
reference standard hyperinsulinaemic-euglycaemic clamp, declined with age, 
but adjusting for BMI removed this relationship 577. However, in the absence of 
more direct assessment of body fat and its distribution, a BMI ≤ 25 kg/m2 was 
used to define the ʻleanʼ group which in turn was used to derive the researchers 
definition of insulin resistance. At these lower BMIs, the correlation between 
BMI and body composition is poor 578,579, which puts the chosen definition in 
question. Other reports support the findings in the present study by indicating 
that age, independent of gender, insulin sensitivity, fasting glucose, BMI and 
waist-to-hip ratio, is associated with a progressive decline in both basal insulin 
release and systemic insulin clearance 580.
A pooled analysis of 10 non-diabetic European cohorts aged 30-88 years and 
adjusted for BMI showed an increase in HOMA-IR assessed insulin resistance 
as well impaired fasting glucose and impaired glucose tolerance with age; the 
latter being the strongest association 581. Age was also inversely associated 
with insulin sensitivity assessed by HOMA-IR independent of BMI and waist hip 
ratio in mexican women aged 30-65 years 582. A French cohort of men and 
women aged 30-64 years has also showed an increased fasting insulin with 
age; division of the cohort into four age classes indicated that the rise occurred 
after the age of 49 years in women and 59 years in men 583. And a longitudinal 
evaluation in US men and women aged over 30 years with normal glucose 
tolerance at baseline and followed up for 4-11 years suggested that baseline 
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insulin resistance, assessed by insulin suppression test, is predictive of age 
related disease incidence 584. 
The frequently observed decrease in insulin activity with age has been 
attributed to the aforementioned changes in body composition and fat 
distribution, and declining physical activity 585. Ectopic fat in the liver (see 
Section 4.4.5) and the pancreas have emerged as likely mediators of central 
insulin resistance, and impaired insulin response, respectively 586. Interestingly, 
HOMA-IR in a healthy cohort of Italian men and women aged 28-110 years, was 
highest in those aged 80-90 years followed by those aged 50-60, while 
centenarians had the lowest average of any group closely followed by 
nonagenarians 587. However, in the same cohort HOMA-β indicated a rise in 
pancreatic β-cell function across age groups with a peak in octogenarians and a 
marked decline in nonagenarians and centenarians. Further, evaluation of the 
Framingham and Framingham offspring cohorts showed those participants 
living for 90 or more years had lower blood glucose, form either spot or fasting 
samples, were lower for all time points after approximately 50 years than for 
those dying earlier 588. Thus although an age-related decline in insulin sensitivity  
and glucose control is seen across much of the age spectrum, observations of 
the most long-lived suggest this decline need not always be rapid and lead to 
morbidity or mortality. 
The elevation of 2-hour glucose with age, observed in the present and other 
cohorts is noteworthy, as 2-hour glucose when exceeding fasting glucose, even 
within the normoglycemic range, is associated with increased cardiovascular 
disease mortality 589,590.
4.4.3 Insulin Sensitivity and Physical Activity 
In the present cohort, comparisons between sedentary and active women 
showed no significant effect of physical activity. However, there was an inverse 
correlation between step count and 2-hour glucose. The latter finding is more 
consistent with expectations as the ability of exercise to improve insulin 
sensitivity and glucose control across a range of ages is well established (see 
Section 1.10). In brief, physical activity, particularly moderate to vigorous 
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aerobic activity, has been demonstrated to increase both insulin mediated and 
insulin independent glucose uptake by muscle, the latter only being observed 
for approximately 60 minutes post exercise 591. The insulin sensitising is 
localised to contracting muscle 591, and has been shown to last 48 hours but 
fewer than five days 592. Even in well-trained endurance athletes displaying 
twice the whole-body glucose uptake rate of sedentary controls 12 hours post-
exercise, cessation of training for just three days abolished substantially 
reduced this difference and 7 days of detraining abolished it 593. Further, nutrient 
intake is a major mediator of this effect as 100 g oral glucose 508, but not fat 
509,510, within three hours of exercise has been shown to prevent the next-day 
increase in insulin-mediated glucose disposal. Both the localised effect and its 
attenuation by restoration of muscle glycogen with post-exercise glucose 
administration indicate glycogen depletion is an important component of 
myocellular insulin sensitisation. Thus the difference in amount or intensity of 
physical activity in the present cohort may not have been sufficient to notice a 
clear difference, especially given glucose control throughout the cohort was 
mostly within the normal range.
Non-exercise physical activity, such as that assessed in the present study, has 
been previously reported to be associated with insulin and glucose metabolism. 
Early work established an association between habitual physical activity, 
assessed by 7-day recall, and fasting insulin in non-diabetic hispanic and non-
hispanic caucasian US men aged 20-75 years, but not in women 594. Similarly, 
in a Canadian cohort of men and women aged 18-79 years, physical activity 
assessed by past-year recall was associated with fasting insulin, independent of 
age, BMI, body fat percentage and waist circumference, but only in men 595. 
The authors of both studies suggested this gender discrepancy may have 
arisen from either the small distribution of physical activity in the female cohort, 
or poorer validity of the questionnaire for women 594,595. Other studies have not 
reported this degree of gender discrepancy. 
In a US cohort of men and women aged 40-69 years and including volunteers 
with normal glucose tolerance, impaired glucose tolerance, and non-insulin 
dependent type 2 diabetes, assessed by physical activity recall, vigorous, non-
vigorous, and total physical activity were associated with insulin sensitivity 
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measured by intravenous glucose tolerance 596. Questionnaire assessed 
physical activity was also associated with mean insulin – average of fasting and 
2-hour post glucose challenge – in nondiabetic samples from two populations 
with differing body compositions, Pima Indians and Mauritians 595.
All-type physical activity was also inversely associated with insulin sensitivity 
across the lifecycle 563,597,598. Both category, leisure time and work-related, and 
intensity of physical activity mediate this relationship. In a Swedish sample, 
leisure time physical activity was inversely associated with insulin sensitivity 
independent of age and the association was stronger in women than in men 563. 
In Iranian women, after adjustment for age and BMI, total physical activity was 
most closely associated with insulin sensitivity followed by an inverse 
association with sedentary time, and positive association with the duration of 
high-intensity activity after adjusting for confounders including age, gender, 
waist circumference, and smoking 597. The association with light physical activity  
remained after adjustment for moderate-to-vigorous activity.
NHANES data from 2003-2006 showed an association and inverse association 
with fasting insulin for questionnaire assessed time spent watching television 
and leisure time physical activity, respectively, but no such association with 
transportation or household physical activity 599. Conversely, self-reported 
physical activity in NHANES 1999-2002 was not associated with insulin 
sensitivity 600, but this may be partly explained by the presence of non-fasting 
samples in the analysis as fasting status was not clearly described.
A similar relationship was shown in a large Australian cohort of non-diabetic 
men and women over 35 years in whom television viewing time was associated 
with 2-hour glucose, fasting insulin, HOMA-IR and HOMA-β, but only in women 
601. Seven-day accelerometry in a small subset of this Australian cohort showed 
sedentary time to be associated with 2-hour glucose, with an inverse 
association for light and moderate-to-vigorous intensity independent of age, 
gender, height, waist circumference 602. The positive effect of light activity 
remained even after adjusting for moderate-to-vigorous intensity. 
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In middle-aged US women 7-day accelerometry assessed time spent doing 
moderate-intensity and vigorous-intensity activity was inversely related to and 
sedentary time related to HOMA-IR 603. Adjusting for air displacement 
plethysmography assessed body fat percentage or waist circumference 
removed these associations. In a multi-country cross-sectional European cohort 
assessing physical activity by accelerometry total activity was associated with 
insulin sensitivity measured by 2-hour hyperinsulinemic-euglycemic clamp 604. 
Sedentary time, intensity of activity, and time spent doing light activity were also 
associated with insulin sensitivity, but this association disappeared after each 
variable was adjusted for total activity.
In a longitudinal observation of healthy middle-aged men and women in the UK, 
sedentary time, assessed by heart rate measurement, at baseline predicted 
fasting insulin at followup; independent of age, gender, fat mass, fasting insulin, 
and smoking status at baseline 605. However in cross-sectional assessment of 
another UK cohort of non-diabetic men and women aged 50-75 years, time 
spent moderately to vigorously physically active defined as 1.75 and 2 times 
resting heart rate, respectively, was inversely associated with fasting insulin 
whereas time spent doing light activity, defined as 1.5 times resting heart rate, 
was not 606. Interestingly, in UK men aged 42-64 although only overall body fat 
was associated with whole body insulin sensitivity after taking into account 
physical activity energy expenditure and VO2peak, but only physical activity 
energy expenditure was associated specifically with hepatic insulin sensitivity 
607.
The importance of sedentary time was recently confirmed by work showing that 
breaking up sedentary time with 2-minute bouts of light- or moderate-intensity 
walking reduced postprandial glucose and insulin response in overweight and 
obese 45-65 year old men and women 25. 
Discrepancies in the associations reported may be due to differences in the 
actual cohorts, but are also to methodological differences. Older studies relied 
more on physical activity recall. Larger cohorts similarly often rely on recall, and 
also simple biomarker measures such as fasting blood glucose and insulin 
measurements, which are less sensitive and less specific than the 
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hyperinsulinaemic-euglycaemic clamp or oral glucose tolerance test 512. Even 
with the employment of accelerometers or heart rate monitors to provide more 
objective assessments of physical activity, there were differences in devices 
used and the parameters employed to define categories of physical activity. 
Despite these variations in methodology and some inconsistency in findings, 
overall physical activity of all intensities and types appears to improve insulin 
sensitivity and glucose control. Conversely, time spent sedentary, especially if 
uninterrupted for prolonged periods, reduces insulin sensitivity and glucose 
control. These associations are somewhat attenuated when controlling for body 
composition, but they are not eliminated. Interestingly, a recent meta-analysis 
reported that television viewing time was causally associated with excessive 
food intake 608. Such a finding highlights that physical activity does not exist in a 
vacuum, and changing it is likely to lead to other lifestyle changes that may be 
unanticipated, but potentially quite beneficial.
4.4.4 Insulin Sensitivity and Body Composition
In the present cohort, body fat percentage and visceral fat area were closely 
associated with 2-hour glucose, and IHTAG with fasting insulin; suggesting 
some independence of peripheral and central insulin resistance. The inverse 
association between obesity, particularly central obesity, and insulin sensitivity is 
a frequent observation609-612. Even in the absence of overt insulin resistance, 
findings from the EGIR pooled cohort showed increased insulin hypersecretion 
among obese volunteers, especially centrally obese women 613. However, the 
inverse association of total body fat and insulin sensitivity is not universal as 
there are those displaying normal glucose and insulin metabolism despite being 
obese. Such obese but metabolically healthy individuals have less central 
adiposity than those with insulin resistance and/or dyslipidaemia 614-617. 
When measured, the association between visceral fat and whole-body insulin 
sensitivity is particularly strong 618-620, but the association between visceral and 
IHTAG is also very strong 238,621,622. Recent work assessing the relationship of 
visceral fat, IHTAG, and insulin sensitivity/glucose control, but with conflicting 
findings. One report suggests visceral fat is independently associated with 
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glucose control and liver fat is not 238. Two reports in much larger cohorts 
suggests that visceral fat and IHTAG are independently associated with insulin 
sensitivity and/or glucose control 622,623. Further, IHTAG is inversely associated 
with hepatic insulin sensitivity 120,624-626.
4.4.5 Liver fat
In the present cohort IHTAG was higher in older women than young women. 
However, only seven women had an IHTAG ≥5%: five in the older group (3 
sedentary and 2 active); one in the young (active) group. Subdividing the cohort 
by physical activity in addition to age maintained this age difference in liver fat 
but only in active young women relative to sedentary older women. Consistent 
with this observation, IHTAG was inversely associated with VO2peakFFM and step 
count, but not age. This suggests physical activity and or cardiorespiratory 
fitness are modifiers of liver fat rather than chronological age. 
The prevalence and severity of fatty liver has previously been shown to 
increase with age 183,187,201. This relationship has been shown in a range of 
populations in: Northeast England 201; Hong Kong 187, and Texas 183; India 627; 
China 157; and Korea 191. However, none of these surveys has controlled for 
physical activity or cardiorespiratory fitness.
Italian cross-sectional data have shown physical activity to also be associated 
with the prevalence of NAFLD even after adjustment for age, gender, BMI, and 
insulin sensitivity 232. Cross-sectional data from Israel confirmed this 
association, however after adjustment for BMI, only the association with 
resistance training remained 233. Longitudinal data, also from Israel, showed 
that total leisure time physical activity and anaerobic/resistance training physical 
activity to be lower in those going on to develop NAFLD 237. Further, 
retrospective analysis of a cohort with NAFLD showed those meeting US 
guidelines for vigorous exercise to be less likely to have NASH 240. However, in 
this same cohort no such association was shown for moderate-intensity or total 
exercise. There is also an inverse association between liver fat and 
cardiorespiratory fitness 238, i.e. VO2peak. Indeed, NAFLD was found to be ~10-
times more prevalent in the lowest relative to the highest tertile of 
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cardiorespiratory fitness independent of BMI, though not independent of waist 
circumference 239. Further, cardiorespiratory fitness was identified as an 
independent  predictor of liver fat reduction in lifestyle therapy 8. Further, 
exercise only interventions using aerobic exercise or resistance training have 
both been shown to reduce liver fat independent of weight reduction 243-245 (see 
Chapter 2 for a more detailed discussion).
Our observations and those of others highlight the protective effect of physical 
activity and both cardiorespiratory fitness and muscle fitness – strength – on 
liver health. These observations also identify the likely problem of confounding 
when physical activity and fitness are not considered in the establishment of risk 
factors for NAFLD.
4.4.6 Strengths and Limitations
The cross-sectional nature of the present study precludes inference about the 
direction of causality in the apparent relationships, while the small sample size 
limits statistical power generally, and limits subdivision of groups to more closely  
assess the mediators of the apparent relationships. Also, the older category 
allowed for a greater heterogeneity of age as it was not limited to a ten year 
span like the young and middle-aged category were. The absence of dietary 
intake data precludes identification of this plausible mediator of the findings. 
The use of a single-centre self-selected sample excluding those with clinical 
symptoms and those participating in regular exercise physical activity, limits the 
extrapolation of the results to the wider community, which encompasses a much 
broader range of lifestyles than this study is able to reflect. The device used to 
assess step count has not been formally validated for this purpose. Further, 
recent work suggests that distance walked is an important determinant of 
adiposity yet step count does not provide information on actual distance 
covered 628. Pooling age groups despite each containing two intentionally 
distinct groups in terms of physical activity may also confound comparisons 
between age groups. Despite these limitations the relatively strong correlations 
consistent with findings in larger cohorts suggests that the study was sufficiently  
large and step counts adequate to identify close relationships. 
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Conversely, applying the specific criteria of age, sex, amount of physical activity, 
and health status ensured a degree of homogeneity within and between groups, 
which strengthens the ability to extrapolate results to similar groups in the 
community. Also, in contrast to longitudinal research a cross-sectional approach 
is not prone to confounding by  environmental changes over the time, e.g. 
increasing prevalence of obesity 567, and increasing fasting glucose 
independent of age 576.
Use of an objective measure physical activity and use of high quality 
quantitative methods to assess, cardiorespiratory fitness, body composition and 
fat distribution, and liver fat improves the methodological rigour of this study 
relative to larger cohort studies that have tended to use self-reported physical 
activity, no or more basic measures of cardiorespiratory fitness, and less 
accurate measures of body composition, fat distribution, and IHTAG. A further 
strength is that, in addition to controlling for cardiorespiratory fitness statistically, 
women taking part in regular planned exercise were excluded so that the 
established relationships are with non-exercise physical activity.
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4.5 Conclusion
Ageing in the present and other cohorts, even in the absence of disease, is 
consistently accompanied by reductions in cardiorespiratory fitness, muscle 
strength and mass, and functional capacity. Ageing is also frequently 
accompanied by increased fat mass, increased hepatic steatosis, decreased 
insulin sensitivity, and reduced glucose control. These changes are closely 
associated with morbidity and mortality irrespective of age. Fortunately, they are 
all at least partly amenable to improvement via appropriate physical activity, 
both general and targeted exercise, as well as reductions in uninterrupted 
sedentary time. Public health focus should therefore be on increasing physical 
activity, cardiorespiratory fitness, and muscle strength, and reducing total and 
uninterrupted sedentary time in the whole population throughout the lifecycle.
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Chapter 5. High-Intensity Intermittent Training in Non-Alcoholic 
Fatty Liver Disease
5.1 Introduction
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in 
much of the World with an estimated prevalence in Western countries of 
20-30% in the general adult population, and greater prevalence among certain 
ethnic groups, the obese, and those with type 2 diabetes 5,629 (see Section 1.6 & 
1.7). A recent UK audit of 1118 primary-care patients indicated a prevalence of 
26.4% 630. However, this is likely to be an underestimate as steatosis was 
assessed by ultrasound, a relatively insensitive technique ( see Section 1.4.4), 
and assessments were done based on abnormal liver enzymes which are also 
insensitive to the presence of hepatic steatosis (see Section 1.4.5).
NALFD is closely associated with the symptoms of the metabolic syndrome, 
notably central obesity, impaired glucose control, elevated blood pressure, 
hypertriacylglyerolaemia, and low high-density lipoprotein 2,270. Thus the 
condition can progress from simple steatosis to non-alcoholic steatohepatitis, 
fibrosis, cirrhosis, and hepatocellular carcinoma, but is also closely linked to the 
development of type 2 diabetes and cardiovascular disease 629(see Section 
1.8).
The recommended, and in the absence of approved pharmacotherapy only, 
treatment for NAFLD, is lifestyle intervention with an emphasis on weight 
reduction 14,311. However, although numerous dietary approaches exist that are 
effective at achieving weight reduction (see Sections 2.3.2.1 and 2.4 ), weight 
maintenance proves challenging for the majority of people 631. This is true even 
in well funded multifactorial lifestyle interventions 358. Weight reduction per se 
may also not be called for in patients with NAFLD but normal body weight. The 
importance of physical activity and physical fitness for the prevention and 
treatment of NAFLD has become apparent with cross-sectional and prospective 
cohort analyses reporting an inverse association of physical activity and 
cardiorespiratory fitness with risk of NAFLD 232,233,237-239. Further, retrospective 
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analysis of a cohort with NAFLD showed those meeting US guidelines for 
vigorous exercise were less likely to have NASH 240. However, the capacity to 
perform vigorous activity in patients with NASH is impaired consistent with 
disease severity 181.
Recent small scale exercise only interventions have demonstrated the potential 
for exercise to modestly reduce liver fat independently of weight change and 
dietary modification 243-245 (see Chapter 2 for extensive discussion). The 
capacity for exercise to improve glucose control is well established 274,408. 
However, exercise interventions in patients with objectively and quantitatively 
assessed liver fat are few and have tended to conduct partly or fully supervised 
sessions that are too resource intensive to be translated into clinical care 244,245. 
No study has previously assessed high- intensity intermittent training (HIIT) in a 
cohort with clinically defined NAFLD. HIIT is time efficient, has a good safety 
record (see Section 3.3.1), and is highly effective at improving fitness in a broad 
range of healthy and clinical populations (see Section 3.3.2). HIIT has also been 
shown, albeit less consistently, to reduce blood pressure (see Section 3.3.2.3 & 
3.3.2.3), improve glucose control (see Section 3.3.4.1 & 3.3.4.2.1), and reduce 
body fat (see Section 3.3.3). 
Given the successful track record of HIIT in improving many of the comorbidities 
of NALFD, this study aimed to define the effect of 12 weeks of thrice weekly 
HIIT on adults with NAFLD; specifically with respect to:
1.  intrahepatic triacylglycerol concentration (IHTAG)
2. glucose control
3. substrate utilisation during rest and submaximal exercise
4. liver enzyme profile
5. fasting blood lipid profile
6. body composition; and
7. blood pressure
The null hypothesis was that there would be no change in liver fat or other 
measured parameters over time between the HIIT intervention and a control 
group given standard care.
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5.2 Methods
5.2.1 Design and Recruitment
This was a single-centre quasi-randomised controlled trial with a parallel design. 
The randomisation was broken in one volunteer who was identified as having 
previously undiagnosed type 2 diabetes and would have been lost to the study if 
allocated to the control group and given standard care. The study aimed to 
enrol 28 sedentary adults aged 18-70 years with non-alcoholic fatty liver 
disease. Excess liver fat was defined as >5% 124, and advanced liver disease 
was ruled out by including only volunteers with a NAFLD Fibrosis Score of 
≤-1.455, corresponding to a negative predictive value of 88-93% for advanced 
(Kleiner F3/4) fibrosis 167. The age range was selected based on apparent 
safety and efficacy of HIIT in this range reported published studies employing 
similar exercise protocols in clinical populations (see Section 3.3.1). 
Exclusion criteria were as follows: pregnancy; inability to adhere to the 
intervention due to physical or mental factors; contraindications to magnetic 
resonance scanning; viral hepatitis; uncontrolled thyroid condition; 
haemochromatosis; mean self-reported alcohol intake exceeding 21 units for 
men or 14 units for women.; suspicion that pharmacotherapy was the cause of 
the hepatic steatosis; self-reported or activity monitor assessed physical activity 
exceeding one hour of vigorous activity (≥ 6 metabolic equivalents) per week; or 
diabetes medication other than metformin. Participants were also required to 
have been weight stable and on a stable regime of prescriptions medication for 
the past six months.
An online random number generator (www.randomization.com) was used to 
establish a treatment allocation sequence. Eligible volunteers were assigned in 
order following baseline assessments. When one participant withdrew prior to 
completion, the next available participant took their place in the sequence.
The study was given ethical approval by the Newcastle and Northeast Tyneside 
Local Research Ethics Committees. All volunteers were provided with a 
participant information sheet (see Appendix 5) before providing written informed 
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consent (see Appendix 6). Volunteers were recruited from the Northeast of 
England by referral from a secondary care (Freeman Hospital, Newcastle upon 
Tyne, UK), advertising in local newspapers, and word of mouth. Recruitment 
was conducted between August 2010 and March 2012. 
Post-intervention assessments took place at least 48 hours following the last 
bout of exercise to avoid observing a last bout effect.
5.2.2 Volunteer Safety and Eligibility Screening 
Prior to taking part in the intervention, volunteers were screened to determine 
their readiness to undertake the exercise required. Full details of procedures 
and copies of forms can be found in Supplementary Document 1: Risk 
Definition and Standard Operating Procedures for Exercise Testing (see 
Appendix 6). A questionnaire was used to establish if magnetic resonance 
scanning was contraindicated due to implanted ferrous material or other 
reasons (see Appendix 7)
5.2.2.1 Medical History and Physical Examination 
Medical history was collected, and physical examination performed as 
described in Section 4.2.2.
5.2.2.2 Maximal Progressive Exercise Test
Exercise testing was carried out as described in Section 4.2.3.
5.2.3 Magnetic Resonance Spectroscopy and Imaging of Liver and Abdominal 
Fat
All magnetic resonance imaging and spectroscopy was done using a 3T Philips 
Achieva scanner (Philips, Netherlands). Intrahepatic lipid triacylglycerol (IHTAG) 
concentration was measured by localised proton-energy magnetic resonance 
spectroscopy (1H-MRS) (PRESS, TR/TR 3000 ms/35 ms, 3x3x3 cm voxel, 
SENSE torso array). Quantification of the spectra (water and CH2 resonances) 
was performed using jMRUI version 3.0 (Claude Bernard University, Lyon, 
France) 632,633. Following manual first and second order phase correction, 
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spectra were analysed using a non-linear least squares algorithm (AMARES) 
634. IHTAG was expressed as a percentage of liver volume, corrected for proton 
density of water and lipid.
Abdominal visceral and subcutaneous fat was measured at L4/L5 using a three-
point Dixon sequence (TR/TE/number of averages/flip angle 50 ms/ 3.45, 4.60, 
5.75 ms/1/308, matrix 160x109, median field of view (FOV) 440 mm, range 
400x480 mm to suit subject size with 70% phase FOV). The slice was acquired 
during a breath-hold and with slice thickness of 10 mm 535,536. Fat and water 
were separated, and binary gating applied to produce a map of structures 
containing more than 50% fat. ImageJ (National Institute of Health, USA) was 
used to calculate total, subcutaneous, and visceral fat area by creating a binary 
image and using a watershed algorithm 537.
5.2.4 Fasted Blood Sample Collection, Storage, and Analysis
All blood samples were collected from antecubital veins by cannulation (22G 
Vasofix® Cero, B Braun Melsungen AG, Melsungen, Germany). Cannula 
patency was maintained using mandrins (B Braun Melsungen AG, Melsungen, 
Germany). Fasted (≥ 10 hours with no food or beverages other than plain water) 
blood samples were collected into BD K3E and SST™ Advance vacutainers 
(BD Diagnostics, Plymouth, UK) for analysis of total (TC) and high-density 
lipoprotein (HDL) cholesterol, triacylglycerols (TAG), aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyltransferase 
(GGT); glycated haemoglobin A1c (HbA1c) and serum ferritin. 
Total cholesterol 538, HDL-cholesterol 539, ALT 540, and AST 541 were measured 
using the Roche Modular P and test kits (Roche Diagnostics Ltd, Burgess Hill, 
UK).  LDL-cholesterol was calculated using the the Friedewald equation 542. 
GGT was measured using a Roche Modular E170 543. HbA1c was measured 
using a TOSOH HLC-723G7 (Tosoh Corporation, Tokyo, Japan). Serum ferritin 
was measured by radioimmunoassay 544. These analyses were carried out by a 
Clinical Pathology Accredited (CPA) laboratory (Newcastle Upon Tyne Hospital 
NHS Foundation Trust, Department of Clinical Biochemistry) on the same day 
as samples were acquired. 
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5.2.5 Frequently Sampled Oral Glucose Tolerance Test
Fasting and blood collection was as described above. Participants were given a 
350 mL Lucozade Original glucose drink (GlaxoSmithKline, Gloucestershire, 
UK), corresponding to 75 g of glucose, to consume within three minutes. Blood 
samples were taken at time: 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, and 120 
minutes. 
Whole blood glucose was collected into fluoride oxalate tubes (Teklab, 
Sacriston, UK) and measured immediately with a YSI 2300 Stat Plus-D (Yellow 
Springs Instruments, Yellow Springs, Ohio, USA). Additional whole blood was 
collected in K-EDTA tubes (Teklab, Sacriston, UK) and uncoated glass tubes 
(Teklab, Sacriston, UK), and centrifuged at 3000 rpm (2133 RCF) for 10 minutes 
in a Sigma 6K15 laboratory centrifuge (Sigma Laborzentrifugen GmbH, 
Osterode am Harz, Germany). The resulting serum and plasma was stored at 
-40 ºC (MDF-U5411 plasma freezer, Sanyo Electric Biomedical Co. Ltd., Osaka, 
Japan) in Nalgene cryogenic vials (Thermo Fisher Scientific, Rosklide, 
Denmark) until analysis of plasma insulin and serum non-esterified fatty acids 
(NEFA) at the end of the study.
Plasma insulin was measured by radioimmunoassay (Coat- A-Count Insulin 
RIA kit; Diagnostic Products Corporation, California, USA), and serum non-
esterified fatty acids (NEFA) by enzymatic colorimetry (NEFA-HA, Wako Ltd, 
Osaka, Japan). Area under the curve for the resulting glucose and insulin 
response profiles was calculated using the trapezoidal rule 635, and insulin 
resistance and β-cell function determined using the homeostasis model 
assessment 2 (HOMA2) (HOMA2 Calculator, University of Oxford, Oxford, UK) 
636. 
Percentage insulin stimulated NEFA suppression at 30 and 60 minutes were 
calculated by 637:
NEFAsup30 % = (NEFA0-NEAF30)/NEFA0 
NEFAsup30 % = (NEFA0-NEAF60)/NEFA0
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where the subscript 0, 30, and 60 indicate baseline, 30 minute and 60 minute 
values, respectively. NEFA suppression was calculated from samples taken 
during the OGTT only. However, fasting NEFA as reported below is the average 
of two fasting NEFA results obtained on non-consecutive days preceding the 
OGTT and submaximal exercise test, respectively.
5.2.6 Substrate Utilisation at Rest and during Exercise
Resting metabolic rate (RMR) was determined by having participants lie supine 
for 30 minutes while respiration and haemodynamic parameters were 
monitored. Respiration was monitored as noted above for the maximal 
progressive exercise test. Haemodynamic monitoring is described below. Data 
from 10-25 minutes were used to reflect a true resting state. Then, still in a 
fasted state, participants cycled for 60 minutes at 50% of the resistance 
corresponding to VO2peak achieved during their screening maximal progressive 
exercise test. Respiration was monitored for five minute periods every 15 
minutes, and a blood sample collected. 
The respiratory exchange ratio (RER) was used to determine substrate 
utilisation, and blood samples to determine concentrations of glucose, insulin, 
and NEFA, as described above. RER was calculated:
RER = VCO2 out/VO2in
where VCO2 and VO2 indicate volume of carbon dioxide and oxygen, 
respectively, in L/min, and the subscripts out and in indicate gas eliminated and 
gas consumed, respectively.The averages from fifteen minutes of supine rest 
and the average of the four five minute respiratory measurements were used to 
determine RER at rest and during submaximal exercise, respectively. For the 
resting measure, patients rested for five minutes before sampling, and during 
exercise measures taken in the first minute were discarded to ensure a steady 
measure.
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5.2.6 Resting Heart Rate and Blood Pressure
Haemodynamics at rest were measured using bioimpedance (Task Force® 
Monitor, CNSystems Medizintechnik GmbH, Graz, Austria), specifically: systolic 
and diastolic, and heart rate.
5.2.7 Body Composition and Anthropometry
Body composition and anthropometry were assessed as described in Section 
4.2.7.1 and Section 4.2.7.2, respectively.
5.2.8 Intervention
Control participants were asked to maintain their current physical activity habits 
and treatment plans including all medication. All participants were instructed to 
retain their current diets, physical activity levels outside of the intervention, and 
body weight. To assist with weight stability during the intervention, participants 
were asked to report their weight on a biweekly basis. If weight change 
exceeded 1% of baseline weight, the participant was  instructed to modestly 
increase or decrease their food intake until their weight approached that at 
baseline.
Participants in the HIIT group were instructed to complete a cycle ergometer-
based training protocol three times per week, where feasible on non-
consecutive days, for twelve weeks. Intensity was based on the 6-20 point Borg 
Rating of Perceived Exertion (RPE) 638. Participants were provided with a 
laminated A4 sheet depicting the RPE scale and a picture guide for exercises 
(see Appendix 1), and an iPod shuffle (Apple Inc. Silicon Valley, CA, USA) 
containing pre-recorded instructions and verbal cues to guide them through 
each session (see Appendix 9). Sessions consisted of a 5 minute warmup 
progressing from an RPE of 9 (very light) to 13 (somewhat hard) followed by 
five intervals of cycling at an RPE of16-17 (very hard) interspersed with three 
minute recovery periods, and followed by a 3 minute cool-down after the last 
interval. Each interval was two minutes long in the first week with 10 seconds 
added per week, so that intervals were three minutes and 50 seconds long by 
week 12. The programme therefore took 30 to 40 minutes to complete 
depending on week. Recovery periods included 90 seconds of passive 
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recovery, 60 seconds of band resisted upper body exercise, and 30 seconds to 
transition back onto the ergometer, start cycling, and programme the required 
settings for the upcoming interval. One upper body exercise was performed per 
recovery period in the following order: face-pull; horizontal push; horizontal pull; 
and 45º push (see Appendix 1). Adequate adherence was defined as self-
reported completion of at least 33 exercise sessions. This was corroborated by 
an exercise diary in which date and maximal heart rate of each session were 
recorded by each participant.
5.2.9 Statistical Analysis
Numeric data was recorded in Excel® 2008 for Mac (Microsoft Corporation, 
Silicon Valley, USA.) and analysed using SPSS version 19 (IBM, New York, 
USA). Prior data indicated that the standard deviation of liver fat in a population 
similar to that of the study was between 7.4 and 9.1 243; thus, assuming a 
standard deviation of 9.0, an 80% chance of detecting a 10% relative change in 
liver fat concentration could at a one-sided 0.05 significance required n=22. A 
target n=28 was chosen to allow for 20% dropout. 
Statistical analysis was per-protocol as this was a phase II trial to establish 
efficacy not effectiveness. Normality of data distribution was established by 
tests of skewness and kurtosis. Where data were non-normally distributed these 
were transformed by their natural logarithm to achieve normality and retested. 
Between group comparisons were made using analysis of covariance with the 
followup result as the dependent variable and the baseline result as the 
covariate. Because liver fat is particularly responsive to weight change, a model 
including weight change and one including change in total fat mass were also 
run. Comparisons of key baseline variables (see Table 5.1) were made using 
independent sample T-Tests. Within group changes were assessed by paired-
sample T-Test. Given not all data were normally distributed, Spearman rank 
correlation coefficient were used on untransformed data to test the association 
of IHTAG and two hour glucose with changes in body composition and baseline 
fitness.
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5.3 Results
5.3.1 Baseline Comparisons and Participant Flow
Participant flow is shown in Figure 5.1. Of 25 people randomised, 20 people 
were analysed: one male withdrew from the control group, and one female was 
excluded due to key missing data; one female withdrew from the HIIT group due 
to prolonged illness, one female did not complete the minimum number of 
exercise session, and one was excluded due to key missing data. There were 
no study related serious adverse events.
Figure 5.1: CONSORT Statement Flow of Participants
Contacts (n=236)
Assessed for eligibility (n= 225)
Screened (n= 63)
Excluded after initial contact (n= 162)
Not eligible (n= 99)
Declined (n= 63)
Excluded after screening (n= 38)
Liver fat < 5% (n= 20)
Failed exercise screening (n= 15)
Too large to scan (n= 2)
Claustrophobic (n= 1)
Randomised (n= 25)
Allocated to Control (n= 10)
Completed (n= 9)
Allocated to HIIT (n= 15)
Completed (n= 14)
Discontinued  intervention (n= 1)
Prolonged illness (n=1)
Analysed (n= 12)
Excluded due to nonadherence (n= 1)
Excluded due to missing data (n= 1)
Discontinued intervention (n= 1)
Time commitment (n=1)
Analysed  (n= 8)
Excluded due to missing data (n= 1)
Could not contact (n= 11)
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Key baseline data are shown in Table 5.1. There were more females in the HIIT 
than the CON group. Age, BMI, weight, height, peak oxygen consumption, and 
peak work rate were similar between groups. Based on 2-hour glucose and no 
prior diagnosis, no controls had type 2 diabetes and one male had impaired 
glucose tolerance, whereas in the HIIT groups one female had type 2 diabetes, 
and three females and two males had impaired glucose tolerance. Prescription 
medication used by participants is shown in Table 5.2. 
Table 5.1: Baseline Characteristics
Parameter Control HIIT p
N (males/females) 8 (7/1) 12 (7/5)
Age (years) 49.8 (42.7, 56.8) 52.9 (47.5, 58.4) 0.499
BMI (kg/m2) 31.1 (27.3, 34.9) 30.3 (27.9, 32.8) 0.731
Weight (kg) 90.0 (82.7, 97.3) 86.7 (78.7, 94.8) 0.562
Height (m) 1.71 (1.64, 1.78) 1.69 (1.65, 1.73) 0.650
VO2peak (L/min) 2.3 (1.9, 2.6) 1.9 (1.4, 2.3) 0.157
VO2peak (ml/kg/min) 24.9 (21.2, 28.6) 22.5 (19.2, 25.8) 0.363
VO2peak (ml/kglean mass/
min)
38.1 (34.6, 41.7) 33.7 (28.9, 38.5) 0.164
Peak work rate (W) 162 (137, 187) 144 (119, 170) 0.341
Table 5.2: Prescription Medication
Medication (Class) Control (n) HIIT (n)
Statin 2
Diuretic 2
Selective seratonin reuptake inhibitor 1
Bisphosphonate (osteoporosis) 1
β-agonist (asthma) 2
Antihistamine/allergy medication 2
Analgesics 1
Topical steroid anti-inflammatory 1
Chapter 5 - High-Intensity Intermittent Training in Non-Alcoholic Fatty Liver Disease
184
5.3.2 Liver Fat and Body Composition
Liver fat and body composition changes are shown in Table 5.2. Between group  
comparisons showed significant reductions in IHTAG, fat mass and body fat 
percentage, and an increase in lean body mass in HIIT vs. controls by (mean
±SD) 4.4±7.4%, 1.6±1.1 kg, and 1.2±1.4%, and 1.0±1.9 kg, respectively (see 
Figure 5.2). Adding weight change as a covariate did not change the 
significance of the finding (p= 0.03), but using change in total fat mass did 
negate statistical significance (p= 0.082). There were no significant correlations 
between changes in IHTAG and changes in body weight, fat mass, fat free 
mass, or baseline VO2peak.
Within group comparisons showed a 
significant reduction in weight, BMI, fat 
mass, and body fat percentage in HIIT. 
However, IHTAG reduction and fat free 
mass increase were not significant in the 
within group comparison (p= 0.066, and p= 
0.095, respectively). IHTAG increased in 6 
controls and decreased in two, whereas it 
increased in only one HIIT and decreased in 
the other 11. 
Visceral fat areas remained similar pre and 
post intervention in both groups. 
Subcutaneous fat area was not analysed as 
there were technical problems with several 
images such that interrater error on many 
images would have exceeded the actual pre 
vs. post differences observed in some 
scans.
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Table 5.3: Changes to Body Composition and Fat Distribution
Parameter
Control HIIT p treatment x 
timeBaseline Post Baseline Post
IHTAG(1H-MRS) (%) 10.1 (7.0, 13.2) 10.0 (5.1, 8.1) 10.9 (7.2, 14.7) 6.6 (5.1, 8.1) 0.031
Weight (kg) 90.0 (82.7, 97.3) 89.9 (83.2, 96.5) 86.7 (78.7, 94.8) 85.6 (77.6, 93.6)! 0.149
BMI (kg/m2) 31.1 (27.3, 34.9) 31.1 (27.3, 34.9) 30.3 (27.9, 32.8) 29.9 (27.5, 32.3)! 0.162
Fat mass (kg) 31.0 (24.1, 37.8) 31.5 (24.3, 38.6) 32.8 (28.3, 37.4) 31.2 (26.6, 35.8)‡ 0.018
Body fat (%) 34.0 (28.3, 39.7) 34.6 (28.2, 41.1) 37.5 (34.1, 40.9) 36.3 (32.7, 39.9)* 0.024
Fat free mass (kg) 59.0 (54.2, 63.8) 58.4 (52.9, 64.0) 53.9 (48.4, 59.4) 54.9 (48.8, 61.0) 0.032
Visceral (cm2) 150 (117, 183) 145 (120, 170) 147 (122, 173) 149 (117, 181) 0.520
Data are shown as means and 95% confidence intervals. Abbreviations: 1H-MRS, proton-energy magnetic resonance spectroscopy; IHTAG, intrahepatic 
triacylglycerol. 
* significantly different from baseline within group p< 0.05
! significantly different from baseline within group p< 0.01
‡ significantly different from baseline within group p< 0.001
5.3.3 Metabolic Changes
Changes to glucose, insulin, NEFA, and energy substrate utilisation are shown 
in Table 5.3. There were no significant between-group changes in fasting or 2-
hour glucose, glucose area under the curve, or HbA1c. There was a significant 
within-group reduction in 2-hour glucose for HIIT. There were no within or 
between group differences in respiratory exchange ratio at rest or during 
exercise.
5.3.4 Liver Enzymes, Blood Lipid Fractions, and Serum Ferritin
Key liver enzymes, blood lipids, and serum ferritin results are shown in Table 
5.4. Both within and between group comparisons indicated a significant 
reduction of ALT and AST, but only between group comparison showed a 
reduction in TAG concentrations. Within group comparisons showed a reduction 
in serum ferritin in both controls and HIIT. 
Chapter 5 - High-Intensity Intermittent Training in Non-Alcoholic Fatty Liver Disease
187
Table 5.4: Metabolic Changes
Parameter Control HIIT p treatment x timeBaseline Post Baseline Post
Fasting glucose (mmol/L) 4.7 (4.5, 5.0) 4.7 (4.4, 5.0) 4.7 (4.5, 5.0) 4.7 (4.5, 4.0) 0.771
Fasting insulin (pmol/L) 84 (64, 104) 87 (69, 105) 125 (92, 157) 100 (72, 127) 0.205
Fasting NEFA (mmol/L) 0.46 (0.36, 0.57) 0.54 (0.43, 0.65) 0.49 (0.39, 0.59) 0.50 (0.42, 0.58) 0.179
2 hour glucose (mmol/L) 5.8 (4.9, 6.8) 5.4 (4.5, 6.2) 8.1 (6.6, 9.6) 6.6 (5.6, 7.5)* 0.799
2 hour insulin (pmol/L) 712 (250, 1173) 884 (473, 1294) 1080 (768, 1391) 1054 (765, 1344) 0.979
fsOGTT glucose AUC 876 (788, 965) 896 (836, 956) 989 (883, 1095) 923 (828, 1019) 0.317
NEFAsuppression 30 minutes (%) 5.5 (-12.9, 23.9) -7.9 (-19.5, 3.8) 7.4 (-6.7, 21.5) -2.8 (-19.8, 14.2) 0.679
NEFAsuppression 60 minutes (%) 17.4 (-5.0, 39.9) 5.4 (-3.0, 13.9) 6.3 (-14.3, 26.9) 6.1 (-18.1, 30.2) 0.884
HOMA2-IR 1.6 (1.2, 1.9) 1.6 (1.3, 1.9) 2.2 (1.7, 2.8) 1.8 (1.3, 2.3)* 0.229
HOMA2-β 142 (114, 170) 152 (124, 180) 183 (152, 215) 156 (130, 182) 0.200
HOMA2- S 72 (54, 90) 69 (53, 85) 55 (38, 72) 70 (46, 94) 0.209
HbA1c (%) 5.5 (5.2, 5.8) 5.6 (5.3, 5.8) 5.9 (5.6, 6.2) 5.9 (5.7, 6.2) 0.913
RERresting 0.87 (0.82, 0.92) 0.91 (0.86, 0.96) 0.90 (0.87, 0.93) 0.88 (0.85, 0.92) 0.259
RERsubmaximal 10-15 minutes 0.98 (0.94, 0.99) 0.97 (0.94, 1.00) 0.99 (0.96, 1.02) 0.98 (0.93, 1.03) 0.758
RERsubmaximal 25-30 minutes 0.94 (0.92, 0.94) 0.94 (0.91, 0.94) 0.95 (0.92, 0.99) 0.96 (0.91, 1.01) 0.682
RERsubmaximal  40-45 minutes 0.92 (0.90, 0.95) 0.92 (0.90, 0.95) 0.95 (0.92, 0.98) 0.95 (0.92, 0.98) 0.270
RERsubmaximal 55-60 minutes 0.92 (0.89, 0.94) 0.91 (0.90, 0.93) 0.93 (0.90, 0.96) 0.94 (0.91, 0.98) 0.281
RERsubmaximal mean 0.93 (0.91, 0.96) 0.94 (0.91, 0.96) 0.95 (0.92, 0.99) 0.96 (0.92, 1.00) 0.529
Data are shown as means and 95% confidence intervals. Abbreviations: AUC, area under the curve; fsOGTT, frequently samples oral glucose tolerance test; HBA1c, 
glycated haemoglobin A1c; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of beta cell function; ISI, 
insulin sensitivity index; NEFA, non-esterified fatty acids, RER, respiratory exchange ratio. 
* significantly different from baseline within group p< 0.05
! significantly different from baseline within group p< 0.01
‡ significantly different from baseline within group p< 0.001
Table 5.5: Changes to Liver Enzymes and Blood Lipids
Parameter
Control HIIT p treatment x 
timeBaseline Post Baseline Post
ALT (IU/L) 48 (31, 65) 53 (33, 72) 59 (39, 79) 43 (28, 58)* 0.019
AST (IU/L) 31 (24, 38) 35 (26, 45) 39 (27, 51) 33 (24, 42)* 0.023
GGT (IU/L) 48 (18, 78) 56 (14, 98) 55 (9, 100) 38 (10, 66) 0.061
Serum ferritin (μg/L) 166 (133, 200) 142 (111, 173)* 110 (65, 154) 78 (43, 113)! 0.065
Total-cholesterol (mmol/L) 5.6 (4.8, 6.5) 5.5 (4.6, 6.5) 5.2 (4.5, 5.8) 5.0 (4.5, 5.6) 0.594
LDL-cholesterol (mmol/L) 3.8 (3.1, 4.5) 3.6 (2.8, 4.3) 3.2 (2.7, 3.8) 3.1 (2.6, 3.6 ) 0.842
HDL-cholesterol (mmol/L) 1.1 (1.0, 1.2) 1.2 (1.0, 1.4) 1.1 (0.9, 1.3) 1.1 (0.9, 1.3) 0.452
Total: HDL-cholesterol 5.0 (4.5, 5.5) 4.9 (4.4, 5.5) 4.9 (4.0, 5.8) 4.7 (3.9, 5.6) 0.617
Triacylglycerols (mmol/L) 1.5 (1.1, 2.0) 1.8 (1.2, 2.5) 1.8 (1.4, 2.1) 1.6 (1.3, 2.0) 0.047
Data are shown as means and 95% confidence intervals. Abbreviations: ALT, alanine aminotransferase; AST , aspartate aminotransferase; GGT, γ-
glutamyltransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
* significantly different from baseline within group p < 0.05
! significantly different from baseline within group p < 0.01
5.3.5 Changes to Cardiac and Haemodynamic Parameters 
Resting heart rate, and systolic and diastolic blood pressure are shown in Table 
6.6. There were no changes over time within or between groups.
Table 5.6: Heart Rate and Blood Pressure
Parameter
Control HIIT p 
treatment 
x timeBaseline Post Baseline Post
HRrest 65 (60, 71) 67 (61, 73) 65 (61, 69) 63 (60, 65) 0.068
SBPrest (mmHg) 123 (118, 127) 124 (119, 130) 131 (124, 137) 128 (118, 139) 0.540
DBPrest (mmHg) 83 (79, 88) 86 (80, 91) 89 (84, 95) 88 (81, 94) 0.595
Data are shown as means and 95% confidence intervals. Abbreviations: BP, blood pressure;
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5.4 Discussion
NAFLD affects a large portion of the Worldʼs adult population and has several 
hepatic and non-hepatic sequelae including NASH, fibrosis, cirrhosis and 
hepatocellular carcinoma on the one hand, and type 2 diabetes and 
cardiovascular disease on the other (see Section 1.8). Lifestyle therapy 
focusing on weight reduction is the preferred, and in the absence of approved 
pharmacological interventions, only means to address NAFLD 14,311. However, 
weight reduction and subsequent maintenance is difficult for many patients 
even when enrolled in research interventions 358. Exercise only interventions 
may offer an alternative independent of weight reduction, but are 
underrepresented in the literature, potentially leading them to be ignored as an 
option in clinical practice (see Chapter 2).
This is the first study to assess the effects of HIIT in patients with clinically 
defined NAFLD. The major findings are that HIIT performed three times per 
week for 12 weeks led to: 1) a 40%reduction in IHTAG; 2) improved body 
composition; 3) and reduced plasma ALT and AST; and 4) improved glucose 
control. The observed 40% relative reduction in IHTAG was greater than the 
10-21% previously reported following resistance or aerobic exercise only 
interventions 243-245, and comparable to several weight reduction trials (see 
Chapter 2). The the greater IHTAG reduction relative to other exercise based 
interventions may be partly accounted for by the present study having a greater 
duration than some 243,244, but not all previous studies 245. Although there may 
have been a difference in exercise related energy expenditure, this was not 
measured in the present study. The best explanation for the reduction in liver fat 
was the notable reduction in body fat mass suggesting increased fat oxidation.
Notably, the present study did not show a significant change in body weight in 
the HIIT group vs. controls; the within group analysis indicated a very modest 1 
kg weight reduction following exercise. This corroborates the findings of 
previous exercise interventions that have shown IHTAG can be reduced in the 
absence of marked body weight reduction 243-245. The minor weight change 
observed in the HIIT group was consistent with similar modest weight 
reductions observed in broadly comparable HIIT trials (see Section 3.3.3). 
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However, patients in the present study were specifically asked to monitor and 
maintain their weight. The HIIT intervention did, however, elicit a significant 
change in body composition. The observed reduction in fat mass is consistent 
with that reported by some, but not all other studies employing an HIIT protocol 
over 12 or more weeks (see Section 3.3.3). Modest increases in fat free mass 
have also been previously reported 494, interestingly in the context of a reduced 
calorie diet. 
Lean body mass is inversely associated with mortality 573,639,640, and loss of lean 
mass is associated with insulin resistance 641, especially in older populations. 
Resistance training has previously been shown to promote retention of lean 
mass during weight reduction 642-645. The finding of the present study suggests 
HIIT may be another means by which to promote maintenance of lean mass 
during weight reduction.
Interestingly, HIIT produced a change in IHTAG without any apparent change in 
visceral fat area. There is increasing evidence that the two depots tend to reflect 
adiposity and are not mechanistically linked 646. Recent findings from the 
Framingham Heart Study show IHTAG to be associated with the dyslipidaemia 
and dysglycaemia independently of visceral fat 622. The observation of 
decreased IHTAG in the absence of any observable change in visceral fat in the 
present sample, provides further information on the separate regulation of 
IHTAG and visceral fat. However, given the modest reductions in total fat, any 
change in visceral fat volume may have been too small to detect using single 
slice analysis 647.
Although no previous studies have directly reported the effects of HIIT on 
IHTAG, HIIT has been shown to reduce hepatic secretion of very-low density 
lipoprotein triacylglycerol 504, and reduced postprandial plasma triacylglycerol 
concentrations 82,83, indicating a direct effect on hepatic metabolism. Indeed, 
there was a relative reduction in fasting plasma triacylglycerol in the present 
HIIT group.
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Glucose control and insulin sensitivity as assessed by frequently sampled oral 
glucose tolerance test, HOMA-IR, NEFA suppression, and HbA1c concentration 
did not following HIIT relative to control conditions. There was a notable within 
group decrease in two-hour glucose concentration in the HIIT group. These 
finding were contrary to some though not all previous reports of the effect of 
HIIT on glucose control (see Section 3.3.4.21). Further, the ability of aerobic 
exercise to transiently improve glucose control by increasing both insulin 
dependent and insulin independent myocellular glucose uptake is well 
documented 64. 
There are a number of factors that are likely to have influenced the present 
results. Most notable are the transient nature of the metabolic changes following 
exercise, and the heterogeneity of the cohort with respect to degree of insulin 
resistance. A cumulative effect of exercise on glucose clearance has been 
observed 104. However, even in endurance trained athletes with high insulin 
sensitivity, three days of detraining resulted in one third reduction in rate of 
glucose clearance, and seven days of detraining resulted in glucose clearance 
similar to that of sedentary controls 593. In a previous HIIT cohort, reductions in 
area under the insulin curve and improvements in the insulin sensitivity index 
were observed 24 but not 72 hours post training 479. This is consistent with 
observations following classic continuous moderate intensity aerobic exercise 
where insulin sensitivity has been shown to stay elevated for 48 hours but not 5 
day 592. Further, high carbohydrate intake in the hours immediately following 
exercise has been shown to blunt the insulin sensitising effect of exercise 
indicating that some degree of glycogen depletion is required 508.
In the present study volunteers were asked to refrain from exercise 48 hours 
prior to assessments to avoid observing changes exclusively due to the last 
bout of exercise, however in practice the period of time between exercise and 
metabolic assessments ranged between 48 hours and several days. Further, no 
data on post exercise dietary practices were collected. Although HbA1c is 
considered a longer-term marker of recent glucose control and not likely to be 
measurably affected by a few days of detraining, most participants had 
concentrations already within the normal range at baseline. Future 
Chapter 5 - High-Intensity Intermittent Training in Non-Alcoholic Fatty Liver Disease
194
investigations would benefit from using techniques such as continuous glucose 
monitoring to obtain a more longitudinal data on the effect of exercise on 
glucose control.
Energy substrate utilisation during rest and sub-maximal exercise showed no 
change within or between groups as assessed by RER. Two previous studies 
reported no change in resting RER 48 504, and 72 hours post-exercise following 
2 and 8 weeks of HIIT 505, respectively. Whereas one 12 week HIIT intervention 
did result in a 2.4% reduction in RER indicating increased fat oxidation and 
decreased carbohydrate oxidation, however the time elapsed since the last bout 
of exercise was unreported 492. An approximate 65% increase in fat oxidation 
and 20% reduction in carbohydrate metabolism has been reported 60 minutes 
post exercise 501. This was already evident after two weeks of training, with no 
further changes at six weeks.No reports of energy substrate utilisation during 
submaximal exercise following an HIIT programme were found in the literature. 
Given the transient nature of changes to glucose metabolism following exercise, 
it is feasible that any change that might take place following exercise was lost 
within the period between exercise and post-intervention assessment in both 
the present and above studies.
HIIT has established itself as both time efficient and effective at substantially 
improving cardiorespiratory fitness in a broad range of clinical and healthy 
populations (see Chapter 3). Increased fitness is desirable given the inverse 
relationship between participation in vigorous exercise and progression from 
uncomplicated steatosis to NASH 240. Time efficiency may be also be critical as 
a lack of time is a frequently cited barrier to regular exercise 648. A HIIT 
approach was also preferred over continuous moderate intensity exercise by 
obese women with and without type 2 diabetes 459, and coronary heart disease 
patients 449.
Metabolic adaptations following HIIT are comparable and sometimes greater 
than those following prolonged continuous moderate intensity exercise 649. 
Single 420, and multiple sessions of HIIT have been shown to improve 24-hour 
and postprandial glucose control in type 2 diabetes 421. HIIT over a number of 
weeks also improved glucose control in people with metabolic syndrome 503. 
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Muscle biopsies following HIIT in both healthy individuals and those with type 2 
diabetes indicate these changes are at least partly accounted for by increased 
mitochondrial biogenesis via an intensity dependent mechanism, and include 
increased expression of glucose transporter and elevated resting glycogen in 
muscle 649.
This study had multiple characteristics that can be viewed as either strengths or 
limitations. The cohorts were small and, despite randomization, somewhat 
heterogeneous with respect to some biochemical, anthropometric, and cardiac 
parameters. The presence of significant fibrosis was all but ruled out using the 
NAFLD fibrosis score, so the present cohort was most representative of the 
majority of NAFLD patients seen in primary care. All but the first 1-2 exercise 
sessions were unsupervised and program adherence was only assessed by 
self-report. This reflects the likely scenario in a clinical setting, but does not 
optimize adherence. Further, the nature of the assessments required they be 
conducted over a minimum of two days, three for most volunteers, and no 
volunteers were able to do them consecutively due to other commitments. 
Although the timeframe of IHTAG change following exercise is not known, 
exercise induced improvements in glucose tolerance and insulin sensitivity, 
although cumulative over several exercise sessions 104, are most marked within 
the first 24-48 hours post exercise, and tend to decline markedly after 72 hours 
even in athletes 479,591. Thus efficacy of the HIIT protocol done as prescribed, 
may have been underestimated due to delays in assessment following 
completion of the intervention.
Assessment of outcomes was by high quality objective, and extensively 
validated methods, specifically: 1H-MRS to quantitatively and objectively assess 
liver fat; MRI to quantify abdominal fat; air displacement plethysmography to 
assess body composition; frequently sampled oral glucose tolerance test to 
assess multiple aspects of glucose control and insulin response; and indirect 
calorimetry to assess metabolism during rest and submaximal exercise.
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5.5 Conclusion
A thrice weekly programme of unsupervised progressive HIIT lasting 30-40 
minutes per session markedly reduced liver fat, decreased ALT and AST, 
improved body composition, and reduced two-hour glucose with minimal 
change in total body weight in adults with NAFLD. This exercise programme 
therefore represents a time efficient means to improve the health of patients 
with NAFLD, particularly those unable or unwilling to adopt lifestyle changes 
resulting in weight reduction.
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Chapter 6. Limitations of the Research in this Thesis
This chapter summarises the limitations of the primary and secondary research 
that form the basis of this thesis, and notes how these might be addressed in 
future work.
6.1 Limitations of Chapter 2
The systematic review of in Chapter 2 was the first of of its kind done assessing 
lifestyle therapy in NAFLD at the time it was published 15; although there was 
already a systematic review looking at weight reduction in NAFLD 336. Applying 
a systematic approach to reviewing lifestyle interventions in NAFLD was 
justified on the basis that such an approach is required to determine gaps in 
knowledge and also in the quality of the evidence base on which that 
knowledge is based.
Chapter 2 shares the key limitation of all systematic reviews in that it can only 
be as good the research it seeks to summarise, which as noted in Chapter 2 is 
of limited quality. Perhaps not sufficiently emphasised is the absence of long-
term follow-up in the studies reviewed. Therefore any inference about the effect 
of the interventions reviewed on NAFLD prognosis must be made very 
tentatively until intervention studies employing large cohorts with multi-year 
follow-up and hard disease end-points can be included. Further, the review did 
not include meta-analytic techniques as study and intervention design was 
considered too heterogenous to justify such analysis. Future reviews should 
seek to pool data from relevant studies, as appropriate, to provide a more 
qualitative assessment of both effectiveness and efficacy, as well as applying 
regression techniques to assess dose response for factors such as: active 
intervention length; degree of weight reduction; degree of body composition 
change; and in the case of exercise also type, frequency, duration, and intensity.
A further specific limitation of the review was the exclusion of non-english 
language papers. Including foreign language papers may have strengthened 
the review and should be included in future reviews.
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As noted in the discussion section of Chapter 2, a common limitation of 
systematic reviews is that they focus on specific tightly defined populations, in 
this case cohorts with established NAFLD. This is necessary to make it clear to 
whom results can be extrapolated. However, there are several practical 
limitations when applying a rigorous population definition:
• Disease genotype and phenotype can still be highly heterogenous even 
if all members of a cohort have been diagnosed with a specific 
condition;
• There are multiple criteria by which the presence of NAFLD is assessed 
and these are not interchangeable;
• There several published interventions in cohorts with common 
comorbidities of NAFLD, notably metabolic syndrome and type 2 
diabetes, which are likely to contain a high proportion of participants 
with NAFLD. Notably, many of these interventions such as the diabetes 
prevention trials and Look AHEAD study are large scale and have many 
years of followup. These were however only considered in the 
discussion section of Chapter 2 and not at all in the published review 15 
Therefore including larger longer term interventions in populations with common 
comorbidities of NAFLD may have strengthened the conclusions of the review 
by providing higher levels of evidence and statistics on hard endpoints. 
Future systematic reviews would benefit from an attempt to focus on integrating 
the findings from high quality interventions with long-term followup focusing on 
primary or secondary prevention in cohorts with or at high risk of common 
metabolic disease; specifically NAFLD, metabolic syndrome, and/or type 2 
diabetes.
6.2 Limitations of Chapter 4
The Physical Activity, Ageing and Metabolism (PAAM) study had several notable 
limitations:
• the sample size was small, leaving the study underpowered
• restricting the study to women introduced the potential for results to be 
influenced by:
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• menstrual status and time during cycle;
• oral contraceptive use;
• parity;
• use of hormone replacement therapy
• the study was cross-sectional
The PAAM study was a pilot study to help establish requirements for a larger 
investigations. Assuming regression analysis is used for statistical assessment, 
the effect size could be used to calculate power. Based on the findings, 
assuming two-sided significance (1-alpha)  of 95%, a desired power (1-beta) of 
80, with an equal ratio of active and sedentary women, and assuming a small 
effect size of 0.10 for primary outcome measures with two predicators (age and 
activity), the minimum sample would be 99 in a given age group.
The choice of restricting the study to women was made due to the more limited 
published data in females relative to males with respect to ageing, physical 
activity and metabolism. Confounders related to hormonal cycles as noted 
above would best be addressed by either a large sample size and the collection 
data on menstrual phase, use of oral contraceptives, parity, time since 
menopause, and use of hormone replacement therapy. These factors could 
then be added as components of statistical regression models to determine the 
size of their influence. This would increase the sample size required as it would 
add to the number of predictors in the model.
Consideration should also be given to the need for longitudinal research 
assessing the relationships between physical activity and metabolism using the 
methods employed in the PAAM study, e.g. accelerometry, are justified. 
6.3 Limitations of Chapter 5
The high-intensity intermittent training intervention had the following limitations:
1. the final analysis included fewer participants than required by the power 
calculation leaving the study underpowered;
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2. numbers of participants in the control vs. exercise intervention were 
uneven which may have contribute to the following:
3. there was a notably uneven sex distribution between the control 
group and exercise intervention group (1 vs. 5);
4. there was also a significant difference between groups in terms of 
2-hour glucose and insulin, and HOMA2-insulin resistance;
5. programme adherence was only assessed by self-report weakening the 
assessment of efficacy; 
6. post-intervention assessments were not standardised in terms of time 
expired since last exercise bout, thereby potentially leading under or 
over estimation of effect.
Future assessments of high-intensity intermittent exercise, and any other forms 
of exercise, should be sufficiently powered for all end-points considered 
important. Further, as this is still likely to result in small sample sizes, 
randomisation should be stratified by sex and primary outcome measure(s) to 
improve similarity between control and intervention groups.
Optimal assessment of adherence with the exercise protocol would require all 
sessions to be supervised and conducted on equipment that allows 
measurement of work rate. Adherence could have been more objectively 
assessed by means of accelerometery or heart rate monitoring to assess 
physical activity, or by using GPS tracking devices or reviewing gym attendance 
databases to confirm attendance; the former options would be preferable as 
they allow assessment of exercise intensity.
It will be important to standardise the timing of post-intervention assessments 
so that they are consistent with the exercise prescription, so that the average 
effects are neither under nor overestimated. This could be best achieved by 
planning the post-intervention assessment during the final week of intervention 
so that all assessments could be done within 48-72 hours of an exercise 
session. 
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There are further limitations with respect to determining effectiveness:
• the sample size was small;
• the intervention was for a short time with no interim assessments 
conducted, thus the study cannot provide information on the time-
course of changes nor does it answer what the changes might be 
observed over longer periods. there was selection bias as patients had 
to volunteer to be given the exercise prescription as opposed to having 
it provided as part of standard care;
• the study was confined to volunteers in who the probability of significant 
fibrosis was small, thus limiting extrapolation to relatively low risk 
patients.
The study was not intended to assess effectiveness in a clinical setting, nor to 
assess exercise in patients with more advanced NAFLD. It was designed to 
provide physiological data on changes following high-intensity intermittent 
training in a group representative of the majority of primary care NAFLD 
patients. 
To address the effectiveness in a clinical setting a much larger study would 
need to be conducted; preferably including participants with more advanced 
liver disease. Treatment allocation in such a study would best be done by block 
randomisation on the basis of site with a multi-year followup, and an intention to 
treat analysis. 
Such a study would also need to employ behaviour change techniques to 
maintain exercise habits over a long period. Assessment of hard endpoints 
including NAFLD disease progression by biopsy or validated surrogates, 
development or regression of impaired glucose metabolism by HbA1c and 
potentially oral glucose tolerance tests, and tracking development of 
cardiovascular disease.
A sample size allowing for subsample analysis, e.g. by sex and genotype, would 
be desirable, as this would allow the identification of those most likely to benefit 
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from the exercise programme. Similarly,assessments at multiple time-points 
would allow the time-course of changes to be determined.
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Chapter 7. Discussion
Non-communicable diseases including type 2 diabetes, non-alcoholic fatty liver 
disease (NAFLD), cardiovascular disease, and some cancers are rising in 
prevalence worldwide 650. In 2008, 25% of deaths in those under 60 years of 
age were attributable to non-communicable diseases 651. Cardiovascular 
disease and diabetes combined accounted for 13.2% of disability adjusted life 
years in high income countries in 2004 652. The worldwide financial burden of 
cardiovascular disease and diabetes was estimated at £539 billion and £312 
billion, respectively, and is predicted to rise to £650 billion and £465 billion, 
respectively, by 2030 650.These costs are threatening to overwhelm many 
healthcare systems and erode the quality of life of large portions of the 
population including in the United Kingdom 12.
This thesis set out to examine these issues of deteriorating population health 
and explore potential lifestyle related solutions through the lens of NAFLD and 
impaired glucose control. Specifically, it set out to assess: the relationship of 
age and physical activity with liver fat and glucose control (Chapter 4); the 
efficacy of diet, weight management, and exercise in addressing markers of 
liver health and glucose control in those with NAFLD (Chapter 2); and examine 
the potential for high-intensity intermittent training as a modifier of metabolism 
and therefore potential therapy for NAFLD and impaired glucose tolerance 
(Chapters 3 & 6).
There is a close association of liver health and glucose control with age, and 
physical (in)activity is a key modifier of this relationship (Chapter 4). Increasing 
population age 653, the rising prevalence of overweight/obesity 654, and a 
predominance of sedentary behaviour 655,  appear central to the rise in chronic 
disease burden 518,654, including the high prevalence of NAFLD 5. Advancing 
age is associated with a decline in physical activity and adverse changes in 
body composition in the form of decreasing lean mass and increasing fat mass 
(see Sections 4.4.1). Likewise, physical inactivity is associated with an increase 
in fat mass and, throughout much of the lifecycle, increased total body weight 
(see Sections 4.4.1). Despite these close associations, the results in Chapter 4 
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suggest these relationships are not entirely causal, nor sequence of events 
inevitable. The decline in physical activity and increase in obesity with age is 
influenced by a population-wide upward trend in sedentariness and overweight/
obesity evident since the early to mid 1990s 567,656. Likewise, the prevalence of 
many chronic diseases and elevated disease risk factors is increasing in all age 
groups, not just the elderly 567,576,657. Further, those over 90 years often display 
a favourable cardiometabolic risk profile 585, highlighting the importance of 
cardiometabolic health in achieving lifelong health and wellbeing. 
The environmental changes associated with declining population health include 
the emergence of numerous labour saving devices and automated transport 
with associated marked decline in work and transport related physical activity 
658,659, and changes to diet presumably driven by the changes in food availability 
and practices surrounding food processing and preparation 659. These changes 
can be, and to some extent are being, addressed on the legislative and policy 
level in the hopes of reducing the burden of chronic disease. General as well as 
disease specific guidelines stress the benefits of physical activity 416, and weight 
management 660. The findings of this thesis support such guidelines, but 
highlight that a broad variety of dietary and physical activity approaches may be 
therapeutic than are presently advocated (Chapter 2).
With respect to diet, although Chapter 2 highlights the utility of energy restricted 
moderate-to-low fat approaches to weight reduction for lowering liver fat, the 
studies reviewed also highlight other potential approaches. Carbohydrate 
restriction appears to effectively and rapidly reduce liver fat and liver glucose 
production, with notable improvements arising before substantial weight 
reduction is achieved 171. One or more weight change independent mechanisms 
of liver fat reduction and glucose control improvement also appear to mediate 
the beneficial effects of exercise (Chapter 2 & 5). 
Current UK physical activity guidelines recommend adults be active daily, and 
accumulate 150 minutes of moderate intensity or 75 minutes of vigorous 
intensity aerobic activity, or a combination of the two, spread across the week 
661. The guidelines also recommend doing some form of strength training on at 
least two days a week and for the first time, minimising sedentary time. 
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Assuming two 30 minute strength training sessions, following these 
recommendations would constitute a time commitment of 135-210 minutes per 
week. Many might see this as a considerable time commitment given that lack 
of time is a commonly reported barrier to exercise 648. But there is also a more 
fundamental problem that lies in the definition of vigorous activity in these 
guidelines, as this intensity is framed in terms of time taken to achieve a desired 
energy expenditure, which Chapter 3 and 5 of this thesis show is not necessary 
to achieve desirable changes in cardiorespiratory fitness or markers of 
cardiometabolic risk. To date, there is little or no mention of a high-intensity 
intermittent approach to exercise, probably due to a lack of published research 
in this area during guideline development, and a perception that this very 
vigorous class of activity would not be attractive to many in the population 662.
The results presented in Chapter 5, and the review in Chapter 3, support the 
benefits of a high-intensity intermittent approach to exercise, where intensity is 
relative to the individual not absolute, and therefore feasible for most healthy 
and clinical populations with appropriate modifications and safety screening 
(Section 3.3.1). The exercise programme presented in Chapter 5 involved 
90-120 minutes per week of structured exercise and resulted in marked 
reductions in liver fat, modest improvements in body composition despite study 
imposed maintenance of total body weight, and improvements in glucose 
metabolism. The observed changes in glucose control and body composition 
were in line with previous reports in broadly similar populations (Chapter 3). The 
relatively short duration should appeal to those citing time as a barrier to 
participate in exercise. The simplicity of the programme, and the novel use of 
pre-recorded auditory instructions, should appeal to clinicians without access to 
well developed exercise referral programmes or teams with clinical exercise 
prescription expertise. The caveat being that patients should always be risk 
assessed before starting an exercise programme. 
In summary, the work in this thesis is particularly relevant to populations with 
NAFLD, who constitute a particularly at risk group for type 2 diabetes 282, 
cardiovascular disease 288, and some cancers 204,297. The systematic review of 
lifestyle therapies in Chapter 2 and the study of high-intensity intermittent 
training in NAFLD patients in Chapter 5, demonstrate the efficacy of exercise in 
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reducing liver fat in those with NAFLD independent of weight reduction, albeit 
not necessarily independent of body composition change. Chapters 3 and 5 
highlights the potential for high-intensity intermittent training to improve body 
body composition, and lower multiple markers of cardiometabolic risk. These 
findings come at a crucial time as lifestyle intervention remains the only 
recommended treatment for NAFLD 13,14. Yet to date, there is no published work 
to suggest this is being effectively translated into clinical care. The minimally 
supervised high-intensity intermittent approach to exercise outlined in Chapter 5 
offers one time efficient and effective way to reduce liver fat in NAFLD patients, 
and the materials developed for this thesis (see Appendices 1 & 9) provide a 
detailed template for clinical exercise prescription.
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7.1 Future Directions
Although the benefits of various forms of exercise are well supported in terms of 
positive changes to many disease risk factors, several questions remain 
unanswered:
• What is the dose response, and more fundamentally;
• To what extent do exercise and physical activity of different types and 
intensities differ with respect to:
• physiological effects;
• acceptability among different groups;
• How do different types and intensities of physical activity interact and to what 
extent are they interchangeable/distinct in terms of benefits; and
• What characterisers good and what poor responders to different exercise 
approaches and how to identify them early so appropriate physical activity 
interventions can be prescribed;
• What is the optimal way to integrate physical activity / exercise and nutrition to 
achieve a sustained improvements in metabolic control; and
• What are the best markers to assess the effect of exercise on general health.
!
However, the prevalence of inactivity and poor diets 663 suggests the main 
challenge lies in finding effective ways to promote broad population adherence 
to existing physical activity and nutrition guidelines and, where needed, 
adherence to patient specific physical activity prescriptions.
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7.2 Conclusion
The findings of this thesis are that a broad range of physical activity, exercise, 
and dietary approaches – one of them being high intensity intermittent training – 
can be prophylactic or therapeutic with respect not only to NAFLD but related 
non-communicable diseases. Physical activity in particular offers the possibility 
of improved health even in the obese and/or elderly. The benefits are largely 
independent of weight change, which tends to stay relatively stable, and more 
commonly relate to improvements in body composition, glucose control, and 
cardiorespiratory fitness. Future successes in translation of these findings into 
clinical care rest on fitting both the lifestyle prescription and means of delivery to 
the individual patient. In the interim, the findings in this thesis strongly suggests 
that the focus of clinical care teams and policy makers should be to promote 
attitudes and environments that encourage patients with metabolic disease to 
stand up and move, both physically and metaphorically, toward a future of 
lifelong health through physical activity.
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Exercise Picture Guide
Face Pull - Start Face Pull - Finish
Chest Press - Start Chest Press - Finish
Row - Start Row - Finish
High Press - FinishHigh Press - Start
Rate of Perceived Exertion
6 No exertion at all
7 Very, very light
8
9 Very light
10
11 Fairly light
12
13 Somewhat hard
14
15 Hard
16
17 Very hard
18
19 Very, very hard
20
Goal for intervals
Progression for warmup
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Patient Information Sheet 
 
Physiological effect of age on metabolism (muscle, cardiac and abdominal) probed 
by MR methods, stratified for age and habitual physical activity. 
 
You are invited to participate in this medical research project. Please take time to 
read the following information carefully. It explains why the research is being done 
and what it involves. If you have any questions about the information, you are very 
welcome to ask for further explanation. Thank you for reading this. 
 
• Part 1 tells you about the purpose of this study and what will happen during 
the study. 
• Part 2 gives more detailed information about the conduct of the study. 
 
Discuss with others if you wish and take time to decide regarding your participation. 
 
Part 1 
 
What is the purpose of the research project? 
 
Recent information has suggested that exercise may contribute to changes in 
metabolism for patients in different age groups.  We aim to compare the effect that 
exercise has on metabolism and overall well being in patients in two different activity 
groups. We will also look at different ages of pages within these two groups.  
 
Why have I been chosen? 
 
You have been chosen because you are aged 20- 30 years, 40-50 years or above 65 
years and do not have type 2 diabetes. The project will involve up to 72 people.  
 
 
Do I have to take part? 
 
Your participation is purely voluntary. If you decide to take part, you are still free to 
withdraw at any time without giving reasons and affecting your medical care. If you 
do decide to take part, you will be given this information sheet to keep and be asked 
to sign a consent form. 
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What will the research project involve? 
You will be asked to attend the MRC Muscle Performance and Training Campus for 
Ageing and Vitality at Newcastle General Hospital or at the Royal Victoria Infirmary to 
be assessed. The study will take place over 12 weeks. Participants will attend the 
study centre for 4 visits in total.  
 
 
Visit 1 (You should arrive for this visit having fasted overnight – 12 hours) 
You will be asked to sign a consent form saying that you would like to take part in this 
research study. You will be asked to sit on a stationary exercise bicycle. During this 
test you will cycle at the same pace but how hard you are cycling will increase every 
minute. You will keep on cycling until you decide to stop or until pedalling becomes 
difficult. Whilst you are cycling you will be asked to wear a mouthpiece and a heart 
rate monitor (ECG). The exercise test will last between 10 - 15 minutes. At the end of 
the test you will feel tried but will recovery very quickly.  
 
Total duration of visit 2 hours 
 
 
Visit 2 (You should arrive for this visit having fasted overnight – 12 hours) 
As you will have fasted overnight, we will take a blood sample so as to obtain fasting 
measures of your liver. We will also be measuring your glucose levels. For this, we 
will take a reading of your glucose when you have been fasted overnight and then 
ask you to drink 75g of glucose (410ml Lucozade). We will then take a further reading 
of your glucose after two hours (This is to confirm that you do not have type 2 
diabetes). During this time we will give you something to eat and also ask you to 
complete two questionnaires that will give us a better understanding of your physical 
activity levels. At the end of this visit, we will provide you with an exercise activity 
monitor which you will be asked to wear on your arm for one week (if you haven’t 
done this already). This will measure the amount of steps that you take throughout 
the day and will allow us to assign you to one of the two study groups in your age 
category (less than 7500 steps will be classed as ‘sedentary’, more than 12500 steps 
will be ‘active’).  
 
Total duration of visit 2.5 hours 
 
 
Visit 3 (You should arrive for this visit having fasted overnight -12 hours) 
As we would like to take measurements of your liver and abdomen fat levels, we 
would ask you to attend this visit having fasted overnight. The samples will be 
collected via a blood sample form your arm. We also need to collect levels of 
glycogen (your bodies energy) for this we will ask you to lie flat on a bed for 10 
minutes and measure your levels, repeating this measurement whilst asking you to 
raise your leg to two different points and at two different time points. We will also ask 
you (with the help of a qualified technician) to complete an assessment prior to 
undergoing a Magnetic Resonance Image scan (MRI) this is a scan which does not 
involve any radiation, but we need to make sure that there is no potential risk to you 
having this scan.  
After the scanning we will measure your body composition to find how much muscle 
and fat you have in your body. In order to do this you will be asked to sit quietly for 2-
3 minutes inside an egg shaped machine (BODPOD) wearing your underwear or 
your swimming suit. 
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Total duration of visit 2 hours 
 
Visit 4  
You will be scanned using an MRI scanner to look at your heart function and an MRS 
(Magnetic Resonance Spectrosocopy) which will look at your metabolic rate.  
 
Total duration of visit 1.5 hours 
 
 
Expenses and payments 
 
Any travel / parking costs for helping with this research will be refunded.  
 
What do I have to do? 
 
You will continue with your usual treatment(s) during the project. You will be asked 
not to drink alcohol or exercise the day before the test days. Arrangements will be 
made for you to attend the research centres if necessary. Most of the assessments 
will be in the morning before breakfast – when asked; you should not eat before you 
come to the centre. Food will be provided for you after the examination.  
 
What are the side effects of treatment received when taking part? 
 
This study involves exercise so there are no side effects (such as may occur with 
drugs).  
 
Are there any other possible disadvantages of taking part? 
 
Giving up time to participate has to be considered. 
 
What are the possible benefits of taking part? 
 
Being more physically active may be beneficial to you and if sustained after the study, 
may help in preventing other complications such as heart disease and diabetes. You 
will be closely monitored and will be shown how to exercise correctly and help you 
become more physically fit.  
 
What happens at the end of the research project? 
 
At the end of the project, we shall be able to inform you of how the exercise affected 
you. 
 
What if there is a problem? 
 
If you have any concern or complaint about any aspect of the study this will be dealt 
with immediately by Dr Trenell. Contact details are given at the end of Part 1.  
 
Will my taking part in the project be kept confidential? 
 
All information obtained during the course of the research project will be kept strictly 
confidential. Your own GP will be informed of your participation in the project. 
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What will happen to the results of the research study? 
 
The results of the project will be presented in national and international meetings and 
will be published in one of the medical journals. You will not be identified in any report 
or publication. You are welcome to have a copy of the results once they are 
published. 
 
 
Who has reviewed the study? 
 
Sunderland Research ethics committee. 
 
 
 
Who are the contacts for further information? 
 
Further information can be obtained from: 
 
Dr D Jakovljevic PhD, MSc, BSc 
Senior Research Associate 
Medical School, ICM 4th Floor Williams Leech Building 
Newcastle University 
NE2 4HH 
 
Tel: 0191 222 8257 
d.jakovljevic@newcastle.ac.uk 
 
Dr M I Trenell PhD, MSc, BSc (hon) 
Diabetes UK RD Lawrence Fellow 
Newcastle Magnetic Resonance Centre  
Campus for Ageing and Vitality 
Newcastle University 
NE3 5JB 
 
Tel: 0191 222 8264 
Michael.I.Trenell@newcastle.ac.uk  
 
 
 
 
 
 
 
 
      
Thank you.                                                                                                        
 
******************************** 
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Part 2 
 
What if relevant new information becomes available? 
 
If new information is published during the course of a study this can sometimes 
change how the research should go forward.  
 
What will happen if I don’t want to carry on with the study? 
 
You can withdraw from the study at any time. Measurements already made would still 
be used if you were to agree to this.  
 
What if there is a problem? 
 
a) Complaints 
If you have any concern or complaint about any aspect of this study you should 
contact Dr Trenell by phone on 0191 222 8264, or write to him at the address at the 
end of Part 1 of this document. If you remain unhappy you can contact Dr Lesley Hall, 
Research Governace Manager,Newcastle upon Tyne Hospitals NHS Foundation 
Trust, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP; Tel 0191 233 6161 
b) Harm 
In the unlikely event that something does go wrong and you suffer in any way the 
arrangements are as follows. If negligence of staff led to harm, then this would be 
covered by the Newcastle upon Tyne Hospitals Trust clinical negligence scheme. 
You may have to meet legal costs. If any harm was non-negligent then the hospital 
trust may consider a discretionary payment.   
 
Will my taking part in the project be kept confidential? 
 
All information obtained during the course of the research project will be kept strictly 
confidential. This will be achieved by storing information in password-protected 
computer files, and appointment information in locked filing systems within the 
Magnetic Resonance Centre.  No individually identifiable information will be stored 
outside these Centres.  
 
Analysis of the detailed results of the research: at this stage no personal information 
is part of the dataset. Results will be sent to participants, presented at scientific 
meetings and published in scientific journals without personal identification of any 
volunteer although thanks to the volunteers will be recorded.  
 
Your own General Practitioner will be informed of your help with this study, and this is 
normal practice. The detailed results of the research tests will not be sent to anybody 
outside the designated research centres.  
 
 
What will happen to blood samples? 
 
The samples will be tested for fasting blood will be analysed for: full blood count, urea 
and electrolytes, liver blood tests, coagulation screen, creatine kinase, bicarbonate, 
LDL, HDL, triglycerides, cholesterol, glucose, insulin and c-peptide.  
Samples will be stored until it is certain that the test results are accurate, and then 
they will be disposed of. During storage samples are identified only by a code 
number, not your name. No genetic or other tests will be carried out on the samples.  
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What will happen to results of the research? 
 
The results will be presented at scientific meetings for discussion by other experts in 
this field. They will be written up in the form of a scientific paper and this will be 
intended to be published in a suitable scientific journal. As soon as the results are 
fully analysed after the end of the entire study you will receive a letter describing what 
we have found, and what implications it has for people as we get older.  
 
Who is organising and funding the research? 
 
This project is funded from a project grant from the Newcastle upon Tyne Biomedical 
Research Centre. The design and organisation of the study is the responsibility of Dr  
Trenell. 
 
There is no payment to any of the researchers involved in this study. They are 
employed by Newcastle University to work in the NHS, to teach and to research and 
have no financial link with the study.  
 
Who has reviewed the study? 
 
Ethical review of the study has been conducted by the Newcastle and North Tyneside 
Research Ethic Committee No. 1.  
 
Design of this information sheet 
 
This document is written in accordance with the requirements of the European 
Clinical Trials Directive 2001/20/EC, the ICH Good Clinical Practice guidelines and 
the UK Medicines for Human Use (Clinical Trials) Regulation 2004.  
 
 
 
Version 1.0   September 2009 
                  MRC Muscle Performance and Training  
   Laborat                Campus for Ageing and  
Vitality 
                                                                             Westgate Road 
                 Newcastle upon Tyne 
                 NE4 5PL 
                                                                             T: +44 (0)191 222 8264 
 
 
 
 
 
Patient Identification number for this trial:  
 
CONSENT FORM 
 
Title of Project: Physiological effect of age on metabolism (muscle, cardiac and 
abdominal) probed by MR methods, stratified for age and habitual physical activity 
 
 
Name of researcher: Dr M Trenell 
                                  Dr D Jakovljevic 
 
Please initial box 
 
 
 
1. I confirm that I have read and understand the information sheet dated 
September 2009 (version 1.0) for the above study and have had the 
opportunity to ask questions.  
 
 
2. I understand that my participant is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected.  
 
 
3. I agree to my GP being informed of my participation in the study 
 
 
4. I agree to take part in the above study.  
 
 
 
 
 
 
Name of participant   Date  Signature 
 
 
 
Name of person taking consent  Date  Signature 
(if different from participant) 
 
 
Researcher    Date  Signature 
 
1 for participant; 1 for researcher; 1 to be kept with hospital notes  
Physical Activity Readiness Questionnaire 
 
Name:  ______________   
 
Date of Birth: ______________ 
  Please 
choose 
1 Has your doctor ever said that you have a heart condition 
and that you should only do physical activity recommended 
by a doctor? 
 
YES NO 
2 Do you ever feel pain in your chest when you do physical 
activity? 
 
YES NO 
3 Have you ever had chest pain when you are not doing 
physical activity? 
 
YES NO 
4 Do you ever feel faint or have spells of dizziness? 
 
YES NO 
5 Do you have a joint problem (also back problem) that could 
be made worse by exercise? 
 
YES NO 
6 Have you ever been told that you have high blood pressure? 
 
YES NO 
7 Do you have any breathing problems?  
 
YES NO 
8 Do you have any problems with your liver, thyroid, kidneys 
or have diabetes? 
 
YES NO 
7 Are you currently taking any medication? 
 
If so, what? __________________ Reason _______ 
 
YES NO 
8 Are you pregnant, have you had a baby in the last 6 
months, or do you plan to have a baby this year? 
 
YES NO 
9 Has your mother or father had any heart problems? 
 
  
10 How many times a week do you do exercise: _______ 
 
  
11 Is there any other reason why you should not participate in 
physical activity? 
If so, what? __________________________________ 
 
YES NO 
 
 
Signed by (staff): ___________________ Print: ____________ 
 
 
Date:   ___________________ 
Appendix 2  Risk Stratification Sheet 
 
Name:    ___________________ 
 
DOB:    ___________________ Age:    _________ 
 
Study ID:   ___________________ 
 
General Practitioner:  ___________________ 
 
GP Address:  ___________________ 
 
    ___________________    
   
 
Height   ___________________ 
 
Weight   ___________________ 
 
Waist    ___________________ 
 
Hip circ.   ___________________ 
 
Blood Pressure  ___________________ 
 
Smoker   YES  NO  or given up <6month 
 
Blood Taken:  YES  NO 
 
Comment: _______________________________________ 
  __________________________________________  
  __________________________________________  
  __________________________________________ 
________________________________________________________________ 
To be completed by investigator:  
Risk Stratification (circle):  Low  Moderate  High 
Action Taken:  Commence exercise (Low Risk)    YES / NO 
  Referred for Exercise ECG (moderate and high risk) YES / NO 
________________________________________________________________ 
 
Competed by  ________________  Date _____________ 
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      Institute of Cellular Medicine 
      William Leech Building 
Newcastle University 
Framlington Place 
      Newcastle upon Tyne 
      NE2 4HH 
T: +44 (0)191 222 5851 
 
 
Patient Information Sheet 
 
Effect of exercise on non-alcoholic fatty liver  
 
You are invited to participate in this medical research project. Please take time to 
read the following information carefully. It explains why the research is being done 
and what it involves. If you have any questions about the information, you are very 
welcome to ask for further explanation. Thank you for reading this. 
• Part 1 tells you about the purpose of this study and what will happen during 
the study. 
• Part 2 gives more detailed information about the conduct of the study. 
Discuss with others if you wish and take time to decide regarding your participation. 
 
Part 1 
 
What is the purpose of the research project? 
 
Recent information suggests that exercise may help people with non-alcoholic fatty 
liver disease reduce the amount of fat in the liver by: 1) increasing the ability of the 
body to burn fat, and 2) increasing the sensitivity of the body to food.  
 
We aim to show the effect of exercise on the levels of liver fat, sensitivity of the body 
to food, and heart function. We will measure liver fat, and how well your heart works 
using a magnetic resonance (MRI) scanner. This research DOES NOT require any 
biopsies.  
 
Understanding the relationship between exercise and liver fat is important in gaining 
acceptance of exercise in the management of fat in the liver and avoiding excess 
weight gain.  
 
Why have I been chosen? 
 
You have been chosen because you have too much fat in your liver (called non-
alcoholic fatty liver disease) and currently do not do any regular exercise. People with 
too much fat in their liver will be asked to help with the research project, as they could 
benefit from the results of this research. The project will involve up to 28 people.  
 
Do I have to take part? 
 
Your participation is purely voluntary. If you decide to take part, you are still free to 
withdraw at any time without giving reasons and without any bad feelings. If you do 
decide to take part, you will be given this information sheet to keep and be asked to 
sign a consent form. 
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What will the research project involve? 
 
You will be asked to attend the Newcastle Magnetic Resonance Centre at the 
Newcastle General Hospital, or the Royal Victoria Infirmary on 5-9 occasions over 3 
months to have your metabolism and liver fat checked. The number of visits will 
depend on whether you choose to do longer visits with more tests at each visit or 
shorter visits with the tests more spaced out. If you take part in the exercise group 
you will also be asked to do prescribed exercise 3 times a week for 12 weeks. What 
time of day you do these will only be limited by the opening hours of the gym you join. 
 
Visit 1: Screening Visit 
 This visit will determine if you are suitable for this study and it is suitable for 
you. You will be asked to sign the consent form saying that you would like to 
take part in this research study, and then complete two screening 
questionnaires. You will then do a cycling test. During this test you will cycle at 
the same pace but how hard you are cycling will steadily increase. You will 
keep on cycling until you decide to stop or until pedalling becomes difficult. 
Whilst you are cycling you will be asked to wear a breathing mask and a heart 
monitor. The exercise test will last 10 - 15 minutes. At the end of the test you 
will feel tired but will recover very quickly. Total visit time: 1 hour 
 
Magnetic Resonance Scans 
The level of fat in your liver and how well your heart works will be measured 
using magnetic resonance imaging (MRI). During this test you will be asked to 
lie on your back for about 60 minutes and then on your front for about 45 
minutes in the MRI machine. This DOES NOT involve a biopsy, is completely 
painless and does not have any dangers associated with the examination. 
Total procedure time: 2 hours 
 
Oral Glucose Tolerance Test 
After an overnight fast, you will be asked to drink a large sugary drink (350 ml 
Lucozade). A cannula (small plastic tube) will be placed in your arm so that 
blood samples can be collected at regular intervals for 2 hours after you drink 
the sugary drink. We usually do this after one of the scans. Total procedure 
time: 2.5 hours 
 
Body Fat Measurement 
The amount of fat and muscle in your body will be measured whilst you sit 
quietly on a chair for 5 minutes. We usually do this before one of the longer 
procedures. Total procedure time: 10 minutes 
 
Resting Metabolism and Exercise Test 
After an overnight fast, you will be asked to lie quietly on a bed whilst your 
resting metabolism is measured. Then you will be asked to cycle for 60 
minutes at an easy pace. You can watch a DVD or listen to music whilst you 
cycle. A cannula (small plastic tube) will be placed in your arm so that blood 
samples can be collected at regular intervals during exercise. You will also be 
asked to wear a breathing mask for some of the time, and a heart rate monitor. 
Total visit time: 2.5 hours 
 
Except for Visit 1, all the tests will be done once at the start of the study and once at 
the end of the study 
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You will be assigned to one of two groups. The first group will do 3 exercise sessions 
per week over 12 weeks. Each exercise session will involve you using a stationary 
cycle and resistance band, and will last about 40 minutes. These sessions will be 
held at a local gym that you choose, your gym membership will be paid for during the 
study. A member of the research team will come with you on your first session to 
familiarise you with doing the exercises safely. It is important that your weight does 
not change over this time. You will be given food supplements (protein milkshake) if 
your weight goes down by more than 1%. The second group will not do the exercise 
sessions or be required to undertake any exercise over the 12 weeks. You will be 
asked to wear a physical acitivity monitor for 7 days before and for 7 days toward the 
end of the12 week study period. 
 
If you are placed in the group which does not attend any exercise sessions, at the 
end of the study you will be given the opportunity to receive an exercise prescription 
after finishing the study, though this is not compulsory. No further tests will be 
required. 
 
Expenses and payments 
 
Any travel / parking costs for helping with this research will be refunded.  
 
What do I have to do? 
 
You will continue with your usual treatment(s) during the project. It will be important 
that you attend at least 32 of the possible 36 exercise sessions. You will be asked not 
to drink alcohol or exercise the day before your visits. There is parking outside the 
Magnetic Resonance Centre, or if you wish, taxi transport will be arranged. Each of 
the metabolic assessments will be in the morning before breakfast – you should not 
eat before you come for your visit. Food will be provided for you after the examination.  
 
What are the side effects of treatment received when taking part? 
 
This study involves exercise so there are no side effects (such as may occur with 
drugs).  
 
Are there any other possible disadvantages of taking part? 
 
Giving up time to participate has to be considered. 
 
What are the possible benefits of taking part? 
 
Being more physically active may be beneficial to the level of fat in your liver and if 
sustained after the study, may help in preventing other complications such as heart 
disease and diabetes. You will have supervised exercise sessions (like a personal 
trainer) which will teach you about your body, show you how to exercise correctly and 
help you become more physically fit.  
 
What happens at the end of the research project? 
 
At the end of the project, we shall be able to inform you of how the exercise affected 
liver fat level and metabolism. 
 
What if there is a problem? 
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If you have any concern or complaint about any aspect of the study this will be dealt 
with immediately by Dr Trenell. Contact details are given at the end of Part 1.  
 
Will my taking part in the project be kept confidential? 
 
All information obtained during the course of the research project will be kept strictly 
confidential. Your own GP and liver doctor will be informed of your participation in the 
project. 
 
What will happen to the results of the research study? 
 
The results of the project will be presented at national and international medical 
meetings and will be published in one or more appropriate scientific journals. You will 
not be identified in any report or publication. You will be welcome to have a copy of 
the results once they are published. 
 
Who has reviewed the study? 
 
Ethical review of the study has been conducted by the Newcastle and North Tyneside 
Research Ethic Committee No. 1.  
 
Who are the contacts for further information? 
 
Further information can be obtained from: 
 
Christian Thoma or Kate Hallsworth 
Institute of Cellular Medicine 
William Leech Building 
Framlington Place  
Newcastle University  
NE2 4HH       
Tel 0191 222 8264       
 Email: christian.thoma@ ncl.ac.uk or kate.hallsworth@ncl.ac.uk 
 
Thank you.                                                                                                        
 
******************************** 
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Part 2 
 
 
What if relevant new information becomes available? 
 
If new information is published during the course of a study this can sometimes 
change how the research should go forward. However, for this study it is most 
unlikely that this would occur. The study design is unique, and there are very few 
research groups worldwide able to carry out magnetic resonance-based research of 
this kind.  
 
What will happen if I don’t want to carry on with the study? 
 
You would be able to withdraw from the study at any time. Measurements already 
made would still be used if you were to agree to this.  
 
What if there is a problem? 
 
a) Complaints 
If you have any concern or complaint about any aspect of this study you should 
contact Dr M Trenell by phone on 0191 248 1150, or write to him at the address at 
the end of Part 1 of this document. If you remain unhappy you can contact the 
Research Manager of the Newcastle upon Tyne Hospitals NHS Trust (Dr C 
Mackerness, Clinical Research Centre, RVI, Queen Victoria Road, Newcastle upon 
Tyne NE1 4LP; Tel 0191 282 5959).  
 
b) Harm 
In the unlikely event that something does go wrong and you suffer in any way the 
arrangements are as follows. If negligence of staff led to harm, then this would be 
covered by the Newcastle upon Tyne Hospitals Trust clinical negligence scheme. 
You may have to meet legal costs. If any harm was non-negligent then the hospital 
trust may consider a discretionary payment.   
 
Will my taking part in the project be kept confidential? 
 
All information obtained during the course of the research project will be kept strictly 
confidential. This will be achieved by storing information in password-protected 
computer files, and appointment information in locked filing systems within the 
Clinical Research Facility, Royal Victoria Infirmary. No individually identifiable 
information will be stored outside the hospital.  
 
Analysis of the detailed results of the research will be done by Dr Trenell, Dr 
Hollingsworth, Professor Taylor and Professor Day. At this stage no personal 
information is part of the dataset. Results will be sent to participants, presented at 
scientific meetings and published in scientific journals without personal identification 
of any volunteer although thanks to the volunteers will be recorded.  
 
Your own General Practitioner will be informed of your help with this study; this is 
normal practice. Similarly, if you attend a specialised clinic for care, your consultant 
will be informed. The detailed results of the research tests will not be sent to anybody 
outside the research team.  
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What will happen to blood samples? 
 
The samples will be tested for liver function, insulin, sugar, fat, and other food derived 
substances. Samples will be stored until it is certain that the test results are accurate, 
and then they will be disposed of. During storage samples are identified only by a 
code number, not your name. No genetic or other tests will be carried out on the 
samples.  
 
What will happen to results of the research? 
 
The results will be presented at scientific meetings for discussion by other experts in 
this field. They will be written up in the form of a scientific paper for publication in a 
suitable journal. As soon as the results are fully analysed after the end of the entire 
study, you will receive a letter describing what we have found, and what implications 
it has for people with non-alcoholic fatty liver disease.  
 
Who is organising and funding the research? 
 
This project is funded by a project grant from the Newcastle Hospitals Trust Joint 
Research Committee. The design and organisation of the study is the responsibility 
of Dr Trenell, Professor Taylor and Professor Day who are internationally recognised 
as experts in this field.  
 
There is no payment to any of the researchers involved in this study. They are 
employed by Newcastle University to work in the NHS, to teach and to research and 
have no financial link with the study.  
 
Who has reviewed the study? 
 
Ethical review of the study has been conducted by the Newcastle and North Tyneside 
Research Ethic Committee No. 1.  
 
Design of this information sheet 
 
This document is written in accordance with the requirements of the European 
Clinical Trials Directive 2001/20/EC, the ICH Good Clinical Practice guidelines and 
the UK Medicines for Human Use (Clinical Trials) Regulation 2004.  
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Framlington Place 
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Patient Identification number for this trial:  
 
CONSENT FORM 
 
Title of Project: Exercise and non-alcoholic fatty liver disease 
 
 
 
Name of researchers: Dr M Trenell, Dr K Hollingsworth, Professor R Taylor, Professor C Day. 
 
Please initial box 
 
 
 
1. I confirm that I have read and understand the information sheet dated January 
2011 (version 4) for the above study and have had the opportunity to ask 
questions.  
 
 
2. I understand that my participant is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected.  
 
 
3. I agree to my GP being informed of my participation in the study 
 
 
4. I agree to take part in the above study.  
 
 
5.   I agree to take part in the Sensewear validation sub-study 
 
 
 
 
 
Name of patient    Date  Signature 
 
 
 
Name of person taking consent  Date  Signature 
(if different from researcher) 
 
 
Researcher    Date  Signature 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
Dr MI Trenell  Active Clinical Therapy 
Version 1.1   
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Executive Summary 
 
This document contains two sections. The first section will define the risks 
associated with exercise and exercise testing of people from the general 
population. The second section will describe the pre-exercise screening 
procedures and operating procedures which will be used at the MRC Muscle 
Performance and Training Laboratory. The document will also outline the 
evidence base underlying the protocols for exercise testing and pre-exercise 
screening.  
 
Habitual physical activity and exercise reduces all cause mortality. 
Nevertheless, vigorous exercise (>75% age predicted maximal heart rate) 
carries risks. In a mixed population or predominantly older people, the risk of 
a cardiac arrest during maximal progressive exercise testing is approximately 
3 events per 10,000 tests.  
 
It is important to remember that exercise only provokes cardiovascular events 
in people with pre-existing heart disease, whether diagnosed or occult. 
Exercise, whether maximal or sub-maximal, does not provoke cardiovascular 
events in individuals with normal cardiovascular systems. The MRC Muscle 
Performance and Exercise Training Laboratory will only study subjects with 
moderate or high risk of having ischemic heart disease after exclusion by 
formal exercise testing. Screening for undiagnosed ischemic heart disease will 
be carried out in the Clinical Research Facility where there is on-site cover by 
the acute hospital resuscitation team. A flow diagram describing this is shown 
in Figure 1. 
 
It is projected that the MRC Muscle Performance and Exercise Training 
Laboratory will investigate approximately 100 people and undertake 250 
exercise tests per year (100 of which are screening tests). Assuming that the 
risks are approximately one quarter that of general population exercise risks, 
as all people will be screened for ischemic heart disease, this produces a 
conservative estimated cardiac arrest rate of one every 50 years. 
 
This document outlines the level of staff qualifications, emergency procedures 
and screening procedures which will be used for exercise testing at the MRC 
Muscle Performance and Exercise Training Laboratory to appropriately 
minimise and manage the risks to research volunteers associated with 
exercise testing and prescription.  
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Figure 1 Schematic representation of the study participant 
screening pathway and related Standard Operating 
Procedure (SOP) defining these. 
 
 
The image part with relationship ID rId13 was not found in the file.
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SECTION 1 – RISK DEFINITION 
 
Exercise related cardiac events in adults 
 
The risks of exercise in older adults (over 50 yr of age) are considerably 
higher than in younger subjects because of the increased prevalence of 
atherosclerotic cardiovascular disease. The most widely cited studies, 
performed in Rhode Island (22) and Seattle (20), estimate an incidence of 
sudden cardiac death during vigorous, unsupervised physical exertion in 
healthy adults as one death per year for every 15,000 to 18,000 individuals. 
This is a low incidence of cardiovascular events, but both studies 
demonstrated that the rate of sudden cardiac death during or immediately 
after vigorous exertion was higher than that for more leisurely activities. 
Exercise is associated with an increased incidence of acute nonfatal 
myocardial infarction (12, 18). Both the incidence of exertion-related sudden 
cardiac death (20), and acute myocardial infarction (12, 18) are higher in 
individuals who exercise infrequently. 
 
The mechanism of sudden cardiac death and acute myocardial infarction in 
previously asymptomatic adults is thought to be acute coronary plaque 
rupture leading to coronary thrombosis. Such atherosclerotic plaque 
disruption with acute thrombotic occlusion has been documented by 
angiography in individuals with exercise induced cardiac events (4, 5, 13).  
 
Risks of cardiac events during exercise testing 
 
 
The risk of exercise varies with the prevalence of underlying coronary artery 
disease in the population. Consequently, the risk of exercise stress testing 
also varies with the populations studied. Exercise stress testing performed in 
previously healthy individuals has a very low rate of cardiovascular events, 
whereas exercise testing in high-risk patients has a higher risk. The overall 
risk of exercise stress testing in a mixed population is approximately 4 cardiac 
events (i.e. 1 myocardial infarction and 3 cardiac arrests) per 10,000 tests 
(see Table 1). These results include exercise testing supervised by non-
physicians (15).  
 
Prevention of exercise-related cardiac events 
 
The development and evaluation of strategies to reduce the risk of vigorous 
exercise is complicated by the low incidence of events. Interventions cannot 
be proposed and tested because an enormous number of subjects would 
have to participate in order for this to achieve sufficient statistical power. 
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Consequently, the recommendations for strategies to reduce risk cardiac 
events are based primarily on expert opinion and consensus. Furthermore, 
the paucity of exercise related cardiac events make it difficult to quantify the 
benefits of any routine screening procedures. Some experts recommend 
extensive pre-participation screening prior to sports participation including 
electrocardiography (16) and echocardiography (6). However, this approach 
is controversial and not broadly supported (1). 
 
The ACSM (1) and AHA (11) recommends exercise stress testing prior to 
initiating exercise for “moderate” or “high risk” people (these groups are 
defined in Table 3, Page 6), including men over 45 and women over 55 years 
of age, individuals with more than one cardiovascular disease risk factor, and 
those with known cardiovascular disease.  
 
Procedures for reducing the risks of vigorous exercise during exercise 
training, exercise stress testing, and cardiac rehabilitation have not been 
tested rigorously (1). 
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Table 1 Cardiac complications during exercise testing in 
suspected ischemic heart disease patients. Total 
events for test and following days expressed per 
10,000 tests.  
 
 
Reference Year Site No. 
Tests 
MI VF Death Hospitalisation Comments 
Rochmis (19) 1971 73 U.S. 170,000 NA NA 1 3 34% of tests wee 
symptom limited; 50% 
of deaths in 8hr; 50% 
over the next 4 days 
Irving (14) 1977 15 Seattle 
facilities 
10,70 NA 4.67 0 NR  
McHenry (17) 1977 Hospital 12,000 0 0 0 0  
Atterhög (3) 1979 20 
Swedish 
Centres 
50,000 0.8 0.8 6.4 5.2  
Stuart (21) 1980 1,375 U.S. 
Centres 
50,000 3.6 4.8 0.5 NR “VF” includes other 
dysrthythmias 
requiring treatment 
Gibbons (9) 1989 Cooper 
Clinic 
518,448 0.6 0.3 0 NR Only 4% of men and 
2% of women had 
CAD 
Knight (15) 1995 Geisinger 
Cardiology 
Service 
28,133 1.4 1.8 0 NR 25% were in-patient 
tests supervised by 
non-MD’s 
         
Average    1.28 2.06 1.13 2.73  
 
 
Abbreviations: MI, myocardial infarction; VF, ventricular fibrillation; CAD, coronary artery 
disease; MD, medical doctor; NA, not applicable; NR, not reported. 
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Table 2 Number of patients for one cardiac event in cardiac 
rehabilitation programs* 
 
Reference Cardiac 
Arrests 
MI Fatalities MI and Arrest 
Van Camp (23) 111,996 293,990 783,972 81,101 
Dgenio (7) 120,000 - 160,000 120,000 
Vongvanich (24) 89,501 268,503 268,503 67,126 
Franklin (8) 146,127 97,418 292,254 58,451 
     
Average 116,906 219,970 732,364 81,669 
 
Adapted from Franklin et al. Safety of medically supervised outpatient cardiac 
rehabilitation exercise therapy: a 16 year follow up. Chest 1998; 114:902-906 
(8) 
 
* Cardiac rehabilitation programs are in general relatively high intensity 
exercise sessions (>70% maximum heart rate).  !
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SECTION 2 – RISK MANAGEMENT 
 
As shown in Figure 1 (page 2), there are three key levels of risk management 
at the MRC Muscle Performance and Exercise Testing Laboratory. These 
follow the guidelines on exercise testing and prescription identified by the 
American College of Sports Medicine and the American Heart Association. 
We will now outline what these stages are and also the Standard Operating 
Procedure describing how they should be done, where they should be done 
and by whom.  
 
The first stage is risk stratification, classifying the participant as Low, 
Moderate, or High risk of having undiagnosed heart disease. These are 
described in the standard Operating Procedure MRC PETL 01. 
 
The second stage of risk management is screening Moderate and High risk of 
undiagnosed heart disease individuals for undiagnosed heart disease and an 
adverse reaction to exercise. These are described in the standard Operating 
Procedure MRC PETL 02. 
 
The final stage is managing any adverse events whilst undergoing exercise 
training. These are described in the standard Operating Procedure MRC 
PETL 03.  
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Standard operating Procedure: MRC PETL 01 
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MRC Muscle Performance and Exercise Training Laboratory 
Standard Operating Procedure 
 
SOP number:  MRC-PETL 01 
SOP full title:  Risk stratification 
SOP category:     
SOP effective:  Review date:  
SOP author signature:  Date:  
 
Dr Michael Trenell 
Scientific Director, MRC Muscle Performance and Training Laboratory 
SOP Reviewer signature: Date: 
 
<name>, <title>  
SOP approval signature: Date: 
 
<name>, <title>  
 
 
Background 
Standard Operating Procedures (SOPs) are designed to ensure that clinical 
research, and its supporting activities, is conducted to the principles of Good Clinical 
Practice (GCP).  GCP is an international ethical and scientific quality standard for the 
design, conduct, performance, monitoring, auditing, recording, analyses, and 
reporting of trials that involve the participation of human subjects. Compliance with 
GCP provides assurance that the data and reported results are credible and 
accurate, and that the rights, wellbeing and safety of participants are protected. 
 
All participants in research projects being undertaken at the MRC Muscle 
Performance and Exercise Training laboratory must be protected from harm, undue 
risk and experience a friendly environment. 
Purpose 
To identify the risk stratification process prior to commencing exercise. 
Scope 
This SOP applies to all exercise studies undertaken by participants at MRC Muscle 
Performance and Exercise Training Laboratory. It will define the procedures, criteria 
and level of professional certification for risk stratification.  
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Procedure 
1. Risk stratification 
The risk of the patient having undiagnosed coronary artery disease, and as a 
consequence an increased risk of an adverse cardiac response to exercise, 
will be  
determined by using the American College of Sports Medicine (1) pre-
participation screening algorithm (Table 1). The first stage of this, defined in 
the Standard Operating Procedure, is Risk Stratification.  
 
During a screening consultation, participants will complete the Physical 
Activity Readiness Questionnaire (Appendix 1) to provide details about their 
medical history Body weight, height, waist and hip circumference and blood 
pressure will be assessed. Where there is insufficient information to determine 
Risk Stratification, blood will be collected for evaluation of a lipid profile and 
fasting glucose.  
 
Using the screening algorithm in Table 2 and 3 (defined by the American 
College of Sports Medicine (1)), participants will then be stratified into Low, 
Moderate, and High Risk of having coronary artery disease and as a 
consequence an adverse response to exercise.  
 
Following the ACSM pre-participation screening algorithm (Table 1), 
participants with Moderate or High risk of undiagnosed coronary artery 
disease will undergo further cardiac examinations (detailed in the SOP MRC 
PETL 02) for assessment of cardiac function and adverse response to 
exercise before commencing further exercise. Participants with Low risk of 
undiagnosed coronary artery disease will not require any additional screening 
before commencing further exercise.  
 
2. Pathway for dealing with undiagnosed risk factors 
Any undiagnosed complications which arise from the Risk Stratification, such 
as hypertension, dyslipidemia, impaired glucose control, or abnormal liver 
function teats will be notified to the participants general practitioner in writing 
by the principle investigator.  
 
A decision about the participant continuing in the research study will be based 
upon the more detailed evaluation outlined in the standard operating 
procedure MRC PETL 02.  
3. Certification for tasks.  
 
Risk stratification will be undertaken by a physician, nurse, physiotherapist, or 
clinical exercise physiologist following this SOP guideline.  
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4. Reporting 
 
The principle investigator will be responsible for administering and retaining 
copies of Risk Stratification documentation (Physical Activity Readiness 
Questionnaire, International Physical Activity Questionnaire, and Risk 
Identification).  
 
The principle investigator is responsible for referring the study participant to 
appropriate clinical support (general physician) following any abnormal 
observations during the study.  
 
References 
1 American College of Sports Medicine. ACSM's guidelines for Exercise 
Testing and Prescription. Ed: Whaley MH, Lippincott, Williams & Wilkins, 
Philadelphia, 7th Edition, 2006.
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Table 1 Pre-participation screening algorithm 
Adapted from the ACSM pre-participation screening 
algorithm (1). 
 
 
 
Screening required prior to professional-guided exercise 
testing/prescription 
Level 1 1 – Determine risk category from Table 3 using Physical Activity 
Readiness Questionnaire 
2 – Determine need for medical clearance prior to testing and/or 
participation and obtain if recommended 
3 – Proceed to level 2 and follow recommendations 
Level 2 Low Risk Moderate Risk High risk 
 • Perform informed 
consent for testing 
• Complete 
appropriate 
assessment 
procedure 
• No requirement for 
pre-exercise 
screening for 
cardiovascular 
disease 
• Medical history 
 
• Perform informed consent for testing 
 
• Intensity of pre-exercise test assessment 
should increase as a function of risk 
category.  
 
Level 3 • Further medical 
examination and 
exercise not 
necessary prior to 
initiation of exercise 
 
• Medical 
examination and 
exercise testing * 
recommended prior 
to initiation of 
vigorous exercise 
training 
 
• Qualified† 
supervision 
recommended for 
maximal exercise 
testing 
 
• Medical 
examination and 
exercise testing*  
recommended 
prior to initiation 
of vigorous 
exercise training 
 
• Qualified† 
supervision 
recommended for 
maximal and sub-
maximal exercise 
testing. 
 
† When qualified supervision is recommended, there should be at least two 
people with up to date ICLS qualifications present at all times and who are 
familiar with the local emergency procedures. 
 
NB: Level 2 and 3 dealt with in SOP MRC-PETL 02 
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Table 2 Risk Stratification Categories adapted from the 
American College of Sports Medicine guidelines (1). 
 
 
 
 
Low Risk Men <45years of age and women <55 years of age who 
are asymptomatic and meet no more than one risk factor 
threshold from Table 4. 
 
Moderate Risk Men >45 years and women >55 years or those who meet 
the threshold for two or more risk factors from Table 4. 
 
High Risk Individuals with one or more signs of cardiovascular 
disease+ and symptoms listed in Table 4 or known 
cardiovascular*, pulmonary#, or metabolic disease†.  
 
 
 
 
 
+ Ankle oedema, palpitations or tachycardia, intermitted claudication, known 
heart murmur, unusual fatigue or shortness of breath with usual activities.  
 
* Cardiac, peripheral vascular, or cerebrovascular disease.  
 
#  Chronic obstructive pulmonary disease, interstitial lung disease, or cystic 
fibrosis.  
 
†  Diabetes mellitus (IDDM, NIDDM), thyroid disorders, renal or liver disease.  
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Table 3 Coronary artery disease risk factor thresholds for 
use with risk stratification. 
 
 
Positive Risk 
Factor 
Defining Criteria 
Family History Myocardial infarction, coronary revascularisation, or 
sudden death before 55 years of age in father or other 
male first-degree relative, or before 65 years of age in 
mother or other female first degree relative.  
 
Cigarette Smoking Current cigarette smoker or those who quit within the 
previous 6 months.  
 
Hypertension Systolic blood pressure >140Hg or diastolic >90 mm Hg, 
confirmed by measurements on at least two separate 
occasions, or on antihypertensive medications 
 
Dyslipidemia Low-density lipoprotein (LDL) cholesterol >3.4mmol.l or 
high density lipoprotein (HDL) cholesterol <1.03 mmol.l 
or on lipid lowering medication. If serum cholesterol is all 
that is available use >5.2mmol.l rather than >3.4mmol.l. 
 
Impaired fasting 
glucose 
Fasting blood glucose > 5.6mmol.l  
 
 
Obesity BMI >30 kg.m2, or 
Waist girth >102 for men and 88 cm for women, or 
Waist / hip ratio > 0.95 for men and >0.86 for women 
 
Sedentary lifestyle Persons not participating in a regular exercise program 
or not meeting the minimal physical activity 
recommendations from the US surgeon general† 
 
 
 
 
 
† Accumulating 30 minutes or more of moderate physical activity on most 
days. 
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Appendix 1 Modified Physical Activity Readiness 
Questionnaire  
 
Physical Activity Readiness Questionnaire 
 
Name:  ______________   
 
Date of Birth: ______________ 
  Please 
choose 
1 Has your doctor ever said that you have a heart condition 
and that you should only do physical activity recommended 
by a doctor? 
 
YES NO 
2 Do you ever feel pain in your chest when you do physical 
activity? 
 
YES NO 
3 Have you ever had chest pain when you are not doing 
physical activity? 
 
YES NO 
4 Do you ever feel faint or have spells of dizziness? 
 
YES NO 
5 Do you have a joint problem (also back problem) that could 
be made worse by exercise? 
 
YES NO 
6 Have you ever been told that you have high blood pressure? 
 
YES NO 
7 Do you have any breathing problems?  
 
YES NO 
8 Do you have any problems with your liver, thyroid, kidneys 
or have diabetes? 
 
YES NO 
7 Are you currently taking any medication? 
 
If so, what? __________________ Reason _______ 
 
YES NO 
8 Are you pregnant, have you had a baby in the last 6 
months, or do you plan to have a baby this year? 
 
YES NO 
9 Has your mother or father had any heart problems? 
 
  
10 How many times a week do you do exercise: _______ 
 
  
11 Is there any other reason why you should not participate in 
physical activity? 
If so, what? __________________________________ 
 
YES NO 
 
 
Signed by (staff): ___________________ Print: ____________ 
 
 
Date:   ___________________ 
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Appendix 2  Risk Stratification Sheet 
 
Name:    ___________________ 
 
DOB:    ___________________ Age:    _________ 
 
Study ID:   ___________________ 
 
General Practitioner:  ___________________ 
 
GP Address:  ___________________ 
 
    ___________________    
   
 
Height   ___________________ 
 
Weight   ___________________ 
 
Waist    ___________________ 
 
Hip circ.   ___________________ 
 
Blood Pressure  ___________________ 
 
Smoker   YES  NO  or given up <6month 
 
Blood Taken:  YES  NO 
 
Comment: _______________________________________ 
  __________________________________________  
  __________________________________________  
  __________________________________________ 
________________________________________________________________ 
To be completed by investigator:  
Risk Stratification (circle):  Low  Moderate  High 
Action Taken:  Commence exercise (Low Risk)    YES / NO 
  Referred for Exercise ECG (moderate and high risk) YES / NO 
________________________________________________________________ 
 
Competed by  ________________  Date _____________ 
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Standard operating Procedure: MRC PETL 02 
Physical examination and exercise testing
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MRC Muscle Performance and Exercise Training Laboratory 
Standard Operating Procedure 
 
SOP number:  MRC PETL 02 
SOP full title:  Pre-exercise training stress testing 
SOP category:     
SOP effective:  Review date:  
SOP author signature:  Date:  
 
Dr Michael Trenell 
Scientific Director, MRC Muscle Performance and Training Laboratory 
SOP Reviewer signature: Date: 
 
<name>, <title>  
SOP approval signature: Date: 
 
<name>, <title>  
 
 
Background 
Standard Operating Procedures (SOPs) are designed to ensure that clinical research, and 
its supporting activities, is conducted to the principles of Good Clinical Practice (GCP).  
GCP is an international ethical and scientific quality standard for the design, conduct, 
performance, monitoring, auditing, recording, analyses, and reporting of trials that involve 
the participation of human subjects. Compliance with GCP provides assurance that the data 
and reported results are credible and accurate, and that the rights, wellbeing and safety of 
participants are protected. 
 
All participants in research projects being undertaken at the MRC Muscle Performance and 
Exercise Training laboratory must be protected from harm, undue risk and experience a 
friendly environment. 
Purpose 
To identify the process of pre-exercise evaluation of cardiac function and response to 
progressive exercise in people classified as Moderate or High risk of undiagnosed heart 
disease following screening (defined in SOP MRC PETL 01). 
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Scope 
This SOP applies to all pre-exercise evaluation of cardiac function in Moderate and High 
Risk patients (defined in SOP MRC PETL 01) undertaken at the MRC Muscle Performance 
and Exercise Training Laboratory. The SOP will define: 
1. Evaluation of Medical History 
2. The procedures for evaluating cardiac function  
3. The criteria for successful completion. 
4. Where these should be undertaken 
5. How many people are required  
6. What level of certification is required to undertake these tests 
7. How people will be certified to begin exercise 
8. Referral of study participant following unsuccessful screening 
9. Management of cardiac event 
Procedures 
1. Screening 
a. Medical history  
 
Participants be screened for their medical history by a physician or qualified 
exercise specialist* (Appendix 1 – Evaluation of Medical History). * see section 5 
 
b. Physical examination  
 
Participants be undergo a physical examination by a physician or qualified 
exercise specialist* (Appendix 2 – Physical Examination Sheet). * see section 5 
 
2. The procedures for undertaking an exercise stress test  
 
Study participants classified as being at Moderate or High Risk of having undiagnosed 
heart disease (defined in SOP MRC PETL 01) will undergo an exercise stress test. During 
this evaluation, expired gases, respiration, blood pressure and cardiac function will be 
monitored. 
 
a. The procedures for undertaking an exercise stress test  
 
The exercise stress examination will have two stages; 1) rest, and 2) exercise. 
Expired gases, respiration, blood pressure and cardiac function will be assessed 
throughout both of these periods. The exercise stress test will be terminated 
when any of the absolute contraindications listed in Appendix 3 occur.  
 
 
3. The criteria for successful completion. 
 
The resting and exercise test should be completed without the occurrence of any absolute 
contraindications to exercise. Absolute contraindications are listed in Appendix 3.  
 
 
4. Level of supervision 
 
During exercise testing, two people will be present at all times.  
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5. Level of certification 
 
Medical history, physical examination and exercise evaluation must be undertaken by a 
physician or by an exercise specialist holding current American College of Sports Medicine 
Clinical Exercise Specialist or Clinical Exercise Physiologist certification. These 
certifications are the highest possible level of clinical certification for exercise testing and 
prescription.  
 
The Knowledge, Skills and Attributes (KSA’s) covered in the American College of Sports 
Medicine certification include: Health Appraisal and Fitness Exercise Testing, Exercise 
Prescription (Training) and Programming, Electrocardiography and Diagnostic Techniques, 
Exercise Physiology and Related Exercise Science, Pathophysiology and Risk Factors, 
Human Behaviour,  Safety, Injury Prevention and Emergency Procedures, Nutrition and 
Weight Management,  Patient Management and Medications, Program Administration, 
Quality Assurance, and Outcome Assessment, Medical and Surgical Management. See 
www.acsm.org/ for further details.  
 
During exercise testing, both supervising investigators should hold at least current 
intermediate cardiac life support (ICLS) qualifications.  
 
 
6. Where will exercise testing be undertaken 
 
Pre-exercise screening of low risk participants requires the supervision of two ICLS trained 
staff and no Advanced Cardiac Life Support (ACLS) trained team. These tests will be 
completed at the MRC Muscle Performance and Exercise Training Laboratory, based at the 
Clinical ageing Research Unit at the Campus for Ageing and Vitality.  
 
Pre-exercise screening of moderate and high-risk groups must be undertaken in the 
presence of an ACLS team as well as the two supervising ICLS trained individuals. Testing 
of moderate and high risk study participants will be undertaken at the Clinical Research 
Facility at the Royal Victoria Infirmary. 
 
All exercise testing must be undertaken with automated defibrillators available for 
use and the supervising personnel familiar with their use.  
 
7. How study participants will be certified to begin exercise 
 
Upon successful completion of the screening procedures, the resting and exercise ECG will 
be certified by the supervising physician as not having undiagnosed heart disease that 
would produce an adverse reaction to exercise.  
 
Successful completion of the screening procedures will be documented in the Physical 
Examination form (Appendix 2). 
 
 
8. Referral of study participant following unsuccessful screening 
 
If a study participant fails the screening process they will be referred back to their general 
physician. A screening report will be provided by the Principle Investigator to the general 
physician and the study participant advised not to undertake exercise until the general 
physician has cleared them to do so.  
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9. Management of an adverse cardiac event 
 
All exercise screening will be undertaken at the Clinical Research Facility at the 
Royal Victoria Infirmary. As such, the Newcastle Hospitals Trust Cardiac Event 
Policy will be followed.  
 
Exercise testing undertaken at the MRC Muscle Performance and Exercise Training 
Laboratory within the Clinical Ageing Research Unit will follow the local guidelines 
for management of an adverse cardiac event.  
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Table 1  Pre-participation screening algorithm. Adapted from the ACSM pre-
participation screening algorithm. 
 
 
 Screening required prior to professional-guided exercise 
testing/prescription 
Level 
1* 
1 – Determine risk category from Table 2 using Physical Activity 
Readiness Questionnaire 
2 – Determine need for medical clearance prior to testing and/or 
participation and obtain if recommended 
3 – Proceed to level 2 and follow recommendations 
Level 2 Low Risk Moderate Risk High risk 
 • Perform informed 
consent for testing 
• Complete 
appropriate 
assessment 
procedure 
• No requirement for 
pre-exercise 
screening for 
cardiovascular 
disease 
• Medical history 
 
• Perform informed consent for testing 
 
• Intensity of pre-exercise test assessment 
should increase as a function of risk 
category.  
 
Level 3 • Further medical 
examination and 
exercise not 
necessary prior to 
initiation of exercise 
 
• Physical 
examination and 
exercise testing 
recommended prior 
to initiation of 
vigorous exercise 
training 
 
• Qualified† 
supervision 
recommended for 
maximal exercise 
testing 
 
• Physical 
examination and 
exercise testing 
recommended 
prior to initiation 
of vigorous 
exercise training 
 
• Qualified† 
supervision 
recommended for 
maximal and sub-
maximal exercise 
testing. 
 
 
 
* The procedures for Level 1 assessment are detailed in MRC PETL SOP1  
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Appendix 1 Evaluation of Medical History  
(on reverse of Physical Activity Readiness Questionnaire from SOP MRC PETL 01) 
 
Medical Diagnosis:  
 History of cardiovascular disease   YES  NO 
 Peripheral vascular disease    YES  NO 
 Hypertension      YES  NO 
 Diabetes      YES  NO 
 Pulmonary disease     YES  NO 
 
Previous Physical Examination 
 Have you had anything reported previously  
from a physical examination?    YES  NO 
 
History of symptoms 
 Discomfort in the chest, jaw, neck, back or arms 
(e.g. pressure, tingling, pain, heaviness,  
burning, tightness, squeezing or numbness)   YES  NO 
 
 Light headedness , dizziness or faint?   YES  NO 
 
Recent Illness 
 Hospitalisation, new medical diagnosis, surgery  YES  NO 
 Details __________________________________________________ 
   __________________________________________________ 
  
Orthopaedic problems 
 Arthritis, joint swelling,  
anything which would make exercise difficult  YES  NO 
 
Medication use 
 Medication      YES  NO 
 Details __________________________________________________ 
   __________________________________________________ 
 Allergies 
 Details __________________________________________________ 
   __________________________________________________ 
  
Other habits 
 Caffeine   YES  NO if yes, units per week ___ 
 Alcohol   YES  NO  if yes, units per week ___ 
 Tobacco   YES  NO  if yes, units per week ___ 
 
Exercise history 
 Frequency (/week)  1 2 3 4 5 6 7 8 
 Duration per session (min)  10 20 30 40 50 60 70 
 
Work history 
 Focus on current of expected physical demands 
 
Family history  
 Cardiac      YES  NO 
Pulmonary     YES  NO 
Metabolic disease    YES  NO 
Stroke      YES  NO 
Sudden death     YES  NO 
 
Comments: 
  __________________________________________________ 
  __________________________________________________ 
  __________________________________________________ 
_______________________________________________________________ 
Competed by  ________________  Date _____________ 
MRC PETL 02 
SOP MRC PETL 02 Pre-exercise training stress testing v1-1 03 02 2009 Page 24 of 33 
 
Appendix 2 Physical examination (page 1 – page 2 on the next page) 
!
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Body weight (kg): _____  Waist Circumference (cm): _____ 
 
%Fat Free Mass: _____  % Fat Mass:   _____ 
 
Apical pulse rate(min): _____  Rhythm:   OK / Not OK 
 
Resting blood pressure, seated. ___ / ____ 
 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Auscultation of the lungs    OK / Not OK 
with specific attention to uniformity of breath Comment:________________________________ 
sounds in all areas (absence of rales and wheezes)  _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________  
Palpation of cardiac apical impulse  OK / Not OK 
point of maximal impulse    Comment:________________________________ 
       _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________      
Auscultation of the heart    OK / Not OK 
with specific attention to murmurs,    Comment:________________________________ 
gallops, clicks and rubs.     _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Evaluation of the abdomen    OK / Not OK 
Bowel sounds, masses, visceromegaly,   Comment:________________________________ 
and tenderness.       _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Evaluation of lower extremities    OK / Not OK 
Oedema and presence of arterial pulse.  Comment:________________________________ 
       _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Inspection of the skin     OK / Not OK 
focus on lower extremities in people with diabetes. Comment: ________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________  
Neurologic function    OK / Not OK 
Reflexes      Comment:________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Any orthopedic or medical condition   YES / NO 
that would limit exercise.    Comment:________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Ventricular tachycardia    OK / Not OK 
      Comment:________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
ST elevation (+1.0 mm)    OK / Not OK 
in leads without diagnostic Q-waves  Comment:________________________________ 
(other than V1 or aVR)     _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
ST or QRS changes     OK / Not OK 
such as excessive ST suppression >2mm  Comment:________________________________ 
horizontal or down sloping ST-segment depression  _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Arrhythmias other than:    OK / Not OK 
sustained ventricular tachycardia, including  Comment:________________________________ 
multiple PVCs, triplets of PVCs, supraventricular  _________________________________ 
tachycardia, heart block, or bradyarrhythmias.  _________________________________. 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
 
 
Cleared to start exercise test    YES / NO 
Competed by:  ________________  Date _____________ 
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Physical examination (page 2 on reverse of page 1) 
 
Exercise Stress Testing 
Exercise Protocol:  _______________________________________________ 
 
Absolute indicators for terminating the Exercise Stress test:  
 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Drop in blood pressure of >10mm Hg   OK / Not OK 
from baseline blood pressure    Comment:________________________________ 
despite an increase in workload,     _________________________________ 
when accompanied by other     _________________________________ 
evidence of ischemia. 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Any form of chest pain or    OK / Not OK 
shortness of breath    Comment:________________________________ 
       _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Increasing nervous system symptoms   OK / Not OK 
(e.g. ataxia, dizziness or near syncope)  Comment:________________________________ 
       _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Technical difficulties monitoring    OK / Not OK 
ECG or blood pressure    Comment:________________________________ 
       _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Ventricular tachycardia    OK / Not OK 
      Comment:________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
ST elevation      OK / Not OK 
(+1.0 mm) in leads without    Comment:________________________________ 
diagnostic Q-waves (other than V1 or aVR)   _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
ST or QRS changes     OK / Not OK 
such as excessive ST suppression >2mm horizontal Comment:________________________________  
or down sloping ST-segment depression   _________________________________  
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Arrhythmias other than:    OK / Not OK 
sustained ventricular tachycardia,    Comment:________________________________ 
including multiple PVCs, triplets of PVCs, supraventricular _________________________________ 
tachycardia, heart block, or bradyarrhythmias.  _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Fatigue, shortness of breath, wheezing,   OK / Not OK 
leg cramps, or patient develops    Comment:________________________________ 
discomfort.      _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Development of bundle-branch block   OK / Not OK 
or intraventricular conduction delay   Comment:________________________________ 
that cannot be distinguished from ventricular tachycardia _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Hypertensive response     OK / Not OK 
Systolic blood pressure of > 250 mm Hg   Comment:________________________________ 
and / or diastolic pressure of >115 mm Hg   _________________________________ 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
 
Comments: 
  ____________________________________________________________________________ 
  ____________________________________________________________________________ 
  ____________________________________________________________________________ 
 
Adverse reaction to exercise:    YES / NO 
 
Cleared to start exercise:     YES / NO 
Competed by: ________________   Date _____________ 
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Appendix 3  Absolute indicators for terminating an exercise test.  
 
 
Absolute Indications 
 
• Drop in blood pressure of >10mm Hg from baseline blood pressure despite 
an increase in workload, when accompanied by other evidence of ischemia. 
• Any form of chest pain or shortness of breath 
• Increasing nervous system symptoms (e.g. ataxia, dizziness or near syncope) 
• Signs of poor perfusion (cyanosis or pallor) 
• Technical difficulties monitoring ECG or blood pressure 
• Subjects desire to stop 
• Ventricular tachycardia 
• ST elevation (+1.0 mm) in leads without diagnostic Q-waves (other than V1 
or aVR) 
• ST or QRS changes such as excessive ST suppression (>2mm horizontal or 
down sloping ST-segment depression) 
• Arrhythmias other than sustained ventricular tachycardia, including multiple 
PVCs, triplets of PVCs, supraventricular tachycardia, heart block, or 
bradyarrhythmias. 
• Fatigue, shortness of breath, wheezing, leg cramps, or patient develops 
discomfort. 
• Development of bundle-branch block or intraventricular conduction delay 
that cannot be distinguished from ventricular tachycardia  
• Hypertensive response (systolic blood pressure of > 250 mm Hg and / or 
diastolic pressure of >115 mm Hg) 
 
 
 
Adapted from the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines (Committee on Exercise Testing) (10).  
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Standard operating Procedure: MRC PETL 03 !
 
Exercise Training 
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MRC Muscle Performance and Exercise Training Laboratory 
Standard Operating Procedure 
 
SOP number:  MRC PETL 03 
SOP full title:  Exercise Training 
SOP category:     
SOP effective:  Review date:  
SOP author signature:  Date:  
 
Dr Michael Trenell 
Scientific Director, MRC Muscle Performance and Training Laboratory 
SOP Reviewer signature: Date: 
 
<name>, <title>  
SOP approval signature: Date: 
 
<name>, <title>  
 
 
Background 
Standard Operating Procedures (SOP s) are designed to ensure that clinical research, and 
its supporting activities, is conducted to the principles of Good Clinical Practice (GCP).  
GCP is an international ethical and scientific quality standard for the design, conduct, 
performance, monitoring, auditing, recording, analyses, and reporting of trials that involve 
the participation of human subjects. Compliance with GCP provides assurance that the data 
and reported results are credible and accurate, and that the rights, wellbeing and safety of 
participants are protected. 
 
All participants in research projects being undertaken at the MRC Muscle Performance and 
Exercise Training laboratory must be protected from harm, undue risk and experience a 
friendly environment. 
Purpose 
To identify the process of exercise training following screening at the MRC Muscle 
Performance and Exercise Training Laboratory (defined in MRC PETL 01 and 02). 
  
Scope 
This SOP applies to all research participants undertaking exercise following screening at 
the MRC Muscle Performance and Exercise Training Laboratory. The SOP will define the 
procedures for an adverse event whilst exercising at: 
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1. Newcastle University Gymnasium 
2. Participants local gymnasium 
3. MRC Muscle Performance and Exercise Training Laboratory 
 
Management of an adverse event 
All exercise training studies performed with participants with chronic disease will be 
undertaken in an environment where support infrastructure is in place to manage an 
adverse reaction to exercise (such as collapse).  
 
However, it should be reiterated that the major risks associated with exercise relate to 
having undiagnosed heart disease. Any individual reaching the stage of exercise training 
will have undergone screening for undiagnosed heart disease so the risk of an adverse 
event are low and are not likely to be serious. This is represented by the level of 
management of an adverse event.  
 
Acute injuries will be managed by the senior physiotherapist team from the MRC Muscle 
Performance and Exercise Training Laboratory. The three locations for exercise training 
are:  
 
 Newcastle University Gymnasium  
Any adverse event will be covered by the local procedures for management of an 
adverse event at the gymnasium. 
  
Participants Local Gymnasium 
Any adverse event will be covered by the local procedures for management of an 
adverse event at the gymnasium.  
 
MRC Muscle Performance and Exercise Training Laboratory 
Any adverse event will be covered by the local procedures of for management of an 
adverse event at CARU (the laboratory is based in CARU). 
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INFORMATION SHEET FOR RECRUITING VOLUNTEERS INTO A 
STUDY INVOLVING MRI SCANS 
 
 
 
 
Please could you pass this information to any team members who are involved in volunteer/patient 
recruitment into any studies that involve an MRI scan. 
 
Volunteer safety is paramount; to this end we will safety screen all volunteers when they arrive at 
NMRC.  In order to prevent an unnecessary booking it is advisable to screen your volunteers prior to 
recruitment into a study. There is a copy of the MR safety screening form attached, this can be used as 
a guide if you wish, and if the answer to any of these questions is yes, then please contact one of the 
NMRC radiographers before making an appointment.   
 
The appointment time given is the time the volunteer will be on the scanner. We need up to 30 minutes 
with each volunteer prior to the scan in order to explain the procedure and to prepare them for the scan, 
and so please take account of this when arranging transport etc.  If you also need to spend time with 
the volunteer prior to the scan then please take this into account also. 
 
We ask that volunteers arrive prepared for an MRI scan, and where possible wearing no jewellery or 
any clothing with metal.  All other metal, e.g. hair grips, must also be removed.  We have a changing 
room with lockers should volunteers prefer to bring alternative clothing to wear for their scan.  Your 
volunteer may also bring along a CD to listen to during the scan. 
 
Please give each volunteer an NMRC appointment letter.  This incorporates the patient/volunteer 
information sheet regarding their MR scan, and also a map and directions to NMRC. 
 
 
If you have any queries or concerns, please do not hesitate to contact the NMRC radiographers. 
 Version 2.0  17/08/2009 
Newcastle University 
VOLUNTEER SAFETY QUESTIONNAIRE 
 
Volunteer’s name:      Date of birth  ___ /  _ _ / ____     
                                
Weight:                           Height:       
 
 
Please check the following carefully.   
Some items can interfere with MR examinations, and may also be hazardous to your safety. 
      
Have you had any surgery: 
 
Have you had any operations/procedures involving your head, chest or heart? 
   
Yes No 
 
Do you have any of the following?  
 
  
Cardiac pacemaker, aneurysm clip, stent, heart valve replacement, cochlear 
implant, programmable shunt, spinal stimulation wires, or any other 
implants. 
Yes No 
   
Is there any possibility that you could have metal fragments in your eye? Yes No 
Do you have any metal fragments anywhere in your body? Yes No 
   
Are you wearing?   
Dentures with metal  Yes No 
A hearing aid Yes No 
Body piercing/jewellery/hair grips Yes No 
Slow-release drug patches on your skin Yes No 
   
Do you have any tattoos? Yes No 
Have you ever had a fit or blackout?  Yes No 
Do you have epilepsy or diabetes? Yes No 
   
FOR WOMEN OF CHILDBEARING AGE:  Could you be pregnant? Yes No 
 
 
ALL metal worn or carried on your person must be removed 
 
 
I understand the procedure of a MRI examination. I also understand the above questions. 
 
 
Volunteer’s Signature: ___________________________________ Date: ____________ 
 
 
Staff Signature: _______________________________________Date: ____________ 
Name: _________________________
Please fill in this diary after every exercise session:
Session Date Max Heart 
Rate
Observations 
(e.g. recent illness, feeling of fatigue…)
1     /     /
2     /     /
3     /     /  Weight (Kg) _____ 
4     /     /
5     /     /
6     /     /  Weight (Kg) _____
7     /     /
8     /     /
9     /     /  Weight (Kg) _____
10     /     /
11     /     /
12     /     /  Weight (Kg) _____
13     /     /
14     /     /
15     /     /  Weight (Kg) _____
16     /     /
17     /     /
18     /     /  Weight (Kg) _____
Exercise Diary
Session Date Max Heart 
Rate
Observations 
(e.g. recent illness, feeling of fatigue…)
19     /     /
20     /     /
21     /     /  Weight (Kg) _____
22     /     /
23     /     /
24     /     /  Weight (Kg) _____
25     /     /
26     /     /
27     /     /  Weight (Kg) _____
28     /     /
29     /     /
30     /     /  Weight (Kg) _____
31     /     /
32     /     /
33     /     /  Weight (Kg) _____
34     /     /
35     /     /
36     /     /  Weight (Kg) _____
Exercise Diary
